

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 30, 2004, 14:44:42 ; Search time 3927 Seconds  
(without alignments)  
9966.580 Million cell updates/sec

Title: US-10-202-687-1  
Perfect score: 903  
Sequence: 1 atggacctgccccgcagct.....ggggcaagtcacgaagtaa 903

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

GenEmbl:

1: gb.ba.\*

2: gb.htg.\*

3: gb.in.\*

4: gb.om.\*

5: gb.ov.\*

6: gb.pat.\*

7: gb.ph.\*

8: gb.pl.\*

9: gb.pr.\*

10: gb.ro.\*

11: gb.sts.\*

12: gb.sy.\*

13: gb.un.\*

14: gb.vi.\*

15: em.ba.\*

16: em.fun.\*

17: em.hum.\*

18: em.in.\*

19: em.mu.\*

20: em.om.\*

21: em.or.\*

22: em.ov.\*

23: em.pat.\*

24: em.ph.\*

25: em.pl.\*

26: em.ro.\*

27: em.ste.\*

28: em.un.\*

29: em.vi.\*

30: em.htg.hum.\*

31: em.htg.inv.\*

32: em.htg.other.\*

33: em.htg.mus.\*

34: em.htg.pln.\*

35: em.htg.rod.\*

36: em.htg.man.\*

37: em.htg.vrt.\*

38: em.sy.\*

39: em.htgo.hum.\*

40: em.htgo.mus.\*

41: em.htgo.other.\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	903	100.0	903	6	AR308734	Sequence
2	903	100.0	903	6	AX549189	Sequence
3	903	100.0	903	6	AX675043	Sequence
4	903	100.0	923	9	AF024687	Homo sapi
5	903	100.0	34791	9	HS062631	Human B-cel
6	898.2	99.5	903	6	AR308751	Sequence
7	843.8	93.4	903	9	AB095743	Macaca fa
8	614	68.0	903	10	AB095746	Mesocric
9	604.4	66.9	903	6	AX675045	Sequence
10	604.4	66.9	903	10	AB095745	Mus muscu
11	602.8	66.8	1819	10	AF539809	Mus muscu
12	602.8	66.8	209873	2	AC087143	Mus muscu
13	598	66.2	154673	2	AC079472	Mus muscu
14	590	65.3	903	10	AB095744	Rattus no
15	590	65.3	907	10	AF539810	Rattus no
16	588.4	65.2	238725	2	AC115260	Rattus no
17	588.4	65.2	253523	2	AC126062	Rattus no
18	582	64.5	154673	2	AC079472	Mus muscu
19	134.6	14.9	207989	2	AC146547	Gasterost
20	123.4	13.7	1841	6	AR140519	Sequence
21	123.4	13.7	1841	6	E41325	cDNA clone
22	121.8	13.5	1041	6	AR308737	Sequence
23	121.8	13.5	1041	6	AX224754	Sequence
24	121.8	13.5	1041	6	AX224756	Sequence
25	121.8	13.5	1041	6	AX549319	Sequence
26	121.8	13.5	1061	9	AF024688	Homo sapi
27	121.8	13.5	1061	9	AF024689	Homo sapi
28	121.8	13.5	1694	9	BC035657	Homo sapi
29	121.8	13.5	98713	9	AC002511	Human DNA
30	118.6	13.1	1041	6	AR308752	Sequence
31	84.6	9.4	1158	9	AY431102	Homo sapi
32	84.6	9.4	1534	6	BD137966	Protease
33	84.6	9.4	1534	9	AF080214	Homo sapi
34	84.6	9.4	4895	6	AR108643	Sequence
35	84.6	9.4	4895	6	AR223400	Sequence
36	84.6	9.4	4895	6	AR242695	Sequence
37	84.6	9.4	4895	6	AX549230	Sequence
38	84.6	9.4	4895	9	AF055917	Homo sapi
39	84.6	9.4	4325	6	AX211769	Sequence
40	84.6	9.4	11828	9	AF384819	Homo sapi
41	84.6	9.4	121886	2	BX663530	Gallus ga
42	84.6	9.4	248281	9	AC008737	Homo sapi
43	84.4	9.3	131743	2	BX663529	Gallus ga
44	83.4	9.2	84653	2	BX663523	Gallus ga
45	83.4	9.2	254295	2	BX663526	Gallus ga

ALIGNMENTS

RESULT 1  
AR308734  
LOCUS  
DEFINITION Sequence 249 from patent US 6555339.  
ACCESSION AR308734  
VERSION AR308734.1 GI:31700263  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 903)  
AUTHORS Liaw,C.W., Behan,D.P. and Chalmers,D.T.  
TITLE Non-endogenous, constitutively activated human protein-coupled receptors  
JOURNAL Patent: US 6555339-A 249 29-APR-2003;  
linear DNA PAT 12-JUN-2003

FEATURES		Location/Qualifiers		1..903		/organism="unknown"		/mol_type="genomic DNA"	
source									
ORIGIN									
Query Match		100.0%; Score 903; DB 6; Length 903;							
Best Local Similarity		100.0%; Pred. No. 1.5e-132;							
Matches 903; Conservative		0; Mismatches 0; Indels 0; Gaps 0;							
QY	1	ATGGACCTGCCCGCAGCTCTCTTTGGCCCTCTATGTGGCGCGCTTTGCGCTGGGCTTC	60						
DB	1	ATGGACCTGCCCGCAGCTCTCTTTGGCCCTCTATGTGGCGCGCTTTGCGCTGGGCTTC	60						
QY	61	CGCTCAACGTCTGGCCATCCGAGCGCGACGGCCACGCCGGCTCCGTCTCACCCCT	120						
DB	61	CGCTCAACGTCTGGCCATCCGAGCGCGACGGCCACGCCGGCTCCGTCTCACCCCT	120						
QY	121	AGCTTGGTCTAGCCCTGAACTGGGCTGCTCGACCTGCTGCTGACAGTCTCTTGCCC	180						
DB	121	AGCTTGGTCTAGCCCTGAACTGGGCTGCTCGACCTGCTGCTGACAGTCTCTTGCCC	180						
QY	181	CTGAAGCGGTGGAGCGCTAGCCTCCGGGGCTGGCCCTCTGCGGGCTCGCTTGCCCC	240						
DB	181	CTGAAGCGGTGGAGCGCTAGCCTCCGGGGCTGGCCCTCTGCGGGCTCGCTTGCCCC	240						
QY	241	GTCTTCGGGTGGCCACCTTCTCCACTCTATGCGGGCGGGGCTTCTTGGCGGCCCTG	300						
DB	241	GTCTTCGGGTGGCCACCTTCTCCACTCTATGCGGGGGGGCTTCTTGGCGGCCCTG	300						
QY	301	AGTCAGGCGCTACCTGGGAGCAGCTTCCCTTGGGGCTACCAAGCTTCGGAGGCGG	360						
DB	301	AGTCAGGCGCGCTACCTGGGAGCAGCTTCCCTTGGGGCTACCAAGCTTCGGAGGCGG	360						
QY	361	TGCTATTCTTGGGGGTGTGCGGGCCATCTGGGGCCCTCGCTGTGTCACTGGGTCTG	420						
DB	361	TGCTATTCTTGGGGGTGTGCGGGCCATCTGGGGCCCTCGCTGTGTCACTGGGTCTG	420						
QY	421	GTCTTTGGGTGGAGGCTTCAGAGGCTGGCTGGACCAAGCAACACTTCCCTGGGCATC	480						
DB	421	GTCTTTGGGTGGAGGCTTCAGAGGCTGGCTGGACCAAGCAACACTTCCCTGGGCATC	480						
QY	481	AACACACCGGTCAAAGGCTTCCGGTCTCGCTGGAGGCTTGGACCCGGCTCTTGGCGG	540						
DB	481	AACACACCGGTCAAAGGCTTCCGGTCTCGCTGGAGGCTTGGACCCGGCTCTTGGCGG	540						
QY	541	CGGGCCGCTTCAAGCT	600						
DB	541	CGGGCCGCTTCAAGCT	600						
QY	601	TGCTACGTGGGCTGGCTTCGGGCACTGGGCGGCTCGGGCTGACGCAAGGCGGAAGCTG	660						
DB	601	TGCTACGTGGGCTGGCTTCGGGCACTGGGCGGCTCGGGCTGACGCAAGGCGGAAGCTG	660						
QY	661	CGGGCGCTGGGTGGCGGGCGGCTTCTCAGCGCTGCTGCTGCTGAGACCCCTAC	720						
DB	661	CGGGCGCTGGGTGGCGGGCGGCTTCTCAGCGCTGCTGCTGCTGAGACCCCTAC	720						
QY	721	AACGCCCTCAAAGTGGCCAGCTTCTGTATACCCCAATCTAGGAGGCTTCTGGCGGAAGCTG	780						
DB	721	AACGCCCTCAAAGTGGCCAGCTTCTGTATACCCCAATCTAGGAGGCTTCTGGCGGAAGCTG	780						
QY	781	GGGCTCATACGGGTGCTGGAGTGGTGTCTTAATCCGGTGGTGAACCGGTTACTTGGGA	840						
DB	781	GGGCTCATACGGGTGCTTGGAGTGGTGTCTTAATCCGGTGGTGAACCGGTTACTTGGGA	840						
QY	841	AGGGGCTCTGGCTGAAGCAGTGTGTGGCGCAAGAACCGCAAGGGGGCAAGTCCCAAGAG	900						
DB	841	AGGGGCTCTGGCTGAAGCAGTGTGTGGCGCAAGAACCGCAAGGGGGCAAGTCCCAAGAG	900						
QY	901	TAA 903							
DB	901	TAA 903							



MEDLINE 98008875  
PUBMED 9344866  
REFERENCE 2 (bases 1 to 923)  
AUTHORS O'Dowd B.F.  
TITLE Direct Submission  
JOURNAL Submitted (15-SEP-1997) Department of Pharmacology, University of  
Toronto, 8 Taddle Creek Rd., Toronto, ON M5S 1A8, Canada  
FEATURES  
source  
1..923  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="19"  
/map="19q13.1"  
11..913  
/gene="GPR40"  
11..913  
/gene="GPR40"  
/codon\_start=1  
/product="putative G protein-coupled receptor"  
/protein\_id="AAB86710.1"  
/db\_xref="GI:2612946"  
/translation="MDLPPLQLSFLGYVAAPALGFPLNVLATRGATAHARLRLTPSLVY  
ALNLGSDLLVTSFLPKAVEALASGAWPLPASLCPVFAVAFHFFLYAGGGFLAALSA  
GRYLGAFFPLGYQAFRRPCYSWGVCAAIWALVLCGLVFLGFAFGWLDHSNLSLGI  
NTPVNGSPVCEAWDPASGAPARFSLILLFPLPLAITAFVYVGCIRALARSGLTHRR  
KLRAAVAGALLTLILLCVGPVNASVASFYLPNLGGSWRKGLITGAWSVVLNPLVT  
GYLGRGPLKTVCAARTQGGKSKQ"

ORIGIN  
Query Match 100.0%; Score 903; DB 9; Length 923;  
Best Local Similarity 100.0%; Pred. No. 1.5e-132;  
Matches 903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGAGCTGCCCGCAGCTCTCTTCGGCCCTCTATGTGGCGCCCTTTGGCTGGGCTTC 60  
DB 11 ATGGAGCTGCCCGCAGCTCTCTTCGGCCCTCTATGTGGCGCCCTTTGGCTGGGCTTC 70  
QY 61 CGCTCAAGCTCTGGCCATCGAGCGGCGAGCGGCCACGCCGGCTCGCTCACCCCT 120  
DB 71 CGCTCAAGCTCTGGCCATCGAGCGGCGAGCGGCCACGCCGGCTCGCTCACCCCT 130  
QY 121 AGCTTGCTAGCCCTGAACTGGGCTGCTCCGACTCTGCTGACAGCTCTCTGCCCC 180  
DB 131 AGCTTGCTAGCCCTGAACTGGGCTGCTCCGACTCTGCTGACAGCTCTCTGCCCC 190  
QY 181 CTGAAGCGGTGAGCGCTAGCTTCGGGCTGCGCTTCGGGCTCGCTGCGCCCTC 240  
DB 191 CTGAAGCGGTGAGCGCTAGCTTCGGGCTGCGCTTCGGGCTCGCTGCGCCCTC 250  
QY 241 GTCTTCGGGTGGCCCACTTCTCCCACTATGCGGGGGGCTTCCTGCGCCCGCTG 300  
DB 251 GTCTTCGGGTGGCCCACTTCTCCCACTATGCGGGGGGCTTCCTGCGCCCGCTG 310  
QY 301 AGTGAGCGCGCTACTCTGGGAGCAGCTTCCCTTGGGCTACCAAGCCCTTCGGAGCGCG 360  
DB 311 AGTGAGCGCGCTACTCTGGGAGCAGCTTCCCTTGGGCTACCAAGCCCTTCGGAGCGCG 370  
QY 361 TGCTATTCTGGGGGTGTGCGCGGCATCTGGGCGCTCTGCTGTGTCACCTGGGTCTG 420  
DB 371 TGCTATTCTGGGGGTGTGCGCGGCATCTGGGCGCTCTGCTGTGTCACCTGGGTCTG 430  
QY 421 GTCTTTGGGTGGAGCTCCAGAGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 480  
DB 431 GTCTTTGGGTGGAGCTCCAGAGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 490  
QY 481 AACACACCGCTCAACGGCTCTCCGGTCTGCTGGAGCGCTGGAGCCCGGCCCTCTGCGCGC 540  
DB 491 AACACACCGCTCAACGGCTCTCCGGTCTGCTGGAGCGCTGGAGCCCGGCCCTCTGCGCGC 550  
QY 541 CCGGCCCGCTTCAGCT 600  
DB 551 CCGGCCCGCTTCAGCT 610

QY 601 TGCTACGTGGGTGCTCTCCGGGCACTGGCCCGCTCCGGCTGACGCAAGCGGGAAGCTG 660  
DB 611 TGCTACGTGGGTGCTCTCCGGGCACTGGCCCGCTCCGGCTGACGCAAGCGGGAAGCTG 670  
QY 661 CGGGCGGCTGGGTGGCGGGGGGCTCTCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
DB 671 CGGGCGGCTGGGTGGCGGGGGGCTCTCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 730  
QY 721 AACGCCTCAACGTGGCCAGCTTCTGTATACCCCAATCTAGGAGGCTCTCTGGCGGAAGCTG 780  
DB 731 AACGCCTCAACGTGGCCAGCTTCTGTATACCCCAATCTAGGAGGCTCTCTGGCGGAAGCTG 790  
QY 781 GGGCTCATACGGGTGCTGGAGTGTGCTGCTTATCCGCTGGTGTGCTGCTGCTGCTGCTGCTGCTGCT 840  
DB 791 GGGCTCATACGGGTGCTGGAGTGTGCTGCTTATCCGCTGGTGTGCTGCTGCTGCTGCTGCTGCTGCT 850  
QY 841 AGGGTCTCTGGCTGAACAGCAGTGTGCTGGGCAAGACGCAAGGGGGCAAGTCCAGAG 900  
DB 851 AGGGTCTCTGGCTGAACAGCAGTGTGCTGGGCAAGACGCAAGGGGGCAAGTCCAGAG 910  
QY 901 TAA 903  
DB 911 TAA 913  
RESULT 5  
HSU62631  
LOCUS 34791 bp DNA linear PRI 15-NOV-2002  
DEFINITION Human B-cell receptor CD22-B isoform and alternatively spliced  
B-cell receptor CD22-A isoform (CD22) gene, complete cds, complete  
sequence.  
ACCESSION U62631.2 GI:24756897  
VERSION U62631  
KEYWORDS HTG.  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1 (sites)  
AUTHORS Wilson,G.L., Fox,C.H., Pauci,A.S. and Kehr,J.H.  
TITLE cDNA cloning of the B cell membrane protein CD22: a mediator of B-B  
cell interactions  
J. Exp. Med. 173 (1), 137-146 (1991)  
MEDLINE 91086838  
PUBMED 1985119  
REFERENCE 2 (bases 1 to 34791)  
AUTHORS Wilson,G.L., Najfeld,V., Kozlow,E., Menniger,J., Ward,D. and  
Kehr,J.H.  
TITLE Genomic structure and chromosomal mapping of the human CD22 gene  
J. Immunol. 150 (11), 5013-5024 (1993)  
MEDLINE 93267103  
PUBMED 8496602  
REFERENCE 3 (bases 1 to 34791)  
AUTHORS Lamerdin,J.E., McCreedy,P., Adamson,A.W., Burkhardt-Schultz,K.,  
Garcia,E., Kyle,A., Ramirez,M., Stilwagen,S., Garnes,J.,  
Danganan,L., Bruce,R., Quan,G., Montgomery,M., Ow,D., Kobayashi,A.,  
Olsen,A.O. and Carrano,A.V.  
TITLE Sequence analysis of a 1 Mb region in human 19q13.1  
JOURNAL Unpublished  
REFERENCE 4 (bases 1 to 34791)  
AUTHORS Lamerdin,J.E., McCreedy,P., Adamson,A.W., Burkhardt-Schultz,K.,  
Garcia,E., Kyle,A., Ramirez,M., Stilwagen,S., Garnes,J.,  
Danganan,L., Bruce,R., Quan,G., Montgomery,M., Ow,D., Kobayashi,A.,  
Olsen,A.O. and Carrano,A.V.  
TITLE Direct Submission  
JOURNAL Submitted (28-JUN-1996) Human Genome Center, Biology and  
Biotechnology Research Program, Lawrence Livermore National  
Laboratory, 7000 East Ave, Livermore, CA 94550, USA  
REFERENCE 5 (bases 1 to 34791)  
AUTHORS Myers,R.M.  
TITLE Direct Submission  
JOURNAL Submitted (07-NOV-2002) DOE Joint Genome Institute, 2800 Mitchell



Drive, Walnut Creek, CA 94598, USA  
6 (bases 1 to 34791)  
DOE Joint Genome Institute and Stanford Human Genome Center.  
Direct Submission  
Submitted (14-NOV-2002) DOE Joint Genome Institute, 2800 Mitchell  
Drive, Walnut Creek, CA 94598, USA  
On Nov 7, 2002 this sequence version replaced gi:1498644.  
NOTE: This insert is not the entire sequence of the clone (entire  
sequence is 40kb). It is clipped at the overlap with AC002511. The  
number of bases overlapped is 6888.  
Location/Qualifiers  
1. 34791  
/organism="Homo sapiens"  
/mol\_type="Genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="19"  
/map="19q13.1 between D19S208 and CANPS"  
/cell\_line="UV5HL9-5B"  
/cell\_type="fibroblast"  
/clone\_lib="cosmid fi6632; LL19NC02 F2 chromosome  
19-specific cosmid library"  
/note="constructed at LNL from flow-sorted chromosomes  
from hybrid UV5HL9-5B, which carries chromosome 19 as its  
only human chromosome"  
complement(128..279)  
/note="88% similarity"  
/rpt\_family="ALU"  
complement(2035..2277)  
/note="76% similarity"  
/rpt\_family="ALU"  
complement(2544..2843)  
/note="85% similarity"  
/rpt\_family="ALU"  
complement(2896..3191)  
/note="88% similarity"  
/rpt\_family="ALU"  
4547..4848  
/note="88% similarity"  
/rpt\_family="ALU"  
complement(5422..5707)  
/note="85% similarity"  
/rpt\_family="ALU"  
6073..6351  
/note="88% similarity"  
/rpt\_family="ALU"  
6537..21193  
/gene="CD22"  
join(<6537..6570,7043..7420,10532..10837,12251..12517,  
12664..12927,15377..15634,15839..16102,16198..16461,  
19325..19421,19547..19622,20098..20216,20647..20731,  
21062..>21193)  
/gene="CD22"  
/product="B-cell receptor CD22-B isoform"  
join(<6537..6570,7043..7420,10532..10837,15377..15634,  
15839..16102,16198..16461,19325..19421,19547..19622,  
20098..20216,20647..20731,21062..>21193)  
/gene="CD22"  
/product="B-cell receptor CD22-A isoform"  
join(<6537..6570,7043..7420,10532..10837,12251..12517,  
12664..12927,15377..15634,15839..16102,16198..16461,  
19325..19421,19547..19622,20098..20216,20647..20731,  
21062..21193)  
/gene="CD22"  
/note="alternatively spliced; B-lymphocyte cell adhesion  
molecule; BL-CAM; human differentiation antigen; B-cell  
receptor CD22 precursor (alpha and beta)"  
/codon\_start=1  
/product="B-cell receptor CD22-B isoform"  
/protein\_id="BAB06448.1"  
/db\_xref="GI:1498645"  
/translation="MHLLGVPWLLLVLELAFSDSSKQVFEHPETLYAMEGACVWIPPC  
TYRALDGLSEFILFHPNPNYKNTSKFDGRLYESTKDGKVPSEQRKQVPLGDKNKC  
TLISHPVLNDSQGLGRLMESKTEKWMERIHANVSERPPPHIQLPPEQSEVTLT  
CLLNPSCVGYPIQLWLLGVPWMAAATVSTLTIKSVFTRSELKSPQWSHHGKIVT  
COLODAGKFLSNDTVOLNVKHPKVTTVIONPMTREGDVTVTLSCNVSSNPTVR  
YENKPHGAWEEPISGLVKIQNVGHDNTTACACNSWCNSPVALNVQVAPRDVVR  
KIKPLSEIHSGNSVSLQDFSSHPKEVQFFWENKRLGKESQLMFDNISPSDASV  
SCWNNISIGTQASKAWTLEVIYAPRRLRVSMSPGDQVMEGKSATLTCESDANPVSH  
TFWNNNSQLPFSQKRLFPVKHSGAYWCQGTNSVKGSRPLSTLTYYSPETIG  
RRVAVGLGSCLAII LAICGLKQRRWKRTQSQGLQENSSGOSFFVRNKKVRAPL  
EGPHSLCNPMMEDGISTYTLRPEPNNIPRTGDAESSEMQRPDPDCCDVTYTSALHK  
RQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAEVNDYVILKH"  
6837..6961  
/note="83% similarity"  
/rpt\_family="ALU"  
complement(8077..8345)  
/note="81% similarity"  
/rpt\_family="ALU"  
9293..9591  
/note="90% similarity"  
/rpt\_family="ALU"  
9789..10357  
/note="89% similarity"  
/rpt\_family="ALU"  
11454..11750  
/note="89% similarity"  
/rpt\_family="ALU"  
join(12252..12472,12715..12736,12746..12807)  
/gene="CD22"  
/note="similar to the EST sequence deposited under GenBank  
Accession Number N79417"  
complement(13119..13424)  
/note="92% similarity"  
/rpt\_family="ALU"  
13457..13745  
/note="78% similarity"  
/rpt\_family="ALU"  
13787..14358  
/note="90% similarity"  
/rpt\_family="ALU"  
complement(14802..15075)  
/note="87% similarity"  
/rpt\_family="ALU"  
16280  
/gene="CD22"  
/note="amino acid 639 changes from 'Y' to 'H'"  
/citation=[1]  
/replace="t"  
16341  
/gene="CD22"  
conflict  
conflict





ORGANISM Mesocricetus auratus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;  
Mesocricetus.

REFERENCE 1  
AUTHORS Itoh, Y., Hosoya, M., Harada, M., Kawamata, Y., Tanaka, H.,  
Kobayashi, M., Fujii, R., Fukusumi, S., Tanaka, Y., Maruyama, M.,  
Uejima, H., Satoh, R., Kizawa, H., Okubo, S., Ogi, K., Komatsu, H.,  
Matsumura, F., Noguchi, Y., Fukatsu, K., Hinuma, S., Fujisawa, Y. and  
Fujino, M.

TITLE Expression of GPR40 in pancreatic cells  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 903)  
AUTHORS Shoji, F., Shioichi, O., Noguchi, Y., Itoh, Y., Kobayashi, M., Fujii, R.  
and Hinuma, S.

TITLE Direct Submission  
JOURNAL Submitted (08-NOV-2002) Shuji Hinuma, Discovery Research  
Laboratories 1, Takeda Chemical Industries, Ltd.; Wadai 10,  
Tsukuba, Ibaraki 300-4293, Japan (E-mail: Hinuma\_Shuji@takeda.co.jp,  
Tel: 81-298-64-5035, Fax: 81-298-64-5000)

FEATURES  
source Location/Qualifiers  
1..903  
/organism="Mesocricetus auratus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10036"  
/cell\_line="HIT-T15"  
/cell\_type="pancreatic beta cell"  
1..903  
/codon\_start=1  
/product="GPR40"  
/protein\_id="BAC82556.1"  
/db\_xref="GI:34392457"  
/translation="MALSQLPALYVSAPALGFPNLILAIRGAVARLRLTPNLVY  
TILHLCSDLLLAITLPRKAEALASGWFPLPLCFVFLVHFAPDLYAGGFLAALSA  
GRYLGAAPFGYQAVRRPYSWGVCAIWLVLGMLVLEAGPMGLNTSSILGI  
NTPVNGSPVCLAWDPNSRPARLSFILLFFVLVITAFYVGLRALAHGLSHKR  
KLRAAWAGGAFLLILCLGPNYASNVASFVNPDLGGSWRKLGLITGSVVNLPLVT  
GYLGASPGRGTVCTTRTQGTIQK"

CDS  
1..903  
/codon\_start=1  
/product="GPR40"  
/protein\_id="BAC82556.1"  
/db\_xref="GI:34392457"  
/translation="MALSQLPALYVSAPALGFPNLILAIRGAVARLRLTPNLVY  
TILHLCSDLLLAITLPRKAEALASGWFPLPLCFVFLVHFAPDLYAGGFLAALSA  
GRYLGAAPFGYQAVRRPYSWGVCAIWLVLGMLVLEAGPMGLNTSSILGI  
NTPVNGSPVCLAWDPNSRPARLSFILLFFVLVITAFYVGLRALAHGLSHKR  
KLRAAWAGGAFLLILCLGPNYASNVASFVNPDLGGSWRKLGLITGSVVNLPLVT  
GYLGASPGRGTVCTTRTQGTIQK"

ORIGIN  
Query Match 68.0%; Score 614; DB 10; Length 903;  
Best Local Similarity 80.0%; Pred. No. 3.9e-87;  
Matches 722; Conservative 0; Mismatches 180; Indels 0; Gaps 0;  
QY 1 ATGGACCTGCCCGCAGCTCTCTTCGGCCCTATGTGGCCGCTTTGGCTGGGCTTC 60  
DB 1 ATGGCCCTGTCTCCCAACTCTCTTCGGCCCTATGTGTCTGCTCGCTTCGGCTGGGCTTC 60  
QY 61 CGCTCAACGTCTCGGCCATCCGAGCGGACCGGCCACCGCGGCTCCGTCTCACCCCT 120  
DB 61 CGCTGAACTGTGGCCATCCGAGCGGCGGTGGCCGCTGCAAGGTGGGCTCACCCCT 120  
QY 121 AGCTCGTCTACGCGCTGAACTGGGCTGCTCCGACCTGCTGCTGCTGCTGCTGCTGCTG 180  
DB 121 AACCTGGTCTATACACTCCACCTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 180  
QY 181 CTGAAGCGGTGAGCGGTAGCTCCGGGCTGAGCTGCTGCGGCTGCTGCTGCTGCTGCTGCTG 240  
DB 181 GTGAAGCGGTGAGCGGCTGCTGCTGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240  
QY 241 GTCTTCGGGTGCGCCACTCTTCCCACTCTATGCGCGGGGGCTTCCTGCGCGCCCTG 300  
DB 241 GTCTTGTCTTGTGTGCACTTGGCCCACTATGCGCGGGGGAGGCTTCCTGCGGCTCTC 300  
QY 301 AGTGAAGCGGCTACCTGGAGCAGCTTCCTCCCTTGGGCTACCAAGCTTCGGAGCGG 360  
DB 301 AGTGAAGCGGCTACCTGGAGCAGCTTCCTCCCTTGGGCTACCAAGCTTCGGAGCGG 360  
QY 361 TGTATTCTTGGGGGTGTGGCGGCATCTGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 420  
DB 361 CGTACTCTCTGGGGGTGTGTGTGGGTATATGGGCTTGTGCTGCTGCTGCTGCTGCTGCTG 420  
QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACACAGCAACACCTCCCTGGGCGATC 480

Db 421 GTCTTCGGGTGGAGGCTCCCGAGGCTGGCTGGAACACCAACAGCAGCTCCCTGGGAATC 480  
QY 481 AACACACCGGTCAACCGGCTCTCCGCTCTCCGCTCTGGAGGCTGGGACCGGCTCTGCGCGC 540  
Db 481 AACACACCGGTGAATGGTTCCCGGCTGCTGGAGGCTGGGATCCCAACTCTGCGCGG 540  
QY 541 CCGGCGGCTTCAGGCT 600  
Db 541 CTGCGCGGCTCAGTTTCTCATCT 600  
QY 601 TGCTACGTGGGCTGCTCTCCGGCACTGGGCGCTCCGGCTCCGGCTGACGACACGAGGCGAGCTG 660  
Db 601 TGCTACGTGGGCTGCTCTGGGCTCTGGGCTCTGGGCTCTGGGCTCTGGGCTCTGGGCTCTG 660  
QY 661 CCGGCGGCTCTGGGCTGGGCGGCGGCT 720  
Db 661 AGGCGAGCTGGGCGGCGGAGGCGCTTCTTCTACACTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720  
QY 721 AACGCTCTCAACGCTGGCAGCTTCTGTACCCCACTCTAGGAGGCTCTCTGGGCGAGCTG 780  
Db 721 AATGCTCTCAATGTGGGAGTTTCTGAACCCGAGCTCTGGGAGGCTCTCTGGAGGAGCTG 780  
QY 781 GGGCTCATCACGGGCTCGCTGGAGTGTGGTGTCTTAATCCGCTGCTGACCGGTTACTTGGGA 840  
Db 781 GGGCTCATCACAGGCTCTCTGGAGTGTGGTGTCTCAACCGCTGCTCACCGGTTACTTGGGA 840  
QY 841 AGGGTCTCTGGCTGAAGACAGTGTGCGGCAAGACGCAAGGCGGCAAGTCCCGAAG 900  
Db 841 GCAAGTCTCTGGCGGAGGACAGTATGTACGACAGGACTCAAGGAGGACAAATTGAGAG 900  
QY 901 TA 902  
Db 901 TA 902

RESULT 9  
AX675045 903 bp DNA linear PAT 27-MAR-2003  
LOCUS Sequence 3 from Patent WO02057783.  
DEFINITION AX675045  
ACCESSION AX675045.1 GI:29333353  
VERSION  
KEYWORDS Mus musculus (house mouse)  
SOURCE  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1  
AUTHORS Andrews, J.L., Briscoe, C.P., Ignar, D.M., Muir, A.I., Sauls, H.R. and  
Tadayyon, M.  
TITLE Method of screening for gpr40 ligands  
JOURNAL Patent: WO 02057783-A 3 25-JUL-2002;  
Glaxo Group Limited (GB); Smithkline Beecham PLC (GB)  
FEATURES  
source Location/Qualifiers  
1..903  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
1..903  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD83805.1"  
/db\_xref="GI:29333354"  
/db\_xref="REMBTREMBL:CAD83805"  
/translation="MDLPPLQSLFADYSAFALGFPNLILAIRGAVSHAKLRLTPSLIVY  
TILHLCSDLLLAITLPRKAEALASGWFPLPLCFVFLAFAHFAFLYAGGFLAALSA  
GRYLGAAPFGYQAVRRPYSWGVCAIWLVLGMLGLETSGWLNSTSSILGI  
NTPVNGSPVCLAWDPDSARPARLSFILLFFVLVITAFYVGLRALVRGSLGSHKR  
KLRAAWAGGALLTLLCLGPNYASNVASFNPDLGGSWRKLGLITGWSVVNLPLVT  
GYLGASPGRGTVCTTRTQGTIQK"

CDS  
1..903  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAD83805.1"  
/db\_xref="GI:29333354"  
/db\_xref="REMBTREMBL:CAD83805"  
/translation="MDLPPLQSLFADYSAFALGFPNLILAIRGAVSHAKLRLTPSLIVY  
TILHLCSDLLLAITLPRKAEALASGWFPLPLCFVFLAFAHFAFLYAGGFLAALSA  
GRYLGAAPFGYQAVRRPYSWGVCAIWLVLGMLGLETSGWLNSTSSILGI  
NTPVNGSPVCLAWDPDSARPARLSFILLFFVLVITAFYVGLRALVRGSLGSHKR  
KLRAAWAGGALLTLLCLGPNYASNVASFNPDLGGSWRKLGLITGWSVVNLPLVT  
GYLGASPGRGTVCTTRTQGTIQK"

ORIGIN  
Query Match 66.9%; Score 604.4; DB 6; Length 903;

Best Local Similarity 79.4%; Pred. No. 1.3e-85; Mismatches 186; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCCGCTTGTGGCTTGGGCTTC 60  
DB 1 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCCGCTTGTGGCTTGGGCTTC 60

QY 61 CCCTCAACCTCTGCGCATCCAGAGCGGACCGGCGGCGGCTTGTGGCTTGGGCTTC 120  
DB 61 CCATTGAACCTTGTAGCATCCAGAGCGGAGCTTCCACGCTAAACCTGCGACTCACTCC 120

QY 121 AGCTGTCTACCGCCCTGACCTGGGCTCTCCGACTGCTGCTGCTGCTGCTGCTGCTG 180  
DB 121 AGCTGTCTACCGCCCTGACCTGGGCTCTCCGACTGCTGCTGCTGCTGCTGCTGCTG 180

QY 181 CTGAAGCGGTGAGGCGCTAGGCTCCGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240  
DB 181 CTGAAGCGGTGAGGCGCTAGGCTCCGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240

QY 241 GTCTTCGGGTGGCCCACTCTTCCCACTATGCGGCGGGGCTTCTGCGCGGCTG 300  
DB 241 GTCTTCGGGTGGCCCACTCTTCCCACTATGCGGCGGGGCTTCTGCGCGGCTG 300

QY 301 AGTCAGGCGGCTACCTGGGAGCAGGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360  
DB 301 AGTCAGGCGGCTACCTGGGAGCAGGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360

QY 361 TGTATTTCTGGGGGTGTGGGGGCTCTGCGGCTCTGCTGCTGCTGCTGCTGCTGCTG 420  
DB 361 TGTATTTCTGGGGGTGTGGGGGCTCTGCGGCTCTGCTGCTGCTGCTGCTGCTGCTG 420

QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGCTGAGGCTGCTGAGGCTGCTGAGGCTGCTG 480  
DB 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGCTGAGGCTGCTGAGGCTGCTGAGGCTGCTG 480

QY 481 AACACACCGGTCAACGGCTCTCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 540  
DB 481 AACACACCGGTCAACGGCTCTCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 540

QY 541 CCGGCGCGCTTACGCT 600  
DB 541 CCGGCGCGCTTACGCT 600

QY 601 TGTACGTGGGCTGCTCCGGGCTGCTGCGGCTGCTGCGGCTGCTGCGGCTGCTGCGGCT 660  
DB 601 TGTACGTGGGCTGCTCCGGGCTGCTGCGGCTGCTGCGGCTGCTGCGGCTGCTGCGGCT 660

QY 661 CCGGCGCGCTTGGTGGCGGCGGCGGCTCTCTCACTGCTGCTGCTGCTGCTGCTGCTG 720  
DB 661 CCGGCGCGCTTGGTGGCGGCGGCGGCTCTCTCACTGCTGCTGCTGCTGCTGCTGCTG 720

QY 721 AACGCTCTCAACGCTGGCCAGCTTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 780  
DB 721 AACGCTCTCAACGCTGGCCAGCTTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 780

QY 781 GGGCTCATACGGGCTGCTGAGTGTGGTGTGCTTAAATCCGCTGCTGCTGCTGCTGCTG 840  
DB 781 GGGCTCATACGGGCTGCTGAGTGTGGTGTGCTTAAATCCGCTGCTGCTGCTGCTGCTG 840

QY 841 AGGGTCTTGGCTGAAGACAGTGTGTGGGCAAGAACGCAAGGGGCAAGTCCCAAGAG 900  
DB 841 AGGGTCTTGGCTGAAGACAGTGTGTGGGCAAGAACGCAAGGGGCAAGTCCCAAGAG 900

QY 901 TA 902  
DB 901 TA 902

RESULT 10  
AB095745  
LOCUS  
DEFINITION  
ACCESSION

AB095745  
Mus musculus mRNA for GPR40, complete cds.  
AB095745

ROD 02-SRP-2003

AB095745.1 GI:34392454  
Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 Itoh, Y., Hosoya, M., Harada, M., Kawamata, Y., Tanaka, H., Kobayashi, M., Fujii, R., Fukusumi, S., Tanaka, Y., Maruyama, M., Uejima, H., Satoh, R., Kizawa, H., Okubo, S., Ogi, K., Komatsu, H., Matsumura, F., Noguchi, Y., Fukateu, K., Hinuma, S., Fujisawa, Y. and Fujino, M.  
Expression of GPR40 in pancreatic cells  
Unpublished  
2 (bases 1 to 903)  
Shoji, F., Shiochi, O., Noguchi, Y., Itoh, Y., Kobayashi, M., Fujii, R. and Hinuma, S.  
Direct Submission  
Submitted (08-NOV-2002) Shuji Hinuma, Discovery Research Laboratories 1, Takeda Chemical Industries, Ltd.; Wadai 10, Tsukuba, Ibaraki 300-4293, Japan (E-mail: Hinuma\_Shuji@takeda.co.jp, Tel: 81-298-64-5035, Fax: 81-298-64-5000)  
Location/Qualifiers  
1..903  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10090"  
1..903  
/codon\_start=1  
/product="GPR40"  
/protein\_id="BAC82555.1"  
/db\_xref="GI:34392455"  
translation="MDLPQLSFALVSPALGFPPLNLLAIRGAVSHAKLRLTPSLVY  
TILHGCCDILLATLPLKAVEALASGAWPLPFCFVFAHPAPLYAGGPTAALSA  
GRYLGAAPFGYQAIRPRYRYSWGVCAIWAIVLCHLGLALGLETSGLDNTSSIGI  
NIPVNGSPVLEANDPDSARPALRSFILLPLVITAFYVGCURLARVSLGSHKR  
KLRAAWAGGALLTLCLGYPYNSVNSVAFINPDLGGSWRKLGLITGAWSVWLPLVT  
GYLGTGPRGTTCVTRTORGTQK"  
ORIGIN  
Query Match 66.9%; Score 604.4; DB 10; Length 903;  
Best Local Similarity 79.4%; Pred. No. 1.3e-85;  
Matches 716; Conservative 0; Mismatches 186; Indels 0; Gaps 0;  
QY 1 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCCGCTTGTGGCTTGGGCTTC 60  
DB 1 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCCGCTTGTGGCTTGGGCTTC 60  
QY 61 CCGCTCAACGCTCTGCGCATCCAGAGCGGAGCGGCGGCTGCTGCTGCTGCTGCTGCTG 120  
DB 61 CCATTGAACCTTGTAGCATCCAGAGCGGAGCTTCCACGCTAAACCTGCGACTCACTCC 120  
QY 121 AGCTGTCTACCGCCCTGAACTGGGCTGCTGCGGCTGCTGCGGCTGCTGCTGCTGCTG 180  
DB 121 AGCTGTCTACCGCCCTGAACTGGGCTGCTGCGGCTGCTGCGGCTGCTGCTGCTGCTG 180  
QY 181 CTGAAGCGGTGAGGCGCTAGGCTCCGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240  
DB 181 CTGAAGCGGTGAGGCGCTAGGCTCCGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 240  
QY 241 GTCTTCGGGCTGGCCCACTTCTTCCCACTATGCGGCGGGGCTTCTGCGCGGCTG 300  
DB 241 GTCTTCGGGCTGGCCCACTTCTTCCCACTATGCGGCGGGGCTTCTGCGCGGCTG 300  
QY 301 AGTCAGGCGGCTACCTGGGAGCAGGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360  
DB 301 AGTCAGGCGGCTACCTGGGAGCAGGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360  
QY 361 TGTATTTCTGGGGGTGTGGGGGCTCTGCGGCTCTGCTGCTGCTGCTGCTGCTGCTG 420  
DB 361 TGTATTTCTGGGGGTGTGGGGGCTCTGCGGCTCTGCTGCTGCTGCTGCTGCTGCTG 420  
QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGCTGAGGCTGCTGAGGCTGCTGAGGCTGCTG 480









\* 124067 132993: contig of 8927 bp in length  
\* 132994 133093: gap of unknown length  
\* 133094 142772: contig of 9679 bp in length  
\* 142773 142872: gap of unknown length  
\* 142873 154673: contig of 11801 bp in length.

## FEATURES

source  
1. .154673  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
/clone="RP23-123D23"  
/clone\_lib="RPMI mouse BAC library 23"

## ORIGIN

Query Match 66.2%; Score 598; DB 2; Length 154673;  
Best Local Similarity 79.3%; Pred. No. 4.4e-85;  
Matches 709; Conservative 0; Mismatches 185; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCGCGAGCTCTCTTTCGGCTCTATGTGGCGCCCTTTGGCTGGGCTTC 60  
DB 114152 ATGGACCTGCCCGCGAGCTCTCTTTCGGCTCTATGTATCTGCTTTGGCTGGGCTTT 114211

QY 61 CGCTCAAGCTCTGGCCATCCGAGCGGAGCGGCCAGCCCGGCTCGTCTCACCCCT 120  
DB 114212 CCATTGAACCTGTAGCCATCCGAGCGCAGTGTCCAGCTAAACTGGACTCACTCC 114271

QY 121 AGCTGTCTACGCTCGAACCTGGGCTGCTCCGACCTGCTGTGCTGACAGTCTCTCGGCC 180  
DB 114272 AGCTGTCTACACTCTCCATCTGGGCTGCTGTGATCTCTACTGCGCATCACTCGCC 114331

QY 181 CTGAAGCGGTGGAGCGCTAGCCTCCGGGCTGCGCTTCGCCGCTTCGCTGTCGCC 240  
DB 114332 CTGAAGCGGTGGAGCGCTGCTTCGAGCGCTGCGGCCCTGCGCTCTCTCGCCA 114391

QY 241 GTCTTCGGGTGGCCCACTCTTCCCACTATGCGGGGGGGCTTCCTGGCGCCCTG 300  
DB 114392 GTCTTCGGCTGGCCCACTTGTCTCCCTCTACGAGCGGAGGCTTCTAGCTGCTCTC 114451

QY 301 AGTGAGCGCGCTTACCTGGGAGCAGCTTCCCTTGGGCTTACCAAGCTTCCGAGGCG 360  
DB 114452 AGCGTGGCGCGTACTCTGGGGGTGCTTCCCTTCGGGTACGAGCATCCGAGGCC 114511

QY 361 TGCTATTCTGGGGGTGTGCGCGGCATCTGCGGCCCTCTGCTGTGTCACTGGGTCTG 420  
DB 114512 CGCTATTCTGGGTGTGTGGCTATATGGGCCCTTGTCTCTGCTGCGACCTGGGGCTG 114571

QY 421 GTCTTTGGGTGGAGGCTCAGAGGCTGGTGACACAGCAACACTCTCCCTGGGCATC 480  
DB 114572 GCCCTTGGCTTGAGACTTCCGGAAGCTGGCTGGCAACAGTACCAAGTTCCCTGGGCATC 114631

QY 481 AACACACCGGTCAACCGCTCTCCGGTCTGCTGGAGGCTGGAGCCCGCTCTGCCGCG 540  
DB 114632 AACATACCGGTGATGGCTTCCCGGTCTGCTGGAGGCTTGGATCCGACTTGCCTCG 114691

QY 541 CGGCGCGCTTCAGCCTCTCTCTCTGCTCTTTTTCGCCCTTGGCCATCAAGCTTC 600  
DB 114692 CTTGCCGCTCTCAGTTTCTCTCATCTGCTCTTCTTCTGCGCTTGTCTCATCTGCTTC 114751

QY 601 TGTACTGTGGGTGCTCTCGGGACATGCGCCGCTCCGGCTGACGACAGGCGGAGCTG 660  
DB 114752 TGTATGTGGGTGCTCTCGGGGCTTGGTGGCTGAGGCTGAGGCTGAGGCTGAGGCTG 114811

QY 661 CGGGCGCTGGGTGGCGCGGGGCTTCTCAGCGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
DB 114812 AGGGGAGCTTGGGTGGCGGAGGCGCTCTCTCAGACTCTGCTCTGCTCTGCTGCTGCT 114871

QY 721 AAGCGCTCAACGCTGGCAGCTCTCTGTATACCCCAATCTAGGAGGCTCTCGGCGAGCTG 780  
DB 114872 AATGCTCTCAATGTGGCTAGTTTCAATAACCGGACCTAGGAGGCTCTCGGAGGATTA 114931

QY 781 GGGCTCATACGGGTGCTGAGTGTGGTGTCTTAATCCGCTGGTGTGACCGGTACTTGGGA 840  
DB 114932 GGAATCATACAGGGGCTGGAGTGTGGTGTCTCAACCCACTGGTCACTGGCTACTTGGGA 114991

QY 841 AGGGGTCTCTGGCTGAAGACAGTGTGTGGCGCAAGAACCAAGGGGCAAGTCC 894  
DB 114992 ACAGGTCTCTGGCGGGGACAAATATGTGTGACGAGGACTCAAGAGGGAACATTC 115045

RESULT 14  
AB095744  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source  
CDS  
ORIGIN

AB095744  
Rattus norvegicus mRNA for GPR40, complete cds.  
AB095744  
AB095744.1 GI:34392452  
Rattus norvegicus (Norway rat)  
Rattus norvegicus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
1 Itoh, Y., Hosoya, M., Harada, M., Kawamata, Y., Tanaka, H.,  
Kobayashi, M., Fujii, R., Fukusumi, S., Tanaka, Y., Maruyama, M.,  
Uejima, H., Satoh, R., Kizawa, H., Okubo, S., Ogi, K., Komatsu, H.,  
Matsumura, F., Noguchi, Y., Fukatsu, K., Hinuma, S., Fujisawa, Y. and  
Fujino, M.  
Expression of GPR40 in pancreatic cells  
Unpublished  
2 (bases 1 to 903)  
Shoji, F., Shiochi, O., Noguchi, Y., Itoh, Y., Kobayashi, M., Fujii, R.  
and Hinuma, S.  
Direct Submission  
Submitted (08-NOV-2002) Shuji Hinuma, Discovery Research  
Laboratories 1, Takeda Chemical Industries, Ltd.; Wadai 10,  
Tsukuba, Ibaraki 300-4293, Japan [E-mail: Hinuma\_Shuji@takeda.co.jp,  
Tel: 81-298-64-5035, Fax: 81-298-64-5000]  
Location/Qualifiers  
1..903  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10116"  
1..903  
/codon\_start=1  
/product="GPR40"  
/protein\_id="BAC82554.1"  
/db\_xref="GI:34392453"  
/translation="MDLPOLSFALVSAFALGFPPLNLAIIRGAVSHAKLRLTPSLVY  
TLHLASDLILAITLPLKAVEALASGWPPLPRCPVFALAHFAPLYAGSGFLAALSA  
GRYLGAAFPFGQAIRPCYSWGVATWLVLHGLGALGLEAPRWVDNTSSIGI  
NIPVNGSPVLEAWDPDSARPALSIFSLFFLPLVITAFYVGVGLURALVHSLGSHR  
KLRAAWAGGALLTLCLGYPYASNVASFNPDLGSRWKLGLITGAWSVVNLPLVT  
GYLGTGPGGTTICVTRTPRGTIQK"

Query Match 65.3%; Score 590; DB 10; Length 903;  
Best Local Similarity 78.4%; Pred. No. 2.3e-83;  
Matches 707; Conservative 0; Mismatches 195; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCGCGAGCTCTCTTTCGGCTCTATGTGGCGCCCTTTGGCTGGGCTTC 60  
DB 1 ATGGACCTGCCCGCGAGCTCTCTTTCGGCTCTATGTATCTAGCTTTGCACTAGGCTTT 60

QY 61 CGCTCAACGCTCTGGCCATCCGAGCGGAGCGGCCAGCCCGGCTCGGTCTCACCCCT 120  
DB 61 CCATTGAACCTGTAGCCATCCGAGGTGCAAGTGTCCACGCGAACTGGGACTCACCCC 120

QY 121 AGCTGTCTAGCCCTGAACTGGGCTGCTCGGACTCTGCTGCTGCTGCTGCTGCTGCTG 180  
DB 121 AGCTGTGTCTACACTCTCCATTGGGCTGCTCTGACTCTCTACTGCGCATCACCTGCCC 180

QY 181 CTGAAGCGGTGGAGCGCTAGCCTCCGGGCTGCTGCGGCTCTGCGGCTCTGCTGCTGCTG 240  
DB 181 CTGAAGCGGTGGAGCGCTGCGCTTCTGGGGGTCTGGCCCCCTGCGCACTCCCTTCTGCCCA 240

QY 241 GTCTTCGGGTGGCGCCACTTCTTCCCACTATGCGCGGGGGCTTCTCTGCGCCCTG 300



Qy	601	TGCTAGTGGGCTGCCTCCGGGCACTGGGCCGCTCGGGCTGACGCACAGGGGGAAGCTG	660
Db	605	TGCTATGTGGGCTGCCTCCGGGCCCTGGTGCACTCGGGGCTGAGCCACAACCGGAAGCTC	664
Qy	661	CGGGCCGCTGGGTGGCGCGGGGCCCTCCTCACGCTGCTGCTGCGTAGGACCCCTAC	720
Db	665	AGGGCAGCTTGGGTGGCTGGAGGACATTCTCACACTCTGCTCTGCTTGGGGCCCTAT	724
Qy	721	AACGCTTCCAACTGGCCAGCTTCTGTATACCCCAATCTAGGAGGCTTCTTGGCGGAAGCTG	780
Db	725	AATGCTTCCAAATGTGGCTAGTTTTCATAAACCCGGGACTTAGAAGGCTCCTGGAGGAAGTTG	784
Qy	781	GGGCTCATCACGGGTGCTGGAGTGTGGTCTTAATCCGCTGCTGACCCGTTACTTGGGA	840
Db	785	GGGCTCATCACAGGAGCTGGAGTGTGGTCTCAACCCACTGGTCACTGGCTACTTGGGA	844
Qy	841	AGGGTCTCTGGCTGAAGACAGTGTGTGGGCAAGAACGCAAGGGGGCAAGTCCCAGAGAG	900
Db	845	ACAGTCTCTGGACAGGGGACAATATGTGTGACCAGGACTCCAGAGGGACAATTTCAGAG	904
Qy	901	TA 902	
Db	905	TA 906	

Search completed: April 30, 2004, 17:38:31  
Job time : 3931 secs

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 30, 2004, 07:46:59 ; Search time 452 Seconds  
(without alignments)  
8486.997 Million cell updates/sec

Title: US-10-202-687-1

Perfect score: 903

Sequence: 1 attgacctgccccgcagct.....ggggcagatccccaagtaa 903

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 337863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : N Geneseq\_29Jan04:\*

1: Geneseqn1980s:\*

2: Geneseqn1990s:\*

3: Geneseqn2000s:\*

4: Geneseqn2001as:\*

5: Geneseqn2001bs:\*

6: Geneseqn2002s:\*

7: Geneseqn2003as:\*

8: Geneseqn2003bs:\*

9: Geneseqn2003cs:\*

10: Geneseqn2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	903	100.0	903	3 AAA30759	Aaa30759 Human G p
2	903	100.0	903	6 ABK90236	Abk90236 Human CDN
3	903	100.0	903	7 ABZ42843	Abz42843 Human G p
4	903	100.0	903	9 ADC22768	Adc22768 Human G p
5	900	99.7	900	9 ADB61405	Adb61405 DNA encod
6	898.2	99.5	903	3 AAA30776	Aaa30776 DNA encod
7	898.2	99.5	903	9 ADC22790	Adc22790 Human G p
8	840.8	93.1	900	9 ADB61417	Adb61417 DNA encod
9	612	67.8	900	9 ADB61429	Adb61429 DNA encod
10	604.4	66.9	903	6 ABK90237	Abk90237 Mouse CDN
11	602.4	66.7	900	9 ADB61401	Adb61401 DNA encod
12	588	65.1	900	9 ADB61403	Adb61403 DNA encod
13	123.4	13.7	1841	2 AAV53631	Aav53631 Human 7-t
14	121.8	13.5	1041	3 AAA30762	Aaa30762 Human G p
15	121.8	13.5	1041	4 AAH26460	Aah26460 Human G-p
16	121.8	13.5	1041	4 AAH26459	Aah26459 Human G-p
17	121.8	13.5	1041	7 ABZ42561	Abz42561 Human G p
18	121.8	13.5	1041	9 ADC22772	Adc22772 Human G p
19	118.6	13.1	1041	3 AAA30777	Aaa30777 DNA encod
20	118.6	13.1	1041	9 ADC22792	Adc22792 Human G p
21	84.6	9.4	1534	2 AAx50981	Aax50981 Human pro
22	84.6	9.4	1534	3 AAA35309	Aaa35309 Human ade
23	84.6	9.4	1534	3 AAF21431	Aaf21431 Human low

#### ALIGNMENTS

##### RESULT 1

AAA30759

ID AAA30759 standard; cDNA; 903 BP.

XX AC AAA30759;

XX AC AAA30759;

DT 21-AUG-2000 (first entry)

XX Human G protein-coupled receptor GPR40 cDNA.

XX G protein-coupled receptor; GPCR; constitutively active;

KW intracellular loop 3; transmembrane domain 6; drug screening; agonist;

KW antagonist; ss.

XX Homo sapiens.

XX WO200022129-A1.

XX 20-APR-2000.

XX 12-OCT-1999; 99WO-US023938.

XX 13-OCT-1998; 98US-00170496.

XX (AREN-) ARENA PHARM INC.

XX Behan DP, Chalmers DT, Liaw CW;

XX WPI; 2000-329165/28.

XX P-PSDB; AAY90679.

XX Non-endogenous constitutively activated human G protein-coupled

XX receptors, useful for identifying agonists for use as pharmaceutical

XX agents.

XX Example 1; Page 307; 341pp; English.

XX The invention relates to constitutively active, non-endogenous versions of endogenous human orphan G protein-coupled receptors (GPCRs, AAY90643-AAY90677 and AAY90683-Y90687), and to DNA encoding them (AAA30709-A30743 and AAA30775-A30779). The mutant proteins of the invention contain a mutation in a portion of the protein comprising intracellular loop 3 (IC3) and transmembrane domain 6 (TM6). A non-endogenous amino acid, X, is substituted for an endogenous residue in IC3 at a position 16 amino acids N-terminal of an endogenous proline in TM6 to form a sequence X-(AA)15-Pro. The endogenous amino acid is selected from Lys, His, Arg or

CC Ala, and is preferably Lys. When the endogenous residue at this position  
CC is Lys, this residue is replaced by His, Arg or preferably Ala. The 15  
CC amino acid stretch between the substituted amino acid and the Pro may be  
CC endogenous, non-endogenous, or a mixture of endogenous and non-endogenous  
CC residues. The constitutively active GPCRs are useful for identifying  
CC antagonists, agonists and partial agonists for use as pharmaceutical  
CC agents. The mutant proteins are also useful in research settings for  
CC elucidating the roles of the receptors in normal and diseased conditions.  
CC Antagonists for a particular GPCR are useful for treating diseases and  
CC disorders associated with that receptor. Because the novel mutant GPCRs  
CC are constitutively active, they can be used directly for screening of  
CC compounds without the need for endogenous ligands. The present sequence  
CC represents cDNA encoding a human wild-type GPCR used in an  
CC exemplification of the invention. This was cloned and subjected to site-  
CC directed mutagenesis (SDM) to generate DNA encoding the corresponding  
CC mutant of the invention  
XX

Sequence 903 BP; 108 A; 327 C; 283 G; 185 T; 0 U; 0 Other;

Query Match 100.0%; Score 903; DB 3; Length 903;  
Best Local Similarity 100.0%; Pred. No. 2e-167;  
Matches 903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCGCAGCTCTCTTCGGCCTCTATGTGGCGCCTTTTGGCTGGGCTTC 60  
DB |||||  
QY 1 ATGGACCTGCCCGCAGCTCTCTTCGGCCTCTATGTGGCGCCTTTTGGCTGGGCTTC 60  
DB |||||  
QY 61 CGGCTCAACGTCCTTGCCATCCGAGCGCGACGCGCCACGCGCGGCTCCGTCTACCCCT 120  
DB |||||  
QY 61 CGGCTCAACGTCCTTGCCATCCGAGCGCGACGCGCCACGCGCGGCTCCGTCTACCCCT 120  
DB |||||  
QY 121 AGCCTGGTCTACGCTGACCTGACCTGGGCTCTCGACCTCTGCTGACGTCCTCTGCCC 180  
DB |||||  
QY 121 AGCCTGGTCTACGCTGACCTGACCTGGGCTCTCGACCTCTGCTGACGTCCTCTGCCC 180  
DB |||||  
QY 181 CTGAAGCGGTGAGCGCTAGCCTCCGGGCGCTGCGCCTCTGCGGCTCTGCTGCCCC 240  
DB |||||  
QY 181 CTGAAGCGGTGAGCGCTAGCCTCCGGGCGCTGCGCCTCTGCGGCTCTGCTGCCCC 240  
DB |||||  
QY 241 GTCTTCGCGGTGGCCCACTTCTCCACTCTATGCGCGGGGGCTTCTGCGCGCCCTG 300  
DB |||||  
QY 241 GTCTTCGCGGTGGCCCACTTCTCCACTCTATGCGCGGGGGCTTCTGCGCGCCCTG 300  
DB |||||  
QY 301 AGTGACGCGCTTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCGG 360  
DB |||||  
QY 301 AGTGACGCGCTTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCGG 360  
DB |||||  
QY 361 TGCTATTCTTGGGGGTGTGCGCGGCATCTGGGCGCTCTGCTGTGTCACTTGGGTCTG 420  
DB |||||  
QY 361 TGCTATTCTTGGGGGTGTGCGCGGCATCTGGGCGCTCTGCTGTGTCACTTGGGTCTG 420  
DB |||||  
QY 421 GTCTTTGGGTGGAGGCTCAGAGGCTGCGTGACACAGCAACACTCCCTGGGCAATC 480  
DB |||||  
QY 421 GTCTTTGGGTGGAGGCTCAGAGGCTGCGTGACACAGCAACACTCCCTGGGCAATC 480  
DB |||||  
QY 481 AACACACCGGTCAACGGCTCTCCGCTGCGGCTTGGGACCGGCGCTCTGCGCGC 540  
DB |||||  
QY 481 AACACACCGGTCAACGGCTCTCCGCTGCGGCTTGGGACCGGCGCTCTGCGCGC 540  
DB |||||  
QY 541 CCGGCGCGCTTACGCT 600  
DB |||||  
QY 541 CCGGCGCGCTTACGCT 600  
DB |||||  
QY 601 TGCTAGTGGGTGCTCTGCGGCACTTGGCGGCTGCGGCTGACGACAGGCGGAAAGCTG 660  
DB |||||  
QY 601 TGCTAGTGGGTGCTCTGCGGCACTTGGCGGCTGCGGCTGACGACAGGCGGAAAGCTG 660  
DB |||||  
QY 661 CCGGCGCGCTTGGGTGCGGCGGCGGCGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
DB |||||  
QY 661 CCGGCGCGCTTGGGTGCGGCGGCGGCGGCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
DB |||||  
QY 721 AACGCTCTCAACGCTGCGCAGCTCTCTGTGTATCCCCCAATCTAGGAGGCTCTCTGGCGGAAAGCTG 780  
DB |||||

DB 721 AACGCTCTCAACGCTGCGCAGCTCTCTGTATACCCCAATCTAGGAGGCTCTCTGGCGGAAAGCTG 780  
QY 781 GGGCTCATCACGGGTGCTGGAGTGTGCTTAATCCGCTGCTGACCGGTTACTTTGGGA 840  
DB |||||  
QY 781 GGGCTCATCACGGGTGCTGGAGTGTGCTTAATCCGCTGCTGACCGGTTACTTTGGGA 840  
DB |||||  
QY 841 AGGGGTCTCTGGCTGAAGACAGTGTGTCGGCAAGAAAGCAAGGGGGCAAGTCCCAAGAG 900  
DB |||||  
QY 841 AGGGGTCTCTGGCTGAAGACAGTGTGTCGGCAAGAAAGCAAGGGGGCAAGTCCCAAGAG 900  
DB |||||  
QY 901 TAA 903  
DB |||||  
QY 901 TAA 903  
DB |||||  
RESULT 2  
ID ABK90236 standard; cDNA; 903 BP.  
XX  
AC ABK90236;  
XX  
DT 21-OCT-2002 (first entry)  
XX  
DE Human cDNA encoding G protein-coupled receptor GPR40.  
XX  
KW Human; ss; gene: GPR40; G protein-coupled receptor; type 2 diabetes;  
KW obesity; antidiabetic; neuroprotective; anorectic; cerobroprotective; Gq;  
KW G protein; reporter gene; glucose intolerance; insulin intolerance;  
KW neurodegenerative disease; Alzheimer's disease; stroke.  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 1..903  
FT /\*tag= a  
FT /product= "GPR40"  
PN WO200257783-A2.  
PD 25-JUL-2002.  
PF 18-DEC-2001; 2001WO-US048985.  
PR 22-DEC-2000; 2000GB-00031527.  
XX (GLAX ) GLAXO GROUP LTD.  
PA (SMIX ) SMITHKLINE BEECHAM PLC.  
XX  
XX Andrews JL, Briscoe CP, Ignar DM, Muir AI, Sauls HR, Tadayyon M;  
WPI; 2002-599726/64.  
DR P-PSDB; ABG31106.  
XX  
XX Identifying GPR40 receptor ligand for treating disorders e.g. obesity,  
XX comprises detecting whether the test compound competitively inhibits the  
XX binding of a fatty acid GPR40 ligand to a GPR40 receptor.  
PS Disclosure; Page 44-48; 53pp; English.  
XX  
XX The invention relates to screening a test compound to determine whether  
XX the compound is a GPR40 receptor (G protein-coupled receptor) ligand  
XX comprises detecting whether the test compound competitively inhibits the  
XX binding of a fatty acid GPR40 ligand to a GPR40 receptor. Also included  
XX are (1) a method of screening a compound for GPR40 antagonist activity,  
XX comprising: (a) measuring any detectable signal produced by a reporter  
XX gene (comprising a reporter gene under the control of G protein Gq  
XX responsive transcriptional element); (b) detecting a decrease in reporter  
XX gene expression in the presence of both test compound and agonist; or (c)  
XX detecting whether the compound decreases glucose-stimulated insulin  
XX release from mammalian pancreatic beta cells in the presence of a GPR40  
XX agonist, compared to glucose-stimulated insulin release that would occur  
XX due to the presence of the GPR40 agonist; (2) a method of screening a  
XX compound for GPR40 agonist activity, which comprises: (a) detecting any

CC reporter gene expression; or (b) detecting whether the compound binds to  
CC GPR40 and increases glucose-stimulated insulin release from mammalian  
CC pancreatic beta cells. The method is useful for identifying GPR40  
CC antagonist or agonist compounds for treating disorders e.g. type 2  
CC diabetes, obesity, glucose or insulin intolerance, neurodegenerative  
CC disease (e.g. Alzheimer's disease) or stroke. The present sequence is the  
CC human cDNA for GPR40  
XX

SQ Sequence 903 BP; 108 A; 327 C; 283 G; 185 T; 0 U; 0 Other;  
Query Match 100.0%; Score 903; DB 6; Length 903;  
Best Local Similarity 100.0%; Pred. No. 28-167;  
Matches 903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCCGAGCTCTCTTGGGCTCTATGTGGCCGCTTTGGCTGGGCTTC 60  
DB |||||  
1 ATGGACCTGCCCCGAGCTCTCTTGGGCTCTATGTGGCCGCTTTGGCTGGGCTTC 60  
QY 61 CGCTCAACGTCCTGGCCATTCGAGGCGGACGGCCGAGCCGCTTCGCTTCACCCCT 120  
DB |||||  
61 CGCTCAACGTCCTGGCCATTCGAGGCGGACGGCCGAGCCGCTTCGCTTCACCCCT 120  
QY 121 AGCTGGTCTACGCTGACCTGACCTGGGCTGCTCGACCTGCTGACAGTCTCTGCCC 180  
DB |||||  
121 AGCTGGTCTACGCTGACCTGACCTGGGCTGCTCGACCTGCTGACAGTCTCTGCCC 180  
QY 181 CTGAAGCGGTGAGCGCTAGGCTCCGGGCTGCGCTCTGCGGCTGCTGTCGCCCC 240  
DB |||||  
181 CTGAAGCGGTGAGCGCTAGGCTCCGGGCTGCGCTCTGCGGCTGCTGTCGCCCC 240  
QY 241 GTCTTCGCGGTGCCCCACTTCTTCCACTTATGCGCGGGGGCTTCTTGGCGGCCCTG 300  
DB |||||  
241 GTCTTCGCGGTGCCCCACTTCTTCCACTTATGCGCGGGGGCTTCTTGGCGGCCCTG 300  
QY 301 AGTGAGGCGCTTACTGGGAGGAGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360  
DB |||||  
301 AGTGAGGCGCTTACTGGGAGGAGCTTCCCTTGGGCTACCAAGCTTCGGAGGCG 360  
QY 361 TGTATTTCTGGGGGTGTGCGGGCCATCTGCGGCTCTGCTGTGTCACTGGGTCTG 420  
DB |||||  
361 TGTATTTCTGGGGGTGTGCGGGCCATCTGCGGCTCTGCTGTGTCACTGGGTCTG 420  
QY 421 GTCTTTGGGTGAGGCTCAGAGGCTGCTGGACCAAGCAACCTTCTTGGGCACTC 480  
DB |||||  
421 GTCTTTGGGTGAGGCTCAGAGGCTGCTGGACCAAGCAACCTTCTTGGGCACTC 480  
QY 481 AACACACCGGTCAACGGCTCTCGGTCTGCGGCTTGGGCTTACCAAGCTTCGGAGGCG 540  
DB |||||  
481 AACACACCGGTCAACGGCTCTCGGTCTGCGGCTTGGGCTTACCAAGCTTCGGAGGCG 540  
QY 541 CCGGCGGCTTCAAGCTCTCTCTCTGCTCTTTTCTGCGCTTGGCCATCACAGCTTC 600  
DB |||||  
541 CCGGCGGCTTCAAGCTCTCTCTCTGCTCTTTTCTGCGCTTGGCCATCACAGCTTC 600  
QY 601 TGTACGTGGGCTGCTCCGGGCACTTGGCCGCTTCCGGCTGACGACAGGCGGAGCTG 660  
DB |||||  
601 TGTACGTGGGCTGCTCCGGGCACTTGGCCGCTTCCGGCTGACGACAGGCGGAGCTG 660  
QY 661 CCGGCGGCTTGGGTGCGGCGGCGGCTTCTCACGCTGCTGTGCTAGGACCTTAC 720  
DB |||||  
661 CCGGCGGCTTGGGTGCGGCGGCGGCTTCTCACGCTGCTGTGCTAGGACCTTAC 720  
QY 721 AAGGCTCTCAACGTGGCCAGCTTCTCTGTTACCCCAATCTAGGAGCTCTTGGGAGCTG 780  
DB |||||  
721 AAGGCTCTCAACGTGGCCAGCTTCTCTGTTACCCCAATCTAGGAGCTCTTGGGAGCTG 780  
QY 781 GGGCTCATCAGGCTGCTGGAGTGTGGTCTTAATCCGCTGGTACCGGTTACTTGGGA 840  
DB |||||  
781 GGGCTCATCAGGCTGCTGGAGTGTGGTCTTAATCCGCTGGTACCGGTTACTTGGGA 840  
QY 841 AGGGGTCTGGCTGAAGACAGTGTGTGGGCAAGAACGAGGGGGCAAGTCCCAAGAG 900  
DB |||||  
841 AGGGGTCTGGCTGAAGACAGTGTGTGGGCAAGAACGAGGGGGCAAGTCCCAAGAG 900

QY 901 TAA 903  
DB |||||  
901 TAA 903

RESULT 3  
ABZ42843  
ID ABZ42843 standard; DNA; 903 BP.  
XX AC ABZ42843;  
XX DT 04-MAR-2003 (first entry)  
XX Human G protein-coupled receptor GPR40 nucleotide SEQ ID NO:474.

DE G protein-coupled receptor; GPCR; antigenic peptide; gene therapy;  
KW G protein-coupled receptor modulator; antibody; immune-related disease;  
KW growth-related disease; cell regeneration-related disease; AIDS; cancer;  
KW immunological-related cell proliferative disease; autoimmune disease;  
KW Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy;  
KW osteoporosis; cardiomyopathy; inflammation; Crohn's disease; diabetes;  
KW graft versus host disease; Parkinson's disease; multiple sclerosis; pain;  
KW psoriasis; anxiety; depression; schizophrenia; dementia; memory loss;  
KW mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea;  
KW hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma;  
KW ulcer; gene; ds.  
XX Homo sapiens.  
OS WO200261087-A2.  
PN 08-AUG-2002.  
PD 19-DEC-2001; 2001WO-US050107.  
PF 19-DEC-2000; 2000US-0257144P.  
PR (LIFE-) LIFESPAN BIOSCIENCES INC.  
XX Burmer GC, Roush CL, Brown JP;  
PI WPI; 2003-046718/04.  
DR P-PSDB; ABP81994.

PT New isolated antigenic peptides e.g., for G protein-coupled receptors  
PT (GPCR), useful for diagnosing and designing drugs for treating conditions  
PT in which GPCRs are involved, e.g. AIDS, Alzheimer's disease, cancer or  
PT autoimmune diseases.  
XX Disclosure; Fig 1; 523pp; English.

PS The present invention describes antigenic peptides (I) comprising: (a)  
CC any one of 1601 sequences (see ABP82019 to ABP83619) of 12-24 amino  
CC acids. Also described: (1) an assay for the detection of a particular G  
CC protein-coupled receptor (GPCR) or a candidate polypeptide in a sample;  
CC and (2) an isolated antibody having high specificity and high affinity or  
CC avidity for a particular GPCR. (I) can be used as GPCR modulators and in  
CC gene therapy. The antigenic peptides for GPCRs are useful in detecting an  
CC antibody against a particular GPCR, and in the production of specific  
CC antibodies. The peptides and antibodies are also useful for detecting the  
CC presence or absence of corresponding GPCRs. The antigenic peptides for  
CC GPCRs and antibodies are useful for diagnosing and designing drugs for  
CC treating immune-related diseases, growth-related diseases, cell  
CC regeneration-related disease, immunological-related cell proliferative  
CC diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease,  
CC atherosclerosis, bacterial, fungal, protozoan or viral infections,  
CC osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute  
CC inflammation, allergies, Crohn's disease, diabetes, graft versus host  
CC disease, Parkinson's disease, multiple sclerosis, pain, psoriasis, memory  
CC anxiety, depression, schizophrenia, dementia, mental retardation, memory  
CC loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension,  
CC hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or

CC any other disorder in which GPCRs are involved. The antibodies may be  
CC used in immunoassays and immunodiagnosis. ABZ42523 to ABZ42869 encode  
CC GPCR proteins given in ABP81675 to ABP82018, which are used in the  
CC exemplification of the present invention

XX	Sequence	903 BP; 108 A; 327 C; 283 G; 185 T; 0 U; 0 Other;
XX	Query Match	100.0%; Score 903; DB 7; Length 903;
XX	Best Local Similarity	100.0%; Pred. No. 2e-167;
XX	Matches	903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1	ATGGACCTGCCCCCGCAGCTCTCTCCCTGGCCCTCTATGTGGCCGCTTTTGGCTGGGCTTC 60
DB	1	ATGGACCTGCCCCCGCAGCTCTCTCCCTGGCCCTCTATGTGGCCGCTTTTGGCTGGGCTTC 60
QY	61	CGCTCAACGTCCTGGCCATCCGAGGCGCAGCGCCACGCCCGGCTCCGTCTCACCCCT 120
DB	61	CGCTCAACGTCCTGGCCATCCGAGGCGCAGCGCCACGCCCGGCTCCGTCTCACCCCT 120
QY	121	AGCCTGGTCTAGCGCTGAACCTGGGCTGCTCGGACCTGCTGACAGTCTCTCTGCC 180
DB	121	AGCCTGGTCTAGCGCTGAACCTGGGCTGCTCGGACCTGCTGACAGTCTCTCTGCC 180
QY	181	CTGAAGCGGCTGGAGCGCTAGCCTCCGGGGCTTGGCCCTCTCGCGCCCTCGCTGTGCC 240
DB	181	CTGAAGCGGCTGGAGCGCTAGCCTCCGGGGCTTGGCCCTCTCGCGCCCTCGCTGTGCC 240
QY	241	GTCTTCGCGGTGGCCACCTTCTCCACCTCTATGCGCGGGGCTTCCTGCGCGCCCTG 300
DB	241	GTCTTCGCGGTGGCCACCTTCTCCACCTCTATGCGCGGGGCTTCCTGCGCGCCCTG 300
QY	301	AGTGACGGCGCTACTGCGGACGAGCTTCCCTTGGGCTACGAGCTTCGCGAGGCG 360
DB	301	AGTGACGGCGCTACTGCGGACGAGCTTCCCTTGGGCTACGAGCTTCGCGAGGCG 360
QY	361	TGCTATTCTGGGGGTGTGCGGGCATCTGGGCCCTCGTCTGTGTACCTGGGTCTG 420
DB	361	TGCTATTCTGGGGGTGTGCGGGCATCTGGGCCCTCGTCTGTGTACCTGGGTCTG 420
QY	421	GTCTTTGGTGTGAGGCTCCAGAGGCTCGGTGGACACAGCAACACTCTCTGGGCAATC 480
DB	421	GTCTTTGGTGTGAGGCTCCAGAGGCTCGGTGGACACAGCAACACTCTCTGGGCAATC 480
QY	481	ACACACCGGTCAACGGCTCTCGGCTCGCTGGAGGCTGGAGGCTTCGCGGCTTCGCGG 540
DB	481	ACACACCGGTCAACGGCTCTCGGCTCGCTGGAGGCTGGAGGCTTCGCGGCTTCGCGG 540
QY	541	CGGGCCGCTTCAGCCTCTCTCTCTGTCTTTTTCGCTTTTTCGCTTTTTCGCTTTTTC 600
DB	541	CGGGCCGCTTCAGCCTCTCTCTCTGTCTTTTTCGCTTTTTCGCTTTTTCGCTTTTTC 600
QY	601	TGCTAGTGGGCTGCTCCGGGCACTGGGCCGCTCGGCTCAGCAGAGGCGAAGCTG 660
DB	601	TGCTAGTGGGCTGCTCCGGGCACTGGGCCGCTCGGCTCAGCAGAGGCGAAGCTG 660
QY	661	CGGGCCGCTGGGTGGCGCGGGGCTTCCTCAGCTGCTCTGCTGCTAGGACCTTAC 720
DB	661	CGGGCCGCTGGGTGGCGCGGGGCTTCCTCAGCTGCTCTGCTGCTAGGACCTTAC 720
QY	721	AACGCTCCAACTGGCCAGTCTCTGTATACCCCAATCTAGGAGGCTTCGCGGGAAGCTG 780
DB	721	AACGCTCCAACTGGCCAGTCTCTGTATACCCCAATCTAGGAGGCTTCGCGGGAAGCTG 780
QY	781	GGGCTCATCAGGGTGCCTGGAGTGTGTGCTTAATCCGCTGTGTACCGGTTACTTGGGA 840
DB	781	GGGCTCATCAGGGTGCCTGGAGTGTGTGCTTAATCCGCTGTGTACCGGTTACTTGGGA 840
QY	841	AGGGTCTGGCTGAAGACGTGTGTGCGGCAAGAACCGCAAGGGGCAAGTCCCAAGAG 900
DB	841	AGGGTCTGGCTGAAGACGTGTGTGCGGCAAGAACCGCAAGGGGCAAGTCCCAAGAG 900
QY	901	TAA 903

DB	901	TAA 903
RESULT 4		
ADC22768		
ID	ADC22768	standard; cDNA; 903 BP.
XX	ADC22768;	
XX	18-DEC-2003	(first entry)
XX	Human G protein-coupled receptor cDNA #36.	
XX	Human; gene; ss; G protein-coupled receptor; GPCR;	
XX	transmembrane-6 region; TM6; intracellular-3 region; IC3.	
XX	Homo sapiens.	
XX	US655339-B1.	
XX	29-APR-2003.	
XX	13-OCT-1998;	98US-00170496.
XX	14-APR-1997;	97US-00839449.
XX	14-APR-1998;	98US-0060188.
XX	26-JUN-1998;	98US-0090783P.
XX	07-AUG-1998;	98US-0095677P.
XX	(AREN-)	ARENA PHARM INC.
XX	Liaw CW, Behan DP, Chalmers DT;	
XX	WPI; 2003-742861/70.	
XX	P-PSDB; ADC22769.	
XX	Creating a constitutively active version of an endogenous human G protein	
XX	coupled receptor (GPCR) comprises substituting a specific amino acid in	
XX	the transmembrane-6 region with a different amino acid, and testing for	
XX	constitutive activity.	
XX	Example 1; SEQ ID NO 249; 221pp; English.	
XX	The invention relates to a method for treating a non-endogenous,	
XX	constitutively active version of an endogenous human G protein-coupled	
XX	receptor (GPCR) that has a transmembrane-6 (TM6) region and an	
XX	intracellular-3 (IC3) region, by substituting a specific amino acid in	
XX	the TM6 region with a different amino acid, and testing for constitutive	
XX	activity. The method is useful for creating a constitutively active	
XX	version of an endogenous human GPCR that comprises a transmembrane 6	
XX	region and an intracellular loop 3 region. The altered human GPCR	
XX	polypeptides are useful for screening test compounds for identification	
XX	of inverse agonists or partial agonists of GPCR polypeptides, which may	
XX	have therapeutic uses. The altered GPCRs may also be used in vivo or in	
XX	vitro in biological research. A nucleic acid encoding the altered GPCR	
XX	may be used to create a transgenic animal expressing the altered GPCR.	
XX	The method allows screening for compounds that modulate the activity of a	
XX	human G protein-coupled receptor without the need for provision of a	
XX	ligand for the receptor. This is particularly useful in allowing	
XX	screening of compounds against orphan receptors for which no ligand is	
XX	currently known. This sequence represents cDNA encoding a human GPCR	
XX	polypeptide of the invention.	
XX	Sequence 903 BP; 108 A; 327 C; 283 G; 185 T; 0 U; 0 Other;	

Query Match	100.0%;	Score 903;	DB 9;	Length 903;
Best Local Similarity	100.0%;	Pred. No. 2e-167;		
Matches	903;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1	ATGGACCTGCCCCCGCAGCTCTCTCCCTGGCCCTCTATGTGGCCGCTTTTGGCTGGGCTTC 60		
DB	1	ATGGACCTGCCCCCGCAGCTCTCTCCCTGGCCCTCTATGTGGCCGCTTTTGGCTGGGCTTC 60		

```
QY 61 CGCCTCAACGCTCTGGCCATCCAGAGCGGCGAGCGGCCCAACGCCCGGCTCGGTCTCACCCCT 120
DB 61 CGCCTCAACGCTCTGGCCATCCAGAGCGGCGAGCGGCCCAACGCCCGGCTCGGTCTCACCCCT 120
QY 121 AGCCTGTCTTACGCCCTTGAACTGGGCTGTCTCGACCTGTCTGACAGTCTCTCTGCCCC 180
DB 121 AGCCTGTCTTACGCCCTTGAACTGGGCTGTCTCGACCTGTCTGACAGTCTCTCTGCCCC 180
QY 181 CTGAAGCGGTGAGCGGCTAGCCTTCGGGGCTGTGGCCCTCTGCGGCTGTGCTGTGCCCC 240
DB 181 CTGAAGCGGTGAGCGGCTAGCCTTCGGGGCTGTGGCCCTCTGCGGCTGTGCTGTGCCCC 240
QY 241 GTCTTCGGGTGGCCCACTTCTTCCCACTATGCGCGGGGGCTTCTGGCGGCGCTG 300
DB 241 GTCTTCGGGTGGCCCACTTCTTCCCACTATGCGCGGGGGCTTCTGGCGGCGCTG 300
QY 301 AGTGACGGCGCTTACCTGGGAGCAGCTTCCCTTGGGGCTACCAAGCTTTCGGGAGCGG 360
DB 301 AGTGACGGCGCTTACCTGGGAGCAGCTTCCCTTGGGGCTACCAAGCTTTCGGGAGCGG 360
QY 361 TGCTATTCTTGGGGGTGTGCGGGCCATCTGGGCCCTCTGCTCTGTGTACCTGGGTCTG 420
DB 361 TGCTATTCTTGGGGGTGTGCGGGCCATCTGGGGCTCTGCTCTGTGTACCTGGGTCTG 420
QY 421 GTCTTTGGGTGGAGGCTCAGAGGCTGTGGACACAGCAACCTCTCTGGGCAAC 480
DB 421 GTCTTTGGGTGGAGGCTCAGAGGCTGTGGACACAGCAACCTCTCTGGGCAAC 480
QY 481 AACACACCGGCTCAACGGCTCTCGGCTCTGGGAGGCTTGGGAGCGGCTTGGCGGCGG 540
DB 481 AACACACCGGCTCAACGGCTCTCGGCTCTGGGAGGCTTGGGAGCGGCTTGGCGGCGG 540
QY 541 CGGGCCGGCTTACAGCTCTCTCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
DB 541 CGGGCCGGCTTACAGCTCTCTCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
QY 601 TGCTAGTGGGTGCTCTCGGGCACTGGGCGGCTCTGGGCGGCTGTAGCACAGGCGGAAGCTG 660
DB 601 TGCTAGTGGGTGCTCTCGGGCACTGGGCGGCTCTGGGCGGCTGTAGCACAGGCGGAAGCTG 660
QY 661 CGGGCGGCTGGGTGGCGGGCGGCGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720
DB 661 CGGGCGGCTGGGTGGCGGGCGGCGGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 720
QY 721 AACGCTTCCAACTGGCCAGCTCTCTGTATACCCCAATCTAGGAGGCTCTTGGCGGAAGCTG 780
DB 721 AACGCTTCCAACTGGCCAGCTCTCTGTATACCCCAATCTAGGAGGCTCTTGGCGGAAGCTG 780
QY 781 GGGCTCATCAGCGGTGCTGGAGTGTGTGCTTTAATCCGCTGTGTACCCGGTTACTTGGGA 840
DB 781 GGGCTCATCAGCGGTGCTGGAGTGTGTGCTTTAATCCGCTGTGTACCCGGTTACTTGGGA 840
QY 841 AGGGGTCTGGCTGAAGACAGTGTCTGGGCAAGAACGCAAGGGGGCAAGTCCCAAGAG 900
DB 841 AGGGGTCTGGCTGAAGACAGTGTCTGGGCAAGAACGCAAGGGGGCAAGTCCCAAGAG 900
QY 901 TAA 903
DB 901 TAA 903
```

## RESULT 5

```
ADB61405
ID ADB61405 standard; DNA; 900 BP.
XX AC ADB61405;
XX DT 04-DEC-2003 (first entry)
XX DE DNA encoding human GPR40 protein.
XX KW fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;
    antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;
```

```
antilipemic; dermatological; antiarteriosclerotic; antiarthritic;
osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cytostatic;
diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;
diabetic retinopathy; hyperlipaemia; skin disease; arthritis;
bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;
memory loss; obesity; hypoglycaemia; edema; insulin resistance;
insulin allergy; fat metabolism disorder; cancer; human; gene; ds.
Homo sapiens.
Key Location/Qualifiers
CDS 1..900
    /*tag= a
    /partial
    /note= "No stop codon"
    /product= "Human GPR40 protein"
WO2003068959-A1.
21-AUG-2003.
13-FEB-2003; 2003WO-JP001483.
14-FEB-2002; 2002JP-00037131.
12-JUL-2002; 2002JP-00204163.
12-NOV-2002; 2002JP-00328696.
22-JAN-2003; 2003JP-00014032.
(TAKE ) TAKEDA CHEM IND LTD.
PA Hinuma S, Hosooya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;
PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;
XX WPI: 2003-671661/63.
DR P-PSDB; ADB61404.
XX Fatty acid and eicosanoid-binding G-protein coupled receptor protein
GPR40 for control of pancreatic function and treatment of diabetes.
PS Disclosure; Page 236-237; 257pp; Japanese.
XX The invention relates to a novel screening method comprising a fatty acid
and eicosanoid-binding G-protein coupled receptor protein, GPR40,
originating in mouse, rat, crab-eating monkey and hamster (sequences
fully defined in the specification), equivalent proteins of similar
activity, and peptides containing partial sequences of the GPR40 protein.
The novel fatty acid and GPR40 protein and their compositions have the
following activities: antidiabetic, anabolic, neuroprotective,
nephrotropic, ophthalmological, antilipemic, dermatological,
antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,
nootropic, anorectic, hypotensive, and cytostatic. The novel fatty acid
and eicosanoid-binding G-protein coupled receptor protein, GPR40, and
further compositions can be used in the treatment, prevention and
diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic
nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,
arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,
indigestion, memory loss, obesity, hypoglycaemia, edema, insulin
resistance, insulin allergy, fat metabolism disorders and cancer. This
polynucleotide sequence represents the DNA encoding a human GPR40 protein
of the invention.
SQ Sequence 900 BP; 106 A; 327 C; 283 G; 184 T; 0 U; 0 Other;
Query Match 99.7%; Score 900; DB 9; Length 900;
Best Local Similarity 100.0%; Fred. No. 7.8e-167;
Matches 900; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 ATGGACCTGCCCCCGCAGCTCTCTCGGCTCTATGTGGCGGCTTGTGGCTGGGCTTC 60
DB 1 ATGGACCTGCCCCCGCAGCTCTCTCGGCTCTATGTGGCGGCTTGTGGCTGGGCTTC 60
QY 61 CGGCTCAACGCTCTGGCCATCCAGAGCGGCGAGCGGCCCAACGCCCGGCTCGGTCTCACCCCT 120
|||||
```





```
QY 361 TGCTATTCTCGGGGTTGTCGGGCGCATCTGGGCGCTCTGCTGTGTCTACCTGGGCTTG 420
DB 361 TGCTATTCTCGGGGTTGTCGGGCGCATCTGGGCGCTCTGCTGTGTCTACCTGGGCTTG 420
QY 421 GTCTTTGGGTTGGAGGCTCCAGAGGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 480
DB 421 GTCTTTGGGTTGGAGGCTCCAGAGGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 480
QY 481 AACACACCGGCTCAACGGCTCTCCGGTCTGCTGGAGGCTGGACCGGGCTCTGCGGCG 540
DB 481 AACACACCGGCTCAACGGCTCTCCGGTCTGCTGGAGGCTGGACCGGGCTCTGCGGCG 540
QY 541 CCGGCCGGCTTACAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
DB 541 CCGGCCGGCTTACAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
QY 601 TGCTAGCTGGGCTGCTCCGGGCACTGGGCGGCTGCGGCTGACGACGAGGCGGAGCTG 660
DB 601 TGCTAGCTGGGCTGCTCCGGGCACTGGGCGGCTGCGGCTGACGACGAGGCGGAGCTG 660
QY 661 CCGGCCGGCTTGGGCTGCGGCGGCGGCTCTCTCACTGCTGCTGCTGCTGCTGCTGCTGCT 720
DB 661 CCGGCCGGCTTGGGCTGCGGCGGCGGCTCTCTCACTGCTGCTGCTGCTGCTGCTGCTGCT 720
QY 721 AAGGCTTCAACGTGGGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 780
DB 721 AAGGCTTCAACGTGGGCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 780
QY 781 GGGCTCATCAAGGCTGCTGGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 840
DB 781 GGGCTCATCAAGGCTGCTGGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 840
QY 841 AGGGGCTCTGGGCTGAAGACAGTGTGTGGGCAAGAACGCAAGGGGGCAAGTCCCAAGAG 900
DB 841 AGGGGCTCTGGGCTGAAGACAGTGTGTGGGCAAGAACGCAAGGGGGCAAGTCCCAAGAG 900
QY 901 TAA 903
DB 901 TAA 903

RESULT 7
ADC22790
ID ADC22790 standard; cDNA; 903 BP.
XX
AC ADC22790;
XX
DE 18-DEC-2003 (first entry)
XX
KW Human G protein-coupled receptor cDNA #76.
XX
KW Human; gene; 88; G protein-coupled receptor; GPCR;
XX
KW transmembrane-6 region; TM6; intracellular-3 region; IC3.
XX
OS Homo sapiens.
XX
PN US6555339-B1.
XX
PD 29-APR-2003.
XX
PF 13-OCT-1998; 98US-00170496.
XX
PR 14-APR-1997; 97US-00839449.
XX
PR 14-APR-1998; 98US-00060188.
XX
PR 26-JUN-1998; 98US-0090783P.
XX
PR 07-AUG-1998; 98US-0095677P.
XX
PA (AREN-) ARENA PHARM INC.
XX
PI Liaw CW, Behan DP, Chalmers DT;
XX
DR WPI; 2003-742861/70.
```

P-PSDB; ADC22791.

Creating a constitutively active version of an endogenous human G protein coupled receptor (GPCR) comprises substituting a specific amino acid in the transmembrane-6 region with a different amino acid, and testing for constitutive activity.

Example 2; SEQ ID NO 271; 221pp; English.

The invention relates to a method for treating a non-endogenous, constitutively active version of an endogenous human G protein-coupled receptor (GPCR) that has a transmembrane-6 (TM6) region and an intracellular-3 (IC3) region, by substituting a specific amino acid in the TM6 region with a different amino acid, and testing for constitutive activity. The method is useful for creating a constitutively active version of an endogenous human GPCR that comprises a transmembrane 6 region and an intracellular loop 3 region. The altered human GPCR polypeptides are useful for screening test compounds for identification of inverse agonists or partial agonists of GPCR polypeptides, which may have therapeutic uses. The altered GPCRs may also be used in vivo or in vitro in biological research. A nucleic acid encoding the altered GPCR may be used to create a transgenic animal expressing the altered GPCR. The method allows screening for compounds that modulate the activity of a human G protein-coupled receptor without the need for provision of a ligand for the receptor. This is particularly useful in allowing screening of compounds against orphan receptors for which no ligand is currently known. This sequence represents cDNA encoding a human GPCR polypeptide of the invention.

Sequence 903 BP; 111 A; 325 C; 282 G; 185 T; 0 U; 0 Other;

Query Match 99.5%; Score 898.2; DB 9; Length 903;  
Best Local Similarity 99.7%; Pred. No. 1.7e-166;  
Matches 900; Conservative 0; Mismatches 3; Indels 0; Gaps -0;

```
QY 1 ATGGACCTCCCGCCGAGCTCTCTTGGGCTCTATGTGGCGGCTTTGGGCTGGGCTTC 60
DB 1 ATGGACCTCCCGCCGAGCTCTCTTGGGCTCTATGTGGCGGCTTTGGGCTGGGCTTC 60
QY 61 CCGCTCAAGTCTTGCCCATCCGAGCGCGAGCGGCCACGCCGGCTTCGCTTCACCCCT 120
DB 61 CCGCTCAAGTCTTGCCCATCCGAGCGCGAGCGGCCACGCCGGCTTCGCTTCACCCCT 120
QY 121 AGCTGTGTCTAGCCCTGAACTGGGCTGCTCCGACCTGCTGTGACAGTCTCTGTGCC 180
DB 121 AGCTGTGTCTAGCCCTGAACTGGGCTGCTCCGACCTGCTGTGACAGTCTCTGTGCC 180
QY 181 CTGAAGCGGTTGAGGCGCTAGCCTCCGGGCTTGCCCTTGCGGCTCGCTGTGCC 240
DB 181 CTGAAGCGGTTGAGGCGCTAGCCTCCGGGCTTGCCCTTGCGGCTCGCTGTGCC 240
QY 241 GTCTTGGGTTGGCCACTTCTCCACTCTATCGCGGGGGCTTCCTGGCGGCTTG 300
DB 241 GTCTTGGGTTGGCCACTTCTTCCACTCTATCGCGGGGGCTTCCTGGCGGCTTG 300
QY 301 AGTGAGGCGGCTTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCG 360
DB 301 AGTGAGGCGGCTTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCG 360
QY 361 TGCTATTCTGGGGTGTGCGCGCATCTGGGCGCTCTGCTGTGTGTCACTGGGCTG 420
DB 361 TGCTATTCTGGGGTGTGCGCGCATCTGGGCGCTCTGCTGTGTGTCACTGGGCTG 420
QY 421 GTCTTTGGGTTGGAGGCTCCAGAGGCTGGCTGGAGGCTGGGACCCCGGCTCTGCGG 480
DB 421 GTCTTTGGGTTGGAGGCTCCAGAGGCTGGCTGGAGGCTGGGACCCCGGCTCTGCGG 480
QY 481 AACACACCGGCTCAACGGCTCTCCGGTCTGCTGGAGGCTGGACCGGGCTCTGCGGCG 540
DB 481 AACACACCGGCTCAACGGCTCTCCGGTCTGCTGGAGGCTGGGACCCCGGCTCTGCGGCG 540
QY 541 CCGGCCGGCTTACAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
DB 541 CCGGCCGGCTTACAGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 600
```





Db 661 AGGCGAGCCTGGCGCGCCGAGGGGCTTTCTCACACTCCTGCTGTGCGGCCCTAC 720  
Qy 721 AACGCTCAACAGTGGCCAGCTTCTGTACCCCAATCTAGGAGGCTCTCGGGGAGCTG 780  
Db 721 AATGCTCCAAATGTGGCGAGTTTCGTAAACCCGGACCTGGGAGGCTCTCTGGAGGAGCTG 780  
Qy 781 GGGCTCATCACCGGTGCTCGAGTGTGGTCTTAATCCGCTGCTGACCGGTTACTTTGGGA 840  
Db 781 GGGCTCATCACAGGCTCTGGAGTGTGGTACTCAACCCGCTGTCACCGTTACTTTGGGA 840  
Qy 841 AGGGTCTCGGCTGAAGACAGTGTGGCGCAAGAACGCAAGGGGCAAGTCCGAGAAG 900  
Db 841 GCAAGTCTCTGGCGGAGGACAGTATGTACGACAGGACTCAAGGAGAACAAATTCAGAG 900

RESULT 10

ABK90237  
ID ABK90237 standard; cDNA; 903 BP.

AC ABK90237;

DT 21-OCT-2002 (first entry)

DE Mouse cDNA encoding G protein-coupled receptor GPR40.

KW Mouse; ss; gene; GPR40; G protein-coupled receptor; type 2 diabetes;  
Qy obesity; antidiabetic; neuroprotective; anorectic; cerebroprotective; Gq;  
KW G protein; reporter gene; glucose intolerance; insulin intolerance;  
KW neurodegenerative disease; Alzheimer's disease; stroke.

OS Mus sp.

Key Location/Qualifiers  
FT i. .903  
CDS /\*tag= a  
/product= "GPR40"

PN WO200257783-A2.

PD 25-JUL-2002.

PF 18-DEC-2001; 2001WO-US048985.

PR 22-DEC-2000; 2000GB-00031527.

PA (GLAXO) GLAXO GROUP LTD.

PA (SMITH) SMITHKLINE BEECHAM PLC.

PI Andrews JL, Briscoe CP, Ignar DM, Muir AI, Sauls HR, Tadavayon M;

DR WPI; 2002-599726/64.

DR P-PSDB; ABG31107.

PT Identifying GPR40 receptor ligand for treating disorders e.g. obesity,  
PT comprises detecting whether the test compound competitively inhibits the  
PT binding of a fatty acid GPR40 ligand to a GPR40 receptor.

PS Disclosure; Page 49-50; 53pp; English.

XX The invention relates to screening a test compound to determine whether  
CC the compound is a GPR40 receptor (G protein-coupled receptor) ligand  
CC comprises detecting whether the test compound competitively inhibits the  
CC binding of a fatty acid GPR40 ligand to a GPR40 receptor. Also included  
CC are (1) a method of screening a compound for GPR40 antagonist activity,  
CC comprising: (a) measuring any detectable signal produced by a reporter  
CC gene (comprising a reporter gene under the control of G protein Gq  
CC responsive transcriptional element); (b) detecting a decrease in reporter  
CC gene expression in the presence of both test compound and agonist; or (c)  
CC detecting whether the compound decreases glucose-stimulated insulin  
CC release from mammalian pancreatic beta cells in the presence of a GPR40  
CC agonist, compared to glucose-stimulated insulin release that would occur  
CC due to the presence of the GPR40 agonist; (2) a method of screening a  
CC compound for GPR40 agonist activity, which comprises: (a) detecting any

CC reporter gene expression; or (b) detecting whether the compound binds to  
CC GPR40 and increases glucose-stimulated insulin release from mammalian  
CC pancreatic beta cells. The method is useful for identifying GPR40  
CC antagonist or agonist compounds for treating disorders e.g. type 2  
CC diabetes, obesity, glucose or insulin intolerance, neurodegenerative  
CC disease (e.g. Alzheimer's disease) or stroke. The present sequence is the  
CC mouse cDNA for GPR40  
XX  
SQ Sequence 903 BP; 138 A; 300 C; 245 G; 220 T; 0 U; 0 Other;

Query Match 66.9%; Score 604.4; DB 6; Length 903;  
Best Local Similarity 79.4%; Pred. No. 4.5e-109;  
Matches 716; Conservative 0; Mismatches 186; Indels 0; Gaps 0;

Qy 1 ATGGACCTGCCCGCAGCTCTCCCTGGSCCTATGTGGCGCTTTGCGCTGGGCTTC 60  
Db 1 ATGGACCTGCCCGCAGCTCTCCCTGGSCCTATGTGGCTCTATGTATCTGGCTTTGGCTGGCTTT 60  
Qy 61 CCGCTCAACAGTCTCGGCCATCCGAGGCGCGAGCGCCACGCCCGCTCCGCTCTCACCCCT 120  
Db 61 CCATTGAATTGTTAGCCATCCGAGGCGAGTGTCCACGCTAACTGGACTCACTCCC 120  
Qy 121 AGCTGTGTACGCTGAACTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTGTGCC 180  
Db 121 AGCTGTGTACACTCTCCATCTGGCTGCTGATCTCTACTTGCCCATCACTCTGCC 180  
Qy 181 CTGAAGCGGTGGAGCGCTAGCTCCGGGGCTGGCTCTGCGGCTCGGCTCGGCTGGCCCC 240  
Db 181 CTGAAGCGGTGGAGCGCTGGCTCTGAGGCTGGCGCTGGCGCTCCGCTCTGCCCCA 240  
Qy 241 GTCTTGGCGGTGGCCCACTTTCTCCCACTCTATGCGCGGGGGCTTCTTGGCGCGCTG 300  
Db 241 GTCTTGGCTTGGCCCACTTTCTCCCTCTACGACAGGGAGGCTTCTAGTGTCTC 300  
Qy 301 AGTGAGCGCGCTACTCGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCGG 360  
Db 301 AGCGCTGGCGCTACTTGGGGCTGCTTCCCTTCCGCTTACCAAGCTTCCGAGGCGG 360  
Qy 361 TGCTATTCTGGGGGTGTGCGGGCCATCTGGGGCTCTGCTGTGTACCTGGCTGTG 420  
Db 361 CGCTATTCTGGGGGTGTGTGTGTGTATATGGGGCTTGTCTCTGTGACCTGGGGCTG 420  
Qy 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACCAAGCAACACCTTCCCTGGGCATC 480  
Db 421 GCCCTTGGCTTGGAGACTTCCGGAAGCTGGCTGGACCAAGTACCACTTCCCTGGGCATC 480  
Qy 481 AACACACGGGTCAACGGCTCTCGGCTGCTGCTGGAGGCTCGGACCCGCGCTCTGCCG 540  
Db 481 AACATACCGGTGAATGGCTTCCCGGTCTGCTTGGAGGCTTGGGATCCCGACTCTGCC 540  
Qy 541 CCGGCGCGCTTCAGGCTCTCTCTCTGCTCTTTTCTGCGCTTGGCCATCACAGGCTTC 600  
Db 541 CCGGCGCGCTTCAGTCTTCTCAATCTGTCTTCTTCTGCGCTTGGTCACTACTGCTTC 600  
Qy 601 TGCTACGTGGGTGCTCTCGGCACTTGGCCCTCGGCTCGGCTGACGACAGGGGGAGCTG 660  
Db 601 TGCTATGTGGGTGCTCTCGGCGCTTGGTGCGCTCAGGCTGAGCCACCAAGAGGCTC 660  
Qy 661 CCGGCGCGCTGGGTGGCGGCGGCGCTCTCTACGCTGCTGCTGTGCTAGACCTTAC 720  
Db 661 AGGGCAGCTTGGGTGGCGGAGGCGCTCTCTCACACTCTGCTCTGCGCTGGGCGCTAT 720  
Qy 721 AACGCTTCAACGCTGGCAGCTTCTGTACCCCAATCTAGGAGGCTTCTGGCGGAGCTG 780  
Db 721 AATGCTTCAATGTGGCTAGTTTCAAAACCCGGACCTAGGAGGCTTCTGGAGGAGTGT 780  
Qy 781 GGGCTCATCACCGGTGCTCGAGTGTGGTGTCTTAATCCGCTGGTGAACCGGTTACTTTGGGA 840  
Db 781 GGACTCATCACAGGGGCTGGAGTGTGGTACTCAACCCCACTGTCTCACTGGCTACTTTGGGA 840  
Qy 841 AGGGTCTCTGGCTGAAGACAGTGTGTGGCGCAAGAACGCAAGGGGGCAAGTCCGAGAAG 900  
Db 841 ACAGGTCTCTGGAGCGGGGAACAAATATGTGTGACGAGGACTCAAGAGAGGAACAATTCAGAAG 900

QY 901 TA 902  
 ||  
 Db 901 TA 902

RESULT 11  
 ADB61401  
 ID ADB61401 standard; DNA; 900 BP.  
 AC ADB61401;  
 XX  
 DT 04-DEC-2003 (first entry)  
 DE  
 XX DNA encoding mouse GPR40 protein.  
 XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
 KW anti-diabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
 KW anti-lipemic; dermatological; anti-arteriosclerotic; anti-arthritic;  
 KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cytosstatic;  
 KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
 KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
 KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
 KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
 KW insulin allergy; fat metabolism disorder; cancer; mouse; murine; gene;  
 ds.  
 KW  
 OS Mus sp.  
 XX  
 FH Key Location/Qualifiers  
 FT CDS 1..900  
 FT /tag= a  
 FT /partial  
 FT /note= "No stop codon"  
 FT /product= "Mouse GPR40 protein"  
 XX  
 PN WO2003068959-A1.  
 XX  
 XX 21-AUG-2003.  
 XX  
 XX 13-FEB-2003; 2003WO-JP001483.  
 XX  
 XX 14-FEB-2002; 2002JP-00037131.  
 PR 12-JUL-2002; 2002JP-00204163.  
 PR 12-NOV-2002; 2002JP-00328696.  
 PR 22-JAN-2003; 2003JP-00014032.  
 XX  
 XX (TAKE ) TAKEDA CHEM IND LTD.  
 PA  
 XX  
 PI Hinuma S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;  
 PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;  
 XX  
 DR WPI: 2003-671661/63.  
 DR P-PSDB; ADB61400.  
 XX  
 PT Fatty acid and eicosanoid-binding G-protein coupled receptor protein  
 PT GPR40 for control of pancreatic function and treatment of diabetes.  
 XX  
 XX Claim 11; Page 232; 257pp; Japanese.  
 PS  
 CC The invention relates to a novel screening method comprising a fatty acid  
 CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,  
 CC originating in mouse, rat, crab-eating monkey and hamster (sequences  
 CC fully defined in the specification), equivalent proteins of similar  
 CC activity, and peptides containing partial sequences of the GPR40 protein.  
 CC The novel fatty acid and GPR40 protein and their compositions have the  
 CC following activities: anti-diabetic, anabolic, neuroprotective,  
 CC nephrotropic, ophthalmological, anti-lipemic, dermatological,  
 CC anti-arteriosclerotic, anti-arthritic, osteopathic, thrombolytic,  
 CC nootropic, anorectic, hypotensive, and cytosstatic. The novel fatty acid  
 CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and  
 CC further compositions can be used in the treatment, prevention and  
 CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic

CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,  
 CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,  
 CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin  
 CC resistance, insulin allergy, fat metabolism disorders and cancer. This  
 CC polynucleotide sequence represents the DNA encoding a mouse GPR40 protein  
 CC of the invention.

XX  
 SQ Sequence 900 BP; 137 A; 300 C; 244 G; 219 T; 0 U; 0 Other;  
 Query Match 66.7%; Score 602.4; DB 9; Length 900;  
 Best Local Similarity 79.3%; Pred. No. 1.1e-108;  
 Matches 714; Conservative 0; Mismatches 186; Indels 0; Gaps 0;  
 QY 1 ATGGACCTGCCCGCAGCTCTCTTCGGGCTCTATGTGGCGCCCTTTTGGCGTGGGCTTC 60  
 Db |||||  
 1 ATGGACCTGCCCGCAGCTCTCTTCGGCTCTCTATGTATCTGCTTTGGCGTGGGCTTT 60  
 QY 61 CGCTCAACGTCTCGGCATTCGAGGCGGAGCGGCCAGCCCGGCTCGTCTCACCCCT 120  
 Db |||||  
 61 CCATTGAACCTTGTAGCCATTCGAGGCGGAGTGTCCACGCTAAACTGCGACTCACTCCC 120  
 QY 121 AGCTGGTCTACGCCCTGAACCTGGGCTGTCCGACCTGCTGCTGACAGTCTCTTGCCC 180  
 Db |||||  
 121 AGCTGGTCTACACTCTCCATCTGGGCTGTCTGATCTCTACTGCGCATCACTCTGCC 180  
 QY 181 CTGAAGCGGTGGAGCGCTAGCCTCCGGGCGCTGGCCCTCTGCGGCGCTCGCTGTGCC 240  
 Db |||||  
 181 CTGAAGCGGTGGAGCGCTTGGCTTCTGGAGCTTGGCCCTTGGCGCTCCCTTCTGCC 240  
 QY 241 GTCTTCGGGTGGGCCCACTTCTTCCACTCTATGCGGGGGGGGCTTCTTGGCGGCCCTG 300  
 Db |||||  
 241 GTCTTTGGCTTGGGCCCACTTGTCTCCCTCTACGAGGCGGAGGCTTCTTAGTGTCTC 300  
 QY 301 AGTGAGGCGCGTACCTGGGAGCAGCTTCCCTTGGGCTTACCAAGCGCTTCCGAGGCG 360  
 Db |||||  
 301 AGCGCTGGCGCGCTACCTGGGGGCTGCTCTTCCCTTGGGTACCAAGCGCATCCGAGG 360  
 QY 361 TGCTATTTCTGGGGGGTGTGCGCGGCATCTGGGCGCTGCTGCTGTGTCTCACCTGGGTCTG 420  
 Db |||||  
 361 CGCTATTTCTGGGGTGTGTGTGGCTATATGGGCCCTTGTCTCTGCCACCTTGGGGCTG 420  
 QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGCTGGAGCACACAGCAACACTCCCTCGGGGATC 480  
 Db |||||  
 421 GCGCTTGGCTTGGAGACTTCCGGAAGCTGGCTGGAGCAACAGTACCACTAGTTCCTCGG 480  
 QY 481 AACACACCGCTCAACGGGCTCTCCGCTGCTGGAGGCGCTGGGACCCGCGCTCTGCGGC 540  
 Db |||||  
 481 AACATACCGGTGAATGGCTCCCGGCTCTGCTGGAGGCTTGGGATCCCGACTCTGCCGC 540  
 QY 541 CCGGCGCGCTTCAGCCCTCTCTCTCTGCTCTTTTCTGCGCCCTTGGCCCATCACAGCTTC 600  
 Db |||||  
 541 CTTGCCCGCTCAGTTTCTTCCATTTCTGCTCTTCTTCTGCGCCCTTGGTCTCATCTGC 600  
 QY 601 TGTAGTGGGTGCTTCCGGGCACTGGCGCGCTCGGGCTGACGACAGGCGGGAAGCTG 660  
 Db |||||  
 601 TGTATGTGGGTGCTTCCGGGCGCTGGTGGCTCAGGGCTGAGGCCACAAACGGAAGCTC 660  
 QY 661 CCGGCGCGCTGGGTGGCGGGGCGCTTCCACGCTGCTGCTGCTGCTAGGACCCCTAC 720  
 Db |||||  
 661 AGGGCAGCTTGGGTGGCGGGGCGCTCTCTCCTCAGACTCTTGTCTTGGGCGCCCTAT 720  
 QY 721 AACGCGCTCCAGCTGGCCAGCTTCTCTGTATACCCCAATCTAGGAGGCTCTTGGCGGAAGCTG 780  
 Db |||||  
 721 AATGCTCCCAATGTGGCTAGTTTCAAAACCCGACCTAGGAGGCTCTTGGAGGAAGTTG 780  
 QY 781 GGGCTCATCAGCGGTGCTGGAGTGTGGTGTAAATCCGCTGGTGTGACCGGTACTTGGGA 840  
 Db |||||  
 781 GGACTCATCAGGCGGCTGGAGTGTGGTGTCAACCCACTGTGTCACTGTGTACTTGGGA 840  
 QY 841 AGGGGTCTCGGCTGAGACAGTGTGGGCGGCAAGAACGAGGGGGGCAAGTCCCAAGAG 900  
 Db |||||  
 841 ACAGGTCTCTGGAGCGGGAACAATATGTGTGACGAGGACTCAAGAGAGGAACAATTCAG 900

RESULT 12  
ADB61403  
ID ADB61403 standard; DNA; 900 BP.  
XX AC  
XX ADB61403;  
XX  
XX 04-DEC-2003 (first entry)  
XX  
XX DE DNA encoding rat GPR40 protein.  
XX  
XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
KW antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
KW antilipaeamic; dermatological; antiarteriosclerotic; antiarthritic;  
KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cytostatic;  
KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
KW insulin allergy; fat metabolism disorder; cancer; rat; gene; ds.  
XX  
OS Rattus sp.  
XX  
XX Key Location/Qualifiers  
FH 1. .900  
CDS /\*tag= a  
/\*partial  
/\*note= "No stop codon"  
/\*product= "Rat GPR40 protein"  
XX  
XX WO2003068959-A1.  
XX  
XX 21-AUG-2003.  
XX  
XX 13-FEB-2003; 2003WO-JP001483.  
XX  
XX 14-FEB-2002; 2002JP-00037131.  
PR 12-JUL-2002; 2002JP-00204163.  
PR 12-NOV-2002; 2002JP-00328696.  
PR 22-JAN-2003; 2003JP-00014032.  
XX  
XX (TAKE ) TAKEDA CHEM IND LTD.  
XX  
XX Hinuma S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;  
PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;  
XX  
XX WPI; 2003-671661/63.  
DR P-PSDB; ADB61402.  
XX  
XX Fatty acid and eicosanoid-binding G-protein coupled receptor protein  
PT GPR40 for control of pancreatic function and treatment of diabetes.  
XX  
XX Example 3; Page 234; 257pp; Japanese.  
XX  
XX The invention relates to a novel screening method comprising a fatty acid  
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,  
CC originating in mouse, rat, crab-eating monkey and hamster (sequences  
CC fully defined in the specification), equivalent proteins of similar  
CC activity, and peptides containing partial sequences of the GPR40 protein.  
CC The novel fatty acid and GPR40 protein and their compositions have the  
CC following activities: antidiabetic, anabolic, neuroprotective,  
CC nephrotropic, ophthalmological, antilipaeamic, dermatological,  
CC antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,  
CC nootropic, anorectic, hypotensive, and cytostatic. The novel fatty acid  
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and  
CC further compositions can be used in the treatment, prevention and  
CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic  
CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,  
CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,  
CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin  
CC resistance, insulin allergy, fat metabolism disorders and cancer. This  
CC polynucleotide sequence represents the DNA encoding a rat GPR40 protein  
CC of the invention.

XX  
SQ Sequence 900 BP; 142 A; 287 C; 244 G; 227 T; 0 U; 0 Other;  
Query Match 65.1%; Score 588; DB 9; Length 900;  
Best Local Similarity 78.3%; Pred. No. 7.3e-106;  
Matches 705; Conservative 0; Mismatches 195; Indels 0; Gaps 0;  
QY 1 ATGGACCTGCCCCCGCAGCTCTCCCTTGGCCCTCTATGTGGCGCTTTGGCGTGGGCTTC 60  
DB 1 ATGGACCTGCCCCCGCAGCTCTCCCTTGGCTCTCTATGTATCAGCCTTTGCATAGGCTTT 60  
QY 61 CGGCTCAAGCTCTCTGGCCATCCGAGCGCGAGCGGCCACGCCCGGCTCCGTCTCACCCCT 120  
DB 61 CCATTGAATTGTTAGCCATCCGAGGTGCAGTGTCCACGCGAAATGCGACTCACCCCC 120  
QY 121 AGCTTGGTCTACGCCCTGAACTCGGGCTGCTCCGAGCTGCTGCTGACAGTCTCTCTGCCC 180  
DB 121 AGCTTGGTCTACACTCTCCATTTGGCCTGCTGACCTCTCTAGCCATCACCTTGGCCC 180  
QY 181 CTGAAGGGGTGGAGGCGCTAGCCTCCGCGGCGCTGCGCTCTGCGGCGCTCGCTGTGCC 240  
DB 181 CTGAAGGCTGTGGAGGCGCTGGCTTCTGGGGTCTGGCCCTGCCACTCCCTTCTGCCCA 240  
QY 241 GTCTTGGCGGTGGCCCACTTCTTCCCACTCTATGCGCGGGGGGCTTCTTGCGCGCCCTG 300  
DB 241 GTCTTGGCTTGGCCCACTTTCGCGCCCTCTATGCAAGTGGAGGCTTCTTGCTGCTCTC 300  
QY 301 AGTGACGGCGCTACTCTGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCGAGAGCGCG 360  
DB 301 AGTGCTGGCGCTACTCTGGAGCTGCTTCCCTTTGGATACCAAGCCATCCGAGGCGC 360  
QY 361 TGCTATTCTGGGGGTGTGGCGGCGCATCTCGGCGCTGCTGCTGTGTCACCTGTGGTCTG 420  
DB 361 TGCTATTCTGGGGGTGTGTGTGGCTATATGGGCGCTTGTCTTTCACCTTGGGACTG 420  
QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACCAACAGCAACACCTTCCCTGGGCATC 480  
DB 421 GCTCTTGGCTTGGAGGCTCCAGAGGCTGGGTGGATACACCAACAGTTCCTTGGGCATC 480  
QY 481 AACACACCGGTCAACGGCTCTCGGTCTGGAGGCGCTGGAGACCGGCGCTTGGCGCGC 540  
DB 481 AACATACCGGTGAATGGCTCCCGGCTCGCTGGAGCGTGGGATCCTGACTCTGCCCGC 540  
QY 541 CGGCGCGCTTCAGCCTCTCTCTGCTGCTTTTCTGCTGCTGCGCTTGGCCATCACAGCTTC 600  
DB 541 CTGCGCGGACTCAGTTTCTCGATTCTGCTCTTCTTCTGCTGCTTGGTTATCACTGCTTC 600  
QY 601 TGCTAGTGGCTGCTCTCGGCACTGGCGCGCTCCGCGCTGACGCACAGCGGGAAGCTG 660  
DB 601 TGCTATGTGGGCTGCTCTCGGCGCGCTGGTGCACCTCGGCGCTGAGCCACAAACGGAAGCTC 660  
QY 661 CGGCGCGCTGGGTGGCGCGGCGCGCTCTCTGAGCTGCTGCTGCTGCTGCTGCTGCTTAC 720  
DB 661 AGGGCAGCTTGGGTGGCTGGAGGAGCACTTCTCACACTCTGCTCTGCTGCTGCGGCGCTAT 720  
QY 721 AACGCTTCAACGCTGCGCAGCTTCTGTACCCCAATCTAGGAGGCTTCTGCGCGGAAGCTG 780  
DB 721 AATGCTTCAATGTGGCTAGTTTCAATAACCCGGACTTAGAAGGCTTCTTGGAGGAAGTTG 780  
QY 781 GGGCTCATCACGGGTGCTTGGAGTGTGGTGTCTTAATCCGCTGGTGAACCGGTTACTTTGGA 840  
DB 781 GGGCTCATCACAGGAGCTTGGAGTGTGGTGTCTCAACCCACTGGTCACTGGCTACTTGGGA 840  
QY 841 AGGGTCTTGGCTGAAGCAGTGTGTCGGGCAAGACGCAAGGGGGCAAGTCCCAAGAG 900  
DB 841 ACAGGTCTTGGACAGGGGACATATATGTGTGACCGAGCTTCAAGAGGGGCAATTCAGAAG 900  
RESULT 13  
AAV53631  
ID AAV53631 standard; cDNA; 1841 BP.  
XX  
XX AAV53631;  
AC







CC coupling to a G-protein; and (2) monitoring for GPR 41 or GPR 42 activity  
CC in the presence of a G-protein, thereby determining whether the test  
CC agent modulates activity. Such agents, which may be an activator of GPR  
CC 41 or GPR 42, an inhibitor of lipolysis, or a polynucleotide encoding GPR  
CC 41, GPR 42 or variant polypeptide, are useful for the treatment of  
CC dyslipidaemia, coronary heart disease, atherosclerosis, thrombosis or  
CC obesity, angina, chronic renal failure, peripheral vascular disease,  
CC stroke, type II diabetes or metabolic syndrome (syndrome X) (all claimed)  
XX  
SQ Sequence 1041 BP; 169 A; 321 C; 317 G; 234 T; 0 U; 0 Other;

Query Match	13.5%;	Score 121.8;	DB 4;	Length 1041;
Best Local Similarity	52.1%;	Pred. NO. 9.4e-15;		
Matches	382;	Conservative	0;	Mismatches 327; Indels 24; Gaps 4;

  

QY	18	GCTCTCCTTCGGCTCTATGTGGCGCTTGTGGCTTCCGCTTCCGCTCAACGTCCTGGC	77
DB	45	GTTCGTCTTCTCGGTGTACTTCTCACTTTCCTGGTGGGCTCCCTCAACTGTGGC	104
QY	78	CATCCGAGGGCGACCGCCACCGCTCGTCTCACCCCTAGCTGTGTCTACGCCCT	137
DB	105	CCTGTGTGTCTTCGTGGCAAGCTGCGGTGCGCCGCGTGGCGTGGACGTGCTCTGCT	164
QY	138	GAACCTGGGCTGTCCGACCTGTGTGACAGTCTCTCTGCCCTGAAGCGGTGGAGC	197
DB	165	CAACCTGACCGCTCGGACCTGTCTCTGTGTCTTCTCTGCTTCCGCTTCCGATGGTGGAGC	224
QY	198	GCTAGCCTCCGGGCTGTGGCTCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGC	257
DB	225	AGCCAATGGATGACATGGCCCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGC	284
QY	258	CTTCTTCCCACTCTATGCGGGGGGGCTTCTGGCGGCTGTGGCTGTGGCTGTGGCTGTGGC	317
DB	285	CTTACCAACCATCTATCTACCGCCCTCTTCTGGCAGCTGTGGATTTGAAGCTTCTCT	344
QY	318	GGGAGCAGCTTCCCTTGGGCTACCAAGCTTTCGGAGGCGCTGTATTTCTTGGGGGT	377
DB	345	GAGTGTGGGCCACCCACTGTGTGTACAAAGACCCGCGGAGCTGGGGCAGGCTCTGGT	404
QY	378	GTGCGGGGCATCTGGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGC	437
DB	405	GAGTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGCTGTGGC	464
QY	438	TCCAGGAGGCTGGCTGGACACAGCAACACCTCTCCCTGGGCTCAACACCGGTCAACGG	497
DB	465	CTCAGGGG-----ACATCTCCACAGCGGGCACCAATGGGACCTG	506
QY	498	CTCTCCGGTCTGGCTGGAGGCTGGGACCGGGCTCTGGGGCCCGGGCCGCTTCAAGCT	557
DB	507	CTACCTGGAGTTCTGGAAGGACGAG--CTAGCCATCTCTCTGGCGGTGGAGA-T	563
QY	558	CT	617
DB	564	GGCTGTGGTCTCTTTTGTGGTCCCGTGATCATCACAGTACTGTCTAGCGGCTGTGT	623
QY	618	CCGGGCACTGGCGCTCCGGCTGACGACAGCGGAAAGCTGCGGGCCGCTTGGGTGGC	677
DB	624	GTGGATCTCTCGGACAGGGGGG---AGCCACCGCGGACAGAGGGTGGCGGGCTGGT	680
QY	678	CGGCGGGGCTCTCAAGCTGTGTCTGTGGTAGGACCTTACAGCCTCCAACTGGC	737
DB	681	GGCGGCGACGCTGCTCAACTCTCTGTGTGTGGGCTTACAGCTGTGCCATGTCTGT	740
QY	738	CAGCTTCTCTGTAC	750
DB	741	GGGCTATATCTGC	753

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 30, 2004, 14:33:11 ; Search time 2948 Seconds  
(without alignments)  
9147.065 Million cell updates/sec

Title: US-10-202-687-1

Perfect score: 903

Sequence: 1 atggacctgccccgcagct.....ggggcaagtcgccagaagtaa 903

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:\*

1: em\_estba:\*

2: em\_esthum:\*

3: em\_estin:\*

4: em\_estmu:\*

5: em\_estov:\*

6: em\_estpl:\*

7: em\_estro:\*

8: em\_htc:\*

9: gb\_est1:\*

10: gb\_est2:\*

11: gb\_htc:\*

12: gb\_est3:\*

13: gb\_est4:\*

14: gb\_est5:\*

15: em\_estfun:\*

16: em\_estom:\*

17: em\_gss\_hum:\*

18: em\_gss\_inv:\*

19: em\_gss\_pin:\*

20: em\_gss\_vrt:\*

21: em\_gss\_fun:\*

22: em\_gss\_mam:\*

23: em\_gss\_mus:\*

24: em\_gss\_pro:\*

25: em\_gss\_rod:\*

26: em\_gss\_phg:\*

27: em\_gss\_vrl:\*

28: gb\_ges1:\*

29: gb\_ges2:\*

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	901.4	99.8	903	29	AY411510 Homo sapi
2	823.6	91.2	834	29	AY411511 Pan trogl
3	602.8	66.8	903	29	AY411512 Mus muscu
4	376.8	41.7	443	10	AW583167 iat111.y

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

5	306	33.9	522	29	CE730455	CE730455 tigr-ges-
6	295.2	32.7	609	14	CA776599	CA776599 ip08c01.y
7	189.8	21.0	234	29	CE038975	CE038975 tigr-ges-
8	132.4	14.7	961	29	CNS041EX	AL270114 Tetraodon
9	130	14.4	774	28	BZ160914	BZ160914 CH230-339
10	128	14.2	543	28	AQ119988	AQ119988 HS_3024.A
11	117.4	13.0	1117	12	BM544968	BM544968 AGENCOURT
12	106.6	11.8	779	14	CD559556	CD559556 AGENCOURT
13	103.6	11.5	696	14	CF147780	CF147780 AGENCOURT
14	102.8	11.4	472	12	B1541693	B1541693 455537.MA
15	95.8	10.6	489	14	CA777066	CA777066 ip02f08.y
16	83.8	9.3	619	28	AZ082043	AZ082043 RPCI-23-2
17	83.8	9.3	672	13	BY741744	BY741744 BY741744
18	81.2	9.0	757	12	BG190636	BG190636 RST9710.A
19	80.2	8.9	1077	29	AY403859	AY403859 Mus muscu
20	80	8.9	738	14	CD559659	CD559659 AGENCOURT
21	80	8.9	745	14	CD559660	CD559660 AGENCOURT
22	80	8.9	766	14	CD559663	CD559663 AGENCOURT
23	80	8.9	772	14	CD559662	CD559662 AGENCOURT
24	80	8.9	1098	29	AY408183	AY408183 Homo sapi
25	76.8	8.5	786	29	AY408184	AY408184 Pan trogl
26	73.6	8.2	681	14	CF365470	CF365470 836101.MA
27	73.2	8.1	2297	11	AK078861	AK078861 Mus muscu
28	71.6	7.9	1257	11	AK050524	AK050524 Mus muscu
29	71.2	7.9	504	10	AW632495	AW632495 92464.MAR
30	70.2	7.8	500	10	BF603623	BF603623 269181.MA
31	70	7.8	557	13	BQ807875	BQ807875 NISC.kk11
32	70	7.8	1046	29	AY407666	AY407666 Mus muscu
33	70	7.8	2323	11	BC009877	BC009877 Homo sapi
34	69.6	7.7	631	14	CB499474	CB499474 ssa1knc01
35	68.8	7.6	2912	11	AK087410	AK087410 Mus muscu
36	68.6	7.6	460	10	AW206493	AW206493 UI-H-B11-
37	68.6	7.6	462	10	AW138148	AW138148 UI-H-B11-
38	68.6	7.6	544	9	AI344017	AI344017 tc01e02.x
39	68.4	7.6	699	10	BE264355	BE264355 601191412
40	68.4	7.6	843	29	CNS00CS1	AL059666 Drosophil
41	68.4	7.6	925	29	CNS0091P	AL053013 Drosophil
42	68.4	7.6	4435	11	AK049671	AK049671 Mus muscu
43	68.2	7.6	916	29	CNS02EZK	AL194406 Tetraodon
44	67.2	7.4	553	12	BM141985	BM141985 if25b05.Y
45	67.2	7.4	611	28	AZ409268	AZ409268 IM0180P17

ALIGNMENTS

RESULT 1	AY411510	903 bp	DNA	linear	GSS 16-DEC-2003
LOCUS	AY411510	Homo sapiens GPR40 gene, genomic survey sequence.			
DEFINITION	AY411510	Homo sapiens GPR40 gene, genomic survey sequence.			
ACCESSION	AY411510	GI:39767478			
VERSION	AY411510.1	G1:39767478			
KEYWORDS	GSS.				
SOURCE	Homo sapiens				
ORGANISM	Homo sapiens (human)				
REFERENCE	1 (bases 1 to 903)				
AUTHORS	Clark, A.G., Gnanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.				
TITLE	Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios				
JOURNAL	Science 302 (5652), 1960-1963 (2003)				
PUBMED	14671302				
REFERENCE	2 (bases 1 to 903)				
AUTHORS	Clark, A.G., Gnanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.				
TITLE	Direct Submission				

JOURNAL Submitted (16-NOV-2003) Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA

COMMENT This sequence was made by sequencing genomic exons and ordering them based on alignment.

FEATURES  
source Location/Qualifiers  
1..903  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
<1..>903  
/gene="GPR40"  
/locus\_tag="HCM4248"

ORIGIN

Query Match 99.8%; Score 901.4; DB 29; Length 903;  
Best Local Similarity 99.9%; Pred. No. 2.2e-148;  
Matches 902; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCCCGCAGCTCTCTTCCGCTCTATGTGGCGCCCTTTTGGCTGGGCTTC 60  
DB 1 ATGGACCTGCCCCCGCAGCTCTCTTCCGCTCTATGTGGCGCCCTTTTGGCTGGGCTTC 60

QY 61 CGCTCAACGTCCTGCGCATCCGAGCGCGACGCCACGCCGCTCCGCTCTCACCCCT 120  
DB 61 CGCTCAACGTCCTGCGCATCCGAGCGCGACGCCACGCCGCTCCGCTCTCACCCCT 120

QY 121 AGCTGGTCTACGCTTGAACCTTGGGCTGCTCGACCTGCTGACAGTCTCTCTGCCC 180  
DB 121 AGCTGGTCTACGCTTGAACCTTGGGCTGCTCGACCTGCTGACAGTCTCTCTGCCC 180

QY 181 CTGAAGCGGTGAGCGCTAGGCTCCGGGCTGCGCTTCCGCGCTCGCTGTCGCCCC 240  
DB 181 CTGAAGCGGTGAGCGCTAGGCTCCGGGCTGCGCTTCCGCGCTCGCTGTCGCCCC 240

QY 241 GTCTTCGGTGGCCCACTTCTTCCACTCTATGCGCGGGGGCTTCTGAGCGCCCTG 300  
DB 241 GTCTTCGGTGGCCCACTTCTTCCACTCTATGCGCGGGGGCTTCTGAGCGCCCTG 300

QY 301 AGTGAGGCGGTACTTGGAGCAGCTTCCCTTGGCTTACCAAGCTTCCGAGGCG 360  
DB 301 AGTGAGGCGGTACTTGGAGCAGCTTCCCTTGGCTTACCAAGCTTCCGAGGCG 360

QY 361 TGCTATTCTGGGGGTGTGCGGGGCATCTGGGCTCTGCTCTGTGTCACTGGGTCTG 420  
DB 361 TGCTATTCTGGGGGTGTGCGGGGCATCTGGGCTCTGCTCTGTGTCACTGGGTCTG 420

QY 421 GTCTTTGGTGGAGGCTCCAGAGGCTGGCTGACCAACAGCAACCTCTCTGGGCATC 480  
DB 421 GTCTTTGGTGGAGGCTCCAGAGGCTGGCTGACCAACAGCAACCTCTCTGGGCATC 480

QY 481 AACACACGGTCAACGGCTCTCGGTCTGCTGGAGGCTGGACCCGGCTCTGCCGCG 540  
DB 481 AACACACGGTCAACGGCTCTCGGTCTGCTGGAGGCTGGACCCGGCTCTGCCGCG 540

QY 541 CCGGCCCGCTCAGCCCTCTCTCTCTCTCTTTTCTGCTTGGCCATCACAGCTTC 600  
DB 541 CCGGCCCGCTCAGCCCTCTCTCTCTCTTTTCTGCTTGGCCATCACAGCTTC 600

QY 601 TGCTAGTGGGCTGCTCCCGGCACTGGCCCGCTCCGCTGACGACAGGCGGAAGCTG 660  
DB 601 TGCTAGTGGGCTGCTCCCGGCACTGGCCCGCTCCGCTGACGACAGGCGGAAGCTG 660

QY 661 CCGGCCCGCTGGGTGGCGGGGCGCTTCCCTCAGCTGCTGCTGAGGACCTTAC 720  
DB 661 CCGGCCCGCTGGGTGGCGGGGCGCTTCCCTCAGCTGCTGCTGAGGACCTTAC 720

QY 721 AACGCTCTCAACGCTGGCAGCTTCTCTGTACCCCAATCTAGGAGCTCTTGGCGGAAGCTG 780  
DB 721 AACGCTCTCAACGCTGGCAGCTTCTCTGTACCCCAATCTAGGAGCTCTTGGCGGAAGCTG 780

QY 781 GGGCTCATACCGGGTGCCTGGAGTGTGGTCTTAAATCCGCTGGTACCGGTTACTTGGGA 840  
DB 781 GGGCTCATACCGGGTGCCTGGAGTGTGGTCTTAAATCCGCTGGTACCGGTTACTTGGGA 840

QY 841 AGGGGTCTTGGCTGAAGACAGTGTGGCAAGAACGCAAGGGGGCAAGTCCCAAG 900  
DB 841 AGGGGTCTTGGCTGAAGACAGTGTGGCAAGAACGCAAGGGGGCAAGTCCCAAG 900

QY 901 TAA 903  
DB 901 TAA 903

RESULT 2  
AY411511 834 bp DNA linear GSS 16-DEC-2003  
LOCUS Pan troglodytes GPR40 gene, VIRTUAL TRANSCRIPT, partial sequence,  
DEFINITION genomic survey sequence.  
ACCESSION AY411511  
VERSION AY411511.1 GI:39767479  
KEYWORDS GSS.  
SOURCE Pan troglodytes (chimpanzee)  
ORGANISM Pan troglodytes  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.  
REFERENCE 1 (bases 1 to 834)  
AUTHORS Clark,A.G., Gnanowski,S., Nielson,R., Thomas,P., Kejariwal,A.,  
Todd,M.A., Tanenbaum,D.M., Civeello,D.R., Lu,F., Murphy,B.,  
Perriera,S., Wang,G., Zheng,X.H., White,T.J., Sninsky,J.J.,  
Adams,M.D. and Cargill,M.  
TITLE Inferring nonneutral evolution from human-chimp-mouse orthologous  
gene trios  
JOURNAL Science 302 (5652), 1960-1963 (2003)  
PUBMED 14671302  
REFERENCE 2 (bases 1 to 834)  
AUTHORS Clark,A.G., Gnanowski,S., Nielson,R., Thomas,P., Kejariwal,A.,  
Todd,M.A., Tanenbaum,D.M., Civeello,D.R., Lu,F., Murphy,B.,  
Perriera,S., Wang,G., Zheng,X.H., White,T.J., Sninsky,J.J.,  
Adams,M.D. and Cargill,M.  
TITLE Direct Submision  
JOURNAL Submitted (16-NOV-2003) Celera Genomics, 45 West Gude Drive,  
Rockville, MD 20850, USA  
COMMENT This sequence was made by sequencing genomic exons and ordering  
them based on alignment.  
FEATURES  
source Location/Qualifiers  
1..834  
/organism="Pan troglodytes"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9598"  
<1..>834  
/gene="GPR40"  
/locus\_tag="HCM4248"

ORIGIN

Query Match 91.2%; Score 823.6; DB 29; Length 834;  
Best Local Similarity 99.0%; Pred. No. 9.9e-135;  
Matches 826; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 70 GTCCTGGCCATCCGAGGCGCAGCGCCACCGCTCCGCTCACACCTAGCCTGGTC 129  
DB 1 GTCCTNNCATCCGAGGCGNAGCGCCACGCGCTCCGCTCACCCCTAGCCTGGTC 60

QY 130 TACGCGCTGAACTCGGCTGCTCCGACCTGCTGACAGTCTCTCTGCCCCCTGAAGCG 189  
DB 61 TACGCGCTGAACTCGGCTGCTCCGACCTGCTGACAGTCTCTCTGCCCCCTGAAGCG 120

QY 190 GTGAGGCGCTAGCCTCCGGGCTTGGCTTGGCGGCTCGCTGTCGCCCTCTTCGCG 249  
DB 121 GTGAGGCGCTAGCCTCCGGGCTTGGCTTGGCGGCTCGCTGTCGCCCTCTTCGCG 180

QY 250 GTGGCCCACTTCTCCCACTATGCGCGCGGGCTTCTCTGCGCGCTAGTGCAGGC 309  
DB 181 GTGGCCCACTTCTTCCCACTATGCGCGCGGGCTTCTCTGCGCGCTAGTGCAGGC 240

QY 310 CGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCTTCCGAGGCGCTGCTATTC 369  
DB 310 CGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCTTCCGAGGCGCTGCTATTC 369







QY 181 CTGAAGCGGTGAGGGCTAGCTCGGGGCTGCGCTTGGCGGCTGCGGCTGCGTGTGCCCC 240  
 Db 309 CTGAAGCGGTGAGGGCTGAGGCTTGGGCGCTTGGGCGCTTGGCGGCTGCGGCTGCGTGTGCCCC 368  
 QY 241 GTCTTGGCGGTGAGGCTTCTTCCCACTATGCGGGGGGGGCTTCTTGGCGGCGGCTG 300  
 Db 369 GCCTTGGCGGTGAGGCTTCTTGGGCGCTTCTTGGGCGGCTTCTTGGCGGCGGCTG 428  
 QY 301 AGTGAAGGCGGTGAGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTG 360  
 Db 429 AGCGTGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGG 488  
 QY 361 TGTATCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGG 394  
 Db 489 CGCTACTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGGCGGCTTCTTGGG 522

## RESULT 6

CA776599 609 bp mRNA linear EST 03-DEC-2002  
 LOCUS ip08c01.y1 HR85 islet Homo sapiens cDNA clone IMAGE:6216192 5'  
 DEFINITION similar to SW:GP40 HUMAN O14842 PUTATIVE G PROTEIN-COUPLED RECEPTOR  
 GPR40, mRNA sequence.

ACCESSION CA776599.1 GI:26014474

VERSION EST.

KEYWORDS

SOURCE

ORGANISM Homo sapiens (human)

REFERENCE

AUTHORS

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.

1 (bases 1 to 609)

Melton, D., Brown, J., Kenty, G., Permutt, A., Lee, C., Kaestner, K.,

Lemshka, I., Seearce, M., Brestelli, J., Gradwohl, G., Clifton, S.,

Hillier, L., Marra, M., Pape, D., Wylie, T., Martin, J., Blistain, A.,

Schmitt, A., Theising, B., Ritter, E., Ronko, I., Bennett, J.,

Cardenas, M., Gibbons, M., McCann, R., Cole, R., Tsagarashvili, R.,

Williams, T., Jackson, F., and Bowers, Y.

Endocrine Pancreas Consortium

Unpublished (2000)

Other ESTs: ip08c01.x1

Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue

Endocrine Pancreas Consortium

Harvard University, Howard Hughes Medical Institute

Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,

MA 02138

Tel: 617-495-1812

Fax: 617-495-8557

Email: dmelton@bionh.harvard.edu

Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:

Washington University Genome Sequencing Center For information on

obtaining a clone please contact: Dr. Hiroshi Inoue

(hinoue@im.wustl.edu)

Seq primer: -40RP from Gibco

High quality sequence stop: 426.

Location/Qualifiers

1. .609

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/clone="IMAGE:6216192"

/issue\_type="Purified pancreatic islet"

/lab\_host="DH10B"

/clone\_lib="HR85 islet"

/notes="Organ: Pancreas; Vector: pBluescript SK(-); Site\_1:

NotI; Site\_2: XhoI; cDNA made by oligo-dT priming. -lkb. 5'

Size-selected on agarose gel. Average insert size ~lkb. 5'

XhoI site was destroyed after directional cloning.

Amplified once. Contact information: Hiroshi Inoue, MD,

Metabolism Div. (Alan Permutt Lab), Washington University

School of Medicine, Box 8127, 660 South Euclid Ave., St.

Louis, MO 63110, E-mail: hinoue@imgate.wustl.edu, Tel:

314-362-1916, Fax: 314-747-2692."

## ORIGIN

Query Match

Best Local Similarity

Matches

Conservative

Mismatches

Indels

Gaps

0;

0;

0;

Query Match 32.7%; Score 295.2; DB 14; Length 609;  
 Best Local Similarity 90.5%; Pred. No. 6.3e-42;  
 Matches 315; Conservative 0; Mismatches 33; Indels 0; Gaps 0;

QY 1 ATGGACCTGCGCGGCGAGCTCTCTTGGGCTCTATGTGGCGGCTTGGGCTTGGGCTTTC 60

Db 262 ATGGACCTGCGCGGCGAGCTCTCTTGGGCTCTATGTGGCGGCTTGGGCTTGGGCTTTC 321

QY 61 CGCTCAAGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 120

Db 322 CGCTCAAGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 381

QY 121 AGCTTGGTCTACGCTTGAACCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 180

Db 382 AGCTTGGTCTACGCTTGAACCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 441

QY 181 CTGAAGGCGGTGAGGCGCTAGCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 240

Db 442 CTGAAGGCGGTGAGGCGCTAGCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 501

QY 241 GTCTTGGGCTGCGGCGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 300

Db 502 GTCTTGGGCTGCGGCGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 561

QY 301 AGTGAAGGCGGTGAGGCGCTAGCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 348

Db 562 AGTGAAGGCGGTGAGGCGCTAGCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTCTTGGGCTTTC 609

## RESULT 7

CE038975/c

LOCUS

DEFINITION

genomic survey sequence.

ACCESSION

CE038975.1

VERSION

GSS.

KEYWORDS

SOURCE

ORGANISM

Canis familiaris (dog)

Canis familiaris

Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;

1 (bases 1 to 234)

Kirkness, E.F., Bafna, V., Halpern, A.L., Levy, S., Remington, K.,

Rusch, D.B., Delcher, A.L., Pop, M., Wang, W., Fraser, C.M. and

Venter, J.C.

The dog genome: survey sequencing and comparative analysis

Science 301 (5641), 1898-1903 (2003)

22875432

14512627

PUBMED

COMMENT

Contact: Kirkness EF

The Institute for Genomic Research

Department of Eukaryotic Genomics, TIGR, 9712 Medical Center Drive,

Rockville, MD 20850, USA

Tel: 301-838-0200

Fax: 301-838-0208

Email: ekirkness@tigr.org

Class: shotgun.

Location/Qualifiers

1. .234

/organism="Canis familiaris"

/mol\_type="genomic DNA"

/strain="Standard Poodle"

/db\_xref="taxon:9615"

/clone\_lib="Dog Library"

/note="Site 1: BstXI; Libraries were prepared from

peripheral blood"

## ORIGIN

Query Match

Best Local Similarity

Matches

Conservative

Mismatches

Indels

Gaps

0;

0;

0;



	ORIGIN	
	Query Match Best Local Similarity 14.2%; Score 128; DB 28; Length 543; Matches 128; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	1 ATGGACTGCGCCCGCAGCTCTCTTCGGGCCTATATGTGGCGCGCTTTTGGCTTGCGGTTC 60 	
Dd	414 ATGGACCTGCCCGCAGCTCTCTCTTGGGCTCTATGTGGCGCGCTTTTGGCTTGCGGTTC 473 	
Qy	61 CCGCTCAACGTCTCTGGCCATCCGAGGCGCACGCGCCCACGCCCGGCTCCGTCTCACCCCT 120 	
Dd	474 CCGCTCAACGTCTCTGGCCATCCGAGGCGCACGCGNCCACGCGGCTCCGTCTCACCCCT 533 	
Qy	121 AGCCTGGTCT 130 	
Dd	534 AGCCTGGTCT 543 	
	RESULT 11 BM544968 LOCUS DEFINITION AGENSCURT_6497637 NIH_MGC_125 Homo sapiens cDNA clone IMAGE:5588752 5', mRNA sequence.  ACCESSION BM544968 VERSION BM544968.1 GI:18776664 KEYWORDS EST. SOURCE Homo sapiens (human) ORGANISM Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
	REFERENCE AUTHORS NTH-MGC http://mgc.nci.nih.gov/ TITLE National Institutes of Health, Mammalian Gene Collection (MGC) JOURNAL Unpublished (1999) COMMENT Contact: Robert Strausberg, Ph.D. Email: cgapbs@mail.nih.gov Tissue Procurement: Invitrogen CDNA Library Preparation: Life Technologies, Inc. CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Agencourt Bioscience Corporation Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Plate: LLAM12360 row: f column: 17 High quality sequence start: 26 High quality sequence stop: 716. Location/Qualifiers 1..1117 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="IMAGE:5588752" /lab_host="DH10B" /clone_lib="NIH MGC 125" /notes="Organ: ovary (pool of three ovaries, from females ranging in age from 38 to 49 yo. Library is oligo-dr primed and directionally cloned (ScRV site is destroyed upon cloning). Average insert size 2.1 kb, insert size range 1-3.5 kb. Library is normalized and enriched for full-length clones and was constructed by C. Gruber (Invitrogen). Research Genetics tracking code 036."	
	FEATURES source	
	ORIGIN	
	Query Match Best Local Similarity 13.0%; Score 117.4; DB 12; Length 1117; Matches 371; Conservative 0; Mismatches 317; Indels 24; Gaps 4;	
Qy	18 GCCTCTCTGGGCTCTATGTGGCGCCCTTTGGCTGGGCTCCCCGTCAAGCTCTGGC 77 	
Dd	125 GTTCGGTCTCTCGGTGTA CCTTCTCTCACTTCTCTGGTGGGCTCCCCCTCAACTGCTGGC 184 	





fat, hypothalamus, and pituitary."

ORIGIN

Query Match 11.4%; Score 102.8; DB 12; Length 472;  
Best Local Similarity 53.8%; Pred. No. 3.7e-08;  
Matches 212; Conservative 0; Mismatches 182; Indels 0; Gaps 0;

QY 18 GCTCTCTCGGCTCTATGCGCGCTTTGGCTGGCTCCGCTCAAGCTCTCTGGC 77  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 76 GCTCTCTCTCGGCTCTATGCGCGCTTTGGCTGGCTCCGCTCAAGCTCTCTGGC 135  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 78 CATCCGAGCGCGAGCGCCCGCGCTCGCTCTCACCCCTAGCTCTGTATAGCCCT 137  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 136 CTGTGTATCTTCGTGGCAAGCTGGCGCGCGCGCTGTGGAGTGTCTTGTCT 195  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 138 GAACCTGGGCTGCTCGAGCTGCTGACATCTCTCTGCGCCCTGAAGCGCGTGGAGGC 197  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 196 AAAACCTCACCCCTCTGGATCTGCTCTGTGTCTCTCTGCGGTTCCGCACTGTTGAGGC 255  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 198 GCTAGCCTCGGGGCTGCGCTCTGCGGCTCGCTGTGCGCCGCTCTTCCGCTGGCCCA 257  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 256 GGCCAGTGCATGCACTGTCTCCCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCT 315  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 258 CTCTCTCCACCTATGCGCGCGGCGCTCTCTCTGCGCGCTCTGAGTGCAGCGCGCTACCT 317  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 316 CTTACCAACCATCTATCTACGTCCTCTCTCTGCGAGCGGTGAGCACAGCGCTCTCT 375  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 318 GGGAGAGCCTTCCCTCTGGCTACCAAGCTCTCGGAGCGCGTGTATCTCTGGGGGT 377  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 376 GAGCGTGGCTACCGCTCTGTGTACAGACTCGGCGAGCGGCGAGGCTGGCTGTGT 435  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 378 GTGCGGGCCATCTGGGCTCTGTCTGTGTCTAC 411  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 436 CAGTGGGCGCTGTGCTCTCTGCGCGCTGTCTAC 469  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

ORIGIN

Query Match 10.6%; Score 95.8; DB 14; Length 489;  
Best Local Similarity 89.1%; Pred. No. 6.3e-07;  
Matches 115; Conservative 0; Mismatches 12; Indels 2; Gaps 1;

QY 1 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCGCTTTTGGCTGGGCTTC 60  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 94 ATGGACCTGCCCCCGCAGCTCTCTTGGGCTCTATGTGGCGCTTTTGGCTGGGCTTC 153  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 61 CCGCTCAAGCTCTGGCCATCCGAGCGCGAGCGGCCACGCCCGGGTTCGTCTTCACCC 118  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 154 CCGCTCAAGCTCTGGCCATCCGAGCGCGAGCGGCCACGCCCGGGTTCGTCTTCACCC 213  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
QY 119 CTAGCCTGG 127  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 214 TTAGCCTGG 222  
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

Search completed: April 30, 2004, 16:32:52  
Job time : 2953 secs

RESULT 15  
CA777066  
LOCUS  
DEFINITION  
ip02f08.y1 HR85 islet Homo sapiens cDNA clone IMAGE:6134918 5'  
similar to SW:GP40 HUMAN O14842 PUTATIVE G PROTEIN-COUPLED RECEPTOR  
GPR40. ;, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 489)  
Melton,D., Brown,J., Kenty,G., Permutt,A., Lee,C., Kaestner,K.,  
Lemishka,I., Searce,M., Brestelli,J., Gradwohl,G., Clifton,S.,  
Hillier,L., Marra,M., Pape,D., Wyllie,T., Martin,J., Blistain,A.,  
Schmitt,A., Theising,B., Ritter,E., Ronko,I., Bennett,J.,  
Cardenas,M., Gibbons,M., McCann,R., Cole,R., Teagareishvili,R.,  
Williams,T., Jackson,Y. and Bowers,Y.  
Endocrine Pancreas Consortium  
Unpublished (2000)  
Other\_ESTs: ip02f08.x1  
Contact: Douglas Melton, Klaus H. Kaestner, & Hiroshi Inoue  
Endocrine Pancreas Consortium  
Harvard University, Howard Hughes Medical Institute  
Dept of Molecular and Cellular Biology, 7 Divinity Ave, Cambridge,  
MA 02138  
Tel: 617-495-1812  
Fax: 617-495-8557  
Email: dmelton@biohp.harvard.edu  
Library was constructed by Dr. Hiroshi Inoue DNA sequencing by:  
Washington University Genome Sequencing Center For information on  
obtaining a clone please contact: Dr. Hiroshi Inoue  
(hinoue@im.wustl.edu)  
Seq primer: -40RP from Gibco  
High quality sequence stop: 64.



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 30, 2004, 07:54:59 ; Search time 90 Seconds  
(without alignments)  
5568.007 Million cell updates/sec

Title: US-10-202-687-1

Perfect score: 903

Sequence: 1 atggacctgccccgcagct.....ggggcaagtcccgagtaag 903

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents NA.\*

- 1: /cgn2\_6/prodata/2/ina/5A COMB.seq\*
- 2: /cgn2\_6/prodata/2/ina/5B COMB.seq\*
- 3: /cgn2\_6/prodata/2/ina/6A COMB.seq\*
- 4: /cgn2\_6/prodata/2/ina/6B COMB.seq\*
- 5: /cgn2\_6/prodata/2/ina/PCUS COMB.seq\*
- 6: /cgn2\_6/prodata/2/ina/backfile1.seq\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	903	100.0	903	4	US-09-170-496D-249
2	898.2	99.5	903	4	US-09-170-496D-271
3	123.4	13.7	1841	2	US-08-820-521-1
4	123.4	13.7	1841	3	US-09-248-715-1
5	123.4	13.7	1841	3	US-09-248-715-1
6	121.8	13.5	1041	4	US-09-170-496D-253
7	118.6	13.1	1041	4	US-09-170-496D-273
8	84.6	9.4	4895	3	US-09-053-866-1
9	84.6	9.4	4895	4	US-09-479-130-1
10	84.6	9.4	4895	4	US-09-472-130A-1
11	80	8.9	1098	4	US-09-170-496D-117
12	80	8.9	1098	4	US-09-170-496D-225
13	80	8.9	1597	2	US-08-724-974A-1
14	80	8.9	1697	4	US-09-364-425B-26
15	78.2	8.7	1050	4	US-09-762-661A-1
16	78.2	8.7	1329	4	US-09-152-060-25
17	77.2	8.5	993	4	US-09-170-496D-257
18	77.2	8.5	2260	2	US-08-788-750-1
19	75.6	8.4	993	4	US-09-170-496D-275
20	73.2	8.1	993	3	US-09-187-710-1
21	70	7.8	1095	4	US-09-743-475-2
22	70	7.8	1910	2	US-09-009-438-1
23	70	7.8	1910	3	US-09-207-493-1
24	70	7.8	4009	4	US-09-743-475-1
25	66.8	7.4	1155	3	US-09-053-866-3
26	66.8	7.4	1155	4	US-09-479-130-3
27	66.8	7.4	1155	4	US-09-472-130A-3

ALIGNMENTS

RESULT 1

US-09-170-496D-249  
; Sequence 249, Application US/09170496D  
; Patent No. 6555339  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; TITLE OF INVENTION: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 249  
; LENGTH: 903  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-170-496D-249

Query Match		100.0%	Score 903;	DB 4;	Length 903;
Best Local Similarity		100.0%	Pred. No. 2.3e-177;		
Matches 903;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	ATGGACCTGCCCCCGCAGCTCTCTTCGGCCTCTATGTGGCGCCTTTGGCTGGGCTTC	60		
Db	1	ATGGACCTGCCCCCGCAGCTCTCTTCGGCCTCTATGTGGCGCCTTTGGCTGGGCTTC	60		
Qy	61	CGCTCAACGTCTGTGGCCATTCGAGGCGGCGAGCGGCCACGCCGGCTTCGGTCTCACCCCT	120		
Db	61	CGCTCAACGTCTGTGGCCATTCGAGGCGGCGAGCGGCCACGCCGGCTTCGGTCTCACCCCT	120		
Qy	121	AGCTGTCTAGCCCTGAACTGGGCTGCTCGACCTGCTGCTGACAGTCTCTCTGCCCC	180		
Db	121	AGCTGTCTAGCCCTGAACTGGGCTGCTCGACCTGCTGCTGACAGTCTCTCTGCCCC	180		
Qy	181	CTGAAGGCGGTGGAGGCGCTAGCCTTCGGGGCGCTGGCCTCTGCGGCGCTGCTGTGCCCC	240		
Db	181	CTGAAGGCGGTGGAGGCGCTAGCCTTCGGGGCGCTGGCCTCTGCGGCGCTGCTGTGCCCC	240		
Qy	241	GTCTTCGGGCTGGCCACTTCTTCCACCTATGCGCGGGGGGGCTTCTGGCGGCGCTG	300		
Db	241	GTCTTCGGGCTGGCCACTTCTTCCACCTATGCGCGGGGGGGCTTCTGGCGGCGCTG	300		
Qy	301	AGTGACGGCGCTACTCTGGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCGGAGGCGG	360		
Db	301	AGTGACGGCGCTACTCTGGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCGGAGGCGG	360		
Qy	361	TGCTATTCTGGGGGGTGTGCGGGCCATCTGGGGCCCTGCTGCTGTGTACCTGGGTCTG	420		

Sequence 5, Appli  
Sequence 5, Appli  
Sequence 15, Appli  
Sequence 15, Appli  
Sequence 14, Appli  
Sequence 14, Appli  
Sequence 2, Appli  
Sequence 2, Appli  
Sequence 1, Appli  
Sequence 1, Appli  
Sequence 3, Appli  
Sequence 165, App  
Sequence 1429, Ap  
Sequence 1, Appli  
Sequence 4, Appli  
Sequence 4, Appli  
Sequence 1366, Ap  
Sequence 61, Appli



[illegible]



Db 970 GCGGCGACGCTCTCAACTTCCTTGTCTGCTTTGGGCCCTACACGCTGCCATGCTCGT 1029  
Qy 738 CAGCTTCCTGTAC 750  
Db 1030 GGGCTATATCTGC 1042

## RESULT 6

US-09-170-496D-253  
; Sequence 253, Application US/09170496D  
; Patent No. 6555339  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 253  
; LENGTH: 1041  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-170-496D-253

Query Match 13.5%; Score 121.8; DB 4; Length 1041;  
Best Local Similarity 52.1%; Pred. No. 1e-16;  
Matches 382; Conservative 0; Mismatches 327; Indels 24; Gaps 4;

Qy 18 GCTCTCTTCGGGCTCTATGTGGCGCGCTTGTGGCTGGGCTCCCGCTCAAGCTCTCTGGC 77  
Db 45 GTTGTCTTCTCGGTGTACTTCTCACTTCTGTGTGGGCTCCCGCTCAAGCTCTCTGGC 104  
Qy 78 CATCCGAGGCGGACCGCCGACCGCGGCTCGTCTCACCCCTAGGCTGTGTCTACGCCCT 137  
Db 105 CTTGTGTGTCTTGTGGCAAGCTGCAGCGCGCGCGGCTGGCGGTGTGTCTCTGTCT 164  
Qy 138 GAACCTGGGCTGTCCGACTGTGTGTGACAGTCTCTGTGCCCTCAAGCGGTGTGAGGC 197  
Db 165 CAACCTGACCGCTCGGACGTGTCTGTGTGTCTGTCTGTCTGTCTGTCTGTCTGTCT 224  
Qy 198 GCTAGGCTCCGGGCTGTGGCTCTGTGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGT 257  
Db 225 AGCAATGGCATGCACTGGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 284  
Qy 258 CTTCTTCCCACTCTATGTGGCGGCGGCTTCTGTGGCGCGCTGTGTGTGTGTGTGTGTGT 317  
Db 285 CTTTACCACCATCTATCTCACCGCCCTTCTGTGGCGAGCTGTGTGTGTGTGTGTGTGT 344  
Qy 318 GGGAGAGAGCTTCCCTTGGGCTACCAAGCTTTCGGAGGCGGTGTGTGTGTGTGTGTGT 377  
Db 345 GAGTGTGGGCTTCCGCTGT 404  
Qy 378 GTGGCGGCGCATCTGGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 437  
Db 405 GAGTGTGGGCTTGT 464  
Qy 438 TCCAGGAGGCTGT 497  
Db 465 CTCAGGGG-----ACATCTCCACAGCGGCGCATCAACACACCGGTCAACGG 506  
Qy 498 CTCCTCGGTCTGT 557  
Db 507 CTACCTGGAGTTCCGGAAGGACAG--CTAGGCACTCTCTGTGCCGTGTGTGTGTGTGT 563  
Qy 558 CTCCTCTCTGT 617  
Db 564 GGCTGTGTGTCTTGT 620

Qy 618 CCGGGCACTGGGCGGCTCGGCTCGGCTGACGACAGCGGAGAGCTCGGCGCGCTGTGGTGGC 677  
Db 621 GGTGTGGATCTCTGGCAGAGGGGGCAGCCACCGCGCAGAGAGGGTGTGGCGGCTGTGT 680  
Qy 678 CCGGGGGGCGCTCTCAAGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 737  
Db 681 GCGGGCCACGCTGTCTCAACTTCTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 740  
Qy 738 CAGCTTCCTGTAC 750  
Db 741 GGGCTATATCTGC 753

## RESULT 7

US-09-170-496D-273  
; Sequence 273, Application US/09170496D  
; Patent No. 6555339  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 273  
; LENGTH: 1041  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-170-496D-273

Query Match 13.1%; Score 118.6; DB 4; Length 1041;  
Best Local Similarity 51.8%; Pred. No. 4.8e-16;  
Matches 380; Conservative 0; Mismatches 329; Indels 24; Gaps 4;

Qy 18 GCTCTCTTCGGGCTCTATGTGGCGCGCTTGTGGCTGGGCTCCCGCTCAAGCTCTCTGGC 77  
Db 45 GTTGTCTTCTCGGTGTACTTCTCACTTCTGTGTGGGCTCCCGCTCAAGCTCTCTGGC 104  
Qy 78 CATCCGAGGCGGACCGCCGACCGCGGCTCGTCTCACCCCTAGGCTGTGTCTACGCCCT 137  
Db 105 CTTGTGTGTCTTGTGGCAAGCTGCAGCGCGCGCGGCTGGCGGTGTGTCTCTGTCT 164  
Qy 138 GAACCTGGGCTGTCCGACTGTGTGTGACAGTCTCTGTGCCCTCAAGCGGTGTGAGGC 197  
Db 165 CAACCTGACCGCTCGGACGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 224  
Qy 198 GCTAGGCTCCGGGCTGTGGCTCTGTGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGT 257  
Db 225 AGCAATGGCATGCACTGGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 284  
Qy 258 CTTCTTCCCACTCTATGTGGCGGCGGCTTCTGTGGCGCGCTGTGTGTGTGTGTGTGTGT 317  
Db 285 CTTTACCACCATCTATCTCACCGCCCTTCTGTGGCGAGCTGTGTGTGTGTGTGTGTGT 344  
Qy 318 GGGAGAGAGCTTCCCTTGGGCTACCAAGCTTTCGGAGGCGGTGTGTGTGTGTGTGTGT 377  
Db 345 GAGTGTGGGCTTCCGCTGT 404  
Qy 378 GTGGCGGCGCATCTGGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 437  
Db 405 GAGTGTGGGCTTGT 464  
Qy 438 TCCAGGAGGCTGT 497  
Db 465 CTCAGGGG-----ACATCTCCACAGCGGCGCATCAACACACCGGTCAACGG 506  
Qy 498 CTCCTCGGTCTGT 557  
Db 507 CTACCTGGAGTTCCGGAAGGACAG--CTAGGCACTCTCTGTGCCGTGTGTGTGTGTGT 563  
Qy 558 CTCCTCTCTGT 617  
Db 564 GGCTGTGTGTCTTGT 620





CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/479,130  
 FILING DATE:  
 CLASSIFICATION:  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER:  
 FILING DATE:  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Leith, Debra K  
 REGISTRATION NUMBER: 32,619  
 REFERENCE/DOCKET NUMBER: 98-10  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 206-442-5674  
 TELEFAX: 206-442-6678  
 TELEX:  
 INFORMATION FOR SEQ ID NO: 1:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 4895 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 FEATURE:  
 NAME/KEY: Coding Sequence  
 LOCATION: 176...1330  
 OTHER INFORMATION:  
 US-09-479-130-1

Query Match 9.4%; Score 84.6; DB 4; Length 4895;  
Best Local Similarity 47.2%; Pred. No. 5.4e-09;  
Matches 329; Conservative 0; Mismatches 359; Indels 9; Gaps 2;

[illegible]

```

Db      990  CGGCCACGGCGCGCGCTACGGCCACGCGCTGAGGCTGACCGCAGTGGTCTGCTGGCCTCCG 1049
Qy      668  CTTGGTGGCGGGGGGGCCCTCTCTCACGCTGCTGCT 704
          |||||
Db      1050  CCGTGGCCTTCTTCTGTCGCCACGCAACCTGCTGCTGCT 1086
          |||||

RESULT 10
US-09-472-130A-1
; Sequence 1, Application US/09472130A
; Patent No. 643765
; GENERAL INFORMATION:
; APPLICANT: Xu, Wenfeng
; APPLICANT: Prensell, Scott R.
; APPLICANT: Yee, David P.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR PARA
; TITLE OF INVENTION: (ZCHEMR2)
; FILE REFERENCE: 98-10D2
; CURRENT APPLICATION NUMBER: US/09/472,130A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/053,866
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Fast-SEQ for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 4895
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (176) ... (1330)
US-09-472-130A-1

```

Query Match 9.4%; Score 84.6; DB 4; Length 4895;

Best Local Similarity 47.2%; Pred. No. 5.4e-09;  
Matches 329; Conservative 0; Mismatches 359; Indels 9; Gaps 2;

Qy	8	TGCCCCCGCAGCTCTCCTTTCGGCGCTCTATGTGCGCGCCTTTTGTGCGTGTGGCTTCCCGCTCA	67
Db	399	TGCCCCACAGGCTGTGTCGCCCGCCTCTATGTGGCTGTGTCCTGTGTGTGGGCTCCCGGCCA	458
Qy	68	ACGTCTGGGCGCATCCGAGGGCGCAGCGGCCACGCGGCTCCGTCCTCACCCCTAGCCTGG	127
Db	459	ATGGGCTTGGCGCTGTGGGTCTGGCACGAGGACCTCGGCTGCGCCTTCACCATGCTGC	518
Qy	128	TCTAGCGCCCTGAACCTTGGGCTGTCCGACCTGCTGTGTGACAGTCTCTCTGTGCCCTGAAGG	187
Db	519	T-----GATGAACCTCGGACGTGTGTGACCTCTGTGTGGCTGTGGGCTGTGCCCGCGGA	572
Qy	188	CGGTGAGGGCGCTAGCCTTCGGGCGCTTGGGCTCTGCGGCTCGCTGTGCGCCGCTTTCG	247
Db	573	TCGCTTACCACCTCGCTTGGCGACGCTTGCGCCTTCGCGGAGGCGCGCTTGGCGCTTGGCCA	632
Qy	248	CGGTGGCCCACTTCTTCCCACTCTATGCGCGCGGGGGCTTCTGTGGCGCGCCTGTAGTGCAG	307
Db	633	CGGCGCGCACTCTATGGTTCATATGATGGTTCAGTGTGCTGTCTGTGGCGCGCGTCAAGCCTGG	692
Qy	308	GCGCTACTCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCTTCGGAGGCGCTGTATT	367
Db	693	ATCGCTACTTGGCGCCTGTGTGACACCGCTGGGCGCGCGCCTTGTGTGCGCGCGCCTGG	752
Qy	368	CTTGGGGGTGTGCGGGGCCATCTGGGCGCCTCTGTGTGTACCTTGGGTCTGGTCTTTG	427
Db	753	CCCTTGGACTCTGCATGGGTGTGTTGG---CTCATGGGCGCGCCTTGGCACTGCCCTGA	809
Qy	428	GGTTGGAGGCTCCAGGAGGCTGGCTGGACACAGCAACCTCCCTGGGCACTCAACACAC	487
Db	810	CACCTGCAGCGGACAGCTTCCGCGCTGGCGGCTCCGATCGGGTGTCTGCGCATGACGCGC	869
Qy	488	CGGTCAACGGCTCTCCGGTCTGTCTGGAGGCTGGGACCGGGCTCTGCGGCGCGGCCCC	547
Db	870	TGCCCTTGGACGCAAGGCTCCCACTGGCAACCGGCGCTTCACTGCTGTGGGCTGTGG	929



```
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: William T. Han
; REGISTRATION NUMBER: 34,344
; REFERENCE/DOCKET NUMBER: ATG50022
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610 270 5024
; TELEFAX: 610 270 5090
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1597
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: NO
US-08-724-974A-1

Query Match      8.9%; Score 80; DB 2; Length 1597;
Best Local Similarity 51.8%; Pred. No. 4.3e-08;
Matches 207; Conservative 0; Mismatches 190; Indels 3; Gaps 1;

QY 6 CTTGCCCCCGAGCTCTCTTGGCCCTCTATGTGGCGCGCTTGTGGCGTGGGCTTCCCGCT 65
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 395 CATCCACAGACGCTGGCCCGGCTGTATGTTACCGTGTGGTGGGCTTCCCGCGC 454
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 66 CAAGTCTCGGCCATCCGAGGCGGAGCGGCCCGGCTCCGCTCAACCCCTAGCCT 125
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 455 CAACTGCCCTGTCCCTCTACTTCCGCTACCTGCGAGATCAAGGCCCGGAAAGAGCTGGGC-- 512
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 126 GGTCTACGGCCCTGAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCCCCCTGAA 185
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 513 -GTGTACCTGTGCAACTGACGGTGGCGGACCTCTTCTACATCTGCTGGCTTCTG 571
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 186 GCGGTGTGAGGCGCTAGCTCCGGGCGCTGGGCTCTGCGCGGCTGCTGCGGCGCTCTT 245
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 572 GCTGCAGTACGTGCTGCAGCAGCAACTGGTCTCACGGCGGACCTGCTGCCAGGTGTG 631
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 246 CCGGTGGCCCACTTCTCCCACTCTATGCGCGGGGCTTCTGCGCGGCGCTGAGTGC 305
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 632 CGCATCTCTCTGTACGAGAACTACATCATCAGCGTGGGCTTCTCTGTGCACTTCCGT 691
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 306 AGCGCCCTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCTTCCGAGGCGCGTGTCTA 365
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 692 GAGCGCTACCTGGCTGTGGCCCATCTCCCTCCGCTTCCAGGCTTCCGAGCCTGAGGC 751
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 366 TTCCTGGGGGTGTGCGCGGCCATCTGGGCGCTTCCGCTG 405
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 752 GCGCGTGGCGGTGAGCGGTGTCATCTGCGGCCAAGGAGCTG 791
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 14
US-09-364-425B-26
; Sequence 26, Application US/09364425B
; Patent No. 6653086
; GENERAL INFORMATION:
; APPLICANT: Behan, Dominic P.
; APPLICANT: Chalmers, Derek T.
; APPLICANT: Liaw, Chen W.
; APPLICANT: Lin, I-Lin
; APPLICANT: Lowitz, Kevin P.
; APPLICANT: Chen, Ruoping
; TITLE OF INVENTION: Endogenous, Constitutively Activated G Protein-Coupled Orphan Receptor
; FILE REFERENCE: Aren0047
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US/09/364,425B
; PRIOR FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: 60/094,879
; PRIOR FILING DATE: 1998-07-31
; PRIOR APPLICATION NUMBER: 60/106,300
; PRIOR FILING DATE: 1998-10-30
; PRIOR APPLICATION NUMBER: 60/110,906
```

```
; PRIOR FILING DATE: 1998-12-04
; PRIOR APPLICATION NUMBER: 60/121,851
; PRIOR FILING DATE: 1999-02-26
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 1697
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-364-425B-26

Query Match      8.9%; Score 80; DB 4; Length 1697;
Best Local Similarity 51.8%; Pred. No. 4.3e-08;
Matches 207; Conservative 0; Mismatches 190; Indels 3; Gaps 1;

QY 6 CTTGCCCCCGAGCTCTCTTGGCCCTCTATGTGGCGCGCTTGTGGCGTGGGCTTCCCGCT 65
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 377 CATCCACAGACGCTGGCCCGGCTGTATGTTACCGTGTGGTGGGCTTCCCGCGC 436
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 66 CAAOGTCTTGGCCATCCGAGGCGGAGCGGCCCGGCTCCGCTCTCACCCCTAGCCT 125
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 437 CAACTGCCCTGTCCCTCTACTTCCGCTACCTGCGAGATCAAGGCCCGGAAAGAGCTGGGC-- 494
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 126 GGTCTACGGCCCTGAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCCCCCTGAA 185
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 495 -GTGTACCTGTGCAACTGACGGTGGCGGACCTCTTCTACATCTGCTGCGCTTCTG 553
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 186 GCGGTGTGAGGCGCTAGCCTCCGGGCGCTGGGCTCTGCGCGGCTGCTGCGGCGCTT 245
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 554 GCTGCAGTACGTGCTGCAGCAGCAACTGGTCTCACGGGAGCCTGCTCTGCCAGGTGTG 613
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 246 CCGGTGGCGCCCACTTCTCCCACTCTATGCGCGGGGCTTCTGCGCGGCGCTGAGTGC 305
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 614 CCGCATCTCTCTGTACGAGAACTACATCATCAGGTGGGCTTCTCTGTGCACTCCGT 673
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 306 AGCGCCCTACCTGGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCCGAGGCGCGTGTCTA 365
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 674 GAGCGCTACCTGGGCTGTGGCCCATCTCCCTCCGCTTCCAGCAGTTCGCGGACCTGAAGGC 733
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 366 TTCCTGGGGGTGTGCGCGGCCATCTGCGGCGCTTCCGCTG 405
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 734 GCGCGTGGCGGTGAGCGGTGTCATCTGGGCGCAAGGAGCTG 773
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 15
US-09-762-661A-1
; Sequence 1, Application US/09762661A
; Patent No. 6645726
; GENERAL INFORMATION:
; APPLICANT: Howard, Andrew D.
; APPLICANT: Palyha, Oksana C.
; APPLICANT: Smith, Roy G.
; APPLICANT: Tan, Carina P.
; TITLE OF INVENTION: CANINE GROWTH HORMONE SECRETAGOGUE
; FILE REFERENCE: 20207P
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: US/09/762,661A
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: PCT/US99/17915
; PRIOR FILING DATE: 1998-08-10
; PRIOR APPLICATION NUMBER: 60/095,960
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 1050
; TYPE: DNA
; ORGANISM: Canis familiaris
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)...(1050)
; OTHER INFORMATION: n = A,T,C or G
US-09-762-661A-1
```

Query Match		8.7%;	Score 78.2;	DB 4;	Length 1050;
Best Local Similarity		47.9%;	Pred. No. 9.7e-08;		
Matches 292;	Conservative	0;	Mismatches 309;	Indels	9; Gaps 2;
Qy	28	GGCCTCTATGTGGCGCCCTTTGGCTGGGCTTC	CGGCTCAACGTCCTGGCCATCCGAGGC	87	
Db	91	GCACCTGGTGGCGTGTTCGCGGTGGCGTTCGGGGCAAC	CTGTGACGGTGTGGTG	150	
Qy	88	GGAGGGCCACGCGCGGCTCGTCTCACCCCTAGGCTGT	TACGCCCTGAACCTGGGC	147	
Db	151	GTGCGCGCTTCGCGAGCTGGGCAACACCAACCTG---	TACCTGTGCAGCCCTGGCC	207	
Qy	148	TGCTCCGACCTGTGTGACAGTCTCTCTGCCCTGAAGCGGT	GGGCGCTAGCCTCC	207	
Db	208	TGCTCCGACCTGTCTATCTCTCTGTGTCATGCCGCTG	ACCTGGTGGCGCTGGCAGTAC	267	
Qy	208	GGGGCTGGCCCTCTGCGGCTCGTGTGCCCGCTCTT	CGGCTGGCCCACTTCTTCCCA	267	
Db	268	CGGCCCTGGACCTTCGGCGACCTGTCTCTGAAACTCT	TCCAGTTCGTGAGCGAGGGCTGC	327	
Qy	268	CTCTATGCGCGGGGGCTTCTGTGGCGCCCTGAGTGC	AGGCGGCTACCTGGGAGGAGCC	327	
Db	328	ACCTAGCCACGCGTGTCAACCATCAGGCGCTGAGCGT	CGAGCGTACTTCCGCATCTGC	387	
Qy	328	TTCCCTTGGGCTACCAAGCCTTCGGAGGCGGTGCT	ATTCTGGGGGTGTGCGGGC	387	
Db	388	TTCCCGCTGCGCGCCAGGTGCTGTGTGACCAAGGCG	CGGTGAAGCTGGCCCTGTGGCC	447	
Qy	388	ATCTGGGCCCTGCTCTGTGTCACTGGGTCTGGTCT	TTGGGTGGAGGCTCCAGGAGGC	447	
Db	448	ATCTGGGCGTGGCCTTCTGACGGCGCGGCCCATCT	TCTGTGTGTG-----GGCGTG	501	
Qy	448	TGGCTGGACCAAGCAACCTCTCCCTGGGCATCAACA	CCGGTCAACGGCTCTCGGTG	507	
Db	502	GAGCACAGAGAGCGCACCGACCCCGGGACACCCGCG	AGTGC	561	
Qy	508	TGCTGGAGGCTTGGGACCGGCGCTCTGCGCGCCGCG	CTTCAAGCCTCTCTCTCTG	567	
Db	562	GTGCGCTCGGGGTGCTCACGGCCATGGTGTGGGTG	TCAGGCTCTCTCTCTGCCC	621	
Qy	568	CTCTTTTCTGCGCTTGGCCATCACAGCCTTCTGTCT	AGCGGCTGCGCTCCGGGCACTG	627	
Db	622	GTCTTCTGCTCACGCTGCTCTACGGCCATGGTGT	TCAGGCTCTCTCTCTCTGCCC	681	
Qy	628	GCCGCTCCG	637		
Db	682	GGCGACACNG	691		

Search completed: April 30, 2004, 15:43:30  
Job time : 93 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 30, 2004, 15:43:35 ; Search time 465 Seconds  
(without alignments)  
8784.275 Million cell updates/sec

Title: US-10-202-687-1

Perfect score: 903

Sequence: 1 atggacctgccccgcagct.....ggggcaagtcccaagaagtaa 903

Scoring table: IDENTITY NUC

Gapop 10\_0 , Gapext 1.0

Searched: 2936184 seqs, 2261732022 residues

Total number of hits satisfying chosen parameters: 5872368

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Published Applications NA:\*
- 1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*
  - 2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*
  - 3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*
  - 4: /cgn2\_6/ptodata/1/pubpna/US06\_PUBCOMB.seq:\*
  - 5: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*
  - 6: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq:\*
  - 7: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*
  - 8: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*
  - 9: /cgn2\_6/ptodata/1/pubpna/US09A\_PUBCOMB.seq:\*
  - 10: /cgn2\_6/ptodata/1/pubpna/US09B\_PUBCOMB.seq:\*
  - 11: /cgn2\_6/ptodata/1/pubpna/US09C\_PUBCOMB.seq:\*
  - 12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*
  - 13: /cgn2\_6/ptodata/1/pubpna/US09A\_NEW\_PUB.seq:\*
  - 14: /cgn2\_6/ptodata/1/pubpna/US10A\_PUBCOMB.seq:\*
  - 15: /cgn2\_6/ptodata/1/pubpna/US10B\_PUBCOMB.seq:\*
  - 16: /cgn2\_6/ptodata/1/pubpna/US10C\_PUBCOMB.seq:\*
  - 17: /cgn2\_6/ptodata/1/pubpna/US10\_NEW\_PUB.seq:\*
  - 18: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*
  - 19: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	903	100.0	903	15	US-10-251-385-249 Sequence 249, App
2	903	100.0	903	15	US-10-225-567A-474 Sequence 474, App
3	903	100.0	903	15	US-10-029-386-22904 Sequence 22904, A
4	903	100.0	903	16	US-10-202-687-1 Sequence 1, Appli
5	898.2	99.5	903	15	US-10-251-385-271 Sequence 271, App
6	154	17.1	550	15	US-10-029-386-9201 Sequence 9201, Ap
7	121.8	13.5	960	15	US-10-029-386-24088 Sequence 24088, A
8	121.8	13.5	1041	15	US-10-251-385-253 Sequence 253, App
9	121.8	13.5	1041	15	US-10-225-567A-604 Sequence 604, App
10	121.8	13.5	1041	15	US-10-203-539-1 Sequence 1, Appli
11	121.8	13.5	1041	15	US-10-203-539-3 Sequence 3, Appli
12	121.8	13.5	1206	15	US-10-029-386-25146 Sequence 25146, A
13	118.6	13.1	1041	15	US-10-251-385-273 Sequence 273, App
14	84.6	9.4	4895	15	US-10-225-567A-515 Sequence 515, App

15	84.6	9.4	4895	15	US-10-187-049-1	Sequence 1, Appli
16	80	8.9	1098	10	US-09-850-948-5	Sequence 5, Appli
17	80	8.9	1098	15	US-10-251-385-117	Sequence 117, App
18	80	8.9	1098	15	US-10-251-385-225	Sequence 225, App
19	80	8.9	1098	15	US-10-273-575-5	Sequence 5, Appli
20	80	8.9	1098	15	US-10-225-567A-282	Sequence 282, App
21	80	8.9	1434	15	US-10-029-386-25332	Sequence 25332, A
22	80	8.9	1697	15	US-10-109-533A-1	Sequence 1, Appli
23	80	8.9	1697	15	US-10-288-222A-11	Sequence 11, Appli
24	78.2	8.7	1329	9	US-09-853-161-25	Sequence 25, Appli
25	78.2	8.7	1329	9	US-09-852-659A-25	Sequence 25, Appli
26	78.2	8.7	1329	9	US-09-852-797-25	Sequence 25, Appli
27	78.2	8.7	1329	13	US-10-058-993-25	Sequence 25, Appli
28	77.2	8.5	993	15	US-10-251-385-257	Sequence 257, App
29	77.2	8.5	993	15	US-10-225-567A-466	Sequence 466, App
30	77.2	8.5	993	15	US-10-337-992-1	Sequence 1, Appli
31	77.2	8.5	994	15	US-10-029-386-25403	Sequence 25403, A
32	77.2	8.5	1616	15	US-10-348-190-3	Sequence 3, Appli
33	75.6	8.4	993	15	US-10-251-385-275	Sequence 275, App
34	73.2	8.1	2426	15	US-10-348-190-1	Sequence 1, Appli
35	70.8	7.8	960	15	US-10-203-539-5	Sequence 5, Appli
36	70.4	7.8	1955	13	US-10-400-991-2	Sequence 2, Appli
37	70.4	7.8	1955	15	US-10-190-469-2	Sequence 2, Appli
38	70	7.8	1116	15	US-10-225-567A-361	Sequence 361, App
39	70	7.8	2427	9	US-09-254-783A-2	Sequence 2, Appli
40	70	7.8	2427	14	US-10-152-058-2	Sequence 2, Appli
41	68.4	7.6	1080	13	US-09-875-076-27	Sequence 27, Appli
42	68.4	7.6	1080	13	US-09-876-252-29	Sequence 29, Appli
43	68.4	7.6	1080	15	US-10-272-983-27	Sequence 27, Appli
44	68.4	7.6	1080	15	US-10-393-807-27	Sequence 27, Appli
45	68.4	7.6	1080	16	US-10-417-820A-29	Sequence 29, Appli

ALIGNMENTS

RESULT 1

US-10-251-385-249  
; Sequence 249, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; PRIOR FILING DATE: 2002-09-20  
; PRIOR APPLICATION NUMBER: US/09/170,496  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: Patentin version 3.1  
; SEQ ID NO 249  
; LENGTH: 903  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-251-385-249

Query Match 100.0%; Score 903; DB 15; Length 903;  
Best Local Similarity 100.0%; Pred. No. 3.8e-210;  
Matches 903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	ATGGACCTGCCCGGAGCTCTCTTCGGCCTCTATGTGGCCGCTTTGGCGTGGGCTTC	60
DB	1	ATGGACCTGCCCGGAGCTCTCTTCGGCCTCTATGTGGCCGCTTTGGCGTGGGCTTC	60
QY	61	CGCTCAACGTCTCTGGCCATCCGAGCGCGAGCCGCGGCTCGGTCTCACCCCT	120
DB	61	CGCTCAACGTCTCTGGCCATCCGAGCGCGAGCCGCGGCTCGGTCTCACCCCT	120
QY	121	AGCCTGGTCTACGCCCTGAACTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCC	180

Db 121 AGCCTGGTCTACGCCCTGAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCCCC 180  
QY 181 CTGAAGGCGGTGAGGCGCTAGCCTCCGGGGCTGSCCTCTGCGGCGCTGCGTGTGCCCC 240  
Db 181 CTGAAGGCGGTGAGGCGCTAGCCTCCGGGGCTGSCCTCTGCGGCGCTGCGTGTGCCCC 240  
QY 241 GTCTTCGGCGGTGGCCACCTTCTCCACCTATGCGGGGGGGCTTCCGTGCGGCCCTG 300  
Db 241 GTCTTCGGCGGTGGCCACCTTCTCCACCTATGCGGGGGGGCTTCCGTGCGGCCCTG 300  
QY 301 AGTGACGCGCGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCCTCCGGAGCGCG 360  
Db 301 AGTGACGCGCGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCCTCCGGAGCGCG 360  
QY 361 TGTATTTCTCTGGGGGTGTGCGGGGCACTGTGGGCCCTCGCTGTGTGCACTGAGGTCTG 420  
Db 361 TGTATTTCTCTGGGGGTGTGCGGGGCACTGTGGGCCCTCGCTGTGTGCACTGAGGTCTG 420  
QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACACAGCAACACCTCCCTGGGCATC 480  
Db 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACACAGCAACACCTCCCTGGGCATC 480  
QY 481 AACACACCGGCTCAACCGGCTCTCGGCTCTGCTGGAGGCTGGGACCCGGGCTCTGCCGCG 540  
Db 481 AACACACCGGCTCAACCGGCTCTCGGCTCTGCTGGAGGCTGGGACCCGGGCTCTGCCGCG 540  
QY 541 CCGGCCGCTTACAGCTCTCTCTCTGCTCTTTTCTGCTGCTGCTGCTGCTGCTGCTGCTG 600  
Db 541 CCGGCCGCTTACAGCTCTCTCTCTGCTCTTTTCTGCTGCTGCTGCTGCTGCTGCTGCTG 600  
QY 601 TGTACGTGGGCTGCTCCGGGCACTGCGCGCTCCGGGCTGACGACAGGCGGAGCTG 660  
Db 601 TGTACGTGGGCTGCTCCGGGCACTGCGCGCTCCGGGCTGACGACAGGCGGAGCTG 660  
QY 661 CCGGCCGCTTGGGTGCGCGGCGCTCCCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
Db 661 CCGGCCGCTTGGGTGCGCGGCGCTCCCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
QY 721 AACGCTTCAACGCTGCGGCTGCTGTAACCCCAATCTAGGAGGCTCTGCGGGAAGCTG 780  
Db 721 AACGCTTCAACGCTGCGGCTGCTGTAACCCCAATCTAGGAGGCTCTGCGGGAAGCTG 780  
QY 781 GGGCTCATCAGCGGTGCTGAGTGTGCTTAATCCGCTGGTGTGACCGGTTACTTGGGA 840  
Db 781 GGGCTCATCAGCGGTGCTGAGTGTGCTTAATCCGCTGGTGTGACCGGTTACTTGGGA 840  
QY 841 AGGGGTCTTGGGCTTGAAGACAGTGTGTGCGGCAAGAAACGCAAGGGGGCAAGTCCCAGAG 900  
Db 841 AGGGGTCTTGGGCTTGAAGACAGTGTGTGCGGCAAGAAACGCAAGGGGGCAAGTCCCAGAG 900  
QY 901 TAA 903  
Db 901 TAA 903

RESULT 2

US-10-225-567A-474  
; Sequence 474, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burmer, Glenna C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; CURRENT FILING DATE: 2001-12-19  
; PRIOR FILING DATE: 2000-12-19  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 474  
; LENGTH: 903  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-225-567A-474

Query Match 100.0%; Score 903; DB 15; Length 903;  
Best Local Similarity 100.0%; Pred. No. 3.8e-210;  
Matches 903; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGAACCTGCCCCCAGCTCTCTTCGCGCTCTATGTGGCGCCTTTGCGTGGGCTTC 60  
Db 1 ATGGAACCTGCCCCCAGCTCTCTTCGCGCTCTATGTGGCGCCTTTGCGTGGGCTTC 60  
QY 61 CCGCTCAAGCTCTGGCCATCCGAGCGGCGGCGCCACGCCGCTCCGCTCTCACCCCT 120  
Db 61 CCGCTCAAGCTCTGGCCATCCGAGCGGCGGCGCCACGCCGCTCCGCTCTCACCCCT 120  
QY 121 AGCCTGGTCTACGCCCTGAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCC 180  
Db 121 AGCCTGGTCTACGCCCTGAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGCC 180  
QY 181 CTGAAGGCGGTGAGGCGCTAGCCTCCGGGCGCTAGCCTCCGGGCGCTGCTGCTGCTGCTG 240  
Db 181 CTGAAGGCGGTGAGGCGCTAGCCTCCGGGCGCTAGCCTCCGGGCGCTGCTGCTGCTGCTG 240  
QY 241 GTCTTCGGCGGTGGCCACCTTCTTCCACCTCTATGCGGGGGGGCTTCCGTGCGGCCCTG 300  
Db 241 GTCTTCGGCGGTGGCCACCTTCTTCCACCTCTATGCGGGGGGGCTTCCGTGCGGCCCTG 300  
QY 301 AGTGACGCGCGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCCTCCGGAGCGCG 360  
Db 301 AGTGACGCGCGCTACCTGGGAGCAGCCTTCCCTTGGGCTACCAAGCCCTCCGGAGCGCG 360  
QY 361 TGTATTTCTCTGGGGGTGTGCGCGGCACTCTGCGGCGCTGCTGCTGCTGCTGCTGCTG 420  
Db 361 TGTATTTCTCTGGGGGTGTGCGCGGCACTCTGCGGCGCTGCTGCTGCTGCTGCTGCTG 420  
QY 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACACAGCAACACCTCCCTGGGCATC 480  
Db 421 GTCTTTGGGTGGAGGCTCCAGAGGCTGGCTGGACACAGCAACACCTCCCTGGGCATC 480  
QY 481 AACACACCGGCTCAACCGGCTCTCGGCTCTGCGCTGGAGGCTGGGACCCGGGCTCTGCCGCG 540  
Db 481 AACACACCGGCTCAACCGGCTCTCGGCTCTGCGCTGGAGGCTGGGACCCGGGCTCTGCCGCG 540  
QY 541 CCGGCCGCTTACAGCTCTCTCTCTGCTCTTTTCTGCTGCTGCTGCTGCTGCTGCTGCTG 600  
Db 541 CCGGCCGCTTACAGCTCTCTCTCTGCTCTTTTCTGCTGCTGCTGCTGCTGCTGCTGCTG 600  
QY 601 TGTACGTGGGCTGCTCCGGGCACTGCGGCGCTCCGGGCTGACGACAGGCGGAGCTG 660  
Db 601 TGTACGTGGGCTGCTCCGGGCACTGCGGCGCTCCGGGCTGACGACAGGCGGAGCTG 660  
QY 661 CCGGCCGCTTGGGTGCGCGGCGCTCCCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
Db 661 CCGGCCGCTTGGGTGCGCGGCGCTCCCTCAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720  
QY 721 AACGCTTCAACGCTGCGGCTGCTGTAACCCCAATCTAGGAGGCTCTGCGGGAAGCTG 780  
Db 721 AACGCTTCAACGCTGCGGCTGCTGTAACCCCAATCTAGGAGGCTCTGCGGGAAGCTG 780  
QY 781 GGGCTCATCAGCGGTGCTGAGTGTGCTTAATCCGCTGGTGTGACCGGTTACTTGGGA 840  
Db 781 GGGCTCATCAGCGGTGCTGAGTGTGCTTAATCCGCTGGTGTGACCGGTTACTTGGGA 840  
QY 841 AGGGGTCTTGGGCTTGAAGACAGTGTGTGCGGCAAGAAACGCAAGGGGGCAAGTCCCAGAG 900  
Db 841 AGGGGTCTTGGGCTTGAAGACAGTGTGTGCGGCAAGAAACGCAAGGGGGCAAGTCCCAGAG 900  
QY 901 TAA 903  
Db 901 TAA 903





301 AGTGAGGCGCTACTGAGAGCAGCTTCCCTTGGGTACAAAGCCTTCGGAGGCG 360  
Db |||||  
301 AGTGAGGCGCTACTGAGAGCAGCTTCCCTTGGGTACAAAGCCTTCGGAGGCG 360  
Qy TGCTATTCTCGGGGGTGTGCGGCGCATCTGGGCGCTCGTCTGTGTACCTGGGTCTG 420  
Db |||||  
361 TGCTATTCTCGGGGGTGTGCGGCGCATCTGGGCGCTCGTCTGTGTACCTGGGTCTG 420  
Qy |||||  
421 GTCCTTGGGTGGAGGCTTCAGAGGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 480  
Db |||||  
421 GTCCTTGGGTGGAGGCTTCAGAGGCTGGCTGGACCAAGCAACCTCCCTGGGCATC 480  
Qy |||||  
481 AACACACGGCTCAACGGCTCTCCGCTCTGCTGGAGGCTGGACCCGCGCTCTCCGCGC 540  
Db |||||  
481 AACACACGGCTCAACGGCTCTCCGCTCTGCTGGAGGCTGGACCCGCGCTCTCCGCGC 540  
Qy |||||  
541 CCGGCGCGCTTCAGGCT 600  
Db |||||  
541 CCGGCGCGCTTCAGGCT 600  
Qy TGCTAGTGGGTGCTCGGCGCTTCGGGCGCTTCGGGCGCTGACGACAGGCGGAAGCTG 660  
Db |||||  
601 TGCTAGTGGGTGCTCGGCGCTTCGGGCGCTTCGGGCGCTGACGACAGGCGGAAGCTG 660  
Qy |||||  
661 CCGGCGCGCTGGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 720  
Db |||||  
661 CCGGCGCGCTGGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 720  
Qy |||||  
721 AACGCTCTCAACGCTGGCGGCTTCCTGTATCCCAATCTAGAGGCTTCCTGGCGGAAGCTG 780  
Db |||||  
721 AACGCTCTCAACGCTGGCGGCTTCCTGTATCCCAATCTAGAGGCTTCCTGGCGGAAGCTG 780  
Qy GGGCTCATCAGGGTGGCTGGAGTGTGTGTATTAATCCGCTGGTGAACCGTTACTTGGGA 840  
Db |||||  
781 GGGCTCATCAGGGTGGCTGGAGTGTGTGTATTAATCCGCTGGTGAACCGTTACTTGGGA 840  
Qy |||||  
841 AGGGTCTCGGCTGAAGACAGTGTGCGGCAAGAACGCAAGGGGGCAAGTCCAGAG 900  
Db |||||  
841 AGGGTCTCGGCTGAAGACAGTGTGCGGCAAGAACGCAAGGGGGCAAGTCCAGAG 900  
Qy 901 TAA 903  
Db 901 TAA 903

## RESULT 5

US-10-251-385-271  
; Sequence 271, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G  
; TITLE OF INVENTION: Protein-Coupled  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; PRIOR FILING DATE: 2002-09-20  
; PRIOR APPLICATION NUMBER: US/09/170,496  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: Patent version 3.1  
; SEQ ID NO 271  
; LENGTH: 903  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-251-385-271

Query Match 99.5%; Score 898.2; DB 15; Length 903;  
Best Local Similarity 99.7%; Pred. No. 5.6e-209;  
Matches 900; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

## RESULT 6

US-10-029-386-9201  
; Sequence 9201, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharron G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.

1 ATGGACCTGCCCGCAGCTCTCTTCCGCTCTATGTGGCGCGCTTTCGCTGGGCTTC 60  
Db |||||  
1 ATGGACCTGCCCGCAGCTCTCTTCCGCTCTATGTGGCGCGCTTTCGCTGGGCTTC 60  
Qy CGCTCAACGCTCTGGCCATCCGAGGCGGAGGCGGCGGCGGCGGCGGCTCCGCTCAACCCCT 120  
Db |||||  
61 CGCTCAACGCTCTGGCCATCCGAGGCGGAGGCGGCGGCGGCGGCGGCTCCGCTCAACCCCT 120  
Qy |||||  
121 AGCTGGTCTAGCGCTCAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGGCC 180  
Db |||||  
121 AGCTGGTCTAGCGCTCAACCTGGGCTGCTCCGACCTGCTGCTGACAGTCTCTCTGGCC 180  
Qy |||||  
181 CTGAAGGCGGTGGAGCGCTAGCCTCGGCGGCTTGGCGCTCTGCGCGGCTCGCTGTGCGCC 240  
Db |||||  
181 CTGAAGGCGGTGGAGCGCTAGCCTCGGCGGCTTGGCGCTCTGCGCGGCTCGCTGTGCGCC 240  
Qy |||||  
241 GTCCTTGGGTGGCGGCTCTTCTTCCACTCTATGCGGCGGCGGCTTCTGCGCGCGCTG 300  
Db |||||  
241 GTCCTTGGGTGGCGGCTCTTCTTCCACTCTATGCGGCGGCGGCTTCTGCGCGCGCTG 300  
Qy AGTGAGGCGCGTACTCTGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCGGAGGCGG 360  
Db |||||  
301 AGTGAGGCGCGTACTCTGGAGCAGCTTCCCTTGGGCTACCAAGCCTTCGGAGGCGG 360  
Qy TGCTATTCTGGGCGGTGTGCGCGCATCTGGGCGCTCTGCTGTGTACCTGTGGTCTG 420  
Db |||||  
361 TGCTATTCTGGGCGGTGTGCGCGCATCTGGGCGCTCTGCTGTGTACCTGTGGTCTG 420  
Qy |||||  
421 GTCCTTGGGTGGAGGCTTCAGAGGCTTCAGAGGCTTCAGAGGCTTCAGAGGCTTCAGAG 480  
Db |||||  
481 AACACACGGCTCAACGGCTTCGCGCTCTGCGGCGCTGCGGCGCTGCGGCGCTTCCGCGG 540  
Qy |||||  
481 AACACACGGCTCAACGGCTTCGCGCTCTGCGGCGCTGCGGCGCTTCCGCGGCGCTTCCGCGG 540  
Qy |||||  
541 CCGGCGCGCTTCAGGCT 600  
Db |||||  
541 CCGGCGCGCTTCAGGCT 600  
Qy TGCTAGTGGGTGCTCGGCGCTTCGGGCGCTTCGGGCGCTGACGACAGGCGGAAGCTG 660  
Db |||||  
661 CCGGCGCGCTGGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 720  
Qy |||||  
661 CCGGCGCGCTGGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 720  
Qy |||||  
721 AACGCTCTCAACGCTGGCGGCTTCCTGTATCCCAATCTAGAGGCTTCCTGGCGGAAGCTG 780  
Db |||||  
721 AACGCTCTCAACGCTGGCGGCTTCCTGTATCCCAATCTAGAGGCTTCCTGGCGGAAGCTG 780  
Qy GGGCTCATCAGGGTGGCTGGAGTGTGTGTATTAATCCGCTGGTGAACCGTTACTTGGGA 840  
Db |||||  
781 GGGCTCATCAGGGTGGCTGGAGTGTGTGTATTAATCCGCTGGTGAACCGTTACTTGGGA 840  
Qy |||||  
841 AGGGTCTCGGCTGAAGACAGTGTGCGGCAAGAACGCAAGGGGGCAAGTCCAGAG 900  
Db |||||  
841 AGGGTCTCGGCTGAAGACAGTGTGCGGCAAGAACGCAAGGGGGCAAGTCCAGAG 900  
Qy 901 TAA 903  
Db 901 TAA 903

## RESULT 6

US-10-029-386-9201  
; Sequence 9201, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharron G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.

; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9201
; LENGTH: 550
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO U62631.1
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.1
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.89
; OTHER INFORMATION: SWISSPROT HIT: O14842, EVALUE 1.00e-22
; OTHER INFORMATION: EST HUMAN HIT: AUL17321.1, EVALUE 2.00e-01
; OTHER INFORMATION: NT HIT: U62631.1, EVALUE 0.00e+00
US-10-029-386-9201

Query Match 17.1%; Score 154; DB 15; Length 550;
Best Local Similarity 100.0%; Pred. No. 3.9e-28;
Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATGGACCTGCCCCCGGAGCTCTCTTCGGCTCTATGTGCGCGCTTTGGCGTGGGCTTC 60
DB 397 ATGGACCTGCCCCCGGAGCTCTCTTCGGCTCTATGTGCGCGCTTTGGCGTGGGCTTC 456

QY 61 CGCTCAAGCTCTGCGCCATCCGAGGCGGAGCGGCCGCGGCTCGCTCACCCCT 120
DB 457 CGCTCAAGCTCTGCGCCATCCGAGGCGGAGCGGCCGCGGCTCGCTCACCCCT 516

QY 121 AGCTGTGTCTACGCGCTTGAACCTGGGCTGTCTCG 154
DB 517 AGCTGTGTCTACGCGCTTGAACCTGGGCTGTCTCG 550

RESULT 7
US-10-029-386-24088
; Sequence 24088, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
; SEQ ID NO 24088
; LENGTH: 960
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO AC002511.1
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 2.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.7
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.5
; OTHER INFORMATION: SWISSPROT HIT: O15529, EVALUE 0.00e+00
; OTHER INFORMATION: NT HIT: AF024689.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST\_HUMAN HIT: AA860692.1, EVALUE 2.20e-02
US-10-029-386-24088

Query Match 13.5%; Score 121.8; DB 15; Length 960;
Best Local Similarity 52.1%; Pred. No. 2.5e-20;
Matches 382; Conservative 0; Mismatches 327; Indels 24; Gaps 4;

QY 18 GCTCTCTTCGGGCTCTATGTGCGCGCTTTGGCGTGGGCTTCGCCCTCAAGCTCTGGC 77
DB 56 GTTCGTCTTCGGTGTACCTTCTCACTTTCTGTTGGGCTCCCGCTCAACCTGTGTC 115

QY 78 CATCCGAGGCGGACGCGCCACGCGCGCTCCGCTCTCACCCCTAGCTGTGTCTACGCCCT 137
DB 116 CTTGGTGGTCTTCTGTCGGCAAGCTGCGGTGCGCGCGCTGGACGTGTCTCTGTCT 175
QY 138 GAACCTGGGCTGTCTCGACCTGTCTGTGAGCTGTCTCTGCCCCCTGAGCGGTGAGGC 197
DB 176 CAACCTGACCGCTCGGACCTGTCTGTCTGTCTCTGCTCTGCTCTGCTCTGCTGAGGC 235
QY 198 GCTAGCTCCGGGCGCTGCGCTCTGCGGCTGCGCTGCGCTGCGCTCTGCGGCTGGCCCA 257
DB 236 AGCCAATGGCATGCACTGCGCCCTCTTCCTCTGCGCCACTCTCTGGAATCATCTT 295
QY 258 CTTCTTCCCACTCTATGCGCGGGGGGCTTCTGCGCGCGCTTCTGAGTGCAGCGCGCTACCT 317
DB 296 CTTTCAACCACTATCTATCTACCGCCCTCTTCTCTGGCAGCTGTGAGCATTTGAACGCTTCT 355
QY 318 GGGAGCAGCGCTTCCCTTGGGCTTACCAAGCTTCCGAGGCGCTGTCTATTTCTCTGGGGGT 377
DB 356 GAGTGTGGGCCACCACTGTGTGTACAAAGACCCGCGCGAGGCTGGGGCAGCGCTCTGTT 415
QY 378 GTGCGGGGCGCATCTGGGCGCTGCTGTGTCTACCTGGGTCTGCTCTTTGGGTTGAGGC 437
DB 416 GAGTGTGGCTGTCTGCTGTGTGCTCTGCTCTCTGAGGCTGTCTACGTCTAGTAATT 475
QY 438 TCAGGAGGCTGTGTGTGACCAAGCAACACCTCTCCCTGGGCGATCAACACACCGGTCAACGG 497
DB 476 CTCAGGGG-----ACATCTCCACAGCCAGGGCACCAATGGGACCTG 517
QY 498 CTCCTCGGTCTGTGTGAGGCTGTGGACCGGGCTCTGCGGGCGCGCGCTTACGCTT 557
DB 518 CTACCTGGAGTTCTTGGAGGACAG--CTAGCCATCTCTCTGCGCGCTGGGCTGGAGA-T 574
QY 558 CTCCTCTCTGCTCTTTTCTGCGCTTGGCCATCAGACGCTTCTGCTAGCTGGGCTGCT 617
DB 575 GGCTGTGTCTCTTTGTGTGCTCCGCTGATCATCAGCTACTGCTACAGCCGCTGCT 634
QY 618 CCGGGCATCTGGCGCTCGGCTGACGACAGCGGGAAGCTGCGGGCGCGCTGGGTGGC 677
DB 635 GTGATCTCTCGGAGAGGGGCG--AGCCACCGCGCGAGAGAGGGTGGCGGGCTGCT 691
QY 678 CGCGGGGCGCTCTCTACGCTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 737
DB 692 GCGGCGCACGCTGCTCAACTTCTCTGCTGCTTTGGGCGCTACAGCTGTCTCCATGTCT 751
QY 738 CAGCTTCTCTGAC 750
DB 752 GGGCTATATCTGC 764

RESULT 8
US-10-251-385-253
; Sequence 253, Application US/10251385
; Publication No. US20030105292A1
; GENERAL INFORMATION:
; APPLICANT: Behan, Dominic P.
; APPLICANT: Chalmers, Derek T.
; APPLICANT: Liaw, Chen W.
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G
; TITLE OF INVENTION: Protein-Coupled
; TITLE OF INVENTION: Receptors
; FILE REFERENCE: AREN-0040
; CURRENT APPLICATION NUMBER: US/10/251,385
; CURRENT FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US/09/170,496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 253
; LENGTH: 1041
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-251-385-253



```

; CURRENT APPLICATION NUMBER: US/10/203,539
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: GB 0003900.8
; PRIOR FILING DATE: 2000-02-18
; PRIOR APPLICATION NUMBER: GB 0007015.1
; PRIOR FILING DATE: 2000-03-22
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 1
; LENGTH: 1041
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(1041)
US-10-203-539-1

```

Query Match	13.5%	Score 121.8	DB 15	Length 1041
Best Local Similarity	52.1%	Pred. No. 2.5e-20		
Matches 382	Conservative 0	Mismatches 327	Indels 24	Gaps 4
Qy	18	GCTCTCCTCGGCGCTCTATGTGGCGCGCTTTGGCGCTGGCGCTTCCCGCTCAACGTCCTGGC	77	
Db	45	GTTCGCTTCTCGGTGTACCTTCTCATTTCTCGGTGGGCTCCCTCAACCTGCTGGC	104	
Qy	78	CATCCGAGGCGCGACGCGCCACGCGCCCGCTCTCACCCCTAGCCTGTGTACGCGCCT	137	
Db	105	CCTGGTGGTCTTCTGTGGCAAGCTGCAGCGCGCCGCGTGGCGCTGCTCCTGCT	164	
Qy	138	GAACCTGGGCTGTCGCAACCTGTGTGACAGTCTCTCTGCGCCCTGAAGGGCGGTGAGGC	197	
Db	165	CAACCTGACCGCCTCGGACCTGCTCTCTGCTGCTTCTGCGCATGTGTGGAGGC	224	
Qy	198	GCTAGCCTCCGGGGCGCTGCGCGGCTCTGCGCGGCTCGCTGTGCGCGCTTTCGCGGTGGGCCA	257	
Db	225	AGCCATGGCATGCACTGGCGCCCTGCGCTTCTGCTCTGCGCATCTCTGGATTCACTT	284	
Qy	258	CTTCTTCCCACTCTATGCGCGGGGCGCTTCTGCGCGCGCTGTGATGAGCGCGCTACCT	317	
Db	285	CTTCACCAACCATCTATCTCACCGCGCTTCTCTGCGAGCTGTGAGCATTTGAAACGCTTCCT	344	
Qy	318	GGGAGCAGCCTTCCCTTTGGGCTACCAAGCCTTCCGGAGCGCGTGTATTCTCTGGGGGCT	377	
Db	345	GAGTGTGGCCCAACCACTGTGTGTAAAGACCCGCGGAGGCTGGGGCAGGAGCTCTGGT	404	
Qy	378	GTGCGCGGCCACTGTGGGCGCTCGTCTGTGTGTCACCTGGGCTGTGCTCTTTGGGTGGAGGC	437	
Db	405	GAGTGTGGCTGTGCTGTGTGGCTCTGTCTCACTGCAGCGTGGTCTACGTCATAGAATT	464	
Qy	438	TCAAGGAGGCTGGCTGGACCAACGACACACTTCCTGGGCAATCAACACACCGGTCAAAGG	497	
Db	465	CTCAGGG-----ACATCTCCACAGCGAGGACCAATGGGACCTG	506	
Qy	498	CTCTCCGGTCTGCTGAGGCGCTGGGACCGGCGCTCTGCGGCGCGCGCTTCAGCCT	557	
Db	507	CTACCTGGAATCCGGAAGGACAG--CTAGCCATCTCTGCGCGCTGGCGCTGGAG-AT	563	
Qy	558	CTCTCTCTGCTCTTTTTTCTGCGCCTTGGCCATCACAGCCTTCTGTGTACGTGGGCTGCCT	617	
Db	564	GGCTGTGGTCTCTTTGTGTGCGCTGATCATCACCAGCTACTGCTAC--AGCGCCT	620	
Qy	618	CCGGGCACTGGCGGCTCCGCGCTGACGCAAGCGGAGGCTGGCGCGCGCTGGGTGGC	677	
Db	621	GGTGTGATCTCTGGCAGAGGGGACGCCACCGCCGCGAGAGGAGGTGGCGGGCTGTT	680	
Qy	678	CGCGGGGGCGCTCTCACTGCTGTGCTGTGCTGTAGGACCTTACAAACCGCTTCCACAGTGGC	737	
Db	681	GGCGGCCACGCTGCTCAACTCTCTTGTCTGTGTGGGCGCTACAAAGTGTCCCATGTGCT	740	
Qy	738	CAGCTTCTCTTAC	750	
Db	741	GGGCTATATCTGC	753	

```

RESULT 11
US-10-203-539-3
; Sequence 3, Application US/10203539
; Publication No. US20030113810A1
; GENERAL INFORMATION:
; APPLICANT: GLAXO GROUP LIMITED
; TITLE OF INVENTION: NOVEL ASSAY
; FILE REFERENCE: PG3849USW
; CURRENT APPLICATION NUMBER: US/10/203,539
; CURRENT FILING DATE: 2002-08-09
; PRIOR APPLICATION NUMBER: GB 0003900.8
; PRIOR FILING DATE: 2000-02-18
; PRIOR APPLICATION NUMBER: GB 0007015.1
; PRIOR FILING DATE: 2000-03-22
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.0
; SEQ ID NO 3
; LENGTH: 1041
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (1)..(1041)
US-10-203-539-3

```

Query Match	13.5%; Score 121.8; DB 15; Length 1041;
Best Local Similarity	52.1%; Pred. No. 2.5e-20;
Matches	382; Conservative 0; Mismatches 327; Indels 24; Gaps 4
Qy	18 GCTCTCCTCGGCGCTCTATGTGGCGCGCTTTGGCGTGGCTTCCCGCTCAACGTCCTGGC 77
Db	45 GTTGGTCTTCTCGGTGTAACCTTCTCACTTTCTCTGGTGGGGCTCCCTCTCAACCTGCTGGC 104
Qy	78 CATCCGAGGCGGACGGCCCCAGCCCGGCTCCGGTCTCACCCCTAGCCTGTGCTTACGCCCT 137
Db	105 CCTGGTGGTCTTCTGGGCAAGCTGCGGTGCGCGCCGGTGGCCGTGGACGTGCTCTGCT 164
Qy	138 GAACCTTGGGCTGCTCCGACCTGCTGTGACAGTCTCTCTGCCCTGAAGGCGGTGGAGGC 197
Db	165 CAACCTGACCGCTCGGACCTGCTCTGCTGTGCTTCTCGCTTTCCGATGTGTGGAGGC 224
Qy	198 GCTPAGCTCCGGGGCTGGCCCTGTGCGGGCTCGCTGTGTCGCCCTTTGCGGGTGGGCCA 257
Db	225 AGCCAAATGGCATGCACTTGGCCCCCTGGCCCTTATCTCTGCCCCACTCTCTGGATTCATCTT 284
Qy	258 CTTCTTCCCACTCTATGTCGGCGGGGGCTTCTTGGCGGCCCTGATGTCAGGCGCGCTACCT 317
Db	285 CTTTCAACCAATCTATCTCAACCGCCCTTCTTCTGGCAGCTGTGAGCAATGAACGCTTCCT 344
Qy	318 GCGAGACGAGCTTCCCTTTGGGCTACCAAGGCTTTCGGAGGCGGTGCTATTCTCGGGGGGT 377
Db	345 GAGTGTGGCCCAACCACTGTGTGTACAAGACCGCGGCCGAGGCTGGGCGAGCGAGTCTGGT 404
Qy	378 GTGGCGGCGCACTGTGGCGCTCGTCTGTGTGTACCTGGGTGTGTCTTTGGGTGGAGGC 437
Db	405 GAGTGTGGCGCTGTGGCTGTGTGGCTCTGTCTCACTGCAGCGTGGTCTTACGTCATAGAAAT 464
Qy	438 TCCAGAGGCGTGGCTGGACCACAGCAACCTCTCCCTGGGCATCAACACCGGTCAACGG 497
Db	465 CTACGGG-----ACATCTCCACAGCAGGGCACAAATGGGACCTG 506
Qy	498 CTTCTCGGTCTGCTGGAGGCTTGGGACCGGGCTCTGCGGGCCCGCCCGCTTCAGCCT 557
Db	507 CTACCTGGAGTCTTGGAAAGGACCAAG--CTAGCCATCTCTCTGCCCCGTGGCGCTGGAGA-T 563
Qy	558 CTTCTCTCTGCTCTTTTCTGCGCTTGGCCATCACAGCTTCTGCTACGTGGGCTGCCT 617
Db	564 GGTGTGTGTCCTCTTTGTGTCCCGCTGATCATCACCAGCTACTGTCTACAGCCGCGCTGGT 623
Qy	618 CCGGGCACTGGCCCGCTCCGGCCCTGACGACAGCGGAAGCTGCGGGCCCGCTGGGTGGC 677
Db	624 GTGAGTCTTCGGCAGAGGGGGG---AGCCACCGCCGACAGAGAGCTGCGGGGCTGGT 680

```
QY 678 CGCGGGGCGCTCCTCACGCTGCTGTGCTCTGCGTAGGACCTTACAGCGCTTCAACGCTGCG 737
Db 681 GCGGGCCAGCTGCTCAACTTCTTCTGCTTGGGCCCTACAGCTGTCCCATGTGCT 740
QY 738 CAGCTTCCTGTATC 750
Db 741 GGGCTATATCTGC 753

RESULT 12
US-10-029-386-25146
; Sequence 25146, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 25146
; LENGTH: 1206
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO U62631.1
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.4
; OTHER INFORMATION: EST HUMAN HIT: BF115946.1, EVALUATE 2.80e-02
; OTHER INFORMATION: SWISSPROT HIT: O14843, EVALUATE 0.00e+00
; OTHER INFORMATION: NT HIT: U62631.1, EVALUATE 0.00e+00
US-10-029-386-25146

Query Match 13.5%; Score 121.8; DB 15; Length 1206;
Best Local Similarity 52.1%; Pred. No. 2.4e-20;
Matches 382; Conservative 0; Mismatches 327; Indels 24; Gaps 4;

QY 18 GCTCTCTTCCGGGCTCTATGTGGCCGCTTTGGCTGGGCTTCCCGCTCAACGCTCTCTGCG 77
Db 210 GTTGGTCTTCTCGGTGTACTTCTCACTTTCCTGGTGGGCTCCCGCTCAACCTGTCTGC 269
QY 78 CATCCAGCGCGGACGCGCCACGCGGCTCGTCTACCCCTAGCCCTGTCTACGCCCT 137
Db 270 CCTGGTGGTCTTTCGTGGCAAGCTGCAGCGCGCGCGCTGGCGGTGGACGTGCTCTGCT 329
QY 138 GAACCTGGGCTGCTCCGACTGCTGACAGTCTCTCTGCCCTGAAGCGGTGGAGGC 197
Db 330 CAACCTGACCGCTCGGACTGCTCTCTGTGCTGTTCCTGGCTTTCCGATGTGGAGGC 389
QY 198 GCTAGCCTCCGGGCTGCGCTCTGCGGCGCTCGCTGTGCGCGCTTCTGCGGTGGCCCA 257
Db 390 AGCCATGGCATGTGGCCCTGCGCTTCACTTCTCTGCCCTGAAGCGGTGGAGGC 449
QY 258 CTTCTTCCACTATATGCGCGGGGCTTCTGCGCGCGCTGAGTGCAGGCGCTACCT 317
Db 450 CTTACACCACTATATCTCACGCGCTTCTCTGCGAGCTGTGAGCATTTGAACGCTTCT 509
QY 318 GGGAGACGCTTCCCTTGGGCTACCAAGCTTCCGAGGCGCTGTATTCCTGGGGGT 377
Db 510 GAGTGTGGGCCCACTGTGGTACAAAGACCGGCGGAGGCTGGGCGAGGCTCTGCT 569
QY 378 GTGCGCGGCGCATCTGGGCGCTCGCTGTGTACCTGGGTCTGGTCTTTGGGTGGAGGC 437
Db 570 GAGTGTGGGCTGTGGCTGTGGCTCTGCTCACTGACGGTGTCTACGTATAGAAAT 629
QY 438 TCAGAGGCTGGCTGGACACAGCAACCTCTCCCTGGGCGATCAACACCGGTCAACGG 497
Db 630 CTCAGGGG-----ACATCTCCACAGCCAGGGGACCAATGGGACCTG 671
```

```
QY 498 CTCTCCGCTCTGCTGGAGGCTTGGACCCCGGCTTCTGCGCGGCCGCTTCAAGCT 557
Db 672 CTACCTGGAGTTCCGAAAGGACCAAG--CTAGCATCTCTCTGCGCGGTGGAG-AT 728
QY 558 CTCTCTCTGCTCTCTTCTGCGCGCTTGGCCATCACAGCCTTCTGCTAGTGGGCTGCT 617
Db 729 GGGCTGTGGTCTCTTGTGGTCCCGCTGATCATCACCACTACTGCTAC---AGCGGCT 785
QY 618 CCGGCACTGGCGCGCTCCGGCTGACGACAGGGGGAGCTGCGGGCGCGCTGGGTGGC 677
Db 786 GGTGTGGATCTCGGCAGAGGGGGAGCCACCGCGGAGAGGGTGGCGGGGCTGTT 845
QY 678 CGCGGGGCGCTCTCAAGCTGCTCTCTGCTAGGACCTTACAAAGCTTCAACGCTGCG 737
Db 846 GCGGGCCAGCTGCTCAACTTCTGCTGCTTTGGGCGCTTACAAAGCTGTCCCATGTCT 905
QY 738 CAGCTTCCTGTATC 750
Db 906 GGGCTATATCTGC 918

RESULT 13
US-10-251-385-273
; Sequence 273, Application US/10251385
; Publication No. US20030105292A1
; GENERAL INFORMATION:
; APPLICANT: Behan, Dominic P.
; APPLICANT: Chalmers, Derek T.
; APPLICANT: Liaw, Chen W.
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G
; TITLE OF INVENTION: Protein-Coupled
; FILE REFERENCE: AREN-0040
; CURRENT APPLICATION NUMBER: US/10/251,385
; CURRENT FILING DATE: 2002-09-20
; PRIOR APPLICATION NUMBER: US/09/170,496
; PRIOR FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 273
; LENGTH: 1041
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-251-385-273

Query Match 13.1%; Score 118.6; DB 15; Length 1041;
Best Local Similarity 51.8%; Pred. No. 1.5e-19;
Matches 380; Conservative 0; Mismatches 329; Indels 24; Gaps 4;

QY 18 GCTCTCTTCCGGCTCTATGTGGCGCGCTTTCGGCTGGGCTTCCCGCTCAACGCTCTCTGCG 77
Db 45 GTTGGTCTTCTCGGTGTACTTCTCACTTCTGCTGGGCTTCCCGCTCAACCTGTGCG 104
QY 78 CATCCAGCGCGGACGCGCCACGCGGCTCGTCTTCAACCCCTAGCCCTGTAGCCCT 137
Db 105 CTTGGTGGTCTTTCGTGGGCAAGCTGCAGCGCGCGCGGTGGCGGTGCTCTCTGCT 164
QY 138 GAACCTGGGCTGCTCGGACTGCTGCTGACAGTCTCTCTGCGCGCTTGAAGCGGTGGAGGC 197
Db 165 CAACCTGACCGCTCGGACCTGCTCTGCTGTGCTTCTCTGCGCTTTCGCGATGGTGGAGGC 224
QY 198 GCTAGCCTCCGGGCTGCGCTCTGCGGCGCTCGCTGTGCGCGCTTCTCGCGGTGGCCCA 257
Db 225 AGCCATGGCATGTGACTGGCCCTTCCCTTCACTCTCTGCGCGCTCTCTGCTGATTCATCT 284
QY 258 CTTCTTCCACTATATGCGCGGGGCTTCTGCGCGCGCTTCTGCGCGCTTCTGAGTGCAGGCGCTACCT 317
Db 285 CTTTACCACTATCTTCTCACGCGCTTCTCTGCGAGCTGTGAGCATTTGAACGCTTCTCT 344
QY 318 GGGAGACGCTTCCCTTGGGCTTACCAAGCTTCCGAGGCGGTGCTATTCCTGGGGGT 377
Db 345 GAGTGTGGGCCCACTGCTGTGGTACAAAGACCGGCGGAGGCTGGGCGAGGCTGTGCT 404
```



Qy	378	GTGGCGGCGCAATCGGGCCCTCGTCTGTGTCACTGGGTCTGGTCTTTGGTGTGGAGCG	437
Db	405	GAGTGTGGCCCTGCTGGCTGTGTGGCCCTCTGCTCACTGCAGCGTGGTCTACGTTCATAGAATT	464
Qy	438	TCCAGGAGGCTGGCTGGACCACAGCAACACCTCCCTGGGCATCAACACACCGGTCAACGG	497
Db	465	CTCAGGG-----ACATCTCCCAACAGCCAGGGACCAATGGGACCTG	506
Qy	498	CTCTCCGGTCTGCTGGAGGCTGGGACCCGGGCTCTGCGGCCCGGCCCGCTTCAGCCT	557
Db	507	CTACCTGAGTTCGGAGGACCAG--CTAGCATCTCTCTGCGCGTGGCTGGAG--AT	563
Qy	558	CTCTCTCTGCTCTTTTCTGCGCCCTGGGCATCAAGCTTCTGTGATAGTGGGCTGCGCT	617
Db	564	GGCTGTGGTCTCTTTTGTGTCCTGATCATCACCACTACTGTGTAC---AGCGCGCT	620
Qy	618	CCGGGCACTGGCCGCTCCGGCTGACGACACAGGCGGAAGCTGCGGGCCGCTGGGTGGC	677
Db	621	GGTGTGGATCTTCGGCAGAGGGGGAGCCACCGCCGGCAGAGAGGGGTGAAGGGGCTGT	680
Qy	678	CGGGGGGCGCTCTCTCAGCTGCTGCTCTGTGGTAGGACCTTACAACGGCTCCCAACGTTGGC	737
Db	681	GGCGGCCAGGCTGCTCACTTCTCTGTCTGCTTTGGGCCCTACACAGTGTCCCATGTGGT	740
Qy	738	CAGCTTCTGTAC	750
Db	741	GGGCTATATCTGC	753

RESULT 14

US-10-225-567A-515

Sequence 515, Application US/10225567A

Publication No. US20030113798A1

GENERAL INFORMATION:

APPLICANT: LifeSpan Biosciences

APPLICANT: Brown, Joseph P.

APPLICANT: Burner, Glenna C.

APPLICANT: Roush, Christine L.

TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS

FILE REFERENCE: 1920-4-4

CURRENT APPLICATION NUMBER: US/10/225,567A

CURRENT FILING DATE: 2001-12-19

PRIOR APPLICATION NUMBER: 60/257,144

PRIOR FILING DATE: 2000-12-19

NUMBER OF SEQ ID NOS: 2292

SOFTWARE: PatentIn version 3.1

SEQ ID NO 515

LENGTH: 4895

TYPE: DNA

ORGANISM: Homo sapiens

US-10-225-567A-515

	Query Match	9.4%	Score 84.6	DB 15	Length 4895
	Best Local Similarity	47.2%	Pred. No. 2.4e-11		
	Matches 329	Conservative	Mismatches 359	Indels 9	Gaps 2
Qy	8	TGCCCCCGCAGCTCTCCCTTGGCGCTCATATGTCGGCGCGCTTTGCGCTGGGCTTCCGGCTCA	67		
Db	399	TGCCCCACAGGCTGGTGCCTCCCTCTATATGGGCTGGTCTGGTGGTGGGCTGCGCGCCA	458		
Qy	68	ACGTCTTGGCCCATCCGAGGCGGACGGCCACGCCCGGCTCCGTCTCACCCCTTACGCTTG	127		
Db	459	ATGGGCTGGCGCTCTGGGTGTGGCCACGACGGACACCTCGGCTGCCCTTCCACCATGTGTC	518		
Qy	128	TCTACGCCCTGAACCTGGGCTGCTCCGACCTGTGCTGCAGAGTCTCTGTGCCCTCTGAAGG	187		
Db	519	T-----GATGAACCTCGGACTGCTGACCTCTGCTGGCCCTGGCGCTGCCCCCGCGGA	572		
Qy	188	CGGTGGAGGCGCTAGCTCCGGGCGCTGGCTCTGCGGGCCCTCGCTGTGCCCGCTCTTCG	247		
Db	573	TCGCCTACACCTCGTGGGCGAGCGCTGGGCCCTTTGGGGGAGCGCGCTTCCGCGCTGGCCA	632		
Qy	248	CGGTGGGCCCACTTCTTCCCACTCATGCGCGGGGGGCTTCTGGCGCGCCCTGAGTGAG	307		

Db	633	CGCGCGCACTCTATGGTTCACATGATGATGGCTCAGTGTGCTGCTGGCGCGGTGAGCCTGG	692
Qy	308	GC CGCTACCTGGGAGCAGCCCTCCCTTGGGCTACCAAGCTTCCGAGAGCCGCTGCTATT	367
Db	693	ATGCTACCTGGCCCTGGTGCACCGGCTGCGGCCCGCGCCCTGCTGGGCGGCGCCTGG	752
Qy	368	CTTGGGGGTGTGCGGCGCCATCTGGGCCCCCTCGTCTGTGTCTCACTGGGTCTGGTCTTTG	427
Db	753	CCCTTGGACTCTGATGGCTGCTTGG--CTCATGGCGCGCGCCCTGGCACTGCCCTCGA	809
Qy	428	GGTTGGAGGCTCAGGAGGCTGGCTGAGCACACAGCAACACTCTCCCTGGGCAATCAACACAC	487
Db	810	CAC TGCAGCGGCAGACCTTCGGCTGCGCGCTCCGATCGCGTGCTCTGCCATGACGCGC	869
Qy	488	CGGTCAACGGCTCTCCGGTCTGCTGGAGGCTGGAGCCCGGGCTCTGCGGCGCCCGGCC	547
Db	870	TGCCCTTGGACGCACAGGCGCTCCACATGGCAACCGGCTTTCACCTGCTGGCGCTGTGG	929
Qy	548	GC TTTACGCTCTCTCTCTGCTCTTTTCTGGCCCTTGGCCATCACAGCCTTCTGCTACG	607
Db	930	GCTGTTTCTGCCCCCTGCTGGCCATGCTGTGTCTACGGGGCCACCTTGCAACGCTGG	989
Qy	608	TGGGCTGCTTCCGGGCACTGGCCCCGTCCGGCCTGACGCACAGGCGGAAGCTCGGGCCG	667
Db	990	CGGCGACGCGCGCGCTACGGCCACGGCTGAGGCTGACCGAGTGGTCTGCGCCTCCG	1049
Qy	668	CTTGGGTGGCGGGGGGCCCTCTCACGTGCTGCT	704
Db	1050	CCGTGGGCTTTCTTCTGTGCGCCAGAACCTGCTGTGCT	1086

RESULT 15  
 US-10-187-049-1  
 : Sequence 1, Application US/10187049  
 : Publication No. US20030143218A1  
 : GENERAL INFORMATION:  
 : APPLICANT: Xu, Wenfeng  
 : Presnell, Scott R.  
 : Yee, David P.  
 : Foster, Donald C.  
 : TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR  
 : PAR4 (ZCHEMR2)  
 : NUMBER OF SEQUENCES: 12  
 : CORRESPONDENCE ADDRESS:  
 : ADDRESSEE: ZymoGenetics, Inc.  
 : STREET: 1201 Eastlake Avenue East  
 : CITY: Seattle  
 : STATE: WA  
 : COUNTRY: USA  
 : ZIP: 98102  
 : COMPUTER READABLE FORM:  
 : MEDIUM TYPE: Diskette  
 : COMPUTER: IBM Compatible  
 : OPERATING SYSTEM: DOS  
 : SOFTWARE: FastSeq for Windows Version 2.0  
 : CURRENT APPLICATION DATA:  
 : APPLICATION NUMBER: US/10/187,049  
 : FILING DATE: 28-Jun-2002  
 : CLASSIFICATION: <Unknown>  
 : PRIOR APPLICATION DATA:  
 : APPLICATION NUMBER: <Unknown>  
 : FILING DATE: <Unknown>  
 : ATTORNEY/AGENT INFORMATION:  
 : NAME: Leitch, Debra K  
 : REGISTRATION NUMBER: 32,619  
 : REFERENCE/DOCKET NUMBER: 98-10  
 : TELECOMMUNICATION INFORMATION:  
 : TELEPHONE: 206-442-6674  
 : TELEFAX: 206-442-6678  
 : TELEX: <Unknown>  
 : INFORMATION FOR SEQ ID NO: 1:  
 : SEQUENCE CHARACTERISTICS:



```

; LENGTH: 4895 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; FEATURE:
; NAME/KEY: Coding Sequence
; LOCATION: 176...1330
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-187-049-1

Query Match          9.4%; Score 84.6; DB 15; Length 4895;
Best Local Similarity 47.2%; Pred. No. 2.4e-11;
Matches 329; Conservative 0; Mismatches 359; Indels 9; Gaps 2;

QY 8 TGGCCCGGAGCTCTCTTGGGCTCTATGTGGCGGCTTTGGGCTGGGCTTCCCGCTCA 67
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 68 AGTCTCTGGCCATCCGAGGCGGAGCGGCCACGCCGGCTCGTCTCACCCCTAGCCTGG 127
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 459 ATGGGCTGGCGCTGTGGGTGTGGCCACGAGGACCTCGGTGCGCTCCACATGCTGC 518
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 128 TCTACGCCCTGAACCTCGGCTGTCTCGACCTGTCTGCTGACAGTCTCTTGCCTTGAAGG 187
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 519 T-----GATGAACCTCGGACTGCTGACCTCTGTGTGGCCCTGGCGCTGCCCGGGA 572
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 188 CGGTGAGGCGGTAGCTCTCGGGCCCTGCGCTCTGCGCGCTCGCTGTGCGCGCTTTGG 247
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 573 TCGCCTACCACTTGCCTGGGCGGCTGGCCCTTCGGGGAGGCGCGCTGCCGCTGGCCA 632
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 248 CGGTGGCCCACTTCTCCACTCTATGCGGGGGGGCTTCTTGGCGCGCTGAGTGCAG 307
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 633 CGGCCGCACTCTATGTGTACATGATGTGTCTGCTGTGTGTGTGTGTGTGTGTGTGT 692
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 308 GCGCTTACCTTGGGAGCAGCTTCTCCCTTGGGCTTACCAAGCTTTCGGAGGCGGTGCTATT 367
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 693 ATCGCTACTCTGGCCCTGTGTGCAACCGCTGGGGCGCGCGCTTGGTGGCGGCGCTGG 752
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 368 CTTGGGGGGTGTGGCGGCACTTGGGCGCTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGT 427
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 753 CCTTGGACTCTGATGGCTGTGTGG---CTATGGCGCGCGCTTGGCACTGCCCTTGA 809
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 428 GGTGGAGGCTCCAGGAGGCTGGCTGACCAAGCAACACCTTCCCTGGGCAACACACAC 487
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 810 CACTGAGCGGAGACCTTCGGCTTGGCGGCTCCGATCGGTGTCTTGTGATGAGCGC 869
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 488 CGGTCAACGGCTCTCCGGTCTGCTGGAGGCTTGGGACCGGCTCTTGGCGCGCGCGCC 547
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 870 TGGCCCTGGAGCGACAGGCTCCCACTGGCAACCGGCTTTCACCTGGCTGGCGCTGTGG 929
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 548 GCTTACGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 607
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 930 GCTGTTCTCTGCCCCCTGTCTGGCCATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 989
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 608 TGGGCTGCTCTCGGGCACTTGGCGGCTCGGCTGACGACAGCGGCGGAGCTGCGGGCG 667
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 990 CGGCCAGCGCGCGGCTACGGCCACGCGCTGAGGCTGACCGAGTGTGTGTGTGTGTGTGT 1049
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 668 CTTGGGTGGCGCGGCGGCTCTCTCACTGTGTGTGT 704
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY 1050 CCGTGGCTTCTCTGTGGCCAGCAACCTGCTGTGTGT 1086
Db  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

Search completed: April 30, 2004, 18:51:27  
Job time : 468 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:03:33 ; Search time 59 Seconds  
(without alignments)  
1436.682 Million cell updates/sec

Title: US-10-202-687-2  
Perfect score: 1584  
Sequence: 1 MDLPQLSLGLYVAAPALGF.....RQPLKTVCAARTQGSQK 300

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_29Jan04:\*1: Geneseq1980s:\*  
2: Geneseq1990s:\*  
3: Geneseq2000s:\*  
4: Geneseq2001s:\*  
5: Geneseq2002s:\*  
6: Geneseq2003as:\*  
7: Geneseq2003bs:\*  
8: Geneseq2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1584	100.0	300	3	AAY90679 Human G p
2	1584	100.0	300	5	ABG31106 Human G p
3	1584	100.0	300	6	ABP81994 Human G p
4	1584	100.0	300	7	ADB61404 Human GPR
5	1584	100.0	300	7	ADC22769 Human G p
6	1579	99.7	300	3	AAY90684 Human mut
7	1579	99.7	300	7	ADC22791 Human G p
8	1519	95.9	300	7	ADB61416 Monkey GP
9	1333	84.2	300	5	ABG31107 Mouse G p
10	1333	84.2	300	7	ADB61400 Mouse GPR
11	1320	83.3	300	7	ADB61402 Rat GPR40
12	1295	81.8	300	7	ADB61428 Hamster G
13	366	23.1	346	4	AAB82759 Human G-p
14	347	21.9	346	3	AAY90680 Human G p
15	347	21.9	346	4	AAB82758 Human G-p
16	347	21.9	346	6	ABP81715 Human G p
17	347	21.9	346	7	ADC22773 Human G p
18	347	21.9	401	2	AAY59924 Human 7-t
19	342	21.6	346	3	AAY90685 Human mut
20	342	21.6	346	7	ADC22793 Human G p
21	340.5	21.5	330	2	AAY05383 Mouse GCR
22	340.5	21.5	330	3	AAY94269 Mouse 7-t
23	334	21.1	330	2	AAY05384 Human GCR
24	332	21.0	330	2	AAY59906 Human HTA
25	332	21.0	330	3	AAY90681 Human G p.

26	332	21.0	330	6	ABP81990	Abp81990 Human G p
27	332	21.0	330	6	ABR82313	AbR82313 Human G-p
28	332	21.0	330	7	ADC22777	Adc22777 Human G p
29	331	20.9	330	3	AAY90686	Aay90686 Human mut
30	331	20.9	330	7	ADC22795	Adc22795 Human G p
31	322	20.3	330	2	AAW75245	Aaw75245 Fragment
32	322	20.3	330	5	AAE27011	Aae27011 Human gen
33	322	20.3	330	5	AAE27149	Aae27149 Human gen
34	322	20.3	330	6	ABU65022	Abu65022 Human sec
35	298.5	18.8	319	4	AAB82760	Aab82760 Rat G-pro
36	244	15.4	420	6	ABG73510	Abg73510 X. laevis
37	233.5	14.7	388	5	AAG79597	Aag79597 Guinea pi
38	231.5	14.6	385	2	AAY50135	Aay50135 Human pro
39	231.5	14.6	385	2	AAY50139	Aay50139 Mutant hu
40	231.5	14.6	385	2	AAY50138	Aay50138 Mutant hu
41	231.5	14.6	385	2	AAV15082	Aay15082 Human pro
42	231.5	14.6	385	3	AAV45036	Aay45036 Human pro
43	231.5	14.6	385	4	AAB47623	Aab47623 Human PAR
44	231.5	14.6	385	5	AAG79604	Aag79604 Human PAR
45	231.5	14.6	385	6	ABG73512	Abg73512 Human par

ALIGNMENTS

RESULT 1  
AAY90679  
ID AAY90679 standard; protein; 300 AA.  
AC AAY90679;  
XX  
XX 21-AUG-2000 (first entry)  
XX  
DE Human G protein-coupled receptor GPR40.  
XX  
XX G protein-coupled receptor; GPCR; constitutively active;  
KW intracellular loop 3; transmembrane domain 6; drug screening; agonist;  
KW antagonist.  
XX  
OS Homo sapiens.  
XX  
XX  
FN WO200022129-A1.  
XX  
PD 20-APR-2000.  
XX  
PF 12-OCT-1999; 99WO-US023938.  
XX  
PR 13-OCT-1998; 98US-00170496.  
(AREN-) ARENA PHARM INC.  
Behan DP, Chalmers DT, Liaw CW;  
WPI; 2000-329165/28.  
N-PSDB; AAA30759.  
Non-endogenous constitutively activated human G protein-coupled receptors, useful for identifying agonists for use as pharmaceutical agents.  
Example 1; Page 308-309; 341pp; English.  
The invention relates to constitutively active, non-endogenous versions of endogenous human orphan G protein-coupled receptors (GPCRs, AAY90643-CC and AAY90677 and AAY90683-Y90687), and to DNA encoding them (AAA30709-A30743 mutation in a portion of the protein comprising intracellular loop 3 (IC3) and transmembrane domain 6 (TM6). A non-endogenous amino acid, X, is substituted for an endogenous residue in IC3 at a position 16 amino acids N-terminal of an endogenous proline in TM6 to form a sequence X-(AA)15-Pro. The endogenous amino acid is selected from Lys, His, Arg or Ala, and is preferably Lys. When the endogenous residue at this position is Lys, this residue is replaced by His, Arg or preferably Ala. The 15

CC amino acid stretch between the substituted amino acid and the Pro may be  
CC endogenous, non-endogenous, or a mixture of endogenous and non-endogenous  
CC residues. The constitutively active GPCRs are useful for identifying  
CC antagonists, agonists and partial agonists for use as pharmaceutical  
CC agents. The mutant proteins are also useful in research settings for  
CC elucidating the roles of the receptors in normal and diseased conditions.  
CC Antagonists for a particular GPCR are useful for treating diseases and  
CC disorders associated with that receptor. Because the novel mutant GPCRs  
CC are constitutively active, they can be used directly for screening of  
CC compounds without the need for endogenous ligands. The present sequence  
CC represents a human wild-type GPCR referred to in an exemplification of  
CC the invention  
XX  
XX

SQ Sequence 300 AA;

Query Match 100.0%; Score 1584; DB 3; Length 300;  
Best Local Similarity 100.0%; Pred. No. 1.6e-149;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPQSLGSLVYVAFALGFPPLNVLAIAGTAAHARLRLTPSLVYALNLGCSDLLLTSLP 60  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1 MDLPQSLGSLVYVAFALGFPPLNVLAIAGTAAHARLRLTPSLVYALNLGCSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFPLVYAGGFLAALSAGRYLGAFFLGYQAFRRP 120  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
61 LKAVEALASGAWPLPASLCPVFAVAHFPLVYAGGFLAALSAGRYLGAFFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWAIVLCHLGLVLEAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
121 CYSWGVCAAIWAIVLCHLGLVLEAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLFLPLAITAFVYVGCCLRALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
181 PARFSLSLFLPLAITAFVYVGCCLRALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240  
QY 241 NASNVASFLYPLNLGGSWRKLGITGAWSVVLPVLTGYLGRGPKLTVCARATQGGKSOK 300  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
241 NASNVASFLYPLNLGGSWRKLGITGAWSVVLPVLTGYLGRGPKLTVCARATQGGKSOK 300

RESULT 2

ABG31106

ID ABG31106 standard; protein; 300 AA.

XX

AC ABG31106;

XX

DT 21-OCT-2002 (first entry)

DE

DE Human G protein-coupled receptor GPR40.

XX

KW Human; GPR40; G protein-coupled; receptor; type 2 diabetes; obesity;  
KW antidiabetic; neuroprotective; anorectic; cerebroprotective; Gq;  
KW G protein; reporter gene; glucose intolerance; insulin intolerance;  
KW neurodegenerative disease; Alzheimer's disease; stroke.

XX

OS Homo sapiens.

XX

FN WO200257783-A2.

XX

PD 25-JUL-2002.

XX

PF 18-DEC-2001; 2001WO-US048985.

XX

PR 22-DEC-2000; 2000GB-00031527.

XX

XX (GLAX ) GLAXO GROUP LTD.

PA (SMIK ) SMITHKLINE BEECHAM PLC.

XX

PI Andrews JL, Briscoe CP, Ignar DM, Muir AI, Sauls HR, Tadavayon M;

XX

DR WPI; 2002-599726/64.

DR

DR N-PSDB; ABK90236.

PT Identifying GPR40 receptor ligand for treating disorders e.g. obesity,  
PT comprises detecting whether the test compound competitively inhibits the  
PT binding of a fatty acid GPR40 ligand to a GPR40 receptor.

XX Disclosure; Page 48-49; 53pp; English.

XX The invention relates to screening a test compound to determine whether  
CC the compound is a GPR40 receptor (G protein-coupled receptor) ligand  
CC comprises detecting whether the test compound competitively inhibits the  
CC binding of a fatty acid GPR40 ligand to a GPR40 receptor. Also included  
CC are (1) a method of screening a compound for GPR40 antagonist activity,  
CC comprising: (a) measuring any detectable signal produced by a reporter  
CC gene (comprising a reporter gene under the control of G protein Gq  
CC responsive transcriptional element); (b) detecting a decrease in reporter  
CC gene expression in the presence of both test compound and agonist; or (c)  
CC detecting whether the compound decreases glucose-stimulated insulin  
CC release from mammalian pancreatic beta cells in the presence of a GPR40  
CC agonist, compared to glucose-stimulated insulin release that would occur  
CC due to the presence of the GPR40 agonist; (2) a method of screening a  
CC compound for GPR40 agonist activity, which comprises: (a) detecting any  
CC reporter gene expression; or (b) detecting whether the compound binds to  
CC GPR40 and increases glucose-stimulated insulin release from mammalian  
CC pancreatic beta cells. The method is useful for identifying GPR40  
CC antagonist or agonist compounds for treating disorders e.g. type 2  
CC diabetes, obesity, glucose or insulin intolerance, neurodegenerative  
CC disease (e.g. Alzheimer's disease) or stroke. The present sequence  
CC represents human GPR40

XX Sequence 300 AA;

Query Match 100.0%; Score 1584; DB 5; Length 300;  
Best Local Similarity 100.0%; Pred. No. 1.6e-149;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPQSLGSLVYVAFALGFPPLNVLAIAGTAAHARLRLTPSLVYALNLGCSDLLLTSLP 60  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
1 MDLPQSLGSLVYVAFALGFPPLNVLAIAGTAAHARLRLTPSLVYALNLGCSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFPLVYAGGFLAALSAGRYLGAFFLGYQAFRRP 120  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
61 LKAVEALASGAWPLPASLCPVFAVAHFPLVYAGGFLAALSAGRYLGAFFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWAIVLCHLGLVLEAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
121 CYSWGVCAAIWAIVLCHLGLVLEAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLFLPLAITAFVYVGCCLRALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
181 PARFSLSLFLPLAITAFVYVGCCLRALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240  
QY 241 NASNVASFLYPLNLGGSWRKLGITGAWSVVLPVLTGYLGRGPKLTVCARATQGGKSOK 300  
DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
241 NASNVASFLYPLNLGGSWRKLGITGAWSVVLPVLTGYLGRGPKLTVCARATQGGKSOK 300

RESULT 3

ABP81994

ID ABP81994 standard; protein; 300 AA.

XX

AC ABP81994;

XX

DT 04-MAR-2003 (first entry)

XX

DE Human G protein-coupled receptor GPR40 protein SEQ ID NO:475.

XX

KW G protein-coupled receptor; GPCR; antigenic peptide; gene therapy;  
KW G protein-coupled receptor modulator; antibody; immune-related disease;  
KW growth-related disease; cell regeneration-related disease; AIDS; cancer;  
KW immunological-related cell proliferative disease; autoimmune disease;  
KW Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy;  
KW osteoporosis; cardiomyopathy; inflammation; Crohn's disease; diabetes;  
KW graft versus host disease; Parkinson's disease; multiple sclerosis; pain;  
KW psoriasis; anxiety; depression; schizophrenia; dementia; memory loss;

KW mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea;  
 KW hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma;  
 ulcer.

OS Homo sapiens.

XX WO200261087-A2.

PN 08-AUG-2002.

XX 19-DEC-2001; 2001WO-US050107.

XX 19-DEC-2000; 2000US-0257144P.

XX (LIFE-) LIFESPAN BIOSCIENCES INC.

XX Burmer GC, Roush CL, Brown JP;

XX WPI; 2003-046718/04.

DR N-PSDB; AB242843.

XX New isolated antigenic peptides e.g., for G protein-coupled receptors  
 PT (GPCR), useful for diagnosing and designing drugs for treating conditions  
 PT in which GPCRs are involved, e.g. AIDS, Alzheimer's disease, cancer or  
 PT autoimmune diseases.

XX Disclosure; Fig 1; 523pp; English.

XX The present invention describes antigenic peptides (I) comprising: (a)  
 CC any one of 1601 sequences (see ABP82019 to ABP83619) of 12-24 amino  
 CC acids. Also described: (1) an assay for the detection of a particular G  
 CC protein-coupled receptor (GPCR) or a candidate polypeptide in a sample;  
 CC and (2) an isolated antibody having high specificity and high affinity or  
 CC avidity for a particular GPCR. (I) can be used as GPCR modulators and in  
 CC gene therapy. The antigenic peptides for GPCRs are useful in detecting an  
 CC antibody against a particular GPCR, and in the production of specific  
 CC antibodies. The peptides and antibodies are also useful for detecting the  
 CC presence or absence of corresponding GPCRs. The antigenic peptides for  
 CC GPCRs and antibodies are useful for diagnosing and designing drugs for  
 CC treating immune-related diseases, growth-related diseases, cell  
 CC regeneration-related diseases, immunological-related cell proliferative  
 CC diseases, or autoimmune diseases, e.g. AIDS, Alzheimer's disease,  
 CC atherosclerosis, bacterial, fungal, protozoan or viral infections,  
 CC osteoarthritis, osteoporosis, cancer, cardiomyopathy, chronic and acute  
 CC inflammation, allergies, Crohn's disease, diabetes, graft versus host  
 CC disease, Parkinson's disease, multiple sclerosis, pain, psoriasis,  
 CC anxiety, depression, schizophrenia, dementia, mental retardation, memory  
 CC loss, epilepsy, asthma, tuberculosis, obesity, nausea, hypertension,  
 CC hypotension, renal disorders, rheumatoid arthritis, trauma, ulcers, or  
 CC any other disorder in which GPCRs are involved. The antibodies may be  
 CC used in immunoassays and immunodiagnosis. AB242523 to AB242869 encode  
 CC GPCR proteins given in ABP81675 to ABP82018, which are used in the  
 CC exemplification of the present invention

XX SQ Sequence 300 AA;

Query Match 100.0%; Score 1584; DB 6; Length 300;  
 Best Local Similarity 100.0%; Pred. No. 1.6e-149;  
 Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPQLSGLVYAAPALGFLPNLVLAIRGATAHARLRLTSLVYALNIGCSDLLLTSLP 60

DB 1 MDLPQLSGLVYAAPALGFLPNLVLAIRGATAHARLRLTSLVYALNIGCSDLLLTSLP 60

QY 61 LKAVELASGAWPLPASLCPVFAVAFPPFLYAGGFLAALSAGRYLGAAPFLGYQAFRRP 120

DB 61 LKAVELASGAWPLPASLCPVFAVAFPPFLYAGGFLAALSAGRYLGAAPFLGYQAFRRP 120

QY 121 CYSWGVCAAIWAIVLCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLRAWDPASAG 180

DB 121 CYSWGVCAAIWAIVLCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLRAWDPASAG 180

QY 181 PARFSLSLLLFFPLAITAFCYVGCULARALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240

DB 181 PARFSLSLLLFFPLAITAFCYVGCULARALARSGLTHRRKLRAAWVAGGALLTLLCVGPY 240  
 QY 241 NASNVASFLYPNLGGSRWRLGLITGAWSVVLNPLVTGYLGRGPGLTVCACARTQGGKSQK 300  
 DB 241 NASNVASFLYPNLGGSRWRLGLITGAWSVVLNPLVTGYLGRGPGLTVCACARTQGGKSQK 300

RESULT 4

ADB61404

ID ADB61404 standard; protein; 300 AA.

XX ADB61404;

XX 04-DEC-2003 (first entry)

XX Human GPR40 protein.

XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
 KW antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
 KW antilipemic; dermatological; antiarteriosclerotic; antiarthritic;  
 KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cycostatic;  
 KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
 KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
 KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
 KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
 KW insulin allergy; fat metabolism disorder; cancer; human.

XX Homo sapiens.

XX WO2003068959-A1.

XX 21-AUG-2003.

XX 13-FEB-2003; 2003WO-JP001483.

XX 14-FEB-2002; 2002JP-00037131.

XX 12-JUL-2002; 2002JP-00204163.

XX 12-NOV-2002; 2002JP-00328696.

XX 22-JAN-2003; 2003JP-00014032.

XX (TAKE ) TAKEDA CHEM IND LTD.

XX Hinuma S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;

XX Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;

XX WPI; 2003-671661/63.

XX N-PSDB; ADB61403.

XX Fatty acid and eicosanoid-binding G-protein coupled receptor protein  
 GPR40 for control of pancreatic function and treatment of diabetes.

XX Claim 34; Page 235-236; 257pp; Japanese.

XX The invention relates to a novel screening method comprising a fatty acid  
 CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,  
 CC originating in mouse, rat, crab-eating monkey and hamster (sequences  
 CC fully defined in the specification), equivalent proteins of similar  
 CC activity, and peptides containing partial sequences of the GPR40 protein.  
 CC The novel fatty acid and GPR40 protein and their compositions have the  
 CC following activities: antidiabetic, anabolic, neuroprotective,  
 CC nephrotropic, ophthalmological, antilipemic, dermatological,  
 CC antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,  
 CC nootropic, anorectic, hypotensive, and cycostatic. The novel fatty acid  
 CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and  
 CC further compositions can be used in the treatment, prevention and  
 CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic  
 CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,  
 CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,  
 CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin  
 CC resistance, insulin allergy, fat metabolism disorders and cancer. This  
 CC sequence represents a human GPR40 protein of the invention.

SQ Sequence 300 AA;  
Query Match 100.0%; Score 1584; DB 7; Length 300;  
Best Local Similarity 100.0%; Pred. No. 1.6e-149;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MDLPQLSGLVVAFAFGFLPLNVLAIAGATAHARLRLTPSLVYALNLGCSDLLLTVSUP 60  
DB 1 MDLPQLSGLVVAFAFGFLPLNVLAIAGATAHARLRLTPSLVYALNLGCSDLLLTVSUP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAFPLVYAGGFLAALSAGRYLGAFFPLGYQAFRRP 120  
DB 61 LKAVEALASGAWPLPASLCPVFAVAFPLVYAGGFLAALSAGRYLGAFFPLGYQAFRRP 120  
QY 121 CYSWGVCAAIWALVILCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 CYSWGVCAAIWALVILCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLLLFPFLPLAITAFVCGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPY 240  
DB 181 PARFSLSLLLFPFLPLAITAFVCGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPNLGGSRWKLGLITGAWSVLNPVLVTGYLGRGPGGLTKVCAARTQGKSK 300  
DB 241 NASNVASFLYPNLGGSRWKLGLITGAWSVLNPVLVTGYLGRGPGGLTKVCAARTQGKSK 300  
RESULT 5  
ADC22769  
ID ADC22769 standard; protein; 300 AA.  
XX AC ADC22769;  
XX XX  
DT 18-DEC-2003 (first entry)  
XX DE Human G protein-coupled receptor (GPCR) polypeptide #36.  
XX DE Human; G protein-coupled receptor; GPCR; transmembrane-6 region; TM6;  
KW intracellular-3 region; IC3; receptor.  
XX XX  
OS Homo sapiens.  
XX XX  
PN US6555339-B1.  
XX XX  
PD 29-APR-2003.  
XX XX  
PF 13-OCT-1998; 98US-00170496.  
XX XX  
PR 14-APR-1997; 97US-00839449.  
PR 14-APR-1998; 98US-00060188.  
PR 26-JUN-1998; 98US-0090783P.  
PR 07-AUG-1998; 98US-0095677P.  
XX XX  
PA (AREN-) ARENA PHARM INC.  
XX XX  
PI Liaw CW, Behan DP, Chalmers DT;  
XX XX  
DR WPI; 2003-742861/70.  
DR N-PSDB; ADC22768.  
XX XX  
PT Creating a constitutively active version of an endogenous human G protein  
coupled receptor (GPCR) comprises substituting a specific amino acid in  
the transmembrane-6 region with a different amino acid, and testing for  
constitutive activity.  
XX XX  
PS Example 1; SEQ ID NO 250; 221dp; English.  
XX XX  
CC The invention relates to a method for treating a non-endogenous,  
constitutively active version of an endogenous human G protein-coupled  
receptor (GPCR) that has a transmembrane-6 (TM6) region and an  
intracellular-3 (IC3) region, by substituting a specific amino acid in  
the TM6 region with a different amino acid, and testing for constitutive  
activity. The method is useful for creating a constitutively active

CC version of an endogenous human GPCR that comprises a transmembrane 6  
region and an intracellular loop 3 region. The altered human GPCR  
polypeptides are useful for screening test compounds for identification  
of inverse agonists or partial agonists of GPCR polypeptides, which may  
have therapeutic uses. The altered GPCRs may also be used in vivo or in  
vitro in biological research. A nucleic acid encoding the altered GPCR  
may be used to create a transgenic animal expressing the altered GPCR.  
CC The method allows screening for compounds that modulate the activity of a  
human G protein-coupled receptor without the need for provision of a  
ligand for the receptor. This is particularly useful in allowing  
screening of compounds against orphan receptors for which no ligand is  
currently known. This sequence represents a human GPCR polypeptide of the  
invention.  
XX SQ Sequence 300 AA;  
Query Match 100.0%; Score 1584; DB 7; Length 300;  
Best Local Similarity 100.0%; Pred. No. 1.6e-149;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MDLPQLSGLVVAFAFGFLPLNVLAIAGATAHARLRLTPSLVYALNLGCSDLLLTVSUP 60  
DB 1 MDLPQLSGLVVAFAFGFLPLNVLAIAGATAHARLRLTPSLVYALNLGCSDLLLTVSUP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAFPLVYAGGFLAALSAGRYLGAFFPLGYQAFRRP 120  
DB 61 LKAVEALASGAWPLPASLCPVFAVAFPLVYAGGFLAALSAGRYLGAFFPLGYQAFRRP 120  
QY 121 CYSWGVCAAIWALVILCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 CYSWGVCAAIWALVILCHLGVLEAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLLLFPFLPLAITAFVCGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPY 240  
DB 181 PARFSLSLLLFPFLPLAITAFVCGCLRALARSGLTHRRKLRAAWVAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPNLGGSRWKLGLITGAWSVLNPVLVTGYLGRGPGGLTKVCAARTQGKSK 300  
DB 241 NASNVASFLYPNLGGSRWKLGLITGAWSVLNPVLVTGYLGRGPGGLTKVCAARTQGKSK 300  
RESULT 6  
AAV90684  
ID AAV90684 standard; protein; 300 AA.  
XX AC AAV90684;  
XX XX  
DT 21-AUG-2000 (first entry)  
XX XX  
DE Human mutant G protein-coupled receptor GPR40 (A223K).  
XX XX  
KW G protein-coupled receptor; GPCR; constitutively active;  
KW intracellular loop 3; transmembrane domain 6; drug screening; agonist;  
KW antagonist; mutant; mutein.  
XX XX  
OS Homo sapiens.  
OS Synthetic.  
XX XX  
PN WO2000022129-A1.  
XX XX  
PD 20-APR-2000.  
XX XX  
PF 12-OCT-1999; 99WO-US023938.  
XX XX  
PR 13-OCT-1998; 98US-00170496.  
XX XX  
PA (AREN-) ARENA PHARM INC.  
XX XX  
PI Behan DP, Chalmers DT, Liaw CW;  
XX XX  
DR WPI; 2000-329165/28.  
DR N-PSDB; AAA30776.  
XX XX

PT Non-endogenous constitutively activated human G protein-coupled  
PT receptors, useful for identifying agonists for use as pharmaceutical  
agents.

PS Example 2; Page 325-326; 341pp; English.

XX The invention relates to constitutively active, non-endogenous versions  
CC of endogenous human orphan G protein-coupled receptors (GPCRs, AAY90643-  
CC AAY90677 and AAY90683-Y90687), and to DNA encoding them (AAA30709-A30743  
CC and AAA30775-A30779). The mutant proteins of the invention contain a  
CC mutation in a portion of the protein comprising intracellular loop 3  
CC (IC3) and transmembrane domain 6 (TM6). A non-endogenous amino acid, X,  
CC is substituted for an endogenous residue in IC3 at a position 16 amino  
CC acids N-terminal of an endogenous proline in TM6 to form a sequence X-  
CC (AA)15-Pro. The endogenous amino acid is selected from Lys, His, Arg or  
CC Ala, and is preferably Lys. When the endogenous residue at this position  
CC is Lys, this residue is replaced by His, Arg or preferably Ala. The 15  
CC amino acid stretch between the substituted amino acid and the Pro may be  
CC endogenous, non-endogenous, or a mixture of endogenous and non-endogenous  
CC residues. The constitutively active GPCRs are useful for identifying  
CC antagonists, agonists and partial agonists for use as pharmaceutical  
CC agents. The mutant proteins are also useful in research settings for  
CC elucidating the roles of the receptors in normal and diseased conditions.  
CC Antagonists for a particular GPCR are useful for treating diseases and  
CC disorders associated with that receptor. Because the novel mutant GPCRs  
CC are constitutively active, they can be used directly for screening of GPCR  
CC compounds without the need for endogenous ligands. Sequences AAY90643-  
CC AAY90677 and AAY90683-Y90687 the mutant human GPCRs of the invention  
XX  
SQ Sequence 300 AA;

Query Match 99.7%; Score 1579; DB 3; Length 300;  
Best Local Similarity 99.7%; Pred. No. 5.1e-149;  
Matches 299; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MDLPQLSFGLYVAAPALGFPPLNVLAIARGATAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
DB 1 MDLPQLSFGLYVAAPALGFPPLNVLAIARGATAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCVPFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
DB 61 LKAVEALASGAWPLPASLCVPFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWALVLCHLGLVFLGAPGGWLDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 CYSWGVCAAIWALVLCHLGLVFLGAPGGWLDHNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLLLFFPLPLAITAFCTVCGCLRALARSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
DB 181 PARFSLSLLLFFPLPLAITAFCTVCGCLRALARSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPLNGLGSRWKLGLITGAWSVVLNPLVTGYLGRGPKLTVCAARTQGGKSOK 300  
DB 241 NASNVASFLYPLNGLGSRWKLGLITGAWSVVLNPLVTGYLGRGPKLTVCAARTQGGKSOK 300

## RESULT 7

ID ADC22791 standard; protein; 300 AA.

XX ADC22791;

XX 18-DEC-2003 (first entry)

DE Human G protein-coupled receptor (GPCR) polypeptide #76.

XX Human; G protein-coupled receptor; GPCR; transmembrane-6 region; TM6;  
KW intracellular-3 region; IC3; receptor.

OS Homo sapiens.

XX US6555339-B1.

PN ADB61416 standard; protein; 300 AA.

PD 29-APR-2003.  
XX 13-OCT-1998; 98US-00170496.  
XX 14-APR-1997; 97US-00839449.  
PR 14-APR-1998; 98US-00060188.  
PR 26-JUN-1998; 98US-0090783P.  
PR 07-AUG-1998; 98US-0095677P.  
XX (AREN-) ARENA PHARM INC.  
XX Liaw CW, Behan DP, Chalmers DT;  
PI WPI; 2003-742861/70.  
XX N-PSDB; ADC22790.  
XX Creating a constitutively active version of an endogenous human G protein  
PT coupled receptor (GPCR) comprises substituting a specific amino acid in  
PT the transmembrane-6 region with a different amino acid, and testing for  
PT constitutive activity.  
XX Example 2; SEQ ID NO 272; 221pp; English.

XX The invention relates to a method for treating a non-endogenous,  
CC constitutively active version of an endogenous human G protein-coupled  
CC receptor (GPCR) that has a transmembrane-6 (TM6) region and an  
CC intracellular-3 (IC3) region, by substituting a specific amino acid in  
CC the TM6 region with a different amino acid, and testing for constitutive  
CC activity. The method is useful for creating a constitutively active  
CC version of an endogenous human GPCR that comprises a transmembrane 6  
CC region and an intracellular loop 3 region. The altered human GPCR  
CC polypeptides are useful for screening test compounds for identification  
CC of inverse agonists or partial agonists of GPCR polypeptides, which may  
CC have therapeutic uses. The altered GPCRs may also be used in vivo or in  
CC vitro in biological research. A nucleic acid encoding the altered GPCR  
CC may be used to create a transgenic animal expressing the altered GPCR.  
CC The method allows screening for compounds that modulate the activity of a  
CC human G protein-coupled receptor without the need for provision of a  
CC ligand for the receptor. This is particularly useful in allowing  
CC screening of compounds against orphan receptors for which no ligand is  
CC currently known. This sequence represents a human GPCR polypeptide of the  
CC invention.

XX Sequence 300 AA;

Query Match 99.7%; Score 1579; DB 7; Length 300;  
Best Local Similarity 99.7%; Pred. No. 5.1e-149;  
Matches 299; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MDLPQLSFGLYVAAPALGFPPLNVLAIARGATAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
DB 1 MDLPQLSFGLYVAAPALGFPPLNVLAIARGATAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCVPFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
DB 61 LKAVEALASGAWPLPASLCVPFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWALVLCHLGLVFLGAPGGWLDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 CYSWGVCAAIWALVLCHLGLVFLGAPGGWLDHNTSLGINTPVNGSPVCLAWDPASAG 180  
QY 181 PARFSLSLLLFFPLPLAITAFCTVCGCLRALARSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
DB 181 PARFSLSLLLFFPLPLAITAFCTVCGCLRALARSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPLNGLGSRWKLGLITGAWSVVLNPLVTGYLGRGPKLTVCAARTQGGKSOK 300  
DB 241 NASNVASFLYPLNGLGSRWKLGLITGAWSVVLNPLVTGYLGRGPKLTVCAARTQGGKSOK 300

## RESULT 8

ID ADB61416

ADB61416;  
 04-DEC-2003 (first entry)  
 Monkey GPR40 protein.  
 fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
 antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
 antilipemic; dermatological; antiarteriosclerotic; antiarthritic;  
 osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cytostatic;  
 diabetic; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
 diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
 bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
 memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
 insulin allergy; fat metabolism disorder; cancer; monkey.  
 Primates.  
 WO2003068959-A1.  
 21-AUG-2003.  
 13-FEB-2003; 2003WO-JP001483.  
 14-FEB-2002; 2002JP-00037131.  
 12-JUL-2002; 2002JP-00204163.  
 12-NOV-2002; 2002JP-00328696.  
 22-JAN-2003; 2003JP-00014032.  
 (TAKE ) TAKEDA CHEM IND LTD.  
 Hinuma S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;  
 Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;  
 WPI; 2003-671661/63.  
 N-PSDB; ADB61417.  
 Fatty acid and eicosanoid-binding G-protein coupled receptor protein  
 GPR40 for control of pancreatic function and treatment of diabetes.  
 Claim 1; Page 240-241; 257pp; Japanese.  
 The invention relates to a novel screening method comprising a fatty acid  
 and eicosanoid-binding G-protein coupled receptor protein, GPR40,  
 originating in mouse, rat, crab-eating monkey and hamster (sequences  
 fully defined in the specification), equivalent proteins of similar  
 activity, and peptides containing partial sequences of the GPR40 protein.  
 The novel fatty acid and GPR40 protein and their compositions have the  
 following activities: antidiabetic, anabolic, neuroprotective,  
 nephrotropic, ophthalmological, antilipemic, dermatological,  
 antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,  
 nootropic, anorectic, hypotensive, and cytostatic. The novel fatty acid  
 and eicosanoid-binding G-protein coupled receptor protein, GPR40, and  
 further compositions can be used in the treatment, prevention and  
 diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic  
 nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,  
 arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,  
 indigestion, memory loss, obesity, hypoglycaemia, edema, insulin  
 resistance, insulin allergy, fat metabolism disorders and cancer. This  
 sequence represents a monkey GPR40 protein of the invention.  
 Query Match 95.9%; Score 1519; DB 7; Length 300;  
 Best Local Similarity 96.7%; Pred. No. 4.9e-143;  
 Matches 290; Conservative 0; Mismatches 10; Indels 0; Gaps 0;  
 QY 1 MDLPQLSGELYVAAPALGFLNVLAIARGATAHARLTPSLVYALNLCGSDLLLTSLP 60  
 DB 1 MDLPQLSGELYVAAPALGFLNVLAIARGATAHARLTPSLVYALNLCGSDLLLTSLP 60  
 QY 61 LKAVEALASGAWPLPASLCPVFAHFPFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120

Db 61 LKAVEALASGAWPLPASLCPVFAHFPFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
 QY 121 CYSWGVCAAIWALVLCGLVFLGAPCGWLDHNSLTSLGINTPVNGSPVCLAWDPASAG 180  
 Db 121 CYSWGVCAAIWALVLCGLVFLGAPCGWLDHNSLTSLGINTPVNGSPVCLAWDPASAG 180  
 QY 181 PARFSLSLLLPFLPLAITAFCCVVGCLRALARSGLTHRRKLRRAAWVAGGALLTLLLCVGPY 240  
 Db 181 PARFSLSLLLPFLPLAITAFCCVVGCLRALARSGLTHRRKLRRAAWVAGGALLTLLLCVGPY 240  
 QY 241 NASNVASFLYPNLGGSRKGLITGAWSVLNLPLVTGLGRPGGLKTVCAARTQGSQK 300  
 Db 241 NASNVASFLYPNLGGSRKGLITGAWSVLNLPLVTGLGRPGGLKTVCAARTQGSQK 300  
 RESULT 9  
 ABG31107  
 ID ABG31107 standard; protein; 300 AA.  
 XX XX ABG31107;  
 AC ABG31107;  
 DT 21-OCT-2002 (first entry)  
 XX XX  
 DE Mouse G protein-coupled receptor GPR40.  
 XX XX  
 KW Mouse; GPR40; G protein-coupled; receptor; type 2 diabetes; obesity;  
 KW antidiabetic; neuroprotective; anorectic; cerobroprotective; Gq;  
 KW G protein; reporter gene; glucose intolerance; insulin intolerance;  
 KW neurodegenerative disease; Alzheimer's disease; stroke.  
 XX OS Mus sp.  
 XX XX WO200257783-A2.  
 PN 25-JUL-2002.  
 XX XX  
 PF 18-DEC-2001; 2001WO-US048985.  
 XX XX  
 PR 22-DEC-2000; 2000GB-00031527.  
 XX XX  
 PA (GLAX ) GLAXO GROUP LTD.  
 PA (SMIK ) SMITHKLINE BEECHAM PLC.  
 XX XX  
 PI Andrews JL, Briscoe CP, Ignar DM, Muir AI, Sauls HR, Tadayyon M;  
 XX WPI; 2002-599726/64.  
 DR N-PSDB; ABK90237.  
 XX XX  
 PT Identifying GPR40 receptor ligand for treating disorders e.g. obesity,  
 PT comprises detecting whether the test compound competitively inhibits the  
 PT binding of a fatty acid GPR40 ligand to a GPR40 receptor.  
 XX PS Disclosure; Page 51; 53pp; English.  
 XX XX  
 CC The invention relates to screening a test compound to determine whether  
 CC the compound is a GPR40 receptor (G protein-coupled receptor) ligand  
 CC comprises detecting whether the test compound competitively inhibits the  
 CC binding of a fatty acid GPR40 ligand to a GPR40 receptor. Also included  
 CC are (1) a method of screening a compound for GPR40 antagonist activity,  
 CC comprising: (a) measuring any detectable signal produced by a reporter  
 CC gene (comprising a reporter gene under the control of G protein Gq  
 CC responsive transcriptional element); (b) detecting a decrease in reporter  
 CC gene expression in the presence of both test compound and agonist; or (c)  
 CC detecting whether the compound decreases glucose-stimulated insulin  
 CC release from mammalian pancreatic beta cells in the presence of a GPR40  
 CC agonist, compared to glucose-stimulated insulin release that would occur  
 CC due to the presence of the GPR40 agonist; (2) a method of screening a  
 CC compound for GPR40 agonist activity, which comprises: (a) detecting any  
 CC reporter gene expression; or (b) detecting whether the compound binds to  
 CC GPR40 and increases glucose-stimulated insulin release from mammalian  
 CC pancreatic beta cells. The method is useful for identifying GPR40  
 CC antagonist or agonist compounds for treating disorders e.g. type 2



CC diabetes, obesity, glucose or insulin intolerance, neurodegenerative  
CC disease (e.g. Alzheimer's disease) or stroke. The present sequence  
CC represents mouse GPR40  
XX  
SQ Sequence 300 AA;  
Query Match 84.2%; Score 1333; DB 5; Length 300;  
Best Local Similarity 83.0%; Pred. No. 1.8e-124;  
Matches 249; Conservative 17; Mismatches 34; Indels 0; Gaps 0;  
QY 1 MDLPOLSGLYVAFAFGFLNVLAIKATGATAHARLRLTPSLVYALNLCGSDLLLTSLP 60  
DB 1 MDLPOLSPALYVSFAFGFLNVLAIKATGATAHARLRLTPSLVYALNLCGSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFFPLVYAGGGFLAALSAGRYLGAAPFGLYQAFRRP 120  
DB 61 LKAVEALASGAWPLPLPFCVFALAHFAPLYAGGGFLAALSAGRYLGAAPFGLYQAFRRP 120  
QY 121 CYSWGVCVAIWALVCHLGLVFLGAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 RYSGWGVCAIWALVCHLGLVFLGAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAR 180  
QY 181 PARFSLALLFPLPLAITAFVCGCLRALARSGLTHRRKLRRAAWAGGALLTLLCVGPY 240  
DB 181 PARLSFILLFPLPLAITAFVCGCLRALARSGLTHRRKLRRAAWAGGALLTLLCVGPY 240  
QY 241 NASNVASFLYPLNLCGSRKGLITGAWSVVNLPLVTGYLGRGPKLTVCAARTQGGKSK 300  
DB 241 NASNVASFINPDLGGSRKGLITGAWSVVNLPLVTGYLGRGPKLTVCAARTQGGKSK 300  
RESULT 10  
ADB61400  
ID ADB61400 standard; protein; 300 AA.  
XX AC ADB61400;  
XX DE Mouse GPR40 protein.  
DT 04-DEC-2003 (first entry)  
XX  
DE  
XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
KW antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
KW antilipemic; dermatological; antiarteriosclerotic; antiarthritic;  
KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cyostatic;  
KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
KW insulin allergy; fat metabolism disorder; cancer; mouse; murine.  
XX Mus sp.  
XX  
XX WO2003068959-A1.  
XX  
XX 21-AUG-2003.  
XX  
XX 13-FEB-2003; 2003WO-JP001483.  
XX  
XX 14-FEB-2002; 2002JP-00037131.  
PR 12-JUL-2002; 2002JP-00204163.  
PR 12-NOV-2002; 2002JP-00328696.  
PR 22-JAN-2003; 2003JP-00014032.  
XX  
XX (TAKE ) TAKEDA CHEM IND LTD.  
XX  
XX Hinuma S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;  
PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;  
XX  
XX WPI; 2003-671661/63.  
DR N-PSDB; ADB61401.  
XX  
PT Fatty acid and eicosanoid-binding G-protein coupled receptor protein

PT GPR40 for control of pancreatic function and treatment of diabetes.  
XX Claim 1; Page 230-231; 257pp; Japanese.  
XX  
CC The invention relates to a novel screening method comprising a fatty acid  
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,  
CC originating in mouse, rat, crab-eating monkey and hamster (sequences  
CC fully defined in the specification), equivalent proteins of similar  
CC activity, and peptides containing partial sequences of the GPR40 protein.  
CC The novel fatty acid and GPR40 protein and their compositions have the  
CC following activities: antidiabetic, anabolic, neuroprotective,  
CC nephrotropic, ophthalmological, antiarthritic, osteopathic, dermatological,  
CC antilipemic, antilipemic, antiarteriosclerotic, thrombolytic,  
CC nootropic, anorectic, hypotensive, and cyostatic. The novel fatty acid  
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and  
CC further compositions can be used in the treatment, prevention and  
CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic  
CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,  
CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,  
CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin  
CC resistance, insulin allergy, fat metabolism disorders and cancer. This  
CC sequence represents a mouse GPR40 protein of the invention.  
XX Sequence 300 AA;  
SQ  
Query Match 84.2%; Score 1333; DB 7; Length 300;  
Best Local Similarity 83.0%; Pred. No. 1.8e-124;  
Matches 249; Conservative 17; Mismatches 34; Indels 0; Gaps 0;  
QY 1 MDLPOLSGLYVAFAFGFLNVLAIKATGATAHARLRLTPSLVYALNLCGSDLLLTSLP 60  
DB 1 MDLPOLSPALYVSFAFGFLNVLAIKATGATAHARLRLTPSLVYALNLCGSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFFPLVYAGGGFLAALSAGRYLGAAPFGLYQAFRRP 120  
DB 61 LKAVEALASGAWPLPLPFCVFALAHFAPLYAGGGFLAALSAGRYLGAAPFGLYQAFRRP 120  
QY 121 CYSWGVCVAIWALVCHLGLVFLGAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAG 180  
DB 121 RYSGWGVCAIWALVCHLGLVFLGAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAR 180  
QY 181 PARFSLALLFPLPLAITAFVCGCLRALARSGLTHRRKLRRAAWAGGALLTLLCVGPY 240  
DB 181 PARLSFILLFPLPLAITAFVCGCLRALARSGLTHRRKLRRAAWAGGALLTLLCVGPY 240  
QY 241 NASNVASFLYPLNLCGSRKGLITGAWSVVNLPLVTGYLGRGPKLTVCAARTQGGKSK 300  
DB 241 NASNVASFINPDLGGSRKGLITGAWSVVNLPLVTGYLGRGPKLTVCAARTQGGKSK 300  
RESULT 11  
ADB61402  
ID ADB61402 standard; protein; 300 AA.  
XX AC ADB61402;  
XX DT 04-DEC-2003 (first entry)  
XX DE Rat GPR40 protein.  
XX  
XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;  
KW antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;  
KW antilipemic; dermatological; antiarteriosclerotic; antiarthritic;  
KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cyostatic;  
KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;  
KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;  
KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;  
KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;  
KW insulin allergy; fat metabolism disorder; cancer; rat.  
XX Rattus sp.  
XX  
XX WO2003068959-A1.

```
XX 21-AUG-2003.
PD 13-FEB-2003; 2003WO-JP001483.
XX 14-FEB-2002; 2002JP-00037131.
XX 12-JUL-2002; 2002JP-00204163.
XX 12-NOV-2002; 2002JP-00328696.
XX 22-JAN-2003; 2003JP-00014032.
XX (TAKE ) TAKEDA CHEM IND LTD.
XX Himura S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;
PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;
XX WPI; 2003-671661/63.
DR N-PSDB; ADB61428.
XX Fatty acid and eicosanoid-binding G-protein coupled receptor protein
PT GPR40 for control of pancreatic function and treatment of diabetes.
XX Claim 1; Page 232-234; 257pp; Japanese.
XX The invention relates to a novel screening method comprising a fatty acid
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,
CC originating in mouse, rat, crab-eating monkey and hamster (sequences
CC fully defined in the specification), equivalent proteins of similar
CC activity, and peptides containing partial sequences of the GPR40 protein.
CC The novel fatty acid and GPR40 protein and their compositions have the
CC following activities: antidiabetic, anabolic, neuroprotective,
CC nephrotropic, ophthalmological antilipemic, dermatological,
CC antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,
CC nootropic, anorectic, hypotensive, and cytostatic. The novel fatty acid
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and
CC further compositions can be used in the treatment, prevention and
CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic
CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,
CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,
CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin
CC resistance, insulin allergy, fat metabolism disorders and cancer. This
CC sequence represents a rat GPR40 protein of the invention.
XX Sequence 300 AA;
Query Match 83.3%; Score 1320; DB 7; Length 300;
Best Local Similarity 81.7%; Pred. No. 3.6e-123;
Matches 245; Conservative 19; Mismatches 36; Indels 0; Gaps 0;
QY 1 MDLPQSLSGLYVAFAFGFLNVLAIKGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60
DB 1 MDLPQSLFALYVSAFALGFLNVLAIKGAVSHAKRLTPSLVYVYUHLACSDLLLAITLP 60
QY 61 LKAVEALASGAWPLPASCVPFAVAHFPPLYAGGGFLAALSAGRYLGAAFPPLGYQAFRRP 120
DB 61 LKAVEALASGWPLPLPFCVPFALAHFAPLYAGGGFLAALSAGRYLGAAFPFGYQAIRP 120
QY 121 CYSWGCAIWAIVLCHGLVFGLEAPGWNHDSNTSLGINTPVNGSPVCLAWDPASAG 180
DB 121 CYSWGCVAIWAIVLCHGLVFGLEAPGWNHDSNTSLGINTPVNGSPVCLAWDPDSAR 180
QY 181 PARFSLILLFPLAITAFYVGCURLARASGLTHRRKLRRAWVAGGALLTLILCVGY 240
DB 181 PARLSFILLFPLVITAFYVGCURLVHSGLSHRKLRRAWVAGGALLTLILCIGY 240
QY 241 NASNVASFYPLNIGSWRKLGLITGAWSVVNLPLVTVGLGRGPKLTVCAARTQGGKSK 300
DB 241 NASNVASFNPDLGSRWKLGLITGAWSVVNLPLVTVGLGTGPGQGTICVTRPRTIQK 300
RESULT 12
ADB61428
ID ADB61428 standard; protein; 300 AA.
XX
```

```
AC ADB61428;
XX 04-DEC-2003 (first entry)
XX Hamster GPR40 protein.
XX fatty acid; eicosanoid-binding G-protein coupled receptor; GPR40;
KW antidiabetic; anabolic; neuroprotective; nephrotropic; ophthalmological;
KW antilipemic; dermatological; antiarteriosclerotic; antiarthritic;
KW osteopathic; thrombolytic; nootropic; anorectic; hypotensive; cytostatic;
KW diabetes; ketosis; acidosis; diabetic neuropathy; diabetic nephropathy;
KW diabetic retinopathy; hyperlipaemia; skin disease; arthritis;
KW bone disease; arteriosclerosis; thrombosis; hypertension; indigestion;
KW memory loss; obesity; hypoglycaemia; edema; insulin resistance;
KW insulin allergy; fat metabolism disorder; cancer; hamster.
XX Cricetinae gen. sp.
XX WO2003068959-A1.
XX 21-AUG-2003.
XX 13-FEB-2003; 2003WO-JP001483.
XX 14-FEB-2002; 2002JP-00037131.
PR 12-JUL-2002; 2002JP-00204163.
PR 12-NOV-2002; 2002JP-00328696.
PR 22-JAN-2003; 2003JP-00014032.
XX (TAKE ) TAKEDA CHEM IND LTD.
XX Himura S, Hosoya M, Ito Y, Kobayashi M, Tanaka H, Okubo S;
PI Fujii R, Kizawa H, Kawamata Y, Ogi K, Harada M, Fukusumi S;
XX WPI; 2003-671661/63.
DR N-PSDB; ADB61429.
XX Fatty acid and eicosanoid-binding G-protein coupled receptor protein
PT GPR40 for control of pancreatic function and treatment of diabetes.
XX Claim 1; Page 245-246; 257pp; Japanese.
XX The invention relates to a novel screening method comprising a fatty acid
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40,
CC originating in mouse, rat, crab-eating monkey and hamster (sequences
CC fully defined in the specification), equivalent proteins of similar
CC activity, and peptides containing partial sequences of the GPR40 protein.
CC The novel fatty acid and GPR40 protein and their compositions have the
CC following activities: antidiabetic, anabolic, neuroprotective,
CC nephrotropic, ophthalmological antilipemic, dermatological,
CC antiarteriosclerotic, antiarthritic, osteopathic, thrombolytic,
CC nootropic, anorectic, hypotensive, and cytostatic. The novel fatty acid
CC and eicosanoid-binding G-protein coupled receptor protein, GPR40, and
CC further compositions can be used in the treatment, prevention and
CC diagnosis of diabetes, ketosis, acidosis, diabetic neuropathy, diabetic
CC nephropathy, diabetic retinopathy, hyperlipaemia, skin diseases,
CC arthritis, bone diseases, arteriosclerosis, thrombosis, hypertension,
CC indigestion, memory loss, obesity, hypoglycaemia, edema, insulin
CC resistance, insulin allergy, fat metabolism disorders and cancer. This
CC sequence represents a hamster GPR40 protein of the invention.
XX Sequence 300 AA;
Query Match 81.8%; Score 1295; DB 7; Length 300;
Best Local Similarity 80.7%; Pred. No. 1.1e-120;
Matches 242; Conservative 21; Mismatches 37; Indels 0; Gaps 0;
QY 1 MDLPQSLSGLYVAFAFGFLNVLAIKGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60
DB 1 MALSPQLFPALYVSAFALGFLNVLAIKGAVARLRLTPNLVYUHLACSDLLLAITLP 60
QY 61 LKAVEALASGAWPLPASCVPFAVAHFPPLYAGGGFLAALSAGRYLGAAFPPLGYQAFRRP 120
XX
```

Db 61 VKAVEALASGAWPLPLCPVFLVHFAPLYAGGGFLAALSAGRYLGAAPFGYQAVRRP 120  
 QY 121 CYSWGVCATWALVCHLGLVFLGAPGGWLDHNSNTSLGINTPVNGSPVCLAWDPASAG 180  
 Db 121 RYSGWVCVATWALVCHLGLVFLGAPGGWLDHNSNTSLGINTPVNGSPVCLAWDPASAR 180  
 QY 181 PARFSLILLFFPLAITAFYVGCCLALARSGLTHRRKLRAAWVAGGALLTLCLVGPY 240  
 Db 181 PARLSFSILLFFPLVITAFYVGCCLRALHSHKRLRAAWAAGGAFLLTLCLGPY 240  
 QY 241 NASNVASFVNPDLGGSRKRLGLITGWSVVLNPLVTGYLGRGPGKLVCAARTGGKSOK 300  
 Db 241 NASNVASFVNPDLGGSRKRLGLITGWSVVLNPLVTGYLGRGPGKLVCAARTGGTIQK 300

## RESULT 13

AAB82759

ID AAB82759 standard; protein; 346 AA.

XX AAB82759;

XX.

DT 29-OCT-2001 (first entry)

DE Human G-protein coupled receptor GPR 42.

XX

KW GPR 42; G-protein coupled receptor 42; human; drug screening;  
 KW dyslipidaemia; coronary heart disease; atherosclerosis; thrombosis;  
 KW obesity; angina; kidney failure; peripheral vascular disease; stroke;  
 KW diabetes; metabolic syndrome; syndrome X; antilipaeamic; cardiac;  
 KW antiatherosclerotic; thrombolytic; anorectic; angiainal; nephrotropic;  
 KW vasotropic; cerebroprotective; antidiabetic; therapy.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Domain

18..41

/label= Transmembrane

FT Domain

52..73

/label= Transmembrane

FT Domain

88..111

/label= Transmembrane

FT Domain

132..153

/label= Transmembrane

FT Domain

188..212

/label= Transmembrane

FT Domain

229..250

/label= Transmembrane

FT Domain

259..278

/label= Transmembrane

FT

XX

PN WO200161359-A2.

XX

XX 23-AUG-2001.

XX

PF 19-FEB-2001; 2001WO-GB000684.

XX

XX 18-FEB-2000; 2000GB-00003900.

PR

XX 22-MAR-2000; 2000GB-00007015.

XX

PA (GLAXO) GLAXO GROUP LTD.

XX

PI Wise A, Brown AJ;

XX

DR WPI; 2001-536581/59.

DR

XX N-PSDB; AAB26460.

XX

Identification of an agent for the modulation of G-protein coupled  
 receptor useful for the treatment of disease i.e. dyslipidemia or stroke.  
 Claim 7; Page 47-48; 53pp; English.  
 The present sequence is that of human G-protein coupled receptor 42 (GPR  
 42). The invention is based on the finding that expression of GPR 42 and

CC GPR 41 (see AAB82758) is restricted to adipose tissue. GPR 41 or GPR 42  
 CC may therefore be used as a screening target for the identification and  
 CC development of novel pharmaceutical agents for use in inhibiting  
 CC lipolysis. Methods are claimed for identifying agents that modulate GPR  
 CC 41 or GPR 42 activity, involving: (1) contacting a test agent with GPR 41  
 CC or GPR 42 or a variant polypeptide capable of coupling to a G-protein;  
 CC and (2) monitoring for GPR 41 or GPR 42 activity in the presence of a G-  
 CC protein, thereby determining whether the test agent modulates activity.  
 CC Such agents, which may be an activator of GPR 41 or GPR 42, an inhibitor  
 CC of lipolysis, or a polynucleotide encoding GPR 41, GPR 42 or variant  
 CC polypeptide, are useful for the treatment of dyslipidaemia, coronary  
 CC heart disease, atherosclerosis, thrombosis or obesity, angina, chronic  
 CC renal failure, peripheral vascular disease, stroke, type II diabetes or  
 CC metabolic syndrome (syndrome X) (all claimed)  
 XX  
 SQ Sequence 346 AA;

Query Match 23.1%; Score 366; DB 4; Length 346;  
 Best Local Similarity 34.1%; Pred. No. 6.8e-28;  
 Matches 101; Conservative 38; Mismatches 129; Indels 28; Gaps 8;

QY 1 MDLPPQLS-----FGLYVAAPALGPPLNVLATRGATAHARLRLTSPSLVVALNLGCS 51  
 Db 1 MTGPDQSYFSGNHWVFVSYLLTFLVGLPLNLALVVFVGKURCPVAVDVLNLTAS 60  
 QY 52 DLLLTVSLPKAVEALASGAWPLPASLCPVFAVAFHFFPLYAGGGFLAALSAGRYLGAAPF 111  
 Db 61 DLLLTLFLPFRVVEAANGHWPFLPFLCPLSGIFPTTYITLTALFLANVIEPLSVNHP 120  
 QY 112 LGYQAFRRPCYSGVCAAIWALVCHLGLVFLGAPGGWLDHNSNTSLGINTPVNGSPVC- 170  
 Db 121 LMYKTRPLGQAGLVSVACWLLASAHCSVYVVFIEFSGD-ISHSQGTNG-----TCY 170  
 QY 171 LEAWDP--ASAGPARELSLILFFFLPLAITAFYVGCCLRALARSGLTHRRKLRANWAGG 228  
 Db 171 LEFWKQDLAILLPVRLEMAVLFVFWPLIITSYCSRLVWLILRGG-SHRRQRVRVAGLVAA 229  
 QY 229 ALITLILLCVGPYNASNVASFLYPNLGGS--WRKLGITGWSVVLNPLVTGYLGRG 282  
 Db 230 TLINFLVCFGPNVSHVGYI---CGESPWRILYVTLTSLNSCVDPFVYFSSG 282

## RESULT 14

AAY90680

ID AAY90680 standard; protein; 346 AA.

XX

AC AAY90680;

XX

DT 21-AUG-2000 (first entry)

XX

DE Human G protein-coupled receptor GPR41.

XX

KW G protein-coupled receptor; GPCR; constitutively active;  
 KW intracellular loop 3; transmembrane domain 6; drug screening; agonist;  
 KW antagonist.

XX

OS Homo sapiens.

XX

PN WO200022129-A1.

XX

PD 20-APR-2000.

XX

PF 12-OCT-1999; 99WO-US023938.

XX

XX 13-OCT-1998; 98US-00170496.

PR

XX (AREN-) ARENA PHARM INC.

XX

XX Behan DP, Chalmers DT, Liaw CW;

XX

DR WPI; 2000-329165/28.

XX

XX N-PSDB; AAA30762.

XX

PT Non-endogenous constitutively activated human G protein-coupled  
PT receptors, useful for identifying agonists for use as pharmaceutical  
PT agents.  
XX  
PS Example 1; Page 310-311; 341pp; English.  
XX  
CC The invention relates to constitutively active, non-endogenous versions  
CC of endogenous human orphan G protein-coupled receptors (GPCRs, AAY90643-  
CC AAY90677 and AAY90683-Y90687), and to DNA encoding them (AAA30709-A30743  
CC and AAA30775-A30779). The mutant proteins of the invention contain a  
CC mutation in a portion of the protein comprising intracellular loop 3  
CC (IC3) and transmembrane domain 6 (TM6). A non-endogenous amino acid, X,  
CC is substituted for an endogenous residue in IC3 at a position 16 amino  
CC acids N-terminal of an endogenous proline in TM6 to form a sequence X-  
CC (AA)15-Pro. The endogenous amino acid is selected from Lys, His, Arg or  
CC Ala, and is preferably Lys. When the endogenous residue at this position  
CC is Lys, this residue is replaced by His, Arg or preferably Ala. The 15  
CC amino acid stretch between the substituted amino acid and the Pro may be  
CC endogenous, non-endogenous, or a mixture of endogenous and non-endogenous  
CC residues. The constitutively active GPCRs are useful for identifying  
CC antagonists, agonists and partial agonists for use as pharmaceutical  
CC agents. The mutant proteins are also useful in research settings for  
CC elucidating the roles of the receptors in normal and diseased conditions.  
CC Antagonists for a particular GPCR are useful for treating diseases and  
CC disorders associated with that receptor. Because the novel mutant GPCRs  
CC are constitutively active, they can be used directly for screening of  
CC compounds without the need for endogenous ligands. The present sequence  
CC represents a human wild-type GPCR referred to in an exemplification of  
CC the invention  
XX  
SQ Sequence 346 AA;

Query Match 21.9%; Score 347; DB 3; Length 346;  
Best Local Similarity 32.3%; Pred. No. 5.4e-26;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPQOLS-----FGLYVAAFALGPPLNVLAIARGATAHARLRLTSLVYALNLGCS 51  
DB 1 MDTGPDQSYFSGNHWVFVSVLLTFLVGLPLNLLAVFVGVKLRPPVAVDVLNLTAS 60  
QY 52 DLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAFHFFPLVYAGGFLAALSAGRYLGAAPP 111  
DB 61 DLLLTLFLPFRVVEAANGHWPFLPILCPLSGFIPTFTIYLTALFLAAVSIERFLSVAHP 120  
QY 112 LGYQAFRRPCYSWGVCAATWAVLCHLVFGLVGLAEPGMDHNSLTSLGINTPVGSPVCL 171  
DB 121 LMYKTRPLRGLQVLSVACWLLASACSVVYVIEFSGD--ISHSQGTNG-----TCY 170  
QY 172 EAW---DPASAGPARFSLALLFPLAITAFYCVGLRALARSGLTHRRKLRAAWVAGG 228  
DB 171 LFERKDQALILPVRLEMAVLFVPLIITSYSLVWLILGKG--SHRQRVAGLLAA 229  
QY 229 ALLTLTLVCPYNASVAFPLNGLGGSWRKLGKITGAWSVVNLPIVTGYLGRG 282  
DB 230 TLLNLFVCFGPNVSHVGVICGE-SPAWRIYVTLTLSTLNSCVDPPVYVYSSG 282

RESULT 15  
AAB82758  
ID AAB82758 standard; protein; 346 AA.  
XX  
AC AAB82758;  
XX  
DT 29-OCT-2001 (first entry)  
DE Human G-protein coupled receptor GPR 41.  
XX  
KW GPR 41; G-protein coupled receptor 41; human; drug screening;  
KW dyslipidaemia; coronary heart disease; atherosclerosis; thrombosis;  
KW obesity; angina; kidney failure; peripheral vascular disease; stroke;  
KW diabetes; metabolic syndrome; syndrome X; antilipaeamic; cardiant;  
KW antiatherosclerotic; thrombolytic; anorectic; anginal; nephrotropic;  
KW vasotrophic; cerebroprotective; antidiabetic; therapy.

XX Homo sapiens.  
OS  
XX  
FH Key Location/Qualifiers  
FT Domain 18..41 /label= Transmembrane  
FT Domain 52..73 /label= Transmembrane  
FT Domain 88..111 /label= Transmembrane  
FT Domain 132..153 /label= Transmembrane  
FT Domain 188..212 /label= Transmembrane  
FT Domain 229..250 /label= Transmembrane  
FT Domain 259..278 /label= Transmembrane  
XX WO200161359-A2.  
XX 23-AUG-2001.  
XX 19-FEB-2001; 2001WO-GB000684.  
XX 18-FEB-2000; 2000GB-00003900.  
XX 22-MAR-2000; 2000GB-00007015.  
XX (GLAX ) GLAXO GROUP LTD.  
XX  
XX Wise A, Brown AJ;  
XX WPI: 2001-536581/59.  
XX N-PSDB; AAB26459.  
XX  
PT Identification of an agent for the modulation of G-protein coupled  
PT receptor useful for the treatment of disease i.e. dyslipidemia or stroke.  
XX  
PS Claim 7; Page 44-46; 53pp; English.  
XX  
CC The present sequence is that of human G-protein coupled receptor 41 (GPR  
CC 41). The invention is based on the finding that expression of GPR 41 and  
CC GPR 42 (see AAB82759) is restricted to adipose tissue. GPR 41 or GPR 42  
CC may therefore be used as a screening target for the identification and  
CC development of novel pharmaceutical agents for use in inhibiting  
CC lipolysis. Methods are claimed for identifying agents that modulate GPR  
CC 41 or GPR 42 activity, involving: (1) contacting a test agent with GPR 41  
CC and (2) monitoring for GPR 41 or GPR 42 activity in the presence of a G-  
CC protein, thereby determining whether the test agent modulates activity.  
CC Such agents, which may be an activator of GPR 41 or GPR 42, an inhibitor  
CC of lipolysis, or a polynucleotide encoding GPR 41, GPR 42 or variant  
CC polypeptide, are useful for the treatment of dyslipidaemia, coronary  
CC heart disease, atherosclerosis, thrombosis or obesity, angina, chronic  
CC renal failure, peripheral vascular disease, stroke, type II diabetes or  
CC metabolic syndrome (syndrome X) (all claimed)  
XX  
SQ Sequence 346 AA;

Query Match 21.9%; Score 347; DB 4; Length 346;  
Best Local Similarity 32.3%; Pred. No. 5.4e-26;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPQOLS-----FGLYVAAFALGPPLNVLAIARGATAHARLRLTSLVYALNLGCS 51  
DB 1 MDTGPDQSYFSGNHWVFVSVLLTFLVGLPLNLLAVFVGVKLRPPVAVDVLNLTAS 60  
QY 52 DLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAFHFFPLVYAGGFLAALSAGRYLGAAPP 111  
DB 61 DLLLTLFLPFRVVEAANGHWPFLPILCPLSGFIPTFTIYLTALFLAAVSIERFLSVAHP 120  
QY 112 LGYQAFRRPCYSWGVCAATWAVLCHLVFGLVGLAEPGMDHNSLTSLGINTPVGSPVCL 171

Db	121	LWYKTRPRLQAGLVSVACWLLASAHCSVVVIEFSGD-ISHSQGTNG-----TCY	170
Qy	172	EAW---DPASAGPARFSLSLFLPLAITAFICYVGCRLALARSGLTHRKLRAAWVAGG	228
Db	171	LEFRKQQLAILLFVRLEMAVVLFWVPLIITSYCVSRVLVWILGRGG-SHREQRRVAGLAA	229
Qy	229	ALLTLLLCVGPYNASNVASFYPNLGGSWRKGLITGANSVVLNPLVTGYLGRG	282
Db	230	TLLNFLVCFGPYNVSHVGYICGE-SPAWRIYVTVTLTLNLSVDPFVYFSSSG	282

Search completed: April 29, 2004, 12:10:03  
Job time : 61 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:07:54 ; Search time 20 Seconds  
(without alignments)  
1442.873 Million cell updates/sec

Title: US-10-202-687-2

Perfect score: 1584

Sequence: 1 MDLPPQLSGLYVAAPALGF.....RPGGLKTVCAARTQGGKSK 300

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR 78:\*

1: pir1:\*

2: pir2:\*

3: pir3:\*

4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1584	100.0	300	2 JCS714	G protein-coupled
2	366	23.1	346	2 JCS716	G protein-coupled
3	347	21.9	346	2 JCS715	G protein-coupled
4	332	21.0	330	2 JCS717	G protein-coupled
5	244	15.4	420	2 I51667	thrombin receptor
6	228	14.4	425	2 A37912	thrombin receptor
7	213	13.4	427	2 S17148	alpha-thrombin rec
8	205.5	13.0	363	2 I57940	somatostatin recep
9	204.5	12.9	355	2 JQ1231	interleukin-8 rece
10	204	12.9	432	2 A43448	thrombin receptor
11	201	12.7	358	2 A53752	interleukin-8 rece
12	198.5	12.5	328	2 JCS4800	P2Y6 receptor - hu
13	197.5	12.5	328	2 I55450	G protein-coupled
14	195.5	12.3	362	2 S68207	G protein-coupled
15	194.5	12.3	350	2 A38445	interleukin-8 rece
16	194	12.2	363	2 J57955	somatostatin recep
17	194	12.2	364	2 JN0763	somatostatin recep
18	190.5	12.0	354	2 I53033	G protein-coupled
19	190.5	12.0	362	2 A57641	G protein-coupled
20	189.5	12.0	359	2 JCS277	G protein-coupled
21	188.5	11.9	352	1 S27357	complement C5a ana
22	186.5	11.8	362	2 B57641	G protein-coupled
23	186	11.7	375	2 A54946	P-2U nucleotide re
24	184	11.6	365	2 S68679	G protein-coupled
25	182.5	11.5	355	2 I49339	macrophage inflam
26	182.5	11.5	360	2 A53611	interleukin-8 rece
27	180.5	11.4	355	2 A45177	chemokine (C-C) re
28	179	11.3	373	2 A47556	ATP receptor P2u -
29	179	11.3	384	2 A47249	brain-specific som

ALIGNMENTS

RESULT 1

JCS714

G protein-coupled receptor 40 - human

C:Species: Homo sapiens (man)

C>Date: 03-Dec-1997 #sequence\_revision 23-Jan-1998 #text\_change 21-Jul-2000

C:Accession: JCS714

R:Sawzdargo, M.; George, S.R.; Nguyen, T.; Xu, S.; Kolakowski Jr., L.P.; O'Dowd, B.P.

Biochem. Biophys. Res. Commun. 239, 543-547, 1997

A:Title: A cluster of four novel human G protein-coupled receptor genes occurring in clon

A:Reference number: JCS714; MUID:98008875; PMID:9344866

A:Accession: JCS714

A:Status: nucleic acid sequence not shown

A:Molecule type: mRNA

A:Residues: 1-300 <SA>

C:Cross-references: GB:AF024687; NID:G2612945; PIDN:AAB86710.1; PID:G2612946

C:Superfamily: G protein-coupled receptor 43

C:Keywords: glycoprotein; lipoprotein; thiolester bond

F:13-32/Domain: transmembrane #status predicted <TM1>

F:43-64/Domain: transmembrane #status predicted <TM2>

F:83-102/Domain: transmembrane #status predicted <TM3>

F:125-144/Domain: transmembrane #status predicted <TM4>

F:184-206/Domain: transmembrane #status predicted <TM5>

F:222-243/Domain: transmembrane #status predicted <TM6>

F:260-280/Domain: transmembrane #status predicted <TM7>

F:155,165/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:289/Binding site: palmitate (Cys) (covalent) #status predicted

Query Match 100.0%; Score 1584; DB 2; Length 300;

Best Local Similarity 100.0%; Pred. No. 2.8e-125;

Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPQLSGLYVAAPALGFLNLVLAIRGATAHAHRLRTPSLVYALNIGCSDLLLTVSUP 60

DB 1 MDLPQLSGLYVAAPALGFLNLVLAIRGATAHAHRLRTPSLVYALNIGCSDLLLTVSUP 60

QY 61 LKAVEALASGAWPLPASLCPVFAVAPPLVAGGFLAALSGRYLGAAPFLGYQAFRRP 120

DB 61 LKAVEALASGAWPLPASLCPVFAVAPPLVAGGFLAALSGRYLGAAPFLGYQAFRRP 120

QY 121 CYSNGVCAAIWALVLCHLGLVFLGLEAPGGWLDHSDNTSLGINTPVGNSPVCLSEAWDPASAG 180

DB 121 CYSNGVCAAIWALVLCHLGLVFLGLEAPGGWLDHSDNTSLGINTPVGNSPVCLSEAWDPASAG 180

QY 181 PARFSLSLLLFFLPLAITAFVCVGCRLARASGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240

DB 181 PARFSLSLLLFFLPLAITAFVCVGCRLARASGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240

QY 241 NASNVASFLYNLGGSWRKGLITGAWSVLNLPLVTGYLGRPGKLTCAARTQGGKSK 300

DB 241 NASNVASFLYNLGGSWRKGLITGAWSVLNLPLVTGYLGRPGKLTCAARTQGGKSK 300

G protein-coupled  
G protein-coupled  
somatostatin recep  
kappa opioid recep  
opioid receptor ho  
G protein-coupled  
G protein-coupled  
G protein-coupled  
bradykinin B1 rece  
heptahelical P2Y5-  
interleukin-8 rece  
delta opioid recep  
G protein-coupled  
somatostatin recep  
G protein-coupled  
intron 17 purinerg





```
Db      182 ELCLVFFIPMAVTFCTYRFVWIMLSQPLVGAQRER--RAVGLAVVTVLLNPLVFCGPGYN 239
QY      242 ASNVASFLYPNLGGSRKGLITGAMSVLNPVTVTGVLGR-----GPGLKTVCAARTQG 295
Db      240 VSHLVGY-HQKSPWRSINAVFSSNLASLDPLLFYFSSSVVTRAFGRGLQVL---RNQG 295

RESULT 5
151667
thrombin receptor - African clawed frog
C:Species: Xenopus laevis (African clawed frog)
C>Date: 13-Sep-1996 #sequence_revision 13-Sep-1996 #text_change 21-Jul-2000
C:Accession: 151667
R:Gerszten, R.E.; Chen, J.; Ishii, M.; Ishii, K.; Nanevich, T.; Turck, C.W.; Vu, T.H.; Nature 368, 648-651, 1994
A:Title: Thrombin receptor's specificity for agonist peptide is determined by its extrac
A:Reference number: 151667, MUID:94195429; PMID:8145852
A:Accession: 151667
A>Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-420 <GER>
A:Cross-references: EMBL:U09632; NID:g495197; PIDN:AAA18498.1; PID:g495198

Query Match      15.4%; Score 244; DB 2; Length 420;
Best Local Similarity 25.0%; Pred. No. 6e-13;
Matches 72; Conservative 44; Mismatches 126; Indels 46; Gaps 7;

QY      11 LYVAALGFPINVLAIARGATAHARLRLTPSLVYALNLGCDLLLTSLPLKAVEALASG 70
Db      107 LYTTFVIVGLPLNLAIIFLFRKVR-KPAVVYMLHLATADVFFVSVLPFKLSYFSGS 165
QY      71 AWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPPLGYQAFRRPCYSWGVCAAI 130
Db      166 DMLFGPMCRIVTAIFYCNMYSVLIASISVDRFLAVVYPMHSLSWRTMSRAYMACSFI 225
QY      131 WALVLCHLGLVFLGAPGGWLDHSNTSLGINTPVNGSP-----VCLEAWDPASAGPARF- 184
Db      226 WLISIA-----STPLLVTEQTKIPRLDITTCDDVLDLKDLDKDFIY 268
QY      185 ---SLSLILFFPLAITAFYVGLRALARAGSLTHR-RKLRAAWVAGGALLTLVLCVGY 240
Db      269 YFSSPCLLFFVFIITTCYIGIRLSRSSSIENCKKTRALFLAVVLCVFIICFGPT 328
QY      241 N-----ASNVASFLYPNLGGSRKGLITGAMSVVLPVTVGY 278
Db      329 NVLFLTHLYQEAENEFLYPAY-----ILSACVGSVSCCLDPLIYY 368

RESULT 6
A37912
thrombin receptor precursor - human
C:Species: Homo sapiens (man)
C>Date: 22-Jan-1993 #sequence_revision 22-Jan-1993 #text_change 05-Nov-1999
C:Accession: A37912
R:Yu, T.K.H.; Hung, D.T.; Wheaton, V.I.; Coughlin, S.R. Cell 64, 1057-1068, 1991
A:Title: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic
A:Reference number: A37912; MUID:91168254; PMID:1672265
A:Accession: A37912
A:Molecule type: mRNA
A:Residues: 1-425 <VUA>
A:Cross-references: GB:M62424; NID:g339676; PIDN:AAA36743.1; PID:g339677
C:Genetics:
A:Gene: GDB:F2R
A:Cross-references: GDB:127373; OMIM:187930
A:Map position: 5q13-5q13
C:Keywords: G protein-coupled receptor; glycoprotein; transmembrane protein
P:1-26/Domain: signal sequence #status predicted <SIG>
P:27-425/Product: thrombin receptor #status predicted <MAT>

Query Match      14.4%; Score 228; DB 2; Length 425;
Best Local Similarity 25.3%; Pred. No. 1.3e-11;
```

```
Matches 65; Conservative 46; Mismatches 104; Indels 42; Gaps 8;
QY      11 LYVAALGFPINVLAIARGATAHARLRLTPSLVYALNLGCDLLLTSLPLKAVEALASG 70
Db      108 VTGVEVSLPLNMAIVVFLKMKVK-KPAVVYMLHLATADVFFVSVLPFKLSYFSGS 166
QY      71 AWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPPLGYQAFRRPCYSWGVCAAI 130
Db      167 DMQFGSELCRFVTAAPFYCNMYASILLMTVISIDRFLAVVYPMQSLSWRTLGRASFTCLAI 226
QY      131 WALVLCHLGLV-----FGLRPGWLDHSNTSLGINTPVNGSPVLCLEAWDPA----- 177
Db      227 WALAIA--GVPLVLKKEQTIQVPG-----LNITT-----CHDVLTNETLLEGYYA 268
QY      178 ---SAGPARFSLILLFFPLAITAFYVGLRALARAGSLTHR-RKLRAAWVAGGALLTL 233
Db      269 YFSA-----FSAVFFFLPILITTCYVSIIRCLSSAVANRKKSRALFLSAANPCIF 322
QY      234 LLCVGPYNASNVASFLY 250
Db      323 IICFGPTNVLLIAHYSF 339

RESULT 7
S17148
alpha-thrombin receptor - Chinese hamster
C:Species: Cricetus griseus (Chinese hamster)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 05-Nov-1999
C:Accession: S17148
R:Rasmussen, U.B.; Vouret-Craviari, V.; Jallat, S.; Schlesinger, Y.; Pages, G.; Pavirani, FEBS Lett. 288, 123-128, 1991
A:Title: cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca(
A:Reference number: S17148; MUID:91348247; PMID:1652467
A:Accession: S17148
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-427 <RAS>
A:Cross-references: EMBL:X61958; NID:g940495; PIDN:CAA43957.1; PID:g49538
C:Keywords: G protein-coupled receptor; transmembrane protein

Query Match      13.4%; Score 213; DB 2; Length 427;
Best Local Similarity 23.4%; Pred. No. 2.4e-10;
Matches 68; Conservative 53; Mismatches 122; Indels 48; Gaps 9;

QY      11 LYVAALGFPINVLAIARGATAHARLRLTPSLVYALNLGCDLLLTSLPLKAVEALASG 70
Db      110 VTFVFSVSLPLNLAIVFLVLMKVK-KPAVVYMLHLAMADVFLVSVLPFKLSYFSGS 168
QY      71 AWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPPLGYQAFRRPCYSWGVCAAI 130
Db      169 DMQFGSGMCRPATAAFYCNMYASIMLTVISIDRFLAVVYPIQSLSWRTLGRANFTCLVI 228
QY      131 WALVLCHLGLVFLG-----EAPGGWLDHSNTSLGINTPVNGSPVLCLEAWDPA----- 177
Db      229 WYMAI--MGVPLLLKKEQTRVPG-----LNITT-----CHDVLTNETLLOGFYS 270
QY      178 ---SAGPARFSLILLFFPLAITAFYVGLRALARAGSLTHR-RKLRAAWVAGGALLTL 233
Db      271 YFSA-----FSAVFFFLPILITTCYVSIIRCLSSSVANRKKSRALFLSAANPCVP 324
QY      234 LLCVGPYNASNVASFLYPNLGGSWRK-----LGLITGAMSVVLPVTVGY 278
Db      325 IVCFGPTNVLLIMHYLLSDSPATEKAYAYLLCVCSVSSVSCCIDPLIYY 375

RESULT 8
157940
somatostatin receptor 5 - rat
N:Alternate names: somatostatin release-inhibiting factor subtype 28 receptor
C:Species: Rattus norvegicus (Norway rat)
C>Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 24-Nov-1999
C:Accession: 157940; 157949; S39244
R:O'Carroll, A.M.; Lolait, S.J.; Konig, M.; Mahan, L.C.
```



QY 130 IVALVICHGLVRL-----EAPGGWLDHNSNTSLGINTPVNGSPVCLEAWDPA-----177  
DB 233 IWMVMAI--MGVPLLLKKEQTQVFG-----LNITT-----CHDVNLTLLHGFY 274  
QY 178 ----SAGPARFSLLLFFPLAITAFYVGLRALSGLTHR-RKLRAAWVAGGALLT 232  
DB 275 SYFSA-----FSAIFFLPLIISTVCTYSIIRCLSSAVANRKKRALFLSAVFCI 328  
QY 233 LLLCVGPYNASNVASF 249  
DB 329 FIVCFGTNVLIVHVL 345  
RESULT 11  
A53752  
C:Species: Oryctolagus cuniculus (domestic rabbit)  
C>Date: 06-Jan-1995 #sequence\_revision 06-Jan-1995 #text\_change 05-Nov-1999  
C:Accession: A53752  
R:Prado, G.N.; Thomas, K.M.; Suzuki, H.; LaRosa, G.J.; Wilkinson, N.; Folco, E.; Navarroc  
J. Biol. Chem. 269, 12391-12394, 1994  
A:Title: Molecular characterization of a novel rabbit interleukin-8 receptor isotype.  
A:Reference number: A53752; MUID:94230294; PMID:8175642  
A:Accession: A53752  
A:Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-358 <PRA>  
A:Cross-references: GB:124445; NID:9437661; PIDN:AAA31378.1; PID:9437662  
C:Superfamily: vertebrate rhodopsin  
C:Keywords: G protein-coupled receptor; transmembrane protein  
Query Match 12.7%; Score 201; DB 2; Length 358;  
Best Local Similarity 25.5%; Pred. No. 2e-09;  
Matches 89; Conservative 34; Mismatches 122; Indels 104; Gaps 14;  
QY 2 DLPP-----QLSFGLYVA--APALGPPPLNLA---TGATAHARLRTPSLVYA 45  
DB 26 DLPPTLDSAPCRSESLNYSVVLITYILVFLSLLSLNSLMLVLSRSTCSVTDVYL 85  
QY 46 LNLGCSDLLLTSLPLKAVENALASGAWPLPASICPVFAVAHPPLPYAGGGFLAALSAGRY 105  
DB 86 LNLAIADLLFATTLPLIWAASKV--HGWTFGTPLCKVSVLVKEVNFYSYGILLACISVDRY 143  
QY 106 LGAAAPFLGYQAFRRP-----CYS--WGVCVAAIWAIVLCHLGLVFLGRLAPGGWLDHNSNTSLG 159  
DB 144 LAIVHATRTMIQKHLVKFICLSMWGVSLILSPILLFNAIF-----186  
QY 160 INTPVNGSPVCLEAWDPAAGPARFSLSLLL-----FPLPLAITAFYVGLRAL--ARSG 213  
DB 187 ---PPNSSPVCEYEDMGNSTA-KRWVVLRIPLQTFGPIPLVLMVLCYVFTLRTLFQAHMG 242  
QY 214 LTHRKLRAAWVAGGALLTLLCVGPN-----ASN 244  
DB 243 QKH-----RAMRVTFVAVVLFLLCWLPYNVLLTDLMTHTVIOETCERNRIDRALDATE 298  
QY 245 VASFLPNLGGWRKLGITGAWSVVNLPLVTVGLGR--GPGIKTVCVAA 291  
DB 299 ILGFLHS-----CLNPIIYAFIQKFRYGLLKILAA 329  
RESULT 12  
JC4800  
C:Species: Homo sapiens (man)  
C>Date: 15-Oct-1995 #sequence\_revision 16-Aug-1996 #text\_change 17-Nov-2000  
C:Accession: JC4800; G02514  
R:Communi, D.; Parmentier, M.; Boeynaems, J.M.  
Biochem. Biophys. Res. Commun. 222, 303-308, 1996  
A:Title: Cloning, functional expression and tissue distribution of the human P2Y6 receptor  
A:Reference number: JC4800; MUID:96222498; PMID:8670200  
A:Accession: JC4800  
A:Molecule type: mRNA

A:Residues: 1-328 <COM>  
A:Cross-references: EMBL:X97058  
A:Experimental source: placenta  
R:Hammet, F.; Southey, M.C.; Somers, G.R.; Hutchins, A.M.; Venter, D.J.  
submitted to the EMBL Data Library, March 1996  
A:Reference number: H01373  
A:Accession: G02514  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 'M', 4-328 <HAM>  
A:Cross-references: EMBL:U52464; NID:91407632; PIDN:BA03572.1; PID:91407633  
C:Genetics:  
C:Gene: P2Y6  
C:Superfamily: ATP receptor P2u  
C:Keywords: glycoprotein; placenta; receptor; transmembrane protein  
F:26-52/Domain: transmembrane #status predicted <TM1>  
F:63-86/Domain: transmembrane #status predicted <TM2>  
F:104-122/Domain: transmembrane #status predicted <TM3>  
F:143-167/Domain: transmembrane #status predicted <TM4>  
F:193-216/Domain: transmembrane #status predicted <TM5>  
F:241-264/Domain: transmembrane #status predicted <TM6>  
F:283-305/Domain: transmembrane #status predicted <TM7>  
F:5,173/Binding site: carbohydrate (Asn) (covalent) #status predicted  
Query Match 12.5%; Score 198.5; DB 2; Length 328;  
Best Local Similarity 27.4%; Pred. No. 3e-09;  
Matches 81; Conservative 29; Mismatches 135; Indels 51; Gaps 12;  
QY 3 LPPQLSFGLYVAAPALGPPPLNLAIRGATAHARLRTPSLVYALNLCSDLLLTSLPLK 62  
DB 29 LPP-----VYSVLAAGLPLNICVIT-QICTERRALTRTAVVYTNLALADLLYACSLPLL 82  
QY 63 AVEALASGAWPLPASICPVFAVAHPPLPYAGGGFLAALSAGRYLGAAPFLG---YQAFRR 119  
DB 83 IYVAGGDHPFGDPACRLVRFYANLHGSILFLTCISFQRYLGLCHPLAPHKRGRR 142  
QY 120 PCYSMGVCAAIWALVL--CHLGLVFLGRLAPGGWLDHNSNTSLGINTPVNGSPVCLEAWDPA 177  
DB 143 A--AMLVCAVWLVAVTTQCLPTAIF-----AATGIQ-----NRRVTCYDLSPPA 184  
QY 178 SAG---PARFSLLLFFPLAITAFYVGLRA--LARG-----LTHRKLRAAWVAG 227  
DB 185 LATHYMPYGMALVTGFLFPFAALLACY--CLLACRLCRQDGPAPFVAQERRGKAAMAV 242  
QY 228 GALLTLLCVGPYNASNVASFLVPLNGLGSRKLGITGAWSVVNLPLVTVGLGRGP 283  
DB 243 VVAAPAFISFLPFHITKTA-----YLAVRSTPGVPCVLEAFAPAAAYKGRTP 288  
RESULT 13  
I55450  
G protein-coupled P2 receptor - rat  
C:Species: Rattus norvegicus (Norway rat)  
C>Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 19-May-2000  
C:Accession: I55450  
R:Chang, K.; Hanaoka, K.; Kumada, M.; Takuwa, Y.  
J. Biol. Chem. 270, 26152-26158, 1995  
A:Title: Molecular cloning and functional analysis of a novel P2 nucleotide receptor.  
A:Reference number: I55450; MUID:96064682; PMID:7592819  
A:Accession: I55450  
A:Status: preliminary; translated from GB/EMBL/DBJ  
A:Molecule type: mRNA  
A:Residues: 1-328 <RES>  
A:Cross-references: GB:D63665; NID:91066007; PIDN:BA09816.1; PID:91066008  
C:Superfamily: ATP receptor P2u  
C:Keywords: G protein-coupled receptor  
Query Match 12.5%; Score 197.5; DB 2; Length 328;  
Best Local Similarity 26.2%; Pred. No. 3.7e-09;  
Matches 77; Conservative 30; Mismatches 140; Indels 47; Gaps 10;  
QY 3 LPPQLSFGLYVAAPALGPPPLNLAIRGATAHARLRTPSLVYALNLCSDLLLTSLPLK 62

```
Db 29 LPP-----VYSVVLVGLPLNVCVIAICA-SRRTLTRSAYVTILNALADLLYACSLPLL 82
Qy 63 AVEALASGAWPLPASLCPVFAVAHFPPLYAGGGFLAALSAGRYLGAAPLGG---YQAFRR 119
Db 83 IYNYARGDMFPGDLACRIVRFLFYANLHGSILFLTCISFQRYLGLCHPLAPWHKRGGR 142
Qy 120 PCYSGVCACAIWALVL--CHLGLVFGLEAPGWLGHSHNTSLGINTPVGNSPVCLBAWDP 177
Db 143 A--AWVVCVWVLVWTAQCLPTAVF-----AATGIQ-----NRTVCYDLSPPI 184
Qy 178 SAG---PARFSLSLALLFFPLAITAFYVYVGLCLARALRS-----LTHRKLRAAAWVAGGA 229
Db 185 LSTRVLPYGMALTVIGFLPFTALLACYCRMARLRCQDGPAGPVAQERRSKAARMVVV 244
Qy 230 LITLLLCVGPYNASNVASFLYPLNGLGSRWKLGLITGANSVVLNPLVTGYLGRGP 283
Db 245 AAVFVISFLPFFHTTKTA-----YLAVRSTGVSCVPVLETFAAAYKGRTP 288

RESULT 14
S68207
G protein-coupled receptor 6C.1 - human
C:Species: Homo sapiens (man)
C>Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 29-Sep-1999
C:Accession: S68207
R:An, S.; Tsai, C.; Goetzl, E.J.
FEBS Lett. 375, 121-124, 1995
A:Title: Cloning, sequencing and tissue distribution of two related G protein-coupled re
A:Reference number: S68207; MUID:96087098; PMID:7498459
C:Superfamily: G protein-coupled receptor 4
C:Keywords: G protein-coupled receptor
A:Status: preliminary; nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 1-362 <NS>
A:Cross-references: EMBL:U35399; NID:G1015420; PIDN:AAA79061.1; PID:G1015421
C:Superfamily: G protein-coupled receptor 4
C:Keywords: G protein-coupled receptor

Query Match 12.3%; Score 195.5; DB 2; Length 362;
Best Local Similarity 27.2%; Pred. No. 5.9e-09;
Matches 74; Conservative 30; Mismatches 115; Indels 53; Gaps 10;

Qy 4 PPQLSGLYVAAFALGFPLNLAIRGATAHARLRLTPSLVYALNLGCSDLLLTLSPLKLA 63
Db 20 PP-----SLIFVIGVGLPTNCLAAWYRQVQR--NELGVYLLNLSIADLLYICSLPLWV 74
Qy 64 VREALSAGWPLPASLCPVFAVAHFPPLYAGGGFLAALSAGRYLGAAPLGGYQAFRRPCYS 123
Db 75 DYFLHHDNWIHGPGSKLFGFIFYTNIYISIAFLCCISVDRYLAHAHPLRFARLRRVKTA 134
Qy 124 WGVCAAIWALVLCHLGLVFGLEAPGWLGHSHNTSLGINTPVGNSPV----- 169
Db 135 VAVSSVYWA-----TELG-----ANSAPLFDHDLFRDYNHTF 167
Qy 170 CLEAWDPASAGPARFSLSL--FFLPLAITAFYVGLCLARALRSGLTHRR--KLRAAWVA 226
Db 168 CREKP--PMEGWAWMNLVYFVCGFLFPWALMLLSYGILRAVRGVSSTERQEKAKIKRLA 226
Qy 227 GGALLTLLLCVGPYNASNVA--SFLYPLNGLGSW 257
Db 227 LSLIAIVLCVFPAPYHVLLLSRSAIY--LGRPW 256

RESULT 15
A39445
interleukin-8 receptor type A - human
N:Alternate names: interleukin-8 receptor, high-affinity
C:Species: Homo sapiens (man)
C:Date: 22-Jan-1993 #sequence_revision 12-Apr-1996 #text_change 05-Nov-1999
C:Accession: I37449; I38710; I38711; A39445
R:Mollereau, C.; Muscatelli, F.; Mattei, M.G.; Vassart, G.; Parmentier, M.
Genomics 16, 248-251, 1993
A:Title: The high-affinity interleukin 8 receptor gene (IL8RA) maps to the 2q33-q36 regi
A:Reference number: I37449, MUID:93252387; PMID:8486366
```

```
A:Accession: I37449
A:Molecule type: DNA
A:Residues: 1-350 <RES>
A:Cross-references: EMBL:X65958; NID:G312046; PIDN:CAA46688.1; PID:G312047
R:Ahuja, S.K.; Shetty, A.; Tiffany, H.L.; Murphy, P.M.
J. Biol. Chem. 269, 26381-26389, 1994
A:Title: Comparison of the genomic organization and promoter function for human interleu
A:Reference number: I37898; MUID:95014476; PMID:7929358
A:Accession: I38710
A:Molecule type: DNA
A:Residues: 1-350 <RES>
A:Cross-references: EMBL:U11870; NID:G511804; PIDN:AAA64378.1; PID:G511805
A:Accession: I38711
A:Molecule type: mRNA
A:Residues: 1-16 <RES>
A:Cross-references: EMBL:U11871; NID:G511806; PIDN:AAA64379.1; PID:G733002
R:Holmes, W.E.; Lee, J.; Kuang, W.J.; Rice, G.C.; Wood, W.I.
Science 253, 1278-1280, 1991
A:Title: Structure and functional expression of a human interleukin-8 receptor.
A:Reference number: A39445; MUID:91368199; PMID:1840701
A:Accession: A39445
A:Molecule type: mRNA
A:Residues: 1-275, 'T', 277-350 <HOL>
A:Cross-references: GB:M68932; NID:G186369; PIDN:AAA59159.1; PID:G186370
C:Genetics:
A:Gene: GDB:IL8RA
A:Cross-references: GDB:I35039; OMIM:146929
A:Map position: 2q35-2q35
C:Superfamily: vertebrate rhodopsin
C:Keywords: G protein-coupled receptor; glycoprotein; membrane protein

Query Match 12.3%; Score 194.5; DB 2; Length 350;
Best Local Similarity 28.3%; Pred. No. 7e-09;
Matches 82; Conservative 39; Mismatches 126; Indels 43; Gaps 11;

Qy 13 VAAFALGFPLNVLA---IRGATAHARLRLTPSLVYALNLGCSDLLLTLSPLKAVEALAS 69
Db 43 ITAYALVFLLSLGNLSVLMVLYLSRVGRSVTDVYLLNALADLLFALTLPWAASKV-- 100
Qy 70 GAWPLPASLCPVFAVAHFPPLYAGGGFLAALSAGRYLGAAPLGGYQAFRRPCYSWGVCAA 129
Db 101 NGWIRGTFLCKVSVLLKEVNFYSIGILLACISVDRYLAIVHATRTLTKRHLVKF--VCIG 159
Qy 130 IWALVCHLGLVFGLEAPGWLGHSHNTSLGINTPVGNSPVCLEAWDPASAGPARFSLSL 189
Db 160 CWGLSM-NLSLDFFLFROA-----YHPNNSSPVCYEVLGNDTA--KRWVLRLL 205
Qy 190 L-----FFLPLAITAFYVGLCLARALRSGLTHRRKLRAAAWVAGGALLTLLLCVGPYNASNV 245
Db 206 PHTFGFIVPLFWMVLCYCGFTLTTLFKAHM--GQKRAMRVIFAIVLLFLLCWLPLYNLVLL 263
Qy 246 ASFLY-----PNLGSRWKLGL--ITGANSVVLNPLVTGYLGR 281
Db 264 ADTLMRTOVIOBSCRRNNIG---RALDATEILGFLHSLCLNPIIYAFIQG 310

Search completed: April 29, 2004, 12:12:04
Job time : 22 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:11:34 ; Search time 47 Seconds  
(without alignments)  
1769.295 Million cell updates/sec

Title: US-10-202-687-2

Perfect score: 1584

Sequence: 1 MDLPOLSLGLYVAAPALGF.....RGPLKTVCAARTQGGKSQK 300

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1138120 seqs, 277189581 residues

Total number of hits satisfying chosen parameters: 1138120

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

- Published Applications\_AA\*  
1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/2/pubpaa/US06\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/2/pubpaa/US10\_NEW\_PUB.pep.\*  
17: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1584	100.0	300	14	US-10-251-385-250
2	1584	100.0	300	14	US-10-225-567A-475
3	1584	100.0	300	14	US-10-029-386-33080
4	1584	100.0	300	15	US-10-202-687-2
5	1579	99.7	300	14	US-10-251-385-272
6	366	23.1	346	14	US-10-203-539-4
7	347	21.9	346	14	US-10-251-385-254
8	347	21.9	346	14	US-10-225-567A-605
9	347	21.9	346	14	US-10-203-539-2
10	347	21.9	401	14	US-10-029-386-33898
11	342	21.6	346	14	US-10-251-385-274
12	340.5	21.5	330	14	US-10-348-190-2
13	334	21.1	330	14	US-10-348-190-4
14	332	21.0	330	14	US-10-251-385-258
15	332	21.0	330	14	US-10-225-567A-467

16	332	21.0	330	14	US-10-337-992-2	Sequence 2, Appli
17	332	21.0	330	14	US-10-029-386-34068	Sequence 34068, A
18	331	20.9	330	14	US-10-251-385-276	Sequence 276, App
19	322	20.3	330	9	US-09-853-161-104	Sequence 104, App
20	322	20.3	330	9	US-09-852-659A-104	Sequence 104, App
21	322	20.3	330	9	US-09-852-797-104	Sequence 104, App
22	322	20.3	330	12	US-10-058-993-104	Sequence 104, App
23	298.5	18.8	319	14	US-10-203-539-6	Sequence 6, Appli
24	244	15.4	420	12	US-10-081-810-41	Sequence 41, Appli
25	231.5	14.6	395	12	US-10-081-810-43	Sequence 43, Appli
26	231.5	14.6	385	14	US-10-225-567A-516	Sequence 516, App
27	231.5	14.6	385	14	US-10-187-049-2	Sequence 2, Appli
28	228	14.4	425	9	US-09-782-980-80	Sequence 80, Appli
29	228	14.4	425	9	US-09-884-430-4	Sequence 4, Appli
30	228	14.4	425	12	US-10-423-543-91	Sequence 91, Appli
31	228	14.4	425	12	US-10-127-691-7	Sequence 7, Appli
32	228	14.4	425	12	US-10-081-810-42	Sequence 42, Appli
33	228	14.4	425	14	US-10-225-567A-324	Sequence 324, App
34	228	14.4	425	14	US-10-336-489-4	Sequence 4, Appli
35	228	14.4	425	14	US-10-177-293-130	Sequence 130, App
36	228	14.4	425	14	US-10-176-464A-3	Sequence 3, Appli
37	226	14.3	488	16	US-10-431-234-5	Sequence 5, Appli
38	226	14.3	488	16	US-10-431-234-11	Sequence 11, Appli
39	225.5	14.2	358	14	US-10-251-385-186	Sequence 186, App
40	223.5	14.1	359	12	US-10-400-991-1	Sequence 1, Appli
41	223.5	14.1	359	14	US-10-190-469-1	Sequence 1, Appli
42	222.5	14.0	372	15	US-10-417-820A-149	Sequence 149, App
43	221.5	14.0	359	9	US-09-739-151-2	Sequence 2, Appli
44	221.5	14.0	359	10	US-09-782-974C-76	Sequence 76, Appli
45	221.5	14.0	359	12	US-10-081-810-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1

US-10-251-385-250  
; Sequence 250, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; CURRENT FILING DATE: 2002-09-20  
; PRIOR APPLICATION NUMBER: US/09/170,496  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 250  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-251-385-250

Query Match 100.0%; Score 1584; DB 14; Length 300;  
Best Local Similarity 100.0%; Pred. No. 4.4e-139;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MDLPOLSLGLYVAAPALGFPLNLVLAIRGNTAHARLRLTSLVYALNLCGSDLLLTSLP	60
Db	1	MDLPOLSLGLYVAAPALGFPLNLVLAIRGNTAHARLRLTSLVYALNLCGSDLLLTSLP	60
Qy	61	LKAVEALASGANPLPASCIPFAVAHFFPLYAGGGFLAALSAAGYLCGAAPFLCYQAFRRP	120
Db	61	LKAVEALASGANPLPASCIPFAVAHFFPLYAGGGFLAALSAAGYLCGAAPFLCYQAFRRP	120
Qy	121	CYSWGVCAAIWALVLCGLVFLGLEAPGGWLDHSNTSLGINTPVNPGSPVCLAEAWDPASAG	180
Db	121	CYSWGVCAAIWALVLCGLVFLGLEAPGGWLDHSNTSLGINTPVNPGSPVCLAEAWDPASAG	180



Db 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180  
QY 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
Db 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300  
Db 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300

## RESULT 2

US-10-225-567A-475  
; Sequence 475, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burner, Glenna C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; PRIOR FILING DATE: 2001-12-19  
; PRIOR APPLICATION NUMBER: 60/257,144  
; PRIOR FILING DATE: 2000-12-19  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: Patent in version 3.1  
; SEQ ID NO 475  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-225-567A-475

Query Match 100.0%; Score 1584; DB 14; Length 300;  
Best Local Similarity 100.0%; Pred. No. 4.4e-139;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
Db 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
Db 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180  
Db 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180  
QY 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
Db 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300  
Db 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300

## RESULT 3

US-10-029-386-33080  
; Sequence 33080, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharron G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.  
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C  
; FILE REFERENCE: AEOMICA-X-2  
; CURRENT APPLICATION NUMBER: US/10/029,386  
; CURRENT FILING DATE: 2001-12-20  
; NUMBER OF SEQ ID NOS: 34288

; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1  
; SEQ ID NO 33080  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: MAP TO U62631.1  
; OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.1  
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 0.89  
; OTHER INFORMATION: SWISSPROT HIT: O14842, EVALU0.00e+00  
US-10-029-386-33080

Query Match 100.0%; Score 1584; DB 14; Length 300;  
Best Local Similarity 100.0%; Pred. No. 4.4e-139;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
Db 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
Db 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180  
Db 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180  
QY 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
Db 181 PARFSLSLLLFFPLPLAITAFVCVGCIALARLSGLTHRRKRLRAAWVAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300  
Db 241 NASNVASFLYPLNLGGSWRKGLITGAWSVVNLNPLVTGYLGRGPGGLTKVCAARTQGGKSOK 300

## RESULT 4

US-10-202-687-2  
; Sequence 2, Application US/10202687  
; Publication No. US20040019109A1  
; GENERAL INFORMATION:  
; APPLICANT: OWMAN, CHRISTER  
; APPLICANT: OLDE, BJORN  
; APPLICANT: KOTARSKY, KNUIT  
; APPLICANT: NILSSON, NICLAS  
; APPLICANT: FLODREN, ERIK  
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS AFFECTING FATTY ACID  
; TITLE OF INVENTION: METABOLISM  
; FILE REFERENCE: 07675.0007 SEQUENCE LISTING  
; CURRENT APPLICATION NUMBER: US/10/202,687  
; CURRENT FILING DATE: 2002-07-24  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: Patent In Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-202-687-2

Query Match 100.0%; Score 1584; DB 15; Length 300;  
Best Local Similarity 100.0%; Pred. No. 4.4e-139;  
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
Db 1 MDLPPLQSLFGLYVAAPALGFPLNVLAIARGATAHARLRLTPSLVYALNLGCSDLLLTVSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
Db 61 LKAVEALASGAWPLPASLCPVFAVAHFPLFYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGVCAAIWAIVLCHLGLVFLGAPGGLWLDHNTSLGINTPVNGSPVCLLEAWDPASAG 180



Db 121 CYSWGCAAIWALVLCGLVFLGAPGGWLDHNSNTSLGINTPVGSPVCLAWDPASAG 180  
QY 181 PARFSLSLFLPLAIFATFCYVGCCLARALSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
Db 181 PARFSLSLFLPLAIFATFCYVGCCLARALSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPNLGGSWRKGLITGAWSVVLPVLTGYLGRGPKLTVCAARTQGGKSOK 300  
Db 241 NASNVASFLYPNLGGSWRKGLITGAWSVVLPVLTGYLGRGPKLTVCAARTQGGKSOK 300

RESULT 5

US-10-251-385-272  
; Sequence 272, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; CURRENT FILING DATE: 2002-09-20  
; PRIOR FILING DATE: 2002-09-20  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: Patent in version 3.1  
; SEQ ID NO 272  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-251-385-272

Query Match 99.7%; Score 1579; DB 14; Length 300;  
Best Local Similarity 99.7%; Pred. No. 1.3e-138;  
Matches 299; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MDLPOLSPGLYVAAPALGPPNVLAIAGTAAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
Db 1 MDLPOLSPGLYVAAPALGPPNVLAIAGTAAHARLRLTSPSLVYALNLCGSDLLLTSLP 60  
QY 61 LKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
Db 61 LKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120  
QY 121 CYSWGCAAIWALVLCGLVFLGAPGGWLDHNSNTSLGINTPVGSPVCLAWDPASAG 180  
Db 121 CYSWGCAAIWALVLCGLVFLGAPGGWLDHNSNTSLGINTPVGSPVCLAWDPASAG 180  
QY 181 PARFSLSLFLPLAIFATFCYVGCCLARALSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
Db 181 PARFSLSLFLPLAIFATFCYVGCCLARALSGLTHRRKLRANWAGGALLTLLLCVGPY 240  
QY 241 NASNVASFLYPNLGGSWRKGLITGAWSVVLPVLTGYLGRGPKLTVCAARTQGGKSOK 300  
Db 241 NASNVASFLYPNLGGSWRKGLITGAWSVVLPVLTGYLGRGPKLTVCAARTQGGKSOK 300

RESULT 6

US-10-203-539-4  
; Sequence 4, Application US/10203539  
; Publication No. US20030113810A1  
; GENERAL INFORMATION:  
; APPLICANT: GLAXO GROUP LIMITED  
; TITLE OF INVENTION: NOVEL ASSAY  
; FILE REFERENCE: PG3849USW  
; CURRENT APPLICATION NUMBER: US/10/203,539  
; CURRENT FILING DATE: 2002-08-09  
; PRIOR FILING DATE: 2000-02-18

; PRIOR APPLICATION NUMBER: GB 0007015.1  
; PRIOR FILING DATE: 2000-03-22  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: Patent in Ver. 3.0  
; SEQ ID NO 4  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo Sapiens  
US-10-203-539-4

Query Match 23.1%; Score 366; DB 14; Length 346;  
Best Local Similarity 34.1%; Pred. No. 1.1e-25;  
Matches 101; Conservative 38; Mismatches 129; Indels 28; Gaps 8;  
QY 1 MDLPOLSPGLYVAAPALGPPNVLAIAGTAAHARLRLTSPSLVYALNLCGCS 51  
Db 1 MDTPDQSYFSGNHWVFVSVLLTFLVGLPLNLLALVWFVKLRCPVAVDVLNLTAS 60  
QY 52 DILLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAP 111  
Db 61 DILLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAP 120  
QY 112 LCVQAFRRPCYSWGCAAIWALVLCGLVFLGAPGGWLDHNSNTSLGINTPVGSPVC- 170  
Db 121 LMYKTRPRLGQAGLVSVACWLLSAHCSVYVIFSGD-ISHSQGTNG-----TCY 170  
QY 171 LEADWP--ASAGPARFSLSLFLPLAIFATFCYVGCCLARALSGLTHRRKLRANWAGG 228  
Db 171 LEFKDQLAILLPVLEMAVLFVPLIITSYSELWILRGG-SHRQRVAGLVAA 229  
QY 229 ALLTLLLCVGPYNASNVASFLYPNLGG--WRKGLITGAWSVVLPVLTGYLGRG 282  
Db 230 TLINFLVCFGPYNVSHVGYI---CGESPVRWRYVTLTSLNSCVDPFVYFSSG 282

RESULT 7

US-10-251-385-254  
; Sequence 254, Application US/10251385  
; Publication No. US20030105292A1  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Protein-Coupled  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/10/251,385  
; CURRENT FILING DATE: 2002-09-20  
; PRIOR FILING DATE: US/09/170,496  
; PRIOR FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: Patent in version 3.1  
; SEQ ID NO 254  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-251-385-254

Query Match 21.9%; Score 347; DB 14; Length 346;  
Best Local Similarity 32.3%; Pred. No. 6.6e-24;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPOLSPGLYVAAPALGPPNVLAIAGTAAHARLRLTSPSLVYALNLCGCS 51  
Db 1 MDTPDQSYFSGNHWVFVSVLLTFLVGLPLNLLALVWFVKLRCPVAVDVLNLTAS 60  
QY 52 DILLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAP 111  
Db 61 DILLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAP 120  
QY 112 LCVQAFRRPCYSWGCAAIWALVLCGLVFLGAPGGWLDHNSNTSLGINTPVGSPVCL 171

Db 121 LWYKTRPRLGQAGLVSVACWLLASAHCSVVVYIEFSGD--ISHSQGTNG-----TCY 170  
QY 172 EAW---DPASAGPARFSLLLFFLPPLAITAFYVGCCLRALARSGLTHRRKLRAAWVAGG 228  
Db 171 LEFRKDQAILLPVRLVLEMAVLFVVPPLIITSYCSRLVWILGRGG-SHRRQRVAGLLAA 229  
QY 229 ALLTLLLCVGPYNASNVASFVLPNLGGSWRKLGLITGAWSVVLPNPLVTGTLGRG 282  
Db 230 TLLNFLVCFGPNVSHVVGICGE-SPAWRIYVTLTLSTLNSCVDPFVYFSSSG 282

RESULT 8  
US-10-225-567A-605  
; Sequence 605, Application US/10225567A  
; Publication No. US20030113798A1  
; GENERAL INFORMATION:  
; APPLICANT: LifeSpan Biosciences  
; APPLICANT: Brown, Joseph P.  
; APPLICANT: Burmer, Glenna C.  
; APPLICANT: Roush, Christine L.  
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
; FILE REFERENCE: 1920-4-4  
; CURRENT APPLICATION NUMBER: US/10/225,567A  
; PRIOR FILING DATE: 2001-12-19  
; PRIOR APPLICATION NUMBER: 60/257,144  
; PRIOR FILING DATE: 2000-12-19  
; NUMBER OF SEQ ID NOS: 2292  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 605  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-225-567A-605

Query Match 21.9%; Score 347; DB 14; Length 346;  
Best Local Similarity 32.3%; Pred. No. 6.6e-24;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPQOLS-----FGLYVAAPALGFPINVLAIAGTAAHARLRLTSPSYVALNLGCS 51  
Db 1 MDTGPDQSYFSGNHWVFVSVYLLTFLVGLPLNLLALVVFVGLQRRPVAVDVLLNLNLTA 60  
QY 52 DLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFPLPYAGGGFLAALSAGRYLGAAPP 111  
Db 61 DULLLLFLPFRVVEAANGHWLPPLFPLCLPSGFIFFTYIYLTALFAVSIERFLSVAHP 120  
QY 112 LGYQAFRRPCYSWGVCAAIWAIVLCHGLVFGLEAPGGWLDHSNTSLGINTPVNGSPVCL 171  
Db 121 LWYKTRPRLGQAGLVSVACWLLASAHCSVVVYIEFSGD--ISHSQGTNG-----TCY 170  
QY 172 EAW---DPASAGPARFSLLLFFLPPLAITAFYVGCCLRALARSGLTHRRKLRAAWVAGG 228  
Db 171 LEFRKDQAILLPVRLVLEMAVLFVVPPLIITSYCSRLVWILGRGG-SHRRQRVAGLLAA 229  
QY 229 ALLTLLLCVGPYNASNVASFVLPNLGGSWRKLGLITGAWSVVLPNPLVTGTLGRG 282  
Db 230 TLLNFLVCFGPNVSHVVGICGE-SPAWRIYVTLTLSTLNSCVDPFVYFSSSG 282

RESULT 9  
US-10-203-539-2  
; Sequence 2, Application US/10203539  
; Publication No. US20030113810A1  
; GENERAL INFORMATION:  
; APPLICANT: GLAXO GROUP LIMITED  
; TITLE OF INVENTION: NOVEL ASSAY  
; FILE REFERENCE: PG3849USW  
; CURRENT APPLICATION NUMBER: US/10/203,539  
; CURRENT FILING DATE: 2002-08-09  
; PRIOR APPLICATION NUMBER: GB 0003900.8  
; PRIOR FILING DATE: 2000-02-18  
; PRIOR APPLICATION NUMBER: GB 0007015.1  
; PRIOR FILING DATE: 2000-03-22

; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn Ver. 3.0  
; SEQ ID NO 2  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (18)..(41)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (52)..(73)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (88)..(111)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (132)..(153)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (188)..(212)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (229)..(250)  
; FEATURE:  
; NAME/KEY: TRANSMEM  
; LOCATION: (259)..(278)  
US-10-203-539-2  
Query Match 21.9%; Score 347; DB 14; Length 346;  
Best Local Similarity 32.3%; Pred. No. 6.6e-24;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPQOLS-----FGLYVAAPALGFPINVLAIAGTAAHARLRLTSPSYVALNLGCS 51  
Db 1 MDTGPDQSYFSGNHWVFVSVYLLTFLVGLPLNLLALVVFVGLQRRPVAVDVLLNLNLTA 60  
QY 52 DLLLTVSLPLKAVEALASGAWPLPASLCPVFAVAHFPLPYAGGGFLAALSAGRYLGAAPP 111  
Db 61 DULLLLFLPFRVVEAANGHWLPPLFPLCLPSGFIFFTYIYLTALFAVSIERFLSVAHP 120  
QY 112 LGYQAFRRPCYSWGVCAAIWAIVLCHGLVFGLEAPGGWLDHSNTSLGINTPVNGSPVCL 171  
Db 121 LWYKTRPRLGQAGLVSVACWLLASAHCSVVVYIEFSGD--ISHSQGTNG-----TCY 170  
QY 172 EAW---DPASAGPARFSLLLFFLPPLAITAFYVGCCLRALARSGLTHRRKLRAAWVAGG 228  
Db 171 LEFRKDQAILLPVRLVLEMAVLFVVPPLIITSYCSRLVWILGRGG-SHRRQRVAGLLAA 229  
QY 229 ALLTLLLCVGPYNASNVASFVLPNLGGSWRKLGLITGAWSVVLPNPLVTGTLGRG 282  
Db 230 TLLNFLVCFGPNVSHVVGICGE-SPAWRIYVTLTLSTLNSCVDPFVYFSSSG 282

RESULT 10  
US-10-029-386-33898  
; Sequence 33898, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharon G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.  
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G  
; FILE REFERENCE: AEOMICA-X-2  
; CURRENT APPLICATION NUMBER: US/10/029,386  
; CURRENT FILING DATE: 2001-12-20  
; NUMBER OF SEQ ID NOS: 34288  
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1  
; SEQ ID NO 33898  
; LENGTH: 401  
; TYPE: PRT  
; ORGANISM: Homo sapiens



APPLICANT: Nicolaides, Nicholas  
APPLICANT: Dong, Qu  
TITLE OF INVENTION: Asthma Associated Factors as Targets for Treating  
TITLE OF INVENTION: Acopic Allergies Including Asthma and Related Disorders  
FILE REFERENCE: 036970-5072  
CURRENT APPLICATION NUMBER: US/10/348,190  
CURRENT FILING DATE: 2003-01-22  
PRIOR APPLICATION NUMBER: US/09/157,24  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/059,510  
PRIOR FILING DATE: EARLIER FILING DATE: 1997-09-19  
PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/032,224  
PRIOR FILING DATE: EARLIER FILING DATE: 1996-12-02  
NUMBER OF SEQ ID NOS: 27  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 4  
LENGTH: 330  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-348-190-4

Query Match 21.1%; Score 334; DB 14; Length 330;  
Best Local Similarity 31.0%; Pred. No. 1e-22;  
Matches 93; Conservative 53; Mismatches 120; Indels 34; Gaps 12;  
QY 12 YVAAFALGPPNLVLAIRGATAHARL-RLTPSLVYALNLGCSDLLLTVSPLKXAVEALASG 70  
DB 14 YIIIFLTGTPANLLAURAFVGRIRQPAPVPHILLSLTLADLLLLLLLPFKIIAASNF 73  
QY 71 AMPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI 130  
DB 74 RYLPKVVCAITSGFYSSIIYCTWRFWMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 131 --WALVLCGLVFGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---PARF 184  
DB 132 VAWMSFGHCTIIVQ-----YLNTEQVR---SGNEITCYENFTDNQDVLVPLVRL 181  
QY 185 SLSLLLFFLPLAITAFYCY---VGCLRALARSGLTHRRKLAARAWAGGALLTLTLLCVGPN 241  
DB 182 ELCLVLFPIPMATVTCYWRFWIMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 242 ASNVASFLYPNLGGSWRKGLITGAWSVVNLPLVTGYLGR-----GPGKTKVCAARTQG 295  
DB 240 VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFYSSVVRRAFRGRLQVL---RNQG 295

RESULT 14  
US-10-251-385-258  
Sequence 258, Application US/10251385  
Publication No. US20030105292A1  
GENERAL INFORMATION:  
APPLICANT: Behan, Dominic P.  
APPLICANT: Chalmers, Derek T.  
APPLICANT: Liaw, Chen W.  
TITLE OF INVENTION: No. US20030105292A1-Endogenous, Constitutively Activated Human G  
TITLE OF INVENTION: Protein-Coupled Receptors  
TITLE OF INVENTION: Receptors  
FILE REFERENCE: AREN-0040  
CURRENT APPLICATION NUMBER: US/10/251,385  
CURRENT FILING DATE: 2002-09-20  
PRIOR APPLICATION NUMBER: US/09/170,496  
PRIOR FILING DATE: 1998-10-13  
NUMBER OF SEQ ID NOS: 294  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 258  
LENGTH: 330  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-251-385-258

Query Match 21.0%; Score 332; DB 14; Length 330;  
Best Local Similarity 31.0%; Pred. No. 1.6e-22;  
Matches 93; Conservative 53; Mismatches 120; Indels 34; Gaps 12;

QY 12 YVAAFALGPPNLVLAIRGATAHARL-RLTPSLVYALNLGCSDLLLTVSPLKXAVEALASG 70  
DB 14 YIIIFLTGTPANLLAURAFVGRIRQPAPVPHILLSLTLADLLLLLLLPFKIIAASNF 73  
QY 71 AMPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI 130  
DB 74 RYLPKVVCAITSGFYSSIIYCTWRFWMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 131 --WALVLCGLVFGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---PARF 184  
DB 132 VAWMSFGHCTIIVQ-----YLNTEQVR---SGNEITCYENFTDNQDVLVPLVRL 181  
QY 185 SLSLLLFFLPLAITAFYCY---VGCLRALARSGLTHRRKLAARAWAGGALLTLTLLCVGPN 241  
DB 182 ELCLVLFPIPMATVTCYWRFWIMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 242 ASNVASFLYPNLGGSWRKGLITGAWSVVNLPLVTGYLGR-----GPGKTKVCAARTQG 295  
DB 240 VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFYSSVVRRAFRGRLQVL---RNQG 295

RESULT 15  
US-10-225-567A-467  
Sequence 467, Application US/10225567A  
Publication No. US20030113798A1  
GENERAL INFORMATION:  
APPLICANT: LifeSpan Biosciences  
APPLICANT: Brown, Joseph P.  
APPLICANT: Burmer, Glenna C.  
APPLICANT: Roush, Christine L.  
TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS  
FILE REFERENCE: 1920-4-4  
CURRENT APPLICATION NUMBER: US/10/225,567A  
CURRENT FILING DATE: 2001-12-19  
PRIOR APPLICATION NUMBER: 60/257,144  
PRIOR FILING DATE: 2000-12-19  
NUMBER OF SEQ ID NOS: 2292  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 467  
LENGTH: 330  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-10-225-567A-467

Query Match 21.0%; Score 332; DB 14; Length 330;  
Best Local Similarity 31.0%; Pred. No. 1.6e-22;  
Matches 93; Conservative 53; Mismatches 120; Indels 34; Gaps 12;  
QY 12 YVAAFALGPPNLVLAIRGATAHARL-RLTPSLVYALNLGCSDLLLTVSPLKXAVEALASG 70  
DB 14 YIIIFLTGTPANLLAURAFVGRIRQPAPVPHILLSLTLADLLLLLLLPFKIIAASNF 73  
QY 71 AMPLPASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI 130  
DB 74 RYLPKVVCAITSGFYSSIIYCTWRFWMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 131 --WALVLCGLVFGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---PARF 184  
DB 132 VAWMSFGHCTIIVQ-----YLNTEQVR---SGNEITCYENFTDNQDVLVPLVRL 181  
QY 185 SLSLLLFFLPLAITAFYCY---VGCLRALARSGLTHRRKLAARAWAGGALLTLTLLCVGPN 241  
DB 182 ELCLVLFPIPMATVTCYWRFWIMLSQPLVGAQRR--RAVGLAVVTLNLFVCGFPYN 239  
QY 242 ASNVASFLYPNLGGSWRKGLITGAWSVVNLPLVTGYLGR-----GPGKTKVCAARTQG 295  
DB 240 VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFYSSVVRRAFRGRLQVL---RNQG 295

Search completed: April 29, 2004, 12:17:26  
Job time : 48 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:08:54 ; Search time 23 Seconds  
(without alignments)  
673.382 Million cell updates/sec

Title: US-10-202-687-2  
Perfect score: 1584  
Sequence: 1 MDLPOLSFGLYVAAPALGF.....RQGLKTVCAARTQGGKSQK 300

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : Issued Patents AA:\*  
1: /cgn2\_6/prodata/2/iaa/5A\_COMB.pep.\*  
2: /cgn2\_6/prodata/2/iaa/5B\_COMB.pep.\*  
3: /cgn2\_6/prodata/2/iaa/6A\_COMB.pep.\*  
4: /cgn2\_6/prodata/2/iaa/6B\_COMB.pep.\*  
5: /cgn2\_6/prodata/2/iaa/PCTUS\_COMB.pep.\*  
6: /cgn2\_6/prodata/2/iaa/backfiles1.pep.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1584	100.0	300	4	US-09-170-496D-250
2	1579	99.7	300	4	US-09-170-496D-272
3	347	21.9	346	4	US-09-170-496D-254
4	347	21.9	401	2	US-08-820-521-2
5	347	21.9	401	3	US-09-248-715-2
6	347	21.9	401	3	US-09-248-715-2
7	342	21.6	346	4	US-09-170-496D-274
8	340.5	21.5	330	3	US-09-187-710-2
9	332	21.0	330	2	US-08-788-750-2
10	332	21.0	330	4	US-09-170-496D-258
11	331	20.9	330	4	US-09-170-496D-276
12	332	20.3	330	4	US-09-152-060-104
13	231.5	14.6	385	3	US-09-053-866-2
14	231.5	14.6	385	4	US-09-479-130-2
15	231.5	14.6	385	4	US-09-472-130A-2
16	228	14.4	425	1	US-07-657-769B-69
17	228	14.4	425	1	US-08-097-938-7
18	228	14.4	425	1	US-08-313-553-13
19	228	14.4	425	1	US-07-789-184-220
20	228	14.4	425	1	US-08-476-000-7
21	228	14.4	425	1	US-08-475-263-220
22	228	14.4	425	1	US-08-472-840-7
23	228	14.4	425	1	US-08-485-886-220
24	228	14.4	425	2	US-08-477-362-220
25	228	14.4	425	2	US-08-477-134-220
26	228	14.4	425	2	US-08-911-320A-3
27	228	14.4	425	2	US-08-476-976-7

28	228	14.4	425	2	US-08-742-440A-7	Sequence 7, Appli
29	228	14.4	425	2	US-08-560-098A-57	Sequence 57, Appl
30	228	14.4	425	3	US-08-767-993-13	Sequence 13, Appl
31	228	14.4	425	3	US-08-473-489A-220	Sequence 220, App
32	228	14.4	425	3	US-08-474-410-7	Sequence 7, Appli
33	228	14.4	425	3	US-08-485-695-220	Sequence 220, App
34	228	14.4	425	3	US-09-217-101-3	Sequence 3, Appli
35	228	14.4	425	3	US-08-018-760-220	Sequence 220, App
36	228	14.4	425	3	US-08-486-673B-7	Sequence 7, Appli
37	225.5	14.2	358	4	US-09-170-496D-186	Sequence 186, App
38	216.5	13.7	358	4	US-09-170-496D-40	Sequence 40, Appl
39	213	13.4	358	3	US-09-041-545-2	Sequence 2, Appli
40	213	13.4	358	3	US-09-327-925-2	Sequence 2, Appli
41	210	13.3	357	5	PCT-US95-07180-3	Sequence 3, Appli
42	205.5	13.0	408	2	US-08-742-440A-6	Sequence 6, Appli
43	202.5	12.8	328	3	US-08-513-974B-56	Sequence 56, Appl
44	202.5	12.8	328	3	US-08-513-974B-380	Sequence 380, App
45	202.5	12.8	328	4	US-09-461-436B-56	Sequence 56, Appl

ALIGNMENTS

RESULT 1  
US-09-170-496D-250  
; Sequence 250, Application US/09170496D  
; Patent No. 6555339  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 250  
; LENGTH: 300  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-170-496D-250

Query Match	100.0%	Score 1584;	DB 4;	Length 300;
Best Local Similarity	100.0%	Pred. No. 3.2e-126;		
Matches	300;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1	MDLPOLSFGLYVAAPALGFPLNVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTVSLP	60	
Db	1	MDLPOLSFGLYVAAPALGFPLNVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTVSLP	60	
Qy	61	LKAVEALASGNWPLPASLCPVFAVAHFFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP	120	
Db	61	LKAVEALASGNWPLPASLCPVFAVAHFFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP	120	
Qy	121	CYSWGCAAIWALVLCGLVFLGFLAPGGLDHSNTSLGINTPVNGSPVCLBAWDPASAG	180	
Db	121	CYSWGCAAIWALVLCGLVFLGFLAPGGLDHSNTSLGINTPVNGSPVCLBAWDPASAG	180	
Qy	181	PARFSLSLFFFLPLAITAFYVGCILRALARSGLTHRRKRLRAAWAGGALLTLLLCVGPY	240	
Db	181	PARFSLSLFFFLPLAITAFYVGCILRALARSGLTHRRKRLRAAWAGGALLTLLLCVGPY	240	
Qy	241	NASNVSFLYPLNLGGSRKLGILITGAWSVVPLVTGYLGRGGLTKTVCAARTQGGKSQK	300	
Db	241	NASNVSFLYPLNLGGSRKLGILITGAWSVVPLVTGYLGRGGLTKTVCAARTQGGKSQK	300	

RESULT 2  
US-09-170-496D-272  
; Sequence 272, Application US/09170496D  
; Patent No. 6555339

```

; GENERAL INFORMATION:
; APPLICANT: Behan, Dominic P.
; APPLICANT: Chalmers, Derek T.
; APPLICANT: Liaw, Chen W.
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-
; TITLE OF INVENTION: Receptors
; FILE REFERENCE: AREN-0040
; CURRENT APPLICATION NUMBER: US/09/170,496D
; CURRENT FILING DATE: 1998-10-13
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 272
; LENGTH: 300
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-170-496D-272

```

Query Match	99.7%;	Score 1579;	DB 4;	Length 300;
Best Local Similarity	99.7%;	Pred. No. 8.5e-136;		
Matches 299;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
Qy	1	MDLPPQLSFGLYVAAAFALGPPLNVLTARGATAHARLRLTTPSLVYALNLGCSDLLLTWSLP	60	
Db	1	MDLPPQLSFGLYVAAAFALGPPLNVLTARGATAHARLRLTTPSLVYALNLGCSDLLLTWSLP	60	
Qy	61	LKAVEALASGAWPLUPASLCPVFAVAHFPPFLYAGGGFLAALASAGRYLGAAFPGLGYQAFRRP	120	
Db	61	LKAVEALASGAWPLUPASLCPVFAVAHFPPFLYAGGGFLAALASAGRYLGAAFPGLGYQAFRRP	120	
Qy	121	CYSWGVCAAITWALVLCHLGLVFLGLEAPGGWLDHNTSLGINTPVGNSPVCLEAWDPSAS	180	
Db	121	CYSWGVCAAITWALVLCHLGLVFLGLEAPGGWLDHNTSLGINTPVGNSPVCLEAWDPSAS	180	
Qy	181	PARFSLSLLLFFLPPLAITAFICYVGCRLALARSGLTHRRKLFRAAAVAGSALLTLLLCVGPY	240	
Db	181	PARFSLSLLLFFLPPLAITAFICYVGCRLALARSGLTHRRKLFRAAAVAGSALLTLLLCVGPY	240	
Qy	241	NASNVASFLYPNLGGSWRKGLITIGAWSVLNPLVTGYLGRGPGIKTVCAARTGGKSQK	300	
Db	241	NASNVASFLYPNLGGSWRKGLITIGAWSVLNPLVTGYLGRGPGIKTVCAARTGGKSQK	300	

RESULT 3  
 US-09-170-496D-254  
 ; Sequence 254, Application US/09170496D  
 ; Patent No. 6555339  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Behan, Dominic P.  
 ; APPLICANT: Chalmers, Derek T.  
 ; APPLICANT: Liaw, Chen W.  
 ; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
 ; TITLE OF INVENTION: Receptors  
 ; FILE REFERENCE: AREN-0040  
 ; CURRENT APPLICATION NUMBER: US/09/170,496D  
 ; CURRENT FILING DATE: 1998-10-13  
 ; NUMBER OF SEQ ID NOS: 294  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 254  
 ; LENGTH: 346  
 ; TYPE: prt  
 ; ORGANISM: Homo sapiens  
 US-09-170-496D-254

	Query Match	21.9%	Score 347;	DB 4;	Length 346;
	Best Local Similarity	32.3%;	Pred. No. 1.1e-21;		
	Matches	95;	Conservative 41;	Mismatches 134;	Indels 24; Gaps 6;
Qy	1 MDLPPQLS-----FGLYVAFAFGFPFLVLAIRGATAHARLRLTSPISVVALNLGCS	51	:	:	:
Db	1 MDTGPDOSYSGNNHFVSFVLLTFVLGLPDLNLAUVFKLQRPPVADVLLNLITAS	60	:	:	:
Qy	52 DLLLTSLPLKVAEPALASGAWLPSPASICPVFAVAHFPELYAGGGFLAALSAGRYLGAAFP	111	:	:	:

61	DL	LLLLFLPFRVMEAGMHWP	LP	IL	CP	LS	GF	FT	FT	TY	LT	AL	AA	VS	IR	FL	SV	AP	120
112	LG	QA	RR	PC	SW	GC	RA	IW	LV	LG	LV	FL	GE	AP	GC	WL	DH	SN	171
121	LW	YK	TR	PL	QO	AG	LV	SV	AC	WL	LA	SA	HC	SV	VV	VI	FS	GD	170
172	EAW	---	DP	AS	AG	PAR	FS	LS	LL	FF	LP	LA	IT	AP	CV	VG	CL	AR	228
171	LE	PK	QD	LA	LL	PV	RE	MA	VV	FV	PL	IT	SV	CS	SR	LV	MI	LG	229
229	AL	TL	LL	CV	GP	YN	AS	NV	AS	FL	YN	LG	SW	RK	LG	LT	GA	VS	282
230	TL	NF	LC	FG	PN	YSH	VGY	TCG	-	SP	AW	Y	IV	TL	LS	NS	CV	DF	282

RESULT 4  
US-08-820-521-2  
; Sequence 2, Application US/08820521  
; Patent No. 5942416  
; GENERAL INFORMATION:  
; APPLICANT: Bergsma, Derek  
; APPLICANT: Gangesh, Sathe  
; APPLICANT: Fuetterer, Wendy  
; APPLICANT: Mao, Joyce  
; TITLE OF INVENTION: cDNA CLONE HNF2Y20 THAT ENCODES  
; TITLE OF INVENTION: A NOVEL HUMAN 7-TRANSMEMBRANE RECEPTOR  
; NUMBER OF SEQUENCES: 2  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: SmithKline Beecham Corporation  
; STREET: 709 Swedeland Road  
; CITY: King of Prussia  
; STATE: PA  
; COUNTRY: USA

13406  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/820,521  
FILING DATE: 19-MAR-1997  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Han, William T  
REGISTRATION NUMBER: 34,344  
REFERENCE/DOCKET NUMBER: GH50011  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 610-270-5219  
TELEFAX: 610-270-4026  
TELEX:  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 401 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-820-521-2

Query Match	21.9%	Score 347;	DB 2;	Length 401;
Best Local Similarity	32.3%;	Pred. No. 1.4e-21;		
Matches	95;	Conservative 41;	Mismatches 134;	Indels 24; Gaps 6;
Qy	1	MDLPPLQLS-----FGLVYAAFAALGCFPLNLVLAIRGATAHAARLRLTSPSLVAYALNLCGS	51	
Db	56	MDTGPDQSYSGNHWFVSFVYLLTFVLGLPPLNLALVVFVKLQRRPVAVDVLLNLNTAS	115	
Qy	52	DLLLTVLSLPKNAEALASGAWPFPASLCPVFVAHFPPLYAGGGFALAALSGRYLGAHAFP	111	





Db 116 D L L L L F L F R V E A A N G M H P L P F I L C P L S G F I F F T T I Y L T A L F L A A V S I E R F L S V A H P 175  
Qy 112 L G V Q A F R P R C Y S W G V C A A T W A L V L C H L G V F G L E A P G W L D H S N T S L G I N T P V N G S P V C L 171  
Db 176 L M Y K T R P R L G Q A G L V S V A C W L L A S A H C S V V Y V I E F S G D - I S H S Q G T N G - - - - - T C Y 225  
Qy 172 E A W - - - D P A S A G P A R F S L L L F L P L A I T A F C Y V G C L R A L A R S G L T H R R K L R A A W A V A G G 228  
Db 226 L E F R K D Q L A I L L P V R L E M A V L F V P L I T S Y C S R L W I L G R G G - S H R Q R V A G L L A A 284  
Qy 229 A L L T L L C V P N A S V A S F L P N I G G S W R K L G L I T G A M S V V L N P L V T G Y L G R G 282  
Db 285 T L L N F L V C F G P Y N V S H V V G Y I C G E - S P A W R I V Y T L L S T L N S C V D P F V Y F S S G 337

RESULT 7  
US-09-170-496D-274  
; Query Match 21.6%; Score 342; DB 4; Length 346;  
; Best Local Similarity 32.0%; Pred. No. 3e-21;  
; Matches 94; Conservative 41; Mismatches 135; Indels 24; Gaps 6;  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 274  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-170-496D-274

Qy 1 M D L P Q L S - - - - - F G L Y V A A F A L G P L N V L A I R G A T A H A R L R L T P S L Y V A L N L G C S 51  
Db 1 M D T G P D Q S Y F S G N H N F V F S Y L L T F L V G L P L N L L A L V F V G K L Q R R P V A V D V L L N L T A S 60  
Qy 52 D L L L T V S L P L K A V E A L A S A N W L P A S L C P V F A V A H P P L Y A G G F L A A S A G R Y L G A A P P 111  
Db 61 D L L L L F L F R V E A A N G M H P L P F I L C P L S G F I F F T T I Y L T A L F L A A V S I E R F L S V A H P 120  
Qy 112 L G V Q A F R P R C Y S W G V C A A T W A L V L C H L G V F G L E A P G W L D H S N T S L G I N T P V N G S P V C L 171  
Db 121 L M Y K T R P R L G Q A G L V S V A C W L L A S A H C S V V Y V I E F S G D - I S H S Q G T N G - - - - - T C Y 170  
Qy 172 E A W - - - D P A S A G P A R F S L L L F L P L A I T A F C Y V G C L R A L A R S G L T H R R K L R A A W A V A G G 228  
Db 171 L E F R K D Q L A I L L P V R L E M A V L F V P L I T S Y C S R L W I L G R G G - S H R Q R V A G L L A A 229  
Qy 229 A L L T L L C V P N A S V A S F L P N I G G S W R K L G L I T G A M S V V L N P L V T G Y L G R G 282  
Db 230 T L L N F L V C F G P Y N V S H V V G Y I C G E - S P A W R I V Y T L L S T L N S C V D P F V Y F S S G 282

RESULT 8  
US-09-187-710-2  
; Query Match 21.6%; Score 342; DB 4; Length 346;  
; Best Local Similarity 32.0%; Pred. No. 3e-21;  
; Matches 94; Conservative 41; Mismatches 135; Indels 24; Gaps 6;  
; GENERAL INFORMATION:  
; APPLICANT: Behan, Dominic P.  
; APPLICANT: Chalmers, Derek T.  
; APPLICANT: Liaw, Chen W.  
; TITLE OF INVENTION: No. 6555339-Endogenous, Constitutively Activated Human G Protein-  
; TITLE OF INVENTION: Receptors  
; FILE REFERENCE: AREN-0040  
; CURRENT APPLICATION NUMBER: US/09/170,496D  
; CURRENT FILING DATE: 1998-10-13  
; NUMBER OF SEQ ID NOS: 294  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 274  
; LENGTH: 346  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-170-496D-274

; CURRENT APPLICATION NUMBER: US/09/187,710A  
; CURRENT FILING DATE: 1998-11-06  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 2  
; LENGTH: 330  
; TYPE: PRT  
; ORGANISM: HOMO SAPIENS  
US-09-187-710-2

Qy 12 Y V A A F A L G P L N V L A I R G A T A H A R L - R L T P S L Y V A L N L G C S D L L I T V S I P L K A V E A L A S G 70  
Db 14 Y I L I F L T G L P A N L L A R A P M G R V Q P A P V H I L L N I T L A D L L L L L L L P F R I V E A A S N F 73  
Qy 71 A W P L P A S L C P V F A V A H P P L Y A G G F L A A L S A G R Y L G A A F P L G Y Q A F R R P C Y S W G V C A A I 130  
Db 74 R W Y L P K I V C A L T G F G F Y S I Y C S T W L L A G I S M E R Y L G V A P V O Y K L S R P L Y - G V I A A L 131  
Qy 131 - - W A L V L C H L G L V F G L E A P G W L D H S N T S L G I N T P V N G S P V C L E A W D P A S A G - - - P A R F S 185  
Db 132 V A W I M S F G H C T I V I V Q - - - - - Y L N S T E Q V G T - - E N Q I T C Y E N F T Q E L D V L P V R L E 182  
Qy 186 L S L L L F L P L A I T A R C Y - - - V G C L R A L A R S G L T H R R K L R A A W A V A G A L L T L L C V P N A 242  
Db 183 L C L V L F F V P M A V T I F C Y W R F V M I M L T Q P H V G A Q R R R - - R A V G L A V V T L L N F L V C F G P Y N M 240  
Qy 243 S N V A S F L P N L G G S W R K L G L I T G A M S V V L N P L V - - - - - T G Y L 279  
Db 241 S H L V C F - Y L R Q S P S W R V E A V F S S L N A S I D P L L F Y F S S V V R A F G K G L L I R N P A S S V L 299  
Qy 280 G R G P G L K T V C A A R T O G G S Q 299  
Db 300 G R G - A K E T V E G T K M D R G G S Q 318

RESULT 9  
US-08-788-750-2  
; Sequence 2, Application US/08788750  
; Patent No. 5910430  
; GENERAL INFORMATION:  
; APPLICANT: Ellis, Catherine  
; APPLICANT: Bergsma, Derek  
; TITLE OF INVENTION: No. 5910430el G-Protein Coupled Receptor  
; TITLE OF INVENTION: (HTADX50)  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Smithkline Beecham Corporation  
; STREET: 709 Swedeland Road  
; CITY: King of Prussia  
; STATE: PA  
; COUNTRY: USA  
; ZIP: 19406  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/788,750  
; FILING DATE: 24-JAN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Han, William T  
; REGISTRATION NUMBER: 34,344  
; REFERENCE/DOCKET NUMBER: ATG50048  
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 610-270-5219	185	SLSLLLFFFLPLAITAFCY---	VCCLRALARSGLT	THRRKLR	AAWVAGGALLTLLLCVGPYN	241
TELEFAX: 610-270-4026	182	ELCLVLFFFPMAVTIFCYWRFV	WIMLSQPLVGAQRRR--	RAVGLAV	VVTLNPLVCFGPGYN	239
TELEX:						
INFORMATION FOR SEQ ID NO: 2:						
SEQUENCE CHARACTERISTICS:						
LENGTH: 330 amino acids						
TYPE: amino acid						
STRANDEDNESS: single						
TOPOLOGY: linear						
US-08-788-750-2						
Query Match	21.0%;	Score 332;	DB 2;	Length 330;		
Best Local Similarity	31.0%;	Pred. No. 2e-20;				
Matches	93;	Conservative	53;	Mismatches 120;	Indels 34;	Gaps 12;
QY	12	YVAAFALGPLNLAIRGATAHARL-RLTPSLVYALNLGCSDLLITVSLPLKAVEALASG	70			
DB	14	YIIIFLTGLPANLLARAFVGRIRQPAPVHILLSLTLADLLLLLPKITEAASNF	73			
QY	71	AWPLPASLCPVFAVAFHFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI	130			
DB	74	RWLPLKVCALTSFGFYSIYCSWLLAGISIERVYLGVAFPVQYKLSRRPLY--GVIAAL	131			
QY	131	--WALVLCGLVFLGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---	PARF 184			
DB	132	VAWVMSFGHCTIVIIVQ-----YLNTEQVR---SGNEITCYENFTDNQLDVLVPLVRL	181			
QY	185	SLSLLLFFFLPLAITAFCY---	VCCLRALARSGLT	THRRKLR	AAWVAGGALLTLLLCVGPYN	241
DB	182	ELCLVLFFFPMAVTIFCYWRFV	WIMLSQPLVGAQRRR--	RAVGLAV	VVTLNPLVCFGPGYN	239
QY	242	ASNVAFLYPNLGGSRWKLGLITGAWSVVLPNPLVTGYLGR-----GPKLTVC	CAARTQG 295			
DB	240	VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFVSSVVRRAFGRGLQVL---	RNOG 295			
RESULT 10						
US-09-170-496D-258						
Query Match	21.0%;	Score 332;	DB 4;	Length 330;		
Best Local Similarity	31.0%;	Pred. No. 2e-20;				
Matches	93;	Conservative	53;	Mismatches 120;	Indels 34;	Gaps 12;
QY	12	YVAAFALGPLNLAIRGATAHARL-RLTPSLVYALNLGCSDLLITVSLPLKAVEALASG	70			
DB	14	YIIIFLTGLPANLLARAFVGRIRQPAPVHILLSLTLADLLLLLPKITEAASNF	73			
QY	71	AWPLPASLCPVFAVAFHFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI	130			
DB	74	RWLPLKVCALTSFGFYSIYCSWLLAGISIERVYLGVAFPVQYKLSRRPLY--GVIAAL	131			
QY	131	--WALVLCGLVFLGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---	PARF 184			
DB	132	VAWVMSFGHCTIVIIVQ-----YLNTEQVR---SGNEITCYENFTDNQLDVLVPLVRL	181			
QY	185	SLSLLLFFFLPLAITAFCY---	VCCLRALARSGLT	THRRKLR	AAWVAGGALLTLLLCVGPYN	241
DB	182	ELCLVLFFFPMAVTIFCYWRFV	WIMLSQPLVGAQRRR--	RAVGLAV	VVTLNPLVCFGPGYN	239
QY	242	ASNVAFLYPNLGGSRWKLGLITGAWSVVLPNPLVTGYLGR-----GPKLTVC	CAARTQG 295			
DB	240	VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFVSSVVRRAFGRGLQVL---	RNOG 295			
RESULT 11						
US-09-170-496D-276						
Query Match	20.9%;	Score 331;	DB 4;	Length 330;		
Best Local Similarity	31.0%;	Pred. No. 2.4e-20;				
Matches	93;	Conservative	53;	Mismatches 120;	Indels 34;	Gaps 12;
QY	12	YVAAFALGPLNLAIRGATAHARL-RLTPSLVYALNLGCSDLLITVSLPLKAVEALASG	70			
DB	14	YIIIFLTGLPANLLARAFVGRIRQPAPVHILLSLTLADLLLLLPKITEAASNF	73			
QY	71	AWPLPASLCPVFAVAFHFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI	130			
DB	74	RWLPLKVCALTSFGFYSIYCSWLLAGISIERVYLGVAFPVQYKLSRRPLY--GVIAAL	131			
QY	131	--WALVLCGLVFLGLEAPGGWLDHSNTSLGINTPVGSPV-CLEAWDPASAG---	PARF 184			
DB	132	VAWVMSFGHCTIVIIVQ-----YLNTEQVR---SGNEITCYENFTDNQLDVLVPLVRL	181			
QY	185	SLSLLLFFFLPLAITAFCY---	VCCLRALARSGLT	THRRKLR	AAWVAGGALLTLLLCVGPYN	241
DB	182	ELCLVLFFFPMAVTIFCYWRFV	WIMLSQPLVGAQRRR--	RAVGLAV	VVTLNPLVCFGPGYN	239
QY	242	ASNVAFLYPNLGGSRWKLGLITGAWSVVLPNPLVTGYLGR-----GPKLTVC	CAARTQG 295			
DB	240	VSHLVGY-HQRKSPWRSIAVVFSSINASLDPLLFVSSVVRRAFGRGLQVL---	RNOG 295			
RESULT 12						
US-09-152-060-104						
Query Match	21.0%;	Score 332;	DB 4;	Length 330;		
Best Local Similarity	31.0%;	Pred. No. 2e-20;				
Matches	93;	Conservative	53;	Mismatches 120;	Indels 34;	Gaps 12;
QY	12	YVAAFALGPLNLAIRGATAHARL-RLTPSLVYALNLGCSDLLITVSLPLKAVEALASG	70			
DB	14	YIIIFLTGLPANLLARAFVGRIRQPAPVHILLSLTLADLLLLLPKITEAASNF	73			
QY	71	AWPLPASLCPVFAVAFHFFLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI	130			
DB	74	RWLPLKVCALTSFGFYSIYCSWLLAGIS				

EARLIER APPLICATION NUMBER: 60/048,100  
EARLIER FILING DATE: 1997-05-30  
EARLIER APPLICATION NUMBER: 60/048,357  
EARLIER FILING DATE: 1997-05-30  
EARLIER APPLICATION NUMBER: 60/048,189  
EARLIER FILING DATE: 1997-05-30  
EARLIER APPLICATION NUMBER: 60/057,765  
EARLIER FILING DATE: 1997-09-05  
EARLIER APPLICATION NUMBER: 60/048,970  
EARLIER FILING DATE: 1997-06-06  
EARLIER APPLICATION NUMBER: 60/068,368  
EARLIER FILING DATE: 1997-12-19  
NUMBER OF SEQ ID NOS: 118  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 104  
LENGTH: 330  
TYPE: PRT  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: SITE  
LOCATION: (7)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
FEATURE:  
NAME/KEY: SITE  
LOCATION: (147)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
FEATURE:  
NAME/KEY: SITE  
LOCATION: (181)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
FEATURE:  
NAME/KEY: SITE  
LOCATION: (190)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
FEATURE:  
NAME/KEY: SITE  
LOCATION: (260)  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-152-060-104

Query Match 20.3%; Score 322; DB 4; Length 330;  
Best Local Similarity 31.0%; Pred. No. 1.4e-19;  
Matches 93; Conservative 50; Mismatches 123; Indels 34; Gaps 12;  
QY 12 YVAAPALGPNLVLAIRGATAHARL-RLTPSLVYALNLCSDLLLTSLPLKXAVEALASG 70  
DB 14 YIIIFLTGLPANLLALRAFVGRIRQPAPVHILLSLTLADLLLLLPFKIIIEASNF 73  
QY 71 ANPLPASLCPVFAVAHFFPLVYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI 130  
DB 74 RNYLPKVVCAITSPFGYSSYICSTWLLAGISIRYLGVAFPVQYKLSRRPLY--GVIAAL 131  
QY 131 --WALVLCGLGVFLGAPGGLDHSNTSLGINTPVNGSPV-CLEAWDPASAG---PARF 184  
DB 132 VAWVMSFGCHTIVIIQ-----YLTTEQVR---SGNEITCYENFTNDQLDVLVPRX 181  
QY 185 SLSLLLPFLPLAITAPCY---VGLCLALARSGLTHRRKURAAWAGGALLTLLCVGPYN 241  
DB 182 ELCLVLFEXPMATVTFYFRWFVIMLSQPLVGAQRER--RAVGLAVVTTLNLFVCFGPYN 239  
QY 242 ASNVASFLPNLGGWRKGLGITGAWSVVLNPLVTGYLGR-----GPGKTKVCAARTOG 295  
DB 240 VSHLVGY-HQRKSPWWRSTAVXVFSSLNASLDPLLFYSSVVRAPGRGLQVLI---RNQG 295

RESULT 13  
US-09-053-866-2  
Sequence 2, Application US/09053866  
Patent No. 6111075  
GENERAL INFORMATION:  
APPLICANT: Xu, Wenfeng  
APPLICANT: Presnell, Scott R.  
APPLICANT: Yee, David P.

APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR  
TITLE OF INVENTION: PARA (ZCHEMR2)  
NUMBER OF SEQUENCES: 12  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ZymoGenetics, Inc.  
STREET: 1201 Eastlake Avenue East  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/053,866  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Leith, Debra K  
REGISTRATION NUMBER: 32,619  
REFERENCE/DOCKET NUMBER: 98-10  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-442-6674  
TELEFAX: 206-442-6678  
TELEX:  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 385 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: internal  
US-09-053-866-2

Query Match 14.6%; Score 231.5; DB 3; Length 385;  
Best Local Similarity 24.9%; Pred. No. 7.3e-12;  
Matches 88; Conservative 29; Mismatches 123; Indels 113; Gaps 8;  
QY 3 LPQPSFGLYVAAPALGPNLVLAIRG-ATAHARLRLTPSLVYALNLCSDLLLTSLPL 61  
DB 75 VPTRLVPALYGLVVLVVGLPANGIALWVLTQAPRL---PSTWLLMNLATADLLALALPP 131  
QY 62 KAVEALASGAWPLPASLCPVFAVAHFFPLVYAGGGFLAALSAGRYLGAAPFLGYQAFRRPC 121  
DB 132 RIAYHLRGQRVPFGGAACKLATAALYGHMVGSVLLLAIVSLDRYLALVHLPLARALRGRR 191  
QY 122 YSWGVCATIAWAL-----VLCHLGLVFLGAPGGLDHSNTSLG 159  
DB 192 LALGLCMAWLLAAALALPLTLQRTFLARSDRVLCHDALPLDAQA----- 238  
QY 160 INTFVNGSPVCLAEWDPAAGPARPSLSLLLPFLPLAITAFYVGCRLALARSGLTHRRK 219  
DB 239 -----SHWQPAFT-----CLALLGCFPLLAMLLCYGATLHTLAASGRYGYHA 281  
QY 220 LR-----AAWVAGGALLTLLLCVGPYNAS 243  
DB 282 LRLTAVVLASAVAFVPSNLLLLHHVSDPSPAWGNLYGAYVPSLALSTLNSCDP----- 337  
QY 244 NVASFLPNLGGWRKGLGITGAWSVVLNPLVTGYLGRGPGLTKVCAARTOGG 296  
DB 338 ----FIYYVSAEFR-----DKVRAGLFQRSEFGDTVASKASAEQG 373  
RESULT 14  
US-09-479-130-2  
Sequence 2, Application US/09479130

Patent No. 6436400  
GENERAL INFORMATION:  
APPLICANT: Xu, Wenfeng  
APPLICANT: Presnell, Scott R.  
APPLICANT: Yee, David P.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR  
NUMBER OF SEQUENCES: 12  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: ZymoGenetics, Inc.  
STREET: 1201 Eastlake Avenue East  
CITY: Seattle  
STATE: WA  
COUNTRY: USA  
ZIP: 98102  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/479,130  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Leith, Debra K  
REGISTRATION NUMBER: 32,619  
REFERENCE/DOCKET NUMBER: 98-10  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-442-6674  
TELEFAX: 206-442-6678  
TELEX:  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 385 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
FRAGMENT TYPE: internal  
US-09-479-130-2

Query Match 14.6%; Score 231.5; DB 4; Length 385;  
Best Local Similarity 24.9%; Pred. No. 7.3e-12;  
Matches 88; Conservative 29; Mismatches 123; Indels 113; Gaps 8;  
QY 3 LPPQLSFGLYVAAPALGFPPLNVLAIRG-ATAHARLRLTPSLVVALNLGCSDDLTLTVSLPL 61  
DB 75 VPTRLVPALYGLVVLVGLPANGALWVLAATQAPRL---PSTMLLMNLAADLALLALALPP 131  
QY 62 KAVEALASGAWPLPASLCPVFAVHFFPLYAGGGFLAALSAGRYLGAAPPLGYQAFRRPC 121  
DB 132 RIAYHLRGQRWPFGEAACRLAATLYGHMYGSVLLLAASVSLDRYLAHVPLRARALRGRR 191  
QY 122 YSWGVCAAIWAAL-----VLCHLGLVFLGEPAGGWLHDSNTSLG 159  
DB 192 LALGLCMAAWLMAAALPLTLQRTFLARSDRVLCDAALPLDAQA----- 238  
QY 160 INTPVNGSPVCLAWDPASAGPARFSLILLPLPLAITAFPCYVGCRLARLSGLTHRRK 219  
DB 239 -----SHWQPAFT-----CLALLGCFPLLLMLLCYGATLHTLAASGRYGYHA 281  
QY 220 LR-----AAWVAGGALLTLILLCVGPYNAS 243  
DB 282 LRLTAVVLASAVAFFVPSNLLLLHYSDPSAMGNLYGAYVPSLALSTLNSCVDP---- 337  
QY 244 NVASFLYPNLGGSWRKGLITGAWSVVLNPLVTGYLGRGPKLTKVCAARTQGG 296  
DB 338 -----FIYYVSAEFR-----DKVRAGLFQSPGDTVASKASAEAGG 373

RESULT 15  
US-09-472-130A-2  
Sequence 2, Application US/094721130A  
Patent No. 6437765  
GENERAL INFORMATION:  
APPLICANT: Xu, Wenfeng  
APPLICANT: Presnell, Scott R.  
APPLICANT: Yee, David P.  
APPLICANT: Foster, Donald C.  
TITLE OF INVENTION: PROTEASE-ACTIVATED RECEPTOR PAR4  
TITLE OF INVENTION: (ZCHEMR2)  
FILE REFERENCE: 98-10D2  
CURRENT APPLICATION NUMBER: US/09/472,130A  
CURRENT FILING DATE: 2000-01-07  
PRIOR APPLICATION NUMBER: US 09/053,866  
PRIOR FILING DATE: 1998-04-01  
NUMBER OF SEQ ID NOS: 21  
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 2  
LENGTH: 385  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-472-130A-2

Query Match 14.6%; Score 231.5; DB 4; Length 385;  
Best Local Similarity 24.9%; Pred. No. 7.3e-12;  
Matches 88; Conservative 29; Mismatches 123; Indels 113; Gaps 8;  
QY 3 LPPQLSFGLYVAAPALGFPPLNVLAIRG-ATAHARLRLTPSLVVALNLGCSDDLTLTVSLPL 61  
DB 75 VPTRLVPALYGLVVLVGLPANGALWVLAATQAPRL---PSTMLLMNLAADLALLALALPP 131  
QY 62 KAVEALASGAWPLPASLCPVFAVHFFPLYAGGGFLAALSAGRYLGAAPPLGYQAFRRPC 121  
DB 132 RIAYHLRGQRWPFGEAACRLAATLYGHMYGSVLLLAASVSLDRYLAHVPLRARALRGRR 191  
QY 122 YSWGVCAAIWAAL-----VLCHLGLVFLGEPAGGWLHDSNTSLG 159  
DB 192 LALGLCMAAWLMAAALPLTLQRTFLARSDRVLCDAALPLDAQA----- 238  
QY 160 INTPVNGSPVCLAWDPASAGPARFSLILLPLPLAITAFPCYVGCRLARLSGLTHRRK 219  
DB 239 -----SHWQPAFT-----CLALLGCFPLLLMLLCYGATLHTLAASGRYGYHA 281  
QY 220 LR-----AAWVAGGALLTLILLCVGPYNAS 243  
DB 282 LRLTAVVLASAVAFFVPSNLLLLHYSDPSAMGNLYGAYVPSLALSTLNSCVDP---- 337  
QY 244 NVASFLYPNLGGSWRKGLITGAWSVVLNPLVTGYLGRGPKLTKVCAARTQGG 296  
DB 338 -----FIYYVSAEFR-----DKVRAGLFQSPGDTVASKASAEAGG 373

Search completed: April 29, 2004, 12:12:39  
Job time : 25 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:07:24 ; Search time 45 Seconds  
(without alignments)  
2103.455 Million cell updates/sec

Title: US-10-202-687-2  
Perfect score: 1584  
Sequence: 1 MDLPQLSGLYVAAPALGF.....RGPLKTVCAARTQGGKQK 300

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : SPTREMBL\_25.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phase.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*  
15: sp\_rvirus.\*  
16: sp\_bacteriaph.\*  
17: sp\_archaeap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1329	83.9	300	11 Q8K3T5	Q8K3T5 mus musculus
2	1320	83.3	300	11 Q8K3T4	Q8K3T4 rattus norv
3	340.5	21.5	330	11 Q8VCK6	Q8VCK6 mus musculus
4	222.5	14.0	396	11 Q8BZ77	Q8BZ77 mus musculus
5	221.5	14.0	359	4 Q86VZ1	Q86VZ1 homo sapien
6	209	13.2	319	4 Q8N580	Q8N580 homo sapien
7	207	13.1	343	13 Q8JZ23	Q8JZ23 oncorhynch
8	206.5	13.0	365	11 Q8BUD0	Q8BUD0 mus musculus
9	203.5	12.8	367	6 Q8MI04	Q8MI04 ovis aries
10	200	12.6	357	11 Q7TMV7	Q7TMV7 mus musculus
11	199	12.6	296	11 Q9WU09	Q9WU09 rattus norv
12	198	12.5	339	4 Q8N5S7	Q8N5S7 homo sapien
13	198	12.5	358	11 Q8BYC4	Q8BYC4 mus musculus
14	198	12.5	376	4 Q7Z3W3	Q7Z3W3 homo sapien
15	197.5	12.5	369	11 Q8BJB7	Q8BJB7 mus musculus
16	197	12.4	247	13 Q7T1E7	Q7T1E7 oncorhynch

17	196	12.4	359	13 Q90VY4	Q90VY4 oncorhynch
18	194.5	12.3	350	4 Q8N6T6	Q8N6T6 homo sapien
19	193.5	12.2	353	11 Q35797	Q35797 rattus norv
20	193	12.2	347	13 Q7Z2A4	Q7Z2A4 brachydanio
21	193	12.2	385	11 Q9TK40	Q9TK40 mus musculus
22	191	12.1	359	13 Q90VZ2	Q90VZ2 oncorhynch
23	191	12.1	377	13 Q7T2S9	Q7T2S9 carassius a
24	190	12.0	390	13 Q8AXM7	Q8AXM7 carassius a
25	188	11.9	319	4 Q9Y2T6	Q9Y2T6 homo sapien
26	188	11.9	355	6 Q8HZN7	Q8HZN7 gorilla gor
27	187.5	11.8	351	6 Q9MYJ9	Q9MYJ9 oryctolagus
28	187	11.8	359	13 Q90Z22	Q90Z22 oncorhynch
29	186	11.7	355	6 Q8HZN5	Q8HZN5 macaca mula
30	186	11.7	380	13 Q9DQ06	Q9DQ06 carassius a
31	185.5	11.7	319	4 Q9NQ20	Q9NQ20 homo sapien
32	185	11.7	355	6 Q8HZN4	Q8HZN4 cercopithec
33	184.5	11.6	352	11 Q810T4	Q810T4 cavia porce
34	184.5	11.6	355	11 Q8BVW4	Q8BVW4 mus musculus
35	184	11.6	355	6 Q8HZN6	Q8HZN6 pongo pygma
36	184	11.6	355	6 Q8HZN3	Q8HZN3 papio hamad
37	184	11.6	359	13 Q90Z21	Q90Z21 oncorhynch
38	184	11.6	359	13 Q90Z23	Q90Z23 oncorhynch
39	184	11.6	366	6 Q867B2	Q867B2 capra hircu
40	183.5	11.6	370	13 Q8UWL5	Q8UWL5 fugu rubrip
41	183	11.6	351	11 Q810W6	Q810W6 mus musculus
42	182.5	11.5	355	4 Q8IUZ1	Q8IUZ1 homo sapien
43	182.5	11.5	355	6 Q8HZN8	Q8HZN8 pan troglod
44	182.5	11.5	355	11 Q8BMH9	Q8BMH9 mus musculus
45	182.5	11.5	359	13 Q9PVY7	Q9PVY7 anguilla an

ALIGNMENTS

RESULT 1

Q8K3T5 PRELIMINARY; PRT; 300 AA.  
ID Q8K3T5  
AC Q8K3T5;  
DT 01-OCT-2002 (Tremblrel. 22, Created)  
DT 01-OCT-2002 (Tremblrel. 22, Last sequence update)  
DT 01-JUN-2003 (Tremblrel. 24, Last annotation update)  
DE GPR40.  
GN GPR40.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Theria; Rodentia; Sciurognathi; Muridae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=BALB/c;  
RA Andrews J.L., Briscoe C.P., Ignar D.M., Muir A.I., Sauls H.R. Jr.,  
RA Tadayyon M.;  
RT "Method of Screening for GPR40 Ligands."  
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=BALB/c;  
RA Ellis C., Elshourbagy N.;  
RL Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AF539809; AA03478.1; -.  
DR GO; GO:0015021; C:integral to membrane; IEA.  
DR GO; GO:0001584; P:rhodopsin-like receptor activity; IEA.  
DR GO; GO:0007186; P:G-protein coupled receptor signalin. .; IEA.  
DR InterPro; IPR000276; GPCR\_Rhodpsn.  
DR Pfam; PF00001; 7tm1; 1.  
DR PRINTS; PR00237; GPCRRHODOPSN.  
DR PROSITE; PS50262; G:PROTEIN RECEPTOR FL 2; 1.  
SQ SEQUENCE 300 AA; 31837 MW; AFF180F1686F8C17 CRC64;

Query Match 83.9%; Score 1329; DB 11; Length 300;  
Best Local Similarity 82.7%; Pred. No. 4.2e-99;  
Matches 248; Conservative 17; Mismatches 35; Indels 0; Gaps 0;

```
QY 1 MDLPPLSGLYVAAPALGFPNLVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTSLP 60
Db 1 MDLPQFSALYVSAFALGFPNLVLAIRGAVSHAKLRLTPSLVYTHLGCSDLLLTAITLP 60
QY 61 LKAVEALASGANPLPASLCPVFAVAFHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120
Db 61 LKAVEALASGANPLPLPFCVFAAHAFAPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120
QY 121 CYSWGVCRAIWAIVLCHGLVGLGAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180
Db 121 RYSWGVCVAIWAIVLCHGLGALGLETSGSWLNDSTSLGINIPVNGSPVCLAWDPDSAR 180
QY 181 PARFSLSLFLFLPLAITAFYVGCILRALARSGLTHRRKLRRAAWAGGALLTLLLCVGPY 240
Db 181 PARLSFILLFPLVITAFYVGCILRALVRSGLSHKRLRAAWAGGALLTLLLCIGPY 240
QY 241 NASNVASFLYPNLGGSWRKGLITGAWSVVNLPLVTGYLGRGFLKTVCAARTQGGKSK 300
Db 241 NASNVASFINPDLGGSWRKGLITGAWSVVNLPLVTGYLGTGPGRTICVTRTQRTGIQK 300

RESULT 2
Q8K3T4 PRELIMINARY; PRT; 300 AA.
AC Q8K3T4;
DT 01-OCT-2002 (TREMBlrel. 22, Created)
DT 01-OCT-2002 (TREMBlrel. 22, Last sequence update)
DE GPR40.
GN GPR40.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Sprague-Dawley;
RA Ellis C.E. Elshourbagy N.;
RT Submitted (DUA-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF539810; AAN03479.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm1.1; 1.
DR PRINTS; PR00237; GPCRHHODPSN.
DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
SQ SEQUENCE 300 AA; 31835 MW; 4E882AB259A5DD4F CRC64;

Query Match 83.3%; Score 1320; DB 11; Length 300;
Best Local Similarity 81.7%; Pred. No. 2.2e-98;
Matches 245; Conservative 19; Mismatches 36; Indels 0; Gaps 0;

QY 1 MDLPPLSGLYVAAPALGFPNLVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTSLP 60
Db 1 MDLPQFSALYVSAFALGFPNLVLAIRGAVSHAKLRLTPSLVYTHLGCSDLLLTAITLP 60
QY 61 LKAVEALASGANPLPASLCPVFAVAFHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120
Db 61 LKAVEALASGANPLPLPFCVFAAHAFAPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120
QY 121 CYSWGVCRAIWAIVLCHGLVGLGAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG 180
Db 121 RYSWGVCVAIWAIVLCHGLGALGLETSGSWLNDSTSLGINIPVNGSPVCLAWDPDSAR 180
QY 181 PARFSLSLFLFLPLAITAFYVGCILRALARSGLTHRRKLRRAAWAGGALLTLLLCVGPY 240
Db 181 PARLSFILLFPLVITAFYVGCILRALVRSGLSHKRLRAAWAGGALLTLLLCIGPY 240
QY 241 NASNVASFLYPNLGGSWRKGLITGAWSVVNLPLVTGYLGRGFLKTVCAARTQGGKSK 300
Db 241 NASNVASFINPDLGGSWRKGLITGAWSVVNLPLVTGYLGTGPGQGTICVTRTQRTGIQK 300
```

```
RESULT 3
Q8VCK6 PRELIMINARY; PRT; 330 AA.
AC Q8VCK6;
DT 01-MAR-2002 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DT 01-JUN-2003 (TREMBlrel. 24, Last annotation update)
DE Similar to G protein-coupled receptor 43 (Orphan GPCR protein).
GN GPR43 OR LSSIG.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Colon;
RA Strausberg R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=SL;
RA Senga T., Iwamoto S., Yoshida T., Yokota T., Adachi K., Azuma E.,
RA Hamaguchi M., Iwamoto T.;
RT "LSSIG is a novel murine leukocyte specific GPCR that is induced by
RT the activation of STAT3.";
RL Blood 0:0-0(2003).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Colon;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA The RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573(2002).
DR EMBL; BC019570; AAH19570.1; -.
DR EMBL; AF545043; AA016236.1; -.
DR EMBL; AK078861; BAC37425.1; -.
DR MGD; MGI:2441731; Gpr43.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm1.1; 1.
DR PRINTS; PR00237; GPCRHHODPSN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
KW Receptor.
SQ SEQUENCE 330 AA; 37123 MW; 7AB16802561B8B46 CRC64;

Query Match 21.5%; Score 340.5; DB 11; Length 330;
Best Local Similarity 30.9%; Pred. No. 1.6e-19;
Matches 99; Conservative 45; Mismatches 129; Indels 47; Gaps 11;

QY 12 YVAAFALGFPNLVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTSLPKAVEALASG 70
Db 12 YLILFLTGALPALLALRAFMRVROPQAPAPVHILLNLTLADLLLLLPFRIVEAASNF 73
QY 71 AWPPLASLCPVFAVAFHFFPLYAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCRAI 130
Db 74 RWYLPKIVCALGFGFYSSIVCYSTWLLAGISMERVLGVAFVQYKLSRRPLY--GVIAL 131
QY 131 --WALVLCGLVGLGAPGGLDHSNTSLGINTPVNGSPVCLAWDPASAG---PARFS 185
Db 132 VAWINSFGHCTIVIVQ-----YLNSTEQVGT--ENQITCVENFTQQLDVLPLVRLE 182
QY 186 ISLILFLPLAITATFCY----VCCLRALARSLTHRRKLRRAAWAGGALLTLLLCVGPYA 242
Db 183 LCLVLFFVPMVAITFCYRWFVIMLTQPHVGAQRRR--RAVGLAVVTLLNLFVFCGPFNM 240
```



[illegible]

```
RESULT 6
Q8N580 PRELIMINARY; PRT; 319 AA.
AC Q8N580;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DE 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Similar to G protein-coupled receptor 55.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Pancreas;
RA Strausberg K.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC032694; AAH32694.1; -.
DR Genew; HGNC:4511; GPR55.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; IEA.
DR InterPro; IPR000276; GPCR_Rhodpsn.
DR Pfam; PF00001; 7tm.1; 1.
DR PRINTS; PR00237; GPCRHHODPSN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
KW Receptor.
SQ SEQUENCE 319 AA; 36637 MW; D6E5C6CA8426E7D5 CRC64;

Query Match 13.2%; Score 209; DB 4; Length 319;
Best Local Similarity 27.4%; Pred. No. 5.8e-09;
Matches 73; Conservative 33; Mismatches 110; Indels 50; Gaps 9;

QY 2 DLPPQLSFGYVAFAALGFPPLNLAIRGATAHARLR---LTPSLVYALNIGSDLLLTVS 58
DB 17 ELMKTLQFAVHTFTFVLGILLNLLAHGFTLKNEWPDYATSIYMINLAVFDLLVLVS 76
QY 59 LPLKAVEALASGAMPULPASLCPVFAVHFFPLPYAGGGFLAALASAGRYLGAAPPLGVQAPR 118
DB 77 LPPFKVLVSQVSPFP---SLCTLVECLYFVSMYGVFTTCFISMDRFLAIRYPLLVSHLR 133
QY 119 RCYSWGVCAATWALVCHLGLVFLGAPGGLDHSNTSLGINTPVNGSPVCLAW---- 174
DB 134 SPRKIFGICCTIWLVLV-----WTG-----SIPIYFHGKVEKIMCFH 170
QY 175 ---DPASAGPARFSLSLLFFLPLAITAFYVGCFLARSLGTHRRKLRAAWAGGALL 231
DB 171 NMSDDTWSAKVFPFLEVFGLPFGIMGFC---CSRSI--HILLGRDHTQDWVQOKA-- 223
QY 232 TLLLCVGPYNAS---NVASFLYPNLG 254
DB 224 ----CIYSTAASLAVFVVSFLPVHLG 245

RESULT 7
Q8JU23 PRELIMINARY; PRT; 343 AA.
AC Q8JU23;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE G protein-coupled receptor rhodopsinL-1.
OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.
OX NCBI_TaxID=8022;
RN [1]
RP SEQUENCE FROM N.A.
RA Kiryu I., Koellner B., Kuroda A., Ootake M., Dijkstra J.M.;
RT "A new probable G-protein coupled receptor gene associated with the

RT immune system of rainbow trout (Oncorhynchus mykiss).";
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF472607; AAM21607.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; IEA.
DR InterPro; IPR000276; GPCR_Rhodpsn.
DR Pfam; PF00001; 7tm.1; 1.
DR PRINTS; PR00237; GPCRHHODPSN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
KW Receptor.
SQ SEQUENCE 343 AA; 38830 MW; 761F06E57F76BB40 CRC64;

Query Match 13.1%; Score 207; DB 13; Length 343;
Best Local Similarity 23.7%; Pred. No. 9e-09;
Matches 76; Conservative 55; Mismatches 124; Indels 66; Gaps 10;

QY 1 MDLPPLQLSFG-----LYVAAFALGFPPLNLAIRGATAHARLR 37
DB 1 MDWTFPSGSGNSLNNEANNCGVDLSQDAIYLPVVISIFIIIGTPTLNLMAFLG-----YR 55
QY 38 LTPS----LVYALNIGSDLLLTSLKXVEBALASGAWPLPASLCPVFAVHFFPLPYAG 93
DB 56 LIKSENVLPVYVYNLLSDLLQLFTVPLWIDYRRGHGSHWFGSTSCQLLGVSFYISITG 115
QY 94 GGFLAALASGRYLGAAFLGVAQFRPCYSGWCAIWAIVLCHLGLVFLGAPGGLDHS 153
DB 116 IAFMCIIALERYLATAKPLRFOALRKLKPFARWIALSIWVVAVPPSIV----- 163
QY 154 SNTSLGINTPVNGSPVCLAWDPASAGPARFSLSL--LLFFPLPLAITAFYVGCCLR--A 208
DB 164 ----LHKQPNQDHTLCIESY--PSKEGFIYKLIITLSFIPLAFIVILHRTKTLRLSLA 218
QY 209 LARSLGTHRRKLRAAWAGGALLTLLCVGPYNASNVASFLYPNLGG----SWRK----- 259
DB 219 IGTGLTEEKHRRIGLLIL--LMVIFILVGPVHTGCVKYIGLLHGDACEWEKTVFVFPV 276
QY 260 -LGLITGAWSVNPLVTGYL 279
DB 277 QLGRGLLSVLDPLTYTFL 297

RESULT 8
Q8BU00 PRELIMINARY; PRT; 365 AA.
AC Q8BU00;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Probable G protein-coupled receptor GPR4.
GN GPR4.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Heart;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium.
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RL Nature 420:563-573 (2002).";
DR EMBL; AK085829; BAC39547.1; -.
DR MGD; MGI:2441992; Gpr4.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; IEA.
DR InterPro; IPR000276; GPCR_Rhodpsn.
DR Pfam; PF00001; 7tm.1; 1.
```

[illegible]

```
KW Hypothetical protein.
SQ SEQUENCE 357 AA; 40191 MW; 56B96775303FBDDF CRC64;

Query Match      12.6%; Score 200; DB 11; Length 357;
Best Local Similarity 25.8%; Pred. No. 3.4e-08;
Matches 65; Conservative 38; Mismatches 103; Indels 46; Gaps 9;

QY 12 YVAAAFALGFLNVLARGATAHARLRLTPSLVVALNLGCSDLLLTVSLPLKAVEALASGA 71
DB 34 YSLVFIIGLVGNLAL-VVIVQNRKKNSTLYSNLVISDLIFTALPTRAYALGPD 92
QY 72 WPLPASLCPVFAVAFHFFPLVAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAIW 131
DB 93 WRIGDALCRVTALVFYINTYAGVNFMTCLSIDRFFAVVHPLRYNKKRIEYAKGVCLSW 152
QY 132 ALVLCVLGVLVGLGAPGWLHDSNTSLGINTPVN-----GSPVCLEAWDPASAGPAR---- 183
DB 153 ILVFAQLFLP-----LTPMSKEEGDKTTCMEY--PNFEGTASLPWI 192
QY 184 -FSLSLLLFFPLAITAFPCY--VGC--LRALARSGLTTHRRKLRAAWAGGALLTL----- 233
DB 193 LLGACLLGVLPITVILLCYSCCKLFTAKQNPLTEK-----SGVNKKALNTILLIIV 247
QY 234 --LLCVGPPYNAS 243
DB 248 VFILCFPTPVHVA 259

RESULT 11
Q9WU09 PRELIMINARY; PRT; 296 AA.
AC Q9WU09
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE G protein-coupled receptor (Fragment).
GN GPR55.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP MEDLINE=99132385; PubMed=9931487;
RA Sawdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H.Q.,
RA George S.R., O'Dowd B.F.;
RT "Identification and cloning of three novel human G protein-coupled
RT receptor genes GPR52, .PSI.GPR53 and GPR55: GPR55 is extensively
RT expressed in human brain.";
RL Mol. Brain Res. 64:193-198(1999).
DR EMBL; AF100789; RAD22411.1; -.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0004872; F:receptor activity; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR000276; GPCR_Rhodpsn.
DR Pfam; PF00001; 7tm1_1; 1.
DR PRINTS; PR00237; GPCRRHODOPSIN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
KW Receptor.
SQ SEQUENCE 339 AA; 37860 MW; BB0CAFD0FC371D63 CRC64;

Query Match      12.5%; Score 198; DB 4; Length 339;
Best Local Similarity 26.6%; Pred. No. 4.7e-08;
Matches 69; Conservative 41; Mismatches 113; Indels 36; Gaps 9;

QY 11 LVYAAFGFLNVLARGATAHARLRL-----TPSLVVALNLGCSDLLLTVSLP 60
DB 33 LPFASYLLDF---LIALVGNT---LALWFFTRDHKSGTPANVFLMHLAVADLSVLVLP 85
QY 61 LKAVEALASGAWPLPASLCPVFAVAFHFFPLVAGGGFLAALSAGRYLGAAPFLGYQAFRRP 120
DB 86 TELVVFHSGNHWPFGEIACRLTGFLFYLNMVASYIFLTICISADRFALIVHPVKSLKLRP 145
QY 121 CYSWGVCVCAAIWALVLCVLGVLGAPGWLHDSNTSLGINTPVNGSPVCLERAWDPASAG 180
DB 146 LYAHLACAFLMVVVAVAMAPL--LVSPQ-----TVQTNHTVCLQLYREKASH 191
QY 181 PARFSLSLLLFFPLAITAFVCYVGCGLRALARSGL--THRRKLRAAWAGGALLTLCLCVG 238
DB 192 HALVSLA-VAFTFPFITTTTCYLLIIRSL-ROGLRVEKRLKTKAVRMIAIVLAIFLVCFV 249
QY 239 PYNASNVASF-L-YPNIGGS 256
DB 250 PYHVNRSVYVLYHRSHGAS 268

RESULT 13
QB5YC4
```

```
ID Q8BYC4 PRELIMINARY; PRT; 358 AA.
AC Q8BYC4;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-WAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Putative G-protein coupled receptor homolog.
GN GPR20 OR A430106B1LR1K.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; TISSUE=Thymus;
RX MEDLINE=22354683; PubMed=12466851;
RA The RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573 (2002).
DR EMBL; AK040547; BAC30623.1; -.
DR MGD; MGI:2441803; Gpr20.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm 1; 1.
DR PRINTS; PR00237; GPCR_RHODOPSN.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
SQ SEQUENCE 358 AA; 39431 MW; C6F7842ABDE9CA8P CRC64;

Query Match 12.5%; Score 198; DB 11; Length 358;
Best Local Similarity 28.0%; Pred. No. 5e-08;
Matches 69; Conservative 41; Mismatches 90; Indels 46; Gaps 9;

QY 16 FAIGPFLNVLIRGATAHARLRLTPSLVYALNLCSDLLLTSLPLK-AVEALASG----- 70
DB 62 FLAAGLVNGLALVFCCTRAK-TPSVVTYINLVVTDLLVGLSLPTRFVAVFYGARGCLRC 120
QY 71 ANPLPASLCPVFAVAFHFFLYAGGFLAALSAGRYLGAAPFLGYQAFRRPCYSGWCAAI 130
DB 121 APP-----HVLGYFLAMHCSILFLTCVDYRLAIVQEGSRWRQPAKACVCFIV 172
QY 131 WALVCHLGLVFLGLEAPGGWLDHNSLTSLGINTVPNGSPVCLEAWDPASAGPARFSLSL 190
DB 173 WLAA-----GVV-----TSLVGVK-----SGRSCTRV-----FALTVLE 203
QY 191 FFLPLAITAFYVGCRLARALSGLT---HRRKLRAAWVAGGALLTLTLCLVGPYNASNVAS 247
DB 204 FLLPLLVISVFTGRIMCALSRPGLLRQGRVRRAMQLLTLVLVFLVCFTTPHARQVAV 263
QY 248 FLYPNL 253
DB 264 ALWPNV 269

RESULT 14
Q723W3 PRELIMINARY; PRT; 376 AA.
AC Q723W3;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein DKFZp686N1782.
GN DKFZp686N1782.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Human retina;

Query Match 12.5%; Score 197.5; DB 11; Length 369;
Best Local Similarity 24.1%; Pred. No. 5.6e-08;
Matches 70; Conservative 45; Mismatches 134; Indels 41; Gaps 11;

QY 3 LPPLQSFGLYVAFAFGFLNVLIRGATAHARLRLTPSLVYALNLCSDLLLTSLPLK 62
DB 91 LSTQVIPAIIILLFVVGVGPANIVTLWKLS--LRTKSISLVIFHTNLAIADLFCVTLPPK 148
QY 63 AVEALASGAWPLPASLCPVFAVAFHFFLYAGGFLAALSAGRYLGAAPFLGYQAFRRPCY 122
```

```
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX537386; CAD97628.1; -.
KW Hypothetical protein.
SQ SEQUENCE 376 AA; 42720 MW; 7638373C15A695DD CRC64;

Query Match 12.5%; Score 198; DB 4; Length 376;
Best Local Similarity 24.5%; Pred. No. 5.2e-08;
Matches 73; Conservative 42; Mismatches 145; Indels 38; Gaps 9;

QY 3 LPPLQSFGLYVAFAFGFLNVLIRGATAHARLRLTPSLVYALNLCSDLLLTSLPLK 62
DB 92 LSTKLIPAIIILLFVVGVGPANAVTL--WMLFFRTRISICTTVFVTNLAIADLFCVTLPPK 149
QY 63 AVEALASGAWPLPASLCPVFAVAFHFFLYAGGFLAALSAGRYLGAAPFLGYQAFRRPCY 122
DB 150 IAYHLNGNNWVGEVLCRAITVIFYGNMYCSILLACISINRYLAIVHPHYRGLPKHTY 209
QY 123 SWGVCAAIWALVLCGLVFLGLEAPGGWLDHNSLTSLG--INTVPNGSPVCLEAWDPASAG 180
DB 210 ALVTCGLVWATVFLYMLPFILKQEYLVQPDITTCDDVHTNCSSSPFQLYYF----- 263
QY 181 PARFSLSLLLFPLAITAFYVGCRLARALSGLTTHRRKLRAAWVAGGALLTL---LCV 237
DB 264 ---ISLAFPGFLIPFVLLIYCYAAIIRTL--NAYDH-----RMLWYVKASLLILVITICF 314
QY 238 GPYNASNV---ASFYPNLCGSSW--RKLGLITGAWSWLNPLV-----TGVL 279
DB 315 ARSNIIILIHANYNYNNDGLYFYLIALCGLGSLNSCLDPLFLYFLMSTRHNSTAYL 372

RESULT 15
Q8BJB7 PRELIMINARY; PRT; 369 AA.
ID Q8BJB7;
AC Q8BJB7;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-WAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Proteinase activated receptor 3 precursor.
GN F2RL2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J;
RX MEDLINE=22354683; PubMed=12466851;
RA The RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573 (2002).
DR EMBL; AK089444; BAC40886.1; -.
DR MGD; MGI:1298208; F2rl2.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0001584; F:rhodopsin-like receptor activity; IEA.
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; IEA.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm 1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
SQ SEQUENCE 369 AA; 41696 MW; C8E6B009710519EF CRC64;

Query Match 12.5%; Score 197.5; DB 11; Length 369;
Best Local Similarity 24.1%; Pred. No. 5.6e-08;
Matches 70; Conservative 45; Mismatches 134; Indels 41; Gaps 11;

QY 3 LPPLQSFGLYVAFAFGFLNVLIRGATAHARLRLTPSLVYALNLCSDLLLTSLPLK 62
DB 91 LSTQVIPAIIILLFVVGVGPANIVTLWKLS--LRTKSISLVIFHTNLAIADLFCVTLPPK 148
QY 63 AVEALASGAWPLPASLCPVFAVAFHFFLYAGGFLAALSAGRYLGAAPFLGYQAFRRPCY 122
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 29, 2004, 12:04:08 ; Search time 18 Seconds  
(without alignments)  
867.836 Million cell updates/sec

Title: US-10-202-687-2

Perfect score: 1584

Sequence: 1 MDLPPLQSLFGLYVAALGF.....RGFLKTVCAARTQGGKQK 300

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_42.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1584	100.0	300	1 GP40 HUMAN	O14842 homo sapien
2	366	23.1	346	1 GP42 HUMAN	O15229 homo sapien
3	347	21.9	346	1 GP41 HUMAN	O14843 homo sapien
4	332	21.0	330	1 GP43 HUMAN	O15552 homo sapien
5	244	15.4	420	1 PARI XENLA	P47749 xenopus lae
6	231.5	14.6	385	1 PARI HUMAN	O96x10 homo sapien
7	228	14.4	425	1 PARI HUMAN	P25116 homo sapien
8	226	14.3	425	1 PARI PAFHA	P56488 papio hamad
9	217.5	13.7	372	1 GP92 HUMAN	O9hic0 homo sapien
10	216.5	13.7	358	1 GP20 HUMAN	O96678 homo sapien
11	213	13.4	428	1 PARI CRIL0	O00991 cricetus
12	208	13.1	328	1 P2V3 MELGA	O93361 meleagris g
13	208	13.1	430	1 PARI MOUSE	P30558 mus musculus
14	205.5	13.0	363	1 SSR5 RAT	P30938 rattus norv
15	204.5	12.9	355	1 IL8A RABIT	P21109 oryctolagus
16	204	12.9	328	1 P2Y3 CHICK	O98907 gallus gall
17	204	12.9	432	1 PARI RAT	P26824 rattus norv
18	201.5	12.7	356	1 IL8B CANFA	O97571 canis famil
19	201	12.7	358	1 IL8B RABIT	P35344 oryctolagus
20	201	12.7	367	1 GP17 HUMAN	Q13304 homo sapien
21	200.5	12.7	396	1 PARI MOUSE	O88634 mus musculus
22	198.5	12.5	328	1 P2Y6 HUMAN	O10077 homo sapien
23	198	12.5	374	1 PARI HUMAN	O00254 homo sapien
24	197.5	12.5	328	1 P2Y6 RAT	O63371 rattus norv
25	197.5	12.5	369	1 PARI MOUSE	O08675 mus musculus
26	197.5	12.5	395	1 PARI RAT	Q92060 rattus norv
27	194.5	12.3	350	1 IL8A HUMAN	P25024 homo sapien
28	194	12.3	364	1 SSR5 HUMAN	P35346 homo sapien
29	193	12.2	362	1 SSR5 MOUSE	O08858 mus musculus
30	191.5	12.1	368	1 PARI RAT	Q92061 rattus norv
31	190.5	12.0	349	1 IL8A RAT	P70612 rattus norv
32	190.5	12.0	350	1 IL8A PANTR	P55920 pan troglod
33	190.5	12.0	362	1 GPR4 HUMAN	P46093 homo sapien

RESULT 1  
GP40\_HUMAN STANDARD; PRT; 300 AA.  
ID GP40\_HUMAN  
AC O14842;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Putative G protein-coupled receptor GPR40.  
GN GPR40.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98008875; PubMed=9344866;  
RA Sawdzargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F. Jr.,  
RA O'Dowd B.F.;  
RT A cluster of four novel human G protein-coupled receptor genes  
occurring in close proximity to CD22 gene on chromosome 19q13.1.;  
RL Biochem. Biophys. Res. Commun. 239:543-547(1997).  
CC -!- FUNCTION: Orphan receptor.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
EMBL: AF024687; AAB86710.1; -.  
PIR: JC5714; JC5714.  
DR Genew; HGNC:4498; GPR40.  
DR MIM; 603820; -.  
DR GO; GO:0005887; C:integral to plasma membrane; TAS.  
DR GO; GO:0004930; F:G-protein coupled receptor activity; TAS.  
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; TAS.  
DR InterPro; IPR000276; GPCR\_Rhodopn.  
DR Pfam; PF00001; 7tm1.1; 1.  
DR PRINTS; PRO0237; GPCRHHODPSN.  
DR PROSITE; P500237; G-PROTEIN RECP F1\_1; FALSE NEG.  
DR PROSITE; P500262; G-PROTEIN RECP F1\_2; 1.  
KW G-protein coupled receptor; Transmembrane.  
FT DOMAIN 1 10  
FT TRANSMEM 11 31  
FT DOMAIN 32 42  
FT CYTOPLASMIC 2 (POTENTIAL).  
FT TRANSMEM 43 63  
FT DOMAIN 64 81  
FT EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 82 102  
FT DOMAIN 103 123  
FT CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 124 144  
FT DOMAIN 145 178  
FT EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 179 197

#### ALIGNMENTS

34 188.5 11.9 352 1 CSAR CANFA  
35 187 11.8 377 1 P2Y2\_HUMAN  
36 186.5 11.8 362 1 GPR4 PIC  
37 185.5 11.7 319 1 GP31 HUMAN  
38 185.5 11.7 353 1 IL8B GORGO  
39 185 11.7 337 1 C5L2\_HUMAN  
40 185 11.7 361 1 P2Y4\_MOUSE  
41 185 11.7 370 1 OPRX\_CAVPO  
42 184.5 11.6 344 1 P2Y5\_MOUSE  
43 184.5 11.6 353 1 IL8B PANTR  
44 184 11.6 365 1 P2Y4\_HUMAN  
45 183.5 11.6 350 1 CSAR\_RABIT

P30992 canis famil  
P41231 homo sapien  
P50132 sus scrofa  
O00270 homo sapien  
Q28422 gorilla gor  
Q9P296 homo sapien  
Q9JJ87 mus musculu  
Q8BNC0 mus musculu  
Q28807 pan troglod  
P51582 homo sapien  
Q9TUEL oryctolagus



```
FT DOMAIN 198 221 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 222 242 6 (POTENTIAL).
FT DOMAIN 243 258 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 259 279 7 (POTENTIAL).
FT DOMAIN 280 300 CYTOPLASMIC (POTENTIAL).
FT CARBOHYD 155 155 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 300 AA; 31457 MW; 77EP27DACD93B80B CRC64;

Query Match 100.0%; Score 1584; DB 1; Length 300;
Best Local Similarity 100.0%; Pred. No. 9.7e-111;
Matches 300; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MDLPPLSGLYVAAPALGFLNVLAIKATAHARLRLTPSLVYALNLCSDLLLTVP 60
Db 1 MDLPPLSGLYVAAPALGFLNVLAIKATAHARLRLTPSLVYALNLCSDLLLTVP 60

QY 61 LKAVEALASGAWPLPASLCVFAVAHFFFLYAGGGFLAALSAGRYLGAFFLGYQAFRRP 120
Db 61 LKAVEALASGAWPLPASLCVFAVAHFFFLYAGGGFLAALSAGRYLGAFFLGYQAFRRP 120

QY 121 CYSWGCAAIWALVCHLGLVLEAPGGLWHDHNTSLGINTPVNGSPVCLAWDPASAG 180
Db 121 CYSWGCAAIWALVCHLGLVLEAPGGLWHDHNTSLGINTPVNGSPVCLAWDPASAG 180

QY 181 PARFSLSLFFFLPLAITAFVCYVGCRLARASGLTHRRKLRRAWVAGGALLTLILCVGPY 240
Db 181 PARFSLSLFFFLPLAITAFVCYVGCRLARASGLTHRRKLRRAWVAGGALLTLILCVGPY 240

QY 241 NASNVASFLYPNLGGSRKGLITGAWSVVLNPLVTGYLGRGFLKTVCAARTQGGKSQK 300
Db 241 NASNVASFLYPNLGGSRKGLITGAWSVVLNPLVTGYLGRGFLKTVCAARTQGGKSQK 300
```

```
DR EMBL; AF024689; AAB86712.1; -.
DR EMBL; AC002511; AAB67885.1; -.
DR FIR; JC5716; JC5716.
DR Genew; HGNC:4500; GPR42.
DR MIM; 603822; -.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0004930; F:G-protein coupled receptor activity; TAS.
DR GO; GO:0007186; F:G-protein coupled receptor protein signalin. . .; TAS.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm_1; 1.
DR PRINTS; PR00237; GPCR_RHODOPSIN.
DR PROSITE; PS00237; G-PROTEIN RECEPTOR_F1_1; 1.
DR PROSITE; PS00262; G-PROTEIN RECEPTOR_F1_2; 1.
KW G-protein coupled receptor; Transmembrane.
FT DOMAIN 1 19 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 20 40 1 (POTENTIAL).
FT DOMAIN 41 47 CYTOPLASMIC.
FT TRANSMEM 48 68 2 (POTENTIAL).
FT DOMAIN 69 90 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 91 111 3 (POTENTIAL).
FT DOMAIN 112 132 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 133 153 4 (POTENTIAL).
FT DOMAIN 154 178 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 179 199 5 (POTENTIAL).
FT DOMAIN 200 222 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 223 243 6 (POTENTIAL).
FT DOMAIN 244 258 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 259 279 7 (POTENTIAL).
FT DOMAIN 280 346 CYTOPLASMIC (POTENTIAL).
FT CARBOHYD 166 166 N-LINKED (GLCNAC. . .) (POTENTIAL).
SQ SEQUENCE 346 AA; 38695 MW; 03F6742DA4B798D0 CRC64;

Query Match 23.1%; Score 366; DB 1; Length 346;
Best Local Similarity 34.1%; Pred. No. 2.3e-20;
Matches 101; Conservative 38; Mismatches 129; Indels 28; Gaps 8;

QY 1 MDLPPLSGLYVAAPALGFLNVLAIKATAHARLRLTPSLVYALNLCGS 51
Db 1 MDLPPLSGLYVAAPALGFLNVLAIKATAHARLRLTPSLVYALNLCGS 51

QY 52 DILLTSLPLKAVEALASGAWPLPASLCVFAVAHFFFLYAGGGFLAALSAGRYLGAAPP 111
Db 52 DILLTSLPLKAVEALASGAWPLPASLCVFAVAHFFFLYAGGGFLAALSAGRYLGAAPP 111

QY 112 LQYQAFRRPCYSWGCAAIWALVCHLGLVLEAPGGLWHDHNTSLGINTPVNGSPVC- 170
Db 112 LQYQAFRRPCYSWGCAAIWALVCHLGLVLEAPGGLWHDHNTSLGINTPVNGSPVC- 170

QY 121 LWYKTRPRLGQAGLVSVACWLLASACSVVYVIEFSGD-ISHSQGTNG-----TCY 170
Db 121 LWYKTRPRLGQAGLVSVACWLLASACSVVYVIEFSGD-ISHSQGTNG-----TCY 170

QY 171 LEAWDP--ASAGPARFSLSLFFFLPLAITAFVCYVGCRLARASGLTHRRKLRRAWVAGG 228
Db 171 LEAWDP--ASAGPARFSLSLFFFLPLAITAFVCYVGCRLARASGLTHRRKLRRAWVAGG 228

QY 171 LEFWKQDLAILLPVLEMAVLLFVVPVLIITSYSRLLWILRGSG-SHRRQRRVAGLVAA 229
Db 171 LEFWKQDLAILLPVLEMAVLLFVVPVLIITSYSRLLWILRGSG-SHRRQRRVAGLVAA 229

QY 229 ALLTLLLCVGPYNASNVASFYLPNLGGSS--WRKGLITGAWSVVLNPLVTGYLGRG 282
Db 229 ALLTLLLCVGPYNASNVASFYLPNLGGSS--WRKGLITGAWSVVLNPLVTGYLGRG 282

QY 230 TLLNFLVLCFPGYVNVSHVVGVI---CGESPVMRIYVYVLLSLTSLNSCVDPFVYFSSSG 282
Db 230 TLLNFLVLCFPGYVNVSHVVGVI---CGESPVMRIYVYVLLSLTSLNSCVDPFVYFSSSG 282

RESULT 3
GP41 HUMAN
ID GP41 HUMAN STANDARD; PRT; 346 AA.
AC O14843;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Putative G protein-coupled receptor GPR41.
GN GPR41.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98008875; PubMed=9344866;
```

SAWZARGO M., George S.R., Nguyen T., Xu S., Kolakowski L.F. Jr.,  
O'Dowd B.F.;  
"A cluster of four novel human G protein-coupled receptor genes  
occurring in close proximity to CD22 gene on chromosome 19q13.1.",  
Biochem. Biophys. Res. Commun. 239:543-547(1997).  
[2]  
SEQUENCE FROM N.A.  
RC TISSUE=Ovary;  
RX MEDLINE=22388257; PubMed=12477932;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.L., Collins F.S., Wagner L.H., Shennan C.M., Schuler G.D.,  
RA Altschul S.P., Zeeberg B., Buettner K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Uesdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,  
RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,  
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length  
human and mouse cDNA sequences";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
CC -1- FUNCTION: Orphan receptor.  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
DR EMBL; AF024688; AAB86711.1; -;  
DR EMBL; BC035657; AAH35657.1; -;  
DR PIR; JCS715; JCS715.  
DR Genew; HGNC:4499; GPR41.  
DR MIM; 603821; -;  
DR CO; GO:0005887; C:integral to plasma membrane; TAS.  
DR CO; GO:0004930; F:G-protein coupled receptor activity; TAS.  
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.  
DR InterPro; IPR00276; GPCR\_Rhodopsin.  
DR Pfam; PF00001; 7tm 1; 1.  
DR PRINTS; PR00237; GPCRHHODOPS.  
DR PROSITE; PS00237; G\_PROTEIN\_RECEP\_F1\_1; 1.  
DR PROSITE; PS00237; G\_PROTEIN\_RECEP\_F1\_2; 1.  
DR PROSITE; PS00237; G\_PROTEIN\_RECEP\_F1\_3; 1.  
KW G-protein coupled receptor; Transmembrane.  
FT DOMAIN 1 19  
FT TRANSMEM 20 40  
FT DOMAIN 41 47  
FT TRANSMEM 48 68  
FT DOMAIN 69 90  
FT TRANSMEM 91 111  
FT DOMAIN 112 132  
FT TRANSMEM 133 153  
FT DOMAIN 154 178  
FT TRANSMEM 179 199  
FT DOMAIN 200 222  
FT TRANSMEM 223 243  
FT DOMAIN 244 258  
FT TRANSMEM 259 279  
FT DOMAIN 280 346  
FT CARBOHYD 166 166  
FT SEQUENCE 346 AA; 38649 MW; B3B19D62D11B6A1 CRC64;

Query Match 21.9%; Score 347; DB 1; Length 346;  
Best Local Similarity 32.3%; Pred. No. 6e-19;  
Matches 95; Conservative 41; Mismatches 134; Indels 24; Gaps 6;  
QY 1 MDLPQOLS-----FGLYVAAPALGFPPLNVAIRGATAHARLRLTSLVVALNGCS 51  
DB 1 MDTGPDQSYFSGNHWVFVSYLLTFLVGLPLNLLALVFGKLRQRPVAVDVLLNLTA 60  
QY 52 DLLLTLSLPLKAVEALASGAWPLPASLCPVFAVAHFFFLYAGGCGFLAALSAGRYLGA 111  
DB 61 DLLLLLLFLPRVERANGHMPLPFTLCPLSGFIPFTTYLTALFLAANSIERFLVAHP 120  
QY 112 LGQAPRRPCYNGVCAAIWALVHLGLVFLGAEAGGWLHDHNTSLGINTPVGSPVCL 171  
DB 121 LMVKTPLRGLQAGLVSAVACWLLASACSVVYVIEFSGD-ISHSQGTNG-----TCY 170  
QY 172 EAW---DPASGAPARFSLSLFFLPLATATFCYVGLARALARSGLTHRRKLAAMVAGG 228  
DB 171 LEPRKQDLALLPLVRLEMAVFLVFPVLIITSYSLRWILRGG-SHRQRRVAGLLAA 229  
QY 229 ALLTLLLCVGPYNASNVASFLYPNLGGSWRKLGLITGAWSVLNLPLVTGYLGRG 282  
DB 230 TLLNLFVLCFPGYNVSHVGVICGE-SPANRIYVTLTLNSCVDPPVYVYESSG 282  
RESULT 4  
GP43 HUMAN STANDARD; PRT; 330 AA.  
ID \_GP43 HUMAN  
AC Q1552;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Probable G protein-coupled receptor GPR43.  
GN GPR43.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98008875; PubMed=9344866;  
RA Sawzargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F. Jr.,  
RA O'Dowd B.F.;  
RT "A cluster of four novel human G protein-coupled receptor genes  
occurring in close proximity to CD22 gene on chromosome 19q13.1.",  
RL Biochem. Biophys. Res. Commun. 239:543-547(1997).  
RN [2]  
RP SEQUENCE FROM N.A.  
RA Lamerdin J.E., McCreedy P.M., Adamson A.W., Burkhardt-Schultz K.,  
RA Garcia E., Kyle A., Ramirez M., Stillwagen S., Ganes J., Danganan L.,  
RA Bruce R., Quan G., Montgomery M., Ow D., Kobayashi A., Olsen A.O.,  
RA Carrano A.V.;  
RL Submitted (SEP-1997) to the EMBL/GenBank/DBJ databases.  
CC -1- FUNCTION: Orphan receptor.  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
DR EMBL; AF024690; AAB86713.1; -;  
DR EMBL; AC002511; AAB67886.1; -;  
DR PIR; JCS717; JCS717.  
DR Genew; HGNC:4501; GPR43.  
DR MIM; 603823; -;  
DR CO; GO:0005887; C:integral to plasma membrane; TAS.  
DR GO; GO:0004930; F:G-protein coupled receptor activity; TAS.  
DR GO; GO:0007186; P:G-protein coupled receptor protein signalin. . .; TAS.

```
DR InterPro; IPR000276; GPCR_Rhodopsin.
DR Pfam; PF00001; 7tm.1; 1.
DR PRINTS; PR00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS00262; G_PROTEIN_RECEP_F1_2; 1.
KW G-protein coupled receptor; Transmembrane; Polymorphism.
FT DOMAIN 1 12
FT TRANSSEM 13 33
FT DOMAIN 34 41
FT TRANSSEM 42 62
FT TRANSSEM 63 84
FT TRANSSEM 85 105
FT TRANSSEM 106 126
FT TRANSSEM 127 147
FT TRANSSEM 148 173
FT TRANSSEM 174 194
FT TRANSSEM 195 219
FT TRANSSEM 220 240
FT TRANSSEM 241 255
FT TRANSSEM 256 276
FT TRANSSEM 277 330
FT CARBOHYD 151 151
FT CARBOHYD 167 167
FT VARIANT 211 211
FT SEQUENCE 330 AA; 37143 MW; F4BAC6FDFD1E90 CRC64;
Query Match 21.0%; Score 332; DB 1; Length 330;
Best Local Similarity 31.0%; Pred. No. 7.4e-18;
Matches 93; Conservative 53; Mismatches 120; Indels 34; Gaps 12;
QY 12 YVAAFALGFLNLAIRGATAHARLRLTPSLVYALNLCSDLLLTSLPLKAVEALASG 70
DB 14 YIIIFUTGFLPALLAURAFVGRIOQPAPVHLLSLTADLLLLLPFKIEASNF 73
QY 71 AMPLPASLCPVFAVAHFFPLVAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGCAAI 130
DB 74 RYVLPKVCALTSFGYSSIIYCSWLLAGISIERVILGVAFVQYKLSRPLY--GVIAL 131
QY 131 --WALVLCGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLVGLV 184
DB 132 VAWVMSFGHCTIIIVQ-----YLTNTEQVR--SGNEITCYENFTDNQDVLVPL 181
QY 185 SLSLFLFLPLAITAFYCY--VCCRLARSLGTHRKLRAAWAGGALLTLKLCVGP 241
DB 182 ELCLVLFIPMAVITFCYWRFWIMLSQPLVGAQR--RAVGLAVVTLNLFVCFGP 239
QY 242 ASNVASFLYNLGGSWRKLGLITGAWSVVNLPLVTGYLGR-----GPKLTKVCAART 295
DB 240 VSHLVGY-HQRKSPWRSATVFFSSINASLDPLLFYSSVVRRAGRGLQVL---RN 295
RESULT 5
PARI_XENLA
ID PARI_XENLA STANDARD; PRT; 420 AA.
AC P47749;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Proteinase activated receptor 1 precursor (PAR-1) (Thrombin receptor).
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94195429; PubMed=8145852;
RA Gerszten R.E., Chen J., Ishii M., Ishii K., Nanavicz T.,
RA Turck C.W., Vu T.-K.H., Coughlin S.R.;
RT "Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface.";
RL Nature 368:648-651(1994).
```

RESULT 6  
ID PAR4 HUMAN STANDARD; PRT; 385 AA.  
AC Q96R10; O76067;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Proteinase activated receptor 4 precursor (PAR-4) (Thrombin receptor-like 3) (Coagulation factor II receptor-like 3).  
DE like 3) (Coagulation factor II receptor-like 3).  
GN F2RL3 OR PAR4;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RN SEQUENCE FROM N.A.  
RX MEDLINE=98389762; PubMed=9722561;  
RA Kahn M.L., Hammes S.R., Botka C., Coughlin S.R.;  
RT "Gene and locus structure and chromosomal localization of the  
RT proteinase-activated receptor gene family.";  
RL J. Biol. Chem. 273:23290-23296(1998).  
RN [2]  
RN SEQUENCE FROM N.A.  
RX MEDLINE=98379991; PubMed=9716134;  
RA Kahn M.L., Zheng Y.-W., Huang W., Bigornia V., Zeng D., Moff S.,  
RA Farese R.V. Jr., Tam C., Coughlin S.R.;  
RT "A dual thrombin receptor system for platelet activation.";  
RL Nature 394:690-694(1998).  
RN [3]  
RN SEQUENCE FROM N.A., AND MUTAGENESIS OF ARG-47 AND ARG-68.  
RX MEDLINE=98283984; PubMed=9618465;  
RA Xu W.-F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P.,  
RA Ching A., Gilbert T., Davie E.W., Foster D.C.;  
RT "Cloning and characterization of human protease-activated receptor  
RT 4.";  
RL Proc. Natl. Acad. Sci. U.S.A. 95:6642-6646(1998).  
RN [4]  
RN SEQUENCE FROM N.A., AND VARIANTS VAL-296 AND LEU-310.  
RA Rieder M.J., Carrington D.P., Chung M.-W., Lee K.L., Yi Q.,  
RA Nickerson D.A.;  
RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.  
RN [5]  
RN FUNCTION  
RX MEDLINE=99178892; PubMed=10079109;  
RA Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H.,  
RA Coughlin S.R.;  
RT "Protease-activated receptors 1 and 4 mediate activation of human  
RT platelets by thrombin.";  
RL J. Clin. Invest. 103:879-887(1999).  
CC -!- FUNCTION: Receptor for activated thrombin or trypsin coupled to G  
CC proteins that stimulate phosphoinositide hydrolysis. May play a  
CC role in platelets activation.  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in lung,  
CC pancreas, thyroid, testis and small intestine. Not expressed in  
CC brain, kidney, spinal cord and peripheral blood leukocytes. Also  
CC detected in platelets.  
CC -!- PTM: A proteolytic cleavage generates a new amino terminus that  
CC functions as a tethered ligand.  
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC  
CC EMBL; AF080214; AAC28860.1; --

DR EMBL; AF055917; AAC25699.1; --  
DR EMBL; AF384819; AAK61908.1; --  
DR Genew; HGNC:3540; F2RL3.  
DR MIM; 602779; --  
DR InterPro: IPR000276; GPCR\_Rhodopsn.  
DR Pfam; PF00001; 7tm1; 1.  
DR PRINTS; PR00237; GPCR\_Rhodopsn.  
DR PROSITE; PS00237; G-PROTEIN RECEPTOR 1; 1.  
DR PROSITE; PS00262; G-PROTEIN RECEPTOR 2; 1.  
KW G-protein coupled receptor; Transmembrane; Glycoprotein; Signal;  
KW Blood coagulation; Polymorphism.  
FT SIGNAL 1 17 POTENTIAL.  
FT PROPEP 18 47 REMOVED FOR RECEPTOR ACTIVATION  
FT (BY SIMILARITY).  
FT CHAIN 48 385 PROTEINASE ACTIVATED RECEPTOR 4.  
FT DOMAIN 48 82 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 83 103 1 (POTENTIAL).  
FT DOMAIN 104 108 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 109 129 2 (POTENTIAL).  
FT DOMAIN 130 151 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 152 172 3 (POTENTIAL).  
FT DOMAIN 173 192 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 193 213 4 (POTENTIAL).  
FT DOMAIN 214 247 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 248 268 5 (POTENTIAL).  
FT DOMAIN 269 283 CYTOPLASMIC (POTENTIAL).  
FT TRANSMEM 284 304 6 (POTENTIAL).  
FT DOMAIN 305 319 EXTRACELLULAR (POTENTIAL).  
FT TRANSMEM 320 343 7 (POTENTIAL).  
FT DOMAIN 344 385 CYTOPLASMIC (POTENTIAL).  
FT DOMAIN 301 305 POLY-LEU.  
FT SITE 47 48 CLEAVAGE (BY THROMBIN OR TRYPSIN) (BY  
FT SIMILARITY).  
FT DISULFID 149 228 BY SIMILARITY.  
FT CARBOHYD 56 56 N-LINKED (GLCNAC. .) (POTENTIAL).  
FT VARIANT 296 296 F -> V.  
FT VARIANT 310 310 /FTIG=VAR 012852.  
FT P -> L.  
FT MUTAGEN 47 47 /FTIG=VAR 012853.  
FT MUTAGEN 68 68 R->A: NO PROTEOLYTIC CLEAVAGE (BY  
FT MUTAGEN 120 120 R->A: NO EFFECT ON RECEPTOR ACTIVATION.  
FT CONFLICT 120 120 T -> A (IN REF. 4).  
SQ SEQUENCE 385 AA; 41162 MW; 6A62B40D5756AE CRC64;

Query Match 14.6%; Score 231.5; DB 1; Length 385;

Best Local Similarity 24.9%; Pred. No. 2.4e-10; Indels 113; Gaps 8;  
Matches 88; Conservative 29; Mismatches 123;

QY 3 LPPQLSFGLYVAFAFGFPLNVLAIKRG-ATAHARLRLTSLVYALMLGSDLLLTVSLPL 61  
Db 75 VTRLVLPALYGLVVLVGLPANGALWVLATQAPRL---ESTMLLNLTATADULLALAPP 131  
QY 62 KAVEALASGAWPLPASLCPVFAVAHFFPLYAGGFLAALAGRYLGAAPPLGVAQFRRPC 121  
Db 132 RIAYHLRGQWPFGEAAACRLATAALYGHMYGSVLLLAASVLSLDRLYALVPLRARALRGRR 191  
QY 122 YSWGVCATWAL-----VLCHGLVFLGFLGAPGGWLDHSDNTSLG 159  
Db 192 LALGLCMAAWLMAAALALPLTQRTFLARSDRVLCHDALPLDAQA----- 238  
QY 160 INTPVNGSPVCLEAWDPASAGAPRPSLSLLLPFLAITAFQCYVGCRLARSLTHRRK 219  
Db 239 -----SHWQPAFT-----CLALLGCFLLPMLLCYGATLHTLAASGRYGA 281  
QY 220 LR-----AAWAGGALLTLLLCVGPYNAS 243  
Db 282 LRLTAVLASAVAFFVPSNLLLLHYSDPSAGWNLGYAVPSLALSTLNSCVDP---- 337  
QY 244 NVASFLYPLNGSWKGLGITGANSVVLNPLVTGYLGRGPKLVCAARTQGG 296  
Db 338 ----FIYYVVAEFR-----DKVRAGLFQRFSPGDTVASKASABGG 373

```

RESULT 7
RA PARI_HUMAN STANDARD; PRT; 425 AA.
AC P25116; Q96RF7; Q9UN4;
DT 01-MAY-1992 (Rel. 22, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Proteinase activated receptor 1 precursor (PAR-1) (Thrombin receptor)
DE (Coagulation factor II receptor).
GN F2R OR PARI OR TR OR CF2R.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91168254; PubMed=1672265;
RA Vu T.-K.H., Hung D.T., Wheaton V.I., Coughlin S.R.;
RT "Molecular cloning of a functional thrombin receptor reveals a novel
RT proteolytic mechanism of receptor activation.";
RL Cell 64:1057-1068 (1991).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length
RT human and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [4]
RP FUNCTION.
RX MEDLINE=99178892; PubMed=10079109;
RA Kahn M.L., Nakanishi-Mateui M., Shapiro M.J., Ishihara H.,
RT "Protease-activated receptors 1 and 4 mediate activation of human
RT platelets by thrombin.";
RL J. Clin. Invest. 103:879-887 (1999).
RN [5]
RP VARIANT GLY-166.
RX MEDLINE=99318093; PubMed=10391209;
RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA Shaw N., Lane C.R., Lim E.P., Kalyanaram N., Nemesh J., Ziaugra L.,
RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA Lander E.S.;
RT "Characterization of single-nucleotide polymorphisms in coding regions
RT of human genes.";
RL Nat. Genet. 22:231-238 (1999).
RN [6]
RP ERRATUM.
RA Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA Shaw N., Lane C.R., Lim E.P., Kalyanaram N., Nemesh J., Ziaugra L.,

```

```

RA Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA Lander E.S.;
RL Nat. Genet. 23:373-373 (1999).
CC -!- FUNCTION: High affinity receptor for activated thrombin coupled to
CC G proteins that stimulate phosphoinositide hydrolysis. May play a
CC role in platelets activation and in vascular development.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- TISSUE SPECIFICITY: Platelets and vascular endothelial cells.
CC -!- PTM: A proteolytic cleavage generates a new amino terminus that
CC functions as a tethered ligand.
CC -!- PTM: Phosphorylated; probably mediating desensitisation prior to
CC the uncoupling and internalization of the receptor.
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M62424; AAA36743.1; -.
DR EMBL; AF391809; AAK69768.1; -.
DR EMBL; BC002464; AAH02464.1; -.
DR EMBL; BC051909; AAH51909.1; -.
DR PIR; A37912; A37912.
DR PDB; INRN; 3I-MAY-94.
DR PDB; INRQ; 3I-MAY-94.
DR PDB; INRR; 3I-MAY-94.
DR Genew; HGNC:3537; F2R.
DR MIM; 187930; -.
DR GO; GO:0005794; C:Golgi apparatus; TAS.
DR GO; GO:0005887; C:integral to plasma membrane; TAS.
DR GO; GO:0005103; F:receptor binding; TAS.
DR GO; GO:0015057; F:thrombin receptor activity; TAS.
DR GO; GO:0006915; P:apoptosis; TAS.
DR GO; GO:0007596; P:blood coagulation; TAS.
DR GO; GO:0006919; P:casepase activation; TAS.
DR GO; GO:0006928; P:cell motility; TAS.
DR GO; GO:0007275; P:development; TAS.
DR GO; GO:0007345; P:embryogenesis and morphogenesis; TAS.
DR GO; GO:0007125; P:invasive growth; TAS.
DR GO; GO:0000074; P:regulation of cell cycle; TAS.
DR GO; GO:0009611; P:response to wounding; TAS.
DR GO; GO:0007165; P:signal transduction; TAS.
DR GO; GO:0007263; P:STAT protein nuclear translocation; TAS.
DR GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; TAS.
DR InterPro; IPR000276; GPCR_Rhodopsn.
DR Pfam; PF00001; 7tm_1; 1.
DR PRINTS; PR00237; GPCRHOOPS.
DR PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR PROSITE; PS0262; G_PROTEIN_RECEP_F1_2; 1.
KW G-protein coupled receptor; Transmembrane; Glycoprotein; Signal;
KW Blood coagulation; Phosphorylation; Polymorphism; 3D-structure.
FT SIGNAL 1 26
FT PROPEP 27 41
FT CHAIN 42 425
FT DOMAIN 103 128
FT TRANSMEM 129 137
FT DOMAIN 138 157
FT TRANSMEM 158 176
FT DOMAIN 177 198
FT TRANSMEM 199 218
FT TRANSMEM 219 239
FT DOMAIN 240 268
FT TRANSMEM 269 288
FT DOMAIN 289 311
FT TRANSMEM 312 334
FT DOMAIN 335 350
FT TRANSMEM 351 374
FT DOMAIN 375 425

```

[illegible]



OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20517346; PubMed=11062477;  
 RA White K.E., Evans W.E., O'Riordan J.L.H., Speer M.C., Econs M.J.,  
 RA Lorenz-DePreux B., Grabowski M., Meitinger T., Strom T.M.;  
 RT "Autosomal dominant hypophosphataemic rickets is associated with  
 mutations in FGF23.";  
 RL Nat. Genet. 26:345-348(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21458557; PubMed=11574155;  
 RA Lee D.K., Nguyen T., Lynch K.R., Cheng R., Vanti W.B., Arkhitko O.,  
 RA Lewis T., Evans J.F., George S.R., O'Dowd B.F.;  
 RT "Discovery and mapping of ten novel G protein-coupled receptor  
 genes.";  
 RL Gene 275:83-91(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22040266; PubMed=12044878;  
 RA Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S.;  
 RT "Identification of G protein-coupled receptor genes from the human  
 genome sequence.";  
 RL FEBS Lett. 520:97-101(2002).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=B-cell;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diachenko L., Marusina K., Farmer A.F., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Donald M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalón D.K., Murthy D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.J., Skalska U., Smalios D.E.,  
 RA Scherch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 human and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 CC -!- FUNCTION: Orphan receptor.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- TISSUE SPECIFICITY: Not expressed in frontal cortex, basal  
 forebrain, caudate putamen, thalamus, or hippocampus.  
 CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AJ272207; CAC03715.1; -  
 DR EMBL; AF411112; BAB26483.1; -  
 DR EMBL; AB083600; BAB89313.1; -  
 DR EMBL; BC033571; AAH33571.1; -  
 DR GenBank; HGNC:13307; GPR92.  
 DR MIM; 606926; -  
 DR InterPro; IPR000276; GPCR\_Rhodpsn.  
 DR Pfam; PF00001; 7tm 1; 1.  
 DR PRINTS; PR00237; GPCRHHODPSN.  
 DR PROSITE; PS00237; G\_PROTEIN\_RECEP\_F1\_1; 1.  
 DR

DR PROSITE; PS0262; G\_PROTEIN\_RECEP\_F1\_2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein.  
 FT DOMAIN 1 26  
 FT TRANSMEM 27 47  
 FT DOMAIN 48 55  
 FT TRANSMEM 56 76  
 FT DOMAIN 77 96  
 FT TRANSMEM 97 117  
 FT DOMAIN 118 136  
 FT TRANSMEM 137 157  
 FT DOMAIN 158 187  
 FT TRANSMEM 188 208  
 FT DOMAIN 209 239  
 FT TRANSMEM 240 260  
 FT DOMAIN 261 276  
 FT TRANSMEM 277 297  
 FT DOMAIN 298 372  
 FT DISULFID 94 175  
 FT CARBOHYD 4 9  
 FT CARBOHYD 9 9  
 SQ SEQUENCE 372 AA; 41346 MW; BA35709084BB6D84 CRC64;  
 Query Match 13.7%; Score 217.5; DB 1; Length 372;  
 Best Local Similarity 29.1%; Pred. No. 2.6e-09;  
 Matches 92; Conservative 36; Mismatches 141; Indels 47; Gaps 14;  
 QY 6 QLSFGLYVAAPAFALGFPANVLA-----IRGATAHARLRLTPSLVYALNLCGSDLLLTSLPL 61  
 DB 23 RLHLVYVSLVLAAGLPLNALAWFLRLRVHSVVS-----VYMCNLAASDLTLTSLSPV 77  
 QY 62 KAVEALASGAWPLASLCPVFAVAHFFPLYAGGGFLAALSAGRYLGAAPFLGQAFRRPC 121  
 DB 78 R-LSYALHWHFFPDLLCQTTCATQFMNMYGSCIFLMLINVDVRYAAIVHLRLHRRR 136  
 QY 122 YSWGCAAIWALVLCGLVFLGLEAPGWLDSHTSLGINTPVNSPVCLEAW-PPASAG 180  
 DB 137 VARLLCLGWALI-----LVFAV--PAARVHRPSRCRYRDLVR---LCFESFSDLMWKG 186  
 QY 181 ---PARPSLSLLFFPLPLAITAFYVGCRLARLSGLT---HRRKLRAAWVAGGALLTL 234  
 DB 187 RLPLVLLAELGFLPLAAVYSSGRVFWTLARPDATQSRRTKTVRLLLAN--LVIFL 244  
 QY 235 LCVGPYNA-----SNVASFLYP---NLGGSWRKLGLITGAWSVLNLPLVTGLGRG 282  
 DB 245 LCFVYNSTLAVYGLLRSLKVAASVPARDVRGVLMMVLLAGA-NCVLDPLVYFESAG 303  
 QY 283 -----PGLKTVCAART 293  
 DB 304 FRNTLRGLGTPHART 319  
 RESULT 10  
 GP20 HUMAN  
 ID GP20 HUMAN STANDARD; PRT; 358 AA.  
 AC Q99678;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Probable G protein-coupled receptor GPR20.  
 GN GPR20.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Euthera; Primates; Catarrhini; Homiidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=97225799; PubMed=9073069;  
 RA O'Dowd B.F., Nguyen T., Jung B.P., Marchese A., Cheng R.,  
 RA Heng H.H.Q., Kolakowski L.F. Jr., Lynch K.R., George S.R.;  
 RT "Cloning and chromosomal mapping of four putative novel human  
 G-protein-coupled receptor genes.";  
 RL Gene 187:75-81(1997).  
 CC -!- FUNCTION: Orphan receptor.



CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -1- TISSUE SPECIFICITY: LIVER AND THE BRAIN REGIONS THALAMUS, PUTAMEN,  
 CC AND CAUDATE, BUT NOT IN FRONTAL CORTEX, PONS AND HYPOTHALAMUS.  
 CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; U66579; AAC51302.1; -;  
 CC Genbank; HGNC:4475; GPR20.  
 CC MIM; 601908; -;  
 CC GO; GO:0005887; C:integral to plasma membrane; TAS.  
 CC GO; GO:0004930; F:G-protein coupled receptor activity; TAS.  
 CC GO; GO:0007186; P:G-protein coupled receptor protein signalin. .; TAS.  
 CC InterPro; IPR000276; GPCR\_Rhodopsin.  
 CC Pfam; PF00001; 7tm 1; 1.  
 CC PRINTS; PR00237; GPCR\_RHODOPSIN.  
 CC PROSITE; PS00237; G PROTEIN RECEPTOR F1.1; 1.  
 CC PROSITE; PS00262; G-PROTEIN RECEPTOR F1.2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein.  
 FT DOMAIN 1 48 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 49 69 1 (POTENTIAL).  
 FT DOMAIN 70 86 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 87 107 2 (POTENTIAL).  
 FT DOMAIN 108 125 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 126 146 3 (POTENTIAL).  
 FT DOMAIN 147 168 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 169 189 4 (POTENTIAL).  
 FT DOMAIN 190 196 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 197 217 5 (POTENTIAL).  
 FT DOMAIN 218 238 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 239 259 6 (POTENTIAL).  
 FT DOMAIN 260 275 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 276 296 7 (POTENTIAL).  
 FT DOMAIN 297 358 CYTOPLASMIC (POTENTIAL).  
 FT CARBOHYD 16 16 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 26 26 N-LINKED (GLCNAC. .) (POTENTIAL).  
 SQ SEQUENCE 358 AA; 38406 MW; 258C6683D455B1EB CRC64;  
 Query Match 13.7%; Score 216.5; DB 1; Length 358;  
 Best Local Similarity 29.0%; Pred. No. 2.9e-09;  
 Matches 73; Conservative 37; Mismatches 87; Indels 55; Gaps 8;  
 QY 14 AAFALGFPLNLVLAIRGATAHARLRLTPSLVYALNLGCSDLLLTVSLPLK-AVEALASG-- 70  
 DB 62 AIFLAGLVNGLALVYVFCRTRAK-TFSVITYINLVVTDLLVGLSLPTFRFVYVGARGCL 120  
 QY 71 --AWPLPASLCPVFAVAHPFPLVYAGGGFLAALSAGRYLGNAPPLGVAQAFRRPCYSNGVCA 128  
 DB 121 RCAFP-----HVLGYFLNHCHSILFLTCICVDRYLAIVREAPACRQPCARAVCA 172  
 QY 129 AYW---ALVCHLGLVFLGLEGAPGWLDRHSNTSLGINTPVNGSPVCLAEWDPASAGPARF 184  
 DB 173 FVWLAGAVTSLVIG-----VTGSRPCRV-----F 198  
 QY 185 SISLLFLFPLLAITAFYCYGCLRALARSGLTH---RRKLRAAWVAGGALLTLCLCVGPYN 241  
 DB 199 ALTVLEFLPLLVISVFTGRIMCALSRPGLLHQGRQRRVRAMQLLTLVLIIFLCVTPPFH 258  
 QY 242 ASNVASFLYPNL 253  
 DB 259 ARQVAVALWPDMD 270  
 RESULT 11  
 PARI\_CRILO  
 ID PARI CRILO STANDARD; PRT; 428 AA.  
 AC Q00991; Q60461;

DT 01-APR-1993 (Rel. 25, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Proteinase activated receptor 1 precursor (PAR-1) (Thrombin receptor).  
 GN P2R OR PAR1  
 OS Cricetus longicaudatus (Long-tailed hamster) (Chinese hamster).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;  
 OC Cricetulus.  
 OX NCBI\_TaxID=10030;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Lung;  
 RX MEDLINE=91348247; PubMed=1652467;  
 RA Rasmussen U.B., Vouret-Craviari V., Jallat S., Schlesinger Y.,  
 RA Pages G., Pavitani A., Lecoq J.P., Pouyssegur J.,  
 RA Obberghen-Schilling E.;  
 RT "cDNA cloning and expression of a hamster alpha-thrombin receptor  
 RL coupled to Ca2+ mobilization.";  
 RL FEBS Lett. 288:123-128 (1991).  
 RN [2]  
 RP SEQUENCE OF 42-428 FROM N.A.  
 RX MEDLINE=96028007; PubMed=7488069;  
 RA Hartmann T., Grace M.B., Buzard G.S., Ruoss S.J.;  
 RA "Thrombin receptor polymorphism in Chinese hamster.";  
 RL Biochem. Biophys. Res. Commun. 215:974-980 (1995).  
 CC -1- FUNCTION: High affinity receptor for activated thrombin coupled to  
 CC G proteins that stimulate phosphoinositide hydrolysis.  
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -1- PTM: A proteolytic cleavage generates a new amino terminus that  
 CC functions as a tethered ligand.  
 CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; X61958; CAA43957.1; -;  
 CC EMBL; U34047; AAA86747.1; -;  
 CC PIR; S17148; S17148.  
 CC HSP; P34996; 1DDD.  
 CC InterPro; IPR000276; GPCR\_Rhodopsin.  
 CC Pfam; PF00001; 7tm 1; 1.  
 CC PRINTS; PR00237; GPCR\_RHODOPSIN.  
 CC PROSITE; PS00237; G PROTEIN RECEPTOR F1.1; 1.  
 CC PROSITE; PS00262; G-PROTEIN RECEPTOR F1.2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein; Signal;  
 KW Blood coagulation; Polymorphism.  
 FT SIGNAL 1 21 POTENTIAL.  
 FT PROPEP 22 41 REMOVED FOR RECEPTOR ACTIVATION (BY  
 FT SIMILARITY).  
 FT CHAIN 42 428 PROTEINASE ACTIVATED RECEPTOR 1.  
 FT DOMAIN 42 105 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 106 131 1 (POTENTIAL).  
 FT DOMAIN 132 140 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 141 160 2 (POTENTIAL).  
 FT DOMAIN 161 179 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 180 201 3 (POTENTIAL).  
 FT DOMAIN 202 221 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 222 242 4 (POTENTIAL).  
 FT DOMAIN 243 271 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 272 291 5 (POTENTIAL).  
 FT DOMAIN 292 314 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 315 337 6 (POTENTIAL).  
 FT DOMAIN 338 352 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 353 377 7 (POTENTIAL).  
 FT DOMAIN 378 428 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 60 63 ASP/GLU-RICH (ACIDIC).  
 FT DOMAIN 301 304 POLY-SER.

```
FT SITE 41 42 CLEAVAGE (BY THROMBIN) (BY SIMILARITY).
FT DISULFID 178 257 BY SIMILARITY.
FT CARBOHYD 65 65 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 78 78 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 253 253 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 262 262 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT VARIANT 84 84 MISSING (IN AN ALLELE).
FT CONFLICT 384 384 H -> T (IN REF. 1).
SQ SEQUENCE 428 AA; 47602 MW; E5492AB2CD877E2F CRC64;

Query Match 13.4%; Score 213; DB 1; Length 428;
Best Local Similarity 23.4%; Pred. No. 6.2e-09;
Matches 68; Conservative 53; Mismatches 122; Indels 48; Gaps 9;

QY 11 LVAAAFALGFLPLNLAIRGATAHARLUTPSLVYALNGLCSDLLLTVSLPLKAVEALASG 70
Db 111 VTFVFLVSLPLNLAIAVFLKMKVK-KPAAVYMLHLAWADVLSVPLPLKISYFFSGS 169

QY 71 AMPLPASLCPVEFAVAHFPLVAGGGFLAALSAGRYLGAAPFLGYQAFRRPCYSWGVCAAI 130
Db 170 DMQFGSGMCRFATAFYCNMYASIMLMTVISIDRFVAVYPIQSLSWRTLGRANFTCLVI 229

QY 131 WALVLCHLGLVFLGL-----EAPGGWLDHSNTSLGINTPVNGSPVCLEAWDPA----- 177
Db 230 WYMAI--MGVPLLLKEQTRVFG-----LNITT-----CHDVNLTLLQGFFYS 271

QY 178 ---SAPARFSLLLFLPLAITAFYCVGCLRALARSLGTHR-RKLRAAVAGGALLTL 233
Db 272 YFSA-----FSAVFPLPLIISTICYMSIIRCLSSSVANRSKRSLFALFSAVFCVF 325

QY 234 LLCVGPYNASNVASFILPNLGGSWRK-----LGLITGAWSVVLNPLVTGY 278
Db 326 IVCFGPTVLLIMHYLLLSDSATEKAYPAYLLCVCSVSSCIDPLIYY 376

RESULT 12
P2Y3 MELGA
ID P2Y3 MELGA STANDARD; PRT; 328 AA.
AC Q93361.
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE P2Y purinoceptor 3 (P2Y3) (Nucleoside diphosphate receptor).
GN P2RY3.
OS Meleagris gallopavo (Common turkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Meleagris.
OX NCBI_TaxID=9103;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=98401046; PubMed=9730913;
RA Li Q., Olesky M., Palmer R.K., Harden T.K., Nicholas R.A.;
RT "Evidence that the p2y3 receptor is the avian homologue of the
mammalian P2Y6 receptor."
RL Mol. Pharmacol. 54:541-546(1998).
CC -!- FUNCTION: RECEPTOR FOR EXTRACELLULAR UDP > ADP = UTP. THE ACTIVITY
OF THIS RECEPTOR IS MEDIATED BY G PROTEINS WHICH ACTIVATE A
PHOSPHATIDYLINOSITOL-CALCIUM SECOND MESSENGER SYSTEM.
CC -!- SUBCELLULAR LOCATION: Integral membrane protein.
CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@sib-sib.ch).
CC -----
CC EMBL; AF069555; AAC23863.1; --
DR HSSP; P34996; 1DDD.
DR InterPro; IPR000276; GPCR_Rhodospn.
DR Pfam; PF00001; 7tm_1; 1.
```

```
DR PRINTS; PR00237; GPCRHHODPSN.
DR PROSITE; PS00237; G-PROTEIN RECEPTOR_F1_1; FALSE_NEG.
DR PROSITE; PS00262; G-PROTEIN RECEPTOR_F1_2; 1.
KW G-protein coupled receptor; Transmembrane; Glycoprotein.
FT DOMAIN 1 22 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 23 43 1 (POTENTIAL).
FT DOMAIN 44 57 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 58 78 2 (POTENTIAL).
FT DOMAIN 79 96 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 97 117 3 (POTENTIAL).
FT DOMAIN 118 139 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 140 160 4 (POTENTIAL).
FT DOMAIN 161 189 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 190 210 5 (POTENTIAL).
FT DOMAIN 211 231 CYTOPLASMIC (POTENTIAL).
FT TRANSMEM 232 252 6 (POTENTIAL).
FT DOMAIN 253 275 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 276 298 7 (POTENTIAL).
FT DOMAIN 299 323 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 5 5
FT DISULFID 94 172 BY SIMILARITY.
SQ SEQUENCE 328 AA; 37594 MW; B74D49B99C7164A5 CRC64;

Query Match 13.1%; Score 208; DB 1; Length 328;
Best Local Similarity 30.3%; Pred. No. 1.2e-08;
Matches 67; Conservative 25; Mismatches 105; Indels 24; Gaps 7;

QY 11 LVAAAFALGFLPLNLAIRGATAHARLUTPSLVYALNGLCSDLLLTVSLPLKAVEALASG 70
Db 27 YSVVFLGLPLNAVVI-GQILARKALTRTIYMLNLATADLLVCSLPLLIYNTQXD 85

QY 71 AMPLPASLCPVEFAVAHFPLVAGGGFLAALSAGRYLGAAPFL-GYQAFRRPCYSWGVCAAI 129
Db 86 YWPGDFTCKVRFPFYNNHGSILFLTCISVQRTWIGICHPLASWHKKGLTWLVCAA 145

QY 130 IWALVLCHLGLVFLGLEAFGGWLDHSNTSLGINTPVNGSPVCLEAWDP---ASAGPARFSL 186
Db 146 VMFIVIAOCLPTFFVASTG-----TQNRRT-VCYDLSPDPSASVFPYGITL 191

QY 187 SLLFLPLAITAFYCVGCLRALARS-----GL-THRRKLRA 222
Db 192 TITGFLPLPAITLACYCSMARILCQKDELIGLAVHKKDKA 232

RESULT 13
PARI_MOUSE
ID PARI_MOUSE STANDARD; PRT; 430 AA.
AC P30558; P97507;
DT 01-APR-1993 (Rel. 25, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 15-NOV-2004 (Rel. 43, Last annotation update)
DE Proteinase activated receptor 1 precursor (PAR-1) (Thrombin receptor).
GN F2R OR PAR1 OR CF2R.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96379236; PubMed=8784787;
RA Kahn M.L., Ishii K., Kuo W.L., Piper M., Connolly A., Shi Y.P.,
Wu R., Lin C.C., Coughlin S.R.;
RT "Conserved structure and adjacent location of the thrombin receptor
and protease-activated receptor 2 genes define a protease-activated
receptor gene cluster."
RL Mol. Med. 2:349-357(1996).
```

[3]  
 RN SEQUENCE FROM N.A.  
 RC STRAIN=FVB/N; TISSUE=Mammary gland;  
 RA MEDLINE=22388257; PubMed=12477932;  
 RX Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zebberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan K.C., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Uedin T.B., Toehiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
 RA Bosak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalilus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 human and mouse cDNA sequences";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [4]  
 RP SEQUENCE OF 1-74 FROM N.A.  
 RC STRAIN=129/Sv;  
 RX MEDLINE=96327649; PubMed=8678993;  
 RA Xue J., Jenkins N.A., Gilbert D.J., Copeland N.G., Sadler J.E.;  
 RT "Structure and localization of the thrombin receptor gene on mouse  
 chromosome 13";  
 RL Mamm. Genome 7:625-626(1996).  
 CC -!- FUNCTION: High affinity receptor for activated thrombin coupled to  
 G proteins that stimulate phosphoinositide hydrolysis.  
 CC -!- SUBCELLULAR LOCATION: Integral membrane protein.  
 CC -!- PTM: A proteolytic cleavage generates a new amino terminus that  
 functions as a tethered ligand.  
 CC -!- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 -----  
 DR EMBL; L03529; AAA40438.1; -;  
 DR EMBL; U36757; AAB38308.1; -;  
 DR EMBL; U36756; AAB38308.1; JOINED.  
 DR EMBL; BC031516; AAB31516.1; -;  
 DR EMBL; U55076; AAB00198.1; -;  
 DR EMBL; U55075; AAB00198.1; JOINED.  
 DR HSSP; P34996; 1DDO.  
 DR MGD; MGI:101802; F2r.  
 DR InterPro; IPR000276; GPCR\_Rhodopsn.  
 DR Pfam; PF00001; 7tm 1; 1.  
 DR PRINTS; PR00237; GPCRHOPOPSN.  
 DR PROSITE; PR00237; G\_PROTEIN\_RECP\_F1\_1; 1.  
 DR PROSITE; PS0262; G\_PROTEIN\_RECP\_F1\_2; 1.  
 KW G-protein coupled receptor; Transmembrane; Glycoprotein; Signal;  
 KW Blood coagulation.  
 FT SIGNAL 1 21 POTENTIAL.  
 FT PROPEP 22 41 REMOVED FOR RECEPTOR ACTIVATION (BY  
 FT SIMILARITY).  
 FT CHAIN 42 430 PROTEINASE ACTIVATED RECEPTOR 1.  
 FT DOMAIN 42 107 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 108 133 1 (POTENTIAL).  
 FT DOMAIN 134 142 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 143 162 2 (POTENTIAL).  
 FT DOMAIN 163 181 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 182 203 3 (POTENTIAL).  
 FT DOMAIN 204 223 CYTOPLASMIC (POTENTIAL).

FT TRANSMEM 224 244 4 (POTENTIAL).  
 FT DOMAIN 245 273 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 274 293 5 (POTENTIAL).  
 FT DOMAIN 294 316 CYTOPLASMIC (POTENTIAL).  
 FT TRANSMEM 317 339 6 (POTENTIAL).  
 FT DOMAIN 340 354 EXTRACELLULAR (POTENTIAL).  
 FT TRANSMEM 355 379 7 (POTENTIAL).  
 FT DOMAIN 380 430 CYTOPLASMIC (POTENTIAL).  
 FT DOMAIN 60 65 ASP/GLU-RICH (ACIDIC).  
 FT DOMAIN 88 91 POLY-PRO.  
 FT SITE 41 42 CLEAVAGE (BY THROMBIN) (BY SIMILARITY).  
 FT DISULFID 180 259 BY SIMILARITY.  
 FT CARBOHYD 67 67 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 80 80 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CARBOHYD 255 255 N-LINKED (GLCNAC. .) (POTENTIAL).  
 FT CONFLICT 162 162 F -> S (IN REF. 1).  
 FT CONFLICT 189 189 G -> Y (IN REF. 1).  
 FT CONFLICT 223 223 R -> G (IN REF. 1).  
 FT CONFLICT 262 262 V -> L (IN REF. 1).  
 FT CONFLICT 365 365 S -> T (IN REF. 1).  
 SQ SEQUENCE 430 AA; 47790 MW; 395PD64PAB52C9BF CRC64;  
 Query Match 13.1%; Score 208; DB 1; Length 430;  
 Best Local Similarity 25.1%; Pred. No. 1.5e-08;  
 Matches 64; Conservative 45; Mismatches 108; Indels 38; Gaps 9;  
 QY 11 LVYAAPALGFFPLNVLAIARGATAHARLRL--TPSLVYALNLGCSLLLTLSPLKAVEALAS 69  
 DB 113 VTIVFIVSLPLNVLAI--AVFLRMKVKPAPVYMLHLMADVLVFLPFKISYFSG 170  
 QY 70 GAWPLPASLCPVFAVAHFPLLYAGGFLAALGAGRYLGAAPFLPGYQAFRRPCYSWGVCAA 129  
 DB 171 TDWQFGSGMCRATAAFYGNMVASIMLTVISIDREFLAVVYQSLSWRTLGRANFTCVV 230  
 QY 130 IVALVLCGLYVFLG-----EAPGWLHDHNTSLGINTPVNGSPVCLAWDPASAGPAR 193  
 DB 231 IVMVAI--MGVVPFLKKEQTTRVPG-----LNITT-----CHDLVSENLMQ 269  
 QY 184 -----FS--LSLLPLPLAITAFVCVGLRALARSLGTHR--RKLRAAVVAGGALLTL 235  
 DB 270 GPYSYFSAFSAIFLVLPLIVSTVCTYSIIRCLSSAVANRKSRLFLSAVFCIFIV 329  
 QY 236 CVGPNASNVAASFY 250  
 DB 330 CFGPTNVLIVHYLP 344  
 RESULT 14  
 SSR5.RAT  
 ID SSR5 RAT STANDARD; PRT; 363 AA.  
 AC P30938;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Somatostatin receptor type 5 (SS5R).  
 GN SSR5.  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Pituitary;  
 RX MEDLINE=93125499; PubMed=1362243;  
 RA O'Carroll A.-M., Lolait S.J., Konig M., Mahan L.C.;  
 RT "Molecular cloning and expression of a pituitary somatostatin  
 receptor with preferential affinity for somatostatin-28";  
 RL Mol. Pharmacol. 42:939-946(1992).  
 RN [2]  
 RP REVISIONS TO C-TERMINUS.  
 RC TISSUE=Pituitary;  
 RX MEDLINE=94195267; PubMed=7908405;  
 RA Panetta R., Greenwood M.T., Warszynska A., Demchyshyn L.L., Day R.,



Search completed: April 29, 2004, 12:10:33  
Job time : 19 secs

**THIS PAGE BLANK (USPTO)**